| Excerpt | Reference |
|---|
| "Ovarian cancer is the most common fatal gynecologic malignant disease." | ( Popkin, DR, 1979) |
| "The main problem in ovarian cancer is late diagnosis." | ( Kuipers, T, 1976) |
| "Cancer of the ovary is the leading cause of death from gynecologic cancer." | ( Barber, HR; Kwon, TH, 1976) |
| "Mortality rate of ovarian cancer is increasing in Japan and the management of advanced cases is an important issue in order to improve long term survival." | ( Kawashima, M; Ochiai, K; Takakura, S, 1992) |
| "The patients with ovarian cancer are apt to combine peritonitis carcinomatosa (PC)." | ( Hando, T; Hirokawa, M; Ohno, M, 1992) |
| "Ovarian cancers are highly invasive." | ( Capony, F; Galtier-Dereure, F; Maudelonde, T; Rochefort, H, 1992) |
| "Chemotherapy for ovarian cancer is frequently limited by cisplatin (CDDP) resistance." | ( Hamilton, TC; Handel, LM; Perez, RP, 1992) |
| "Ovarian cancer is responsible for 4% of all cancers in females and 6% of all their cancer deaths." | ( Rao, BR; Slotman, BJ, 1991) |
| "The prognosis of ovarian cancer is affected by various kinds of factor as age, ps, stage, histology, histological grading and the volume of residual tumor." | ( Murae, M; Niimi, S; Ochiai, K; Sasaki, H; Terashima, Y; Yokoyama, S, 1990) |
| "Cancer of the ovary is the commonest cause of death from gynaecological neoplasms." | ( Haije, WG, 1982) |
| "Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV)." | ( Kapp, DS; Katz, ME; Luikart, S; Schwartz, PE, 1981) |
| "Since ovarian cancer is a disease of the entire abdominal cavity, biopsy of selected sites will often detect unsuspected involvement by microscopic foci of metastatic carcinoma." | ( Herson, J; Wharton, JT, 1981) |
| "Advanced-stage cancer of the ovary is the most lethal of gynecologic malignancies, affecting African-American and white women with approximately equal frequency." | ( Reed, E, 1994) |
| "Epithelial ovarian cancer is the fifth most common cause of cancer death in women." | ( Caldas, C; McGuire, WP, 1993) |
| "Advanced epithelial ovarian cancer is a highly chemosensitive solid tumor with response rates of 70-80% to first-line chemotherapy, including a high proportion of complete responses." | ( Christian, MC; Trimble, EL, 1994) |
| "Ovarian cancer is the leading cause of death from gynecologic cancers in women in the United States." | ( Bookman, MA; Ozols, RF, 1993) |
| "Ovarian cancer is an important disease due to its occurrence in women in the prime of life (40-70) and its responsiveness to therapy but generally poor outcome due to the emergence of drug-resistant cells." | ( Hurwitz, HI; McGuire, WP, 1994) |
| "Ovarian cancer is a disease of the elderly." | ( Hamilton, TC; Johnson, SW; Ozols, RF, 1993) |
| "Ovarian cancer is the most fatal gynecologic cancer in the United States, and prostate cancer is the most prevalent form of cancer in men." | ( Fanning, J; Neal, CE; Swenson, LC; Texter, JH, 1993) |
| "Although ovarian cancer is the most common gynecological malignancy with a relatively poor 5-yr survival record, the mechanism(s) by which these tumors arise is not well understood." | ( Crowley, WF; Di Simone, N; Schneyer, AL; Sluss, PM; Wang, QF, 1996) |
| "Advanced stage ovarian cancer is the most lethal gynecologic cancer." | ( Fields, AL; Goldberg, GL; Runowicz, CD, 1995) |
| "Ovarian cancer is the most malignant cancer in women, where it is the fifth leading cause of cancer-related death." | ( Gillis, CR; McEwen, J; Montazeri, A, 1996) |
| "Ovarian cancer is one of the significant and deadly disease." | ( Kamura, T, 1996) |
| "Ovarian cancer is a highly heterogeneous neoplasm and the expression of markers of chemoresistance reflects this heterogeneity." | ( Brisson, J; Cherian, MG; Germain, I; Mondor, M; Têtu, B, 1996) |
| "Ovarian cancer is a highly invasive type of malignancy." | ( Höyhtyä, M; Hujanen, E; Puistola, U; Turpeenniemi-Hujanen, T; Westerlund, A, 1997) |
| "Ovarian cancer is a major clinical problem with no rewarding treatment protocol currently available." | ( Al-Hendy, A; Auersperg, N, 1997) |
| "Ovarian cancer is the second most common malignancy of the female reproductive tract." | ( Connor, JP; Ferrer, K; Ilekis, JV; Niederberger, C; Prins, GS; Scoccia, B, 1997) |
| "Ovarian cancer is the most common gynecologic malignancy cause of death in women." | ( Bohdiewicz, PJ, 1998) |
| "Epithelial ovarian cancer is a major cause of cancer-related mortality in women, making the search for new treatment modalities essential." | ( Abbruzzese, JL; Ferrandina, G; Freedman, RS; Loercher, A; Melichar, B; Verschraegen, CF, 1998) |
| "Ovarian cancer is the leading cause of death from gynecological malignancy and the fourth leading cause of cancer death among American women, yet little is known about its molecular aetiology." | ( Baldocchi, R; Collins, C; Godfrey, T; Gray, JW; Kuo, WL; Lu, Y; Mills, GB; Pinkel, D; Powell, B; Shayesteh, L, 1999) |
| "Ovarian cancer is the leading cause of death from gynecological malignancies and the fourth most frequent fatal malignancy in women." | ( Dent, SF; Klaassen, D; Pater, JL; Whitehead, M; Zee, B, 2000) |
| "Ovarian cancer is wellknown to be chemosensitive since more than thirty years." | ( Cholet, P; Cure, H; Dauplat, J, 2000) |
| "Ovarian cancer is the seventh most common cancer in women worldwide, after breast, cervix, colon/rectum, stomach, corpus uteri, and lung cancers." | ( Holmes, WF; Soprano, DR; Soprano, KJ; Wu, S; Zhang, D, 2000) |
| "Ongoing trials in ovarian cancer are examining the clinical utility of this approach as a second-line treatment option in carefully defined paclitaxel-resistant disease and as a consolidation strategy in high-risk, early stage disease following initial therapy with a carboplatin/paclitaxel combination regimen." | ( Markman, M, 2000) |
| "Ovarian cancer is a primary cancer against which these new agents are being tested." | ( Blanchette, JO; Brown, MR; Kohn, EC, 2000) |
| "Ovarian cancer is the most common gynaecological cancer with an annual incidence of 21." | ( Bagnall, AM; Duffy, S; Forbes, C; Shirran, L; ter Riet, G, 2001) |
| "(1) Most cases of ovarian cancer are diagnosed at an advanced stage (peritoneal extension beyond the pelvis or distant metastases)." | ( , 2002) |
| "Epithelial ovarian cancer is the most lethal of all gynecologic malignancies." | ( Hensley, ML, 2002) |
| "Ovarian cancer is one of the most aggressive gynecologic cancers." | ( Harper, P, 2002) |
| "Ovarian cancer is the fifth leading cause of cancer death in women." | ( Herzog, TJ, 2002) |
| "Ovarian cancer is characterized by rapid growth of solid intraperitoneal tumors and production of large volumes of ascites." | ( Ferrara, N; Hamilton, T; Hofmann, J; Hu, L; Jaffe, RB; Zaloudek, C, 2002) |
| "Although breast and ovarian cancers are rare in Japan compared with other developed countries, the death rates for both are increasing." | ( Ganmaa, D; Li, XM; Sato, A, 2003) |
| "Ovarian cancer is the leading cause of death among women from gynecological malignancies inthe United States." | ( Bao, R; Hamilton, TC; Pisarcik, DA; Selvakumaran, M; Yeung, AT, 2003) |
| "Epithelial ovarian cancer is moderate sensitivity to chemotherapy; the survival has been improved by aggressive cytoreductive surgery followed by combination chemotherapy with cisplatin-based regimen." | ( Huang, MN; Li, N; Liu, LY; Wang, GX; Wu, LY; Zhang, R, 2003) |
| "Ovarian cancer is a common gynecological malignancy and a leading cause of death in women." | ( Kim, JR; Kim, KK; Shim, JC, 2003) |
| "Ovarian cancer is currently the most lethal gynecological malignancy in the United States." | ( Duan, Z; Lamendola, DE; Seiden, MV; Yusuf, RZ, 2003) |
| "Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States." | ( Arbel, R; Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N, 2003) |
| "Ovarian cancer is the most prevalent gynecologic cancer in women." | ( Capri, S; Cattaneo, G, 2003) |
| "Advanced ovarian cancer is largely incurable, but initially it is frequently confined to the i." | ( Borchardt, PE; McDevitt, MR; Miederer, M; Scheinberg, DA; Yuan, RR, 2003) |
| "Epithelial ovarian cancer is the gynecological malignancy with the highest mortality." | ( D'Agostino, G; Ferrandina, G; Fruscella, E; Gallo, D; Scambia, G, 2003) |
| "Ovarian cancer is the fifth most frequent cause of death in women and, when related to the number of patients affected, the most common cause of death from gynecological malignancies." | ( Du Bois, A; Hilpert, F; Meier, W; Pfisterer, J; Wagner, U, 2003) |
| "Ovarian cancer is the leading cause of death due to gynecological malignancies among women." | ( Aranganathan, S; Nalini, N; Senthil, K, 2004) |
| "Ovarian cancer is the most frequent cause of death due to gynecologic malignancy in both the United States and in Europe." | ( Durand-Zaleski, I; Girre, V; Pujade-Lauraine, E, 2003) |
| "Epithelial ovarian cancer is the fifth most common visceral malignancy in U." | ( Elson, DL; Natarajan, M; Saravanan, SM, 2003) |
| "Ovarian cancer is the fifth leading cause of cancer death among women." | ( Almadrones, LA, 2003) |
| "Ovarian cancer is one of the most common cancers among women." | ( Flynn, DC; Gao, N; Jiang, BH; Liu, KJ; Shi, X; Walker, V; Zhang, Z; Zhong, XS, 2004) |
| "Ovarian cancer is the leading cause of death from gynecological malignancy and has the worst prognosis of all gynecological cancers." | ( Cao, Z; Chen, YC; Fang, J; Jiang, BH; Reed, E, 2004) |
| "Ovarian cancer is the leading cause of death among the gynecological malignancy mainly due to lacking of effective early diagnostic methods." | ( Kononen, J; Mihatsch, MJ; Moch, H; Sauter, G; Simon, R; Zheng, M, 2004) |
| "Ovarian cancer is currently the most lethal gynecologic malignancy in developed countries, and paclitaxel is a cornerstone in the treatment of this malignancy." | ( Brakora, KA; Duan, Z; Seiden, MV, 2004) |
| "OVERVIEW SUMMARY: Ovarian cancer is the most lethal of the gynecologic malignancies." | ( Bodurka, DC; Deavers, M; Gano, JB; Gershenson, DM; Levenback, C; Ramirez, PT; Ramondetta, L; Wolf, JK, 2004) |
| "Ovarian cancer is the most frequent cause of cancer death among all gynecologic cancers." | ( Hasuwa, H; Hirata, M; Kageyama, T; Kai, M; Kanoh, H; Mekada, E; Miyamoto, S; Mizushima, H; Nakano, H; Sonoda, K; Tanaka, Y; Yagi, H; Yamazaki, A, 2004) |
| "Ovarian cancer is the fifth leading cause of cancer deaths in women." | ( Ahmad, T; Gore, M, 2004) |
| "Human epithelial ovarian cancer is the most lethal female cancer." | ( Munir, S; Peng, C; Tsang, BK; Xu, G; Yang, BB; Zhong, Y, 2004) |
| "Animal models of ovarian cancer are crucial for understanding the pathogenesis of the disease and for testing new treatment strategies." | ( Babb, JS; Bao, R; Gruver, BN; Hamilton, TC; Klein-Szanto, A; Koutroukides, T; Ochman, AR; Patriotis, C; Pinnola, AD; Querec, TD; Stewart, SL; Wong, TS, 2004) |
| "Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response." | ( Herzog, TJ, 2004) |
| "Ovarian cancer is the fifth most common cause of cancer death among women and the leading cause of gynaecological cancer death in the United States." | ( Hashi, A; Hoshi, K; Qin, LQ; Sato, A; Wang, PY; Xu, JY, 2005) |
| "Human ovarian cancer is predominantly of epithelial cell origin (>90% of malignant tumors) and most often presents at an advanced stage with poor prognosis." | ( Conran, PB; Crist, KA; Gunning, WT; Lubet, RA; Steele, VE; You, M; Zhang, Z, 2005) |
| "Ovarian cancer is characterized by diffuse peritoneal carcinomatosis and often by large volumes of ascites." | ( Hashimoto, K; Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Tahara, M; Tasaka, K, 2005) |
| "Ovarian cancer is one of the most common causes of cancer death among women." | ( Cao, Z; Fang, J; Jiang, BH; Reed, E; Xia, C; Zheng, JZ, 2005) |
| "Ovarian cancer is the most lethal gynecological cancer affecting women." | ( Rodland, KD; Stouffer, RL; Wright, JW, 2005) |
| "Stage 1 ovarian cancer is curable in 95% of cases; however, due to inadequate screening tools and lack of symptoms in early disease, ovarian cancer is generally at Stage 3 or 4 when finally diagnosed." | ( Aouizerat, B; McLemore, MR, 2005) |
| "Ovarian cancer is the leading cause of death due to gynecological malignancies." | ( Aranganathan, S; Nalini, N; Senthil, K, 2005) |
| "Many patients with ovarian cancer are at high risk of recurrence especially in the 2 years following first-line therapy." | ( De Iaco, P; Erba, P; Fanti, S; Farsad, M; Mariani, G; Nanni, C; Rampin, L; Rubello, D; Sansovini, M, 2005) |
| "Recurrent ovarian cancer is refractory and resistant to treatment in most patients, and no effective treatment for it has been established." | ( Maeda, M; Ozawa, T; Takekuma, M; Torizuka, T; Yasumi, K, 2005) |
| "Ovarian cancer is characterized by i." | ( Hofmann, J; Holash, J; Hu, L; Jaffe, RB; Sood, AK; Yancopoulos, GD, 2005) |
| "Ovarian cancer is the most common cause of death from gynecologic malignancies in the United States." | ( McGuire, WP; Tummala, MK, 2005) |
| "Ovarian cancers are known to have the highest mortality rate among the gynaecological tumours." | ( Lehoczky, O, 2005) |
| "Ovarian cancer is a gynecological malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment." | ( Bratasz, A; Ignarro, LJ; Kuppusamy, P; Parinandi, NL; Sridhar, R; Weir, NM; Zweier, JL, 2006) |
| "Ovarian cancer is a deadly disease often diagnosed late in development when there is little chance for a successful recovery." | ( Giles, JR; Johnson, PA, 2006) |
| "Ovarian cancer is the leading cause of death among gynecological malignancies in the US and the poor outcome of current treatments necessitates the development of novel therapeutic strategies to fight against it." | ( Bai, W; Nicosia, SV; Zhang, X, 2006) |
| "Ovarian cancer is more fatal than all the other gynaecological malignancies combined." | ( Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A, 2006) |
| "Advanced ovarian cancers are initially responsive to chemotherapy with platinum drugs but develop drug resistance in most cases." | ( Calogero, R; Coltella, N; Crispi, S; Di Cunto, F; Di Renzo, MF; Olivero, M; Rasola, A; Ruggiero, T; Saviozzi, S, 2006) |
| "Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States." | ( Bhoola, S; Hoskins, WJ, 2006) |
| "Epithelial ovarian cancer is the fourth leading cause of cancer-related deaths in women and is the most lethal of the gynecological malignancies." | ( Alvero, AB; Fu, HH; Mor, G, 2006) |
| "Ovarian cancer is the most fatal gynecologic malignancy." | ( Dizon, DS; Granai, CO; Koelliker, S; Steinhoff, M; Tejada-Berges, T, 2006) |
| "Ovarian cancer is currently the second leading cause of gynecological malignancy and cisplatin or cisplatin-based regimens have been the standard of care for the treatment of advance epithelial ovarian cancers." | ( Huynh, H; Leong, CT; Ong, CK; Tay, SK, 2007) |
| "Ovarian cancer is one of the leading causes of mortality due to gynaecological cancer." | ( Baudin, B; Deslandes, E; Gauduchon, P; Hubert-Roux, M; Lange, C; Le Moguen, K; Lincet, H; Poulain, L, 2006) |
| "Ovarian cancer is resistant to the antiproliferative effects of transforming growth factor-beta (TGF-beta); however, the mechanism of this resistance remains unclear." | ( Birrer, MJ; Bonome, T; Brady, J; Donninger, H; Johnson, ME; Mok, SC; Pestell, RG; Rose, GS; Sunde, JS; Wu, K, 2006) |
| "Ovarian cancer is chemosensitive, but most patients with advanced disease die from tumor progression." | ( Berdel, WE; Frickhofen, N; Haas, R; Heimpel, H; Hinke, A; Hossfeld, DK; Kreienberg, R; Kuhn, W; Möbus, V; Opri, F; Sandherr, M; Schneeweiss, A; Thomssen, C, 2006) |
| "Ovarian cancer is currently the most lethal gynecologic malignancy in Europe and the US." | ( Breidenbach, M; Hille, S; Kurbacher, CM; Neumann, R; Pfützner, A; Rein, DT; Riffelmann, M; Sartorius, J; Schöndorf, T, 2006) |
| "Ovarian cancer is hormone-dependent, and epidemiological evidence links hyperthyroidism, inflammation of the ovarian surface, and increased risk of ovarian cancer." | ( Critchley, HO; Gubbay, O; Hillier, SG; Kostogiannou, A; Price, D; Rae, MT, 2007) |
| "Ovarian cancer is the sixth most common cancer among women worldwide, and mortality rates from this cancer are higher than for other gynecological cancers." | ( Bhat, RA; Krishna, CM; Kushtagi, P; Manfait, M; Pluot, M; Sockalingum, GD; Venteo, L, 2007) |
| "Ovarian cancer is a morphologically and biologically heterogeneous disease." | ( Cho, KR; Katabuchi, H; Lubman, DM; Sangha, N; Shedden, KA; Wu, R; Yoo, C; Zhu, Y, 2006) |
| "Ovarian cancer is the leading cause of gynecologic cancer deaths in the U." | ( Alberts, DS; Bookman, MA; Chen, T; Curtin, J; Eldermire, E; Hess, LM; Liebes, L; Markman, M; Muggia, F; Ozols, RF; Trimble, E; Young, RC, 2006) |
| "Ovarian cancer is the fourth most common cause of cancer deaths among females in the western world after cancer of the breast, colon and lung." | ( Boerman, OC; Corstens, FH; Dijkgraaf, I; Frielink, C; Kruijtzer, JA; Liskamp, RM; Oyen, WJ, 2007) |
| "Ovarian cancer is a highly metastatic disease." | ( Belinson, J; Berk, MP; Escobar, P; Kim, KS; Li, W; Lindner, DJ; Oates, R; Sengupta, S; Williams, B; Xu, Y, 2007) |
| "Advanced ovarian cancers are initially responsive to combinatorial chemotherapy with platinum drugs and taxanes but, in most cases, develop drug resistance." | ( Bardella, C; Coltella, N; Dettori, D; Di Renzo, MF; Mazzone, M; Olivero, M, 2007) |
| "Ovarian cancer is one of the leading causes of cancer death in women." | ( Jiang, T; Soprano, DR; Soprano, KJ, 2007) |
| "Ovarian cancer is the leading cause of gynecological cancer-related death in Western countries." | ( Chauffert, B; Combe, M; Delroeux, D; Guardiola, E; Heyd, B; Hoizey, G; Kantelip, JP; Montange, D; Pivot, X; Royer, B, 2008) |
| "Ovarian cancer is the leading cause of death in women with gynecological malignancies, with prognosis of advanced stage tumors determined by chemotherapeutic response and the success of tumor resection." | ( Baba, T; Fujii, S; Fukuda, MN; Higuchi, T; Kariya, M; Kondoh, E; Kuroda, H; Kusakari, T; Mandai, M; Matsumura, N; Mori, S; Murphy, SK; Takakura, K, 2007) |
| "Ovarian cancer is chemosensitive." | ( Kato, Y; Katsumata, N, 2007) |
| "Ovarian cancer is the primary cause of death from gynecological malignancies with a poor prognosis characterized by widespread peritoneal dissemination." | ( Pon, YL; Wong, AS; Zhou, HY, 2007) |
| "Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon." | ( Bengala, C; Champion, K; Frickhofen, N; Hinke, A; Kimmig, R; Ledermann, JA; Möbus, V; Ostermann, H; Wandt, H, 2007) |
| "Ovarian cancer is the leading cause of death from gynaecological malignancy, especially because of late diagnosis." | ( Deffieux, X; Faivre, E; Fernandez, H; Frydman, R; Morice, P; Touboul, C; Uzan, C, 2007) |
| "Ovarian cancer is the fourth most common cancer among women and existing treatment is not routinely curative." | ( Akiyama, M; Einfeld, DA; King, CR; Murugesan, SR; Wickham, TJ, 2007) |
| "Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate." | ( du Bois, A; Harter, P; Hilpert, F; Pfisterer, J, 2007) |
| "Ovarian cancer is one of the leading causes of mortality by gynecological cancer." | ( Baudin, B; Duval, M; Gauduchon, P; Heutte, N; Le Moguen, K; Lemoisson, E; Lincet, H; Marcelo, P; Poulain, L; Vinh, J, 2007) |
| "Ovarian cancer is the leading cause of death from gynecologic cancer." | ( Huynh, H; Soo, KC; Teo, CC, 2007) |
| "Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses." | ( Aslan, Y; Buyukberber, S; Camci, C; Kalender, ME; Sevinc, A, 2009) |
| "Ovarian cancer is the leading cause of death among all gynecological malignancies in Western countries." | ( Kumar, S; Liang, SL; Liu, H; Liu, W; Weyman, CM; Zhou, A, 2009) |
| "Ovarian cancer is one of the leading causes of death from gynecological cancers in the United States." | ( Choi, YS; Connolly, D; Hoory, T; Hung, CF; Monie, A; Wu, A, 2008) |
| "Ovarian cancer is the leading cause of gynaecological cancer mortality." | ( Cicchillitti, L; Del Boccio, P; Della Corte, A; Di Michele, M; Donati, MB; Ferlini, C; Rotilio, D; Scambia, G; Urbani, A, 2009) |
| "Ovarian cancer is the most lethal of all gynaecological cancers among women." | ( Dwek, RA; Rudd, PM; Saldova, R; Wormald, MR, 2008) |
| "Platinum resistant ovarian cancer is a current challenge in Oncology." | ( Alberola Candel, V; Esteban González, E; Gasent Blesa, JM; Martín Algarra, S; Provencio Pulla, M, 2009) |
| "Ovarian cancer is the fifth leading cause of cancer deaths in women." | ( Oskay-Ozcelik, G; Sehouli, J, 2009) |
| "Ovarian cancer is the leading cause of death from gynecological malignancies." | ( Donahue, RN; McLaughlin, PJ; Zagon, IS, 2009) |
| "Furthermore, ovarian cancer is often associated with tumor anemia." | ( Bruckner, T; Eichbaum, MH; Fersis, N; Gebauer, G; Kussmaul, J; Schneeweiss, A; Sinn, HP; Sohn, C; Weiss, LM, 2009) |
| "Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries." | ( Chauffert, B; Guardiola, E; Heyd, B; Jullien, V; Kantelip, JP; Pivot, X; Royer, B, 2009) |
| "Ovarian cancer is the leading cause of mortality from gynecological malignancies, often undetectable in early stages." | ( Batchu, RB; Bryant, CS; Chamala, S; Kumar, S; Malone, JM; Morris, R; Pal, J; Prasad, M; Qazi, A; Seward, S; Shammas, MA; Steffes, CP; Weaver, DW, 2009) |
| "Ovarian cancer is the fourth most common cause of cancer deaths in the UK." | ( Kehoe, S; Morrison, J, 2009) |
| "Ovarian cancer is a leading cause of death among gynecological malignancies." | ( Cho, H; Choi, JS; Kang, ES; Kim, JH; Lim, BJ, 2009) |
| "Ovarian cancer is the most lethal gynecologic malignancy, often diagnosed at advanced stage leading to poor prognosis." | ( Kalchenko, V; Kohen, F; Meir, G; Migalovich, HS; Neeman, M; Nevo, N, 2009) |
| "Ovarian cancer is today the most lethal female cancer with an overall survival of only 49." | ( Sivanesaratnam, V, 2009) |
| "Epithelial ovarian cancer is diagnosed in 4500 women in the UK each year of whom 1700 will ultimately die of their disease." | ( Dickinson, HO; Kitchener, HC; Winter-Roach, BA, 2009) |
| "Epithelial ovarian cancer is the leading cause of gynecological cancer mortality." | ( Cicchillitti, L; Di Michele, M; Donat, MB; Ferlini, C; Rotilio, D; Scambia, G; Urbani, A, 2009) |
| "Epithelial ovarian cancer is the sixth most common cancer in women worldwide and the most important cause of death from gynaecological cancers in the Western world." | ( Berns, EM; Burger, C; Helleman, J; Jansen, MP; van der Burg, ME, 2010) |
| "Ovarian cancer is a highly metastatic disease and the leading cause of death from gynecologic malignancy." | ( Collinet, P; Fournier, I; Lucot, JP; Merlot, B; Salzet, M; Vergara, D; Vinatier, D, 2010) |
| "Ovarian cancer is the sixth cause of cancer-related death in Western countries." | ( Cicchillitti, L; Della Corte, A; Di Michele, M; Donati, MB; Ferlini, C; Marcone, S; Rotilio, D; Scambia, G, 2010) |
| "Ovarian cancer is known to be highly invasive." | ( Hashimoto, K; Kawase, C; Kimura, T; Mabuchi, S; Morishige, K; Ogata, S; Ooyagi, C; Sakata, M; Sawada, K, 2009) |
| "Most patients with ovarian cancer are candidates for second-line or salvage treatments often for prolonged periods." | ( Daniele, A; Ferrero, A; Fuso, L; Logrippo, V; Perotto, S; Spanu, PG; Zola, P, 2009) |
| "Epithelial ovarian cancer is the leading cause of death for gynecological cancer in most of the Western world; lethality ensues from the occurrence of occult metastasis within the peritoneal cavity, a process requiring the acquisition of capacity for migration and invasiveness by ovarian tumor cells (metastatic phenotype), and characterized by a complex series of interrelated cellular events." | ( Ferlini, C; Gallo, D; Scambia, G, 2010) |
| "Epithelial ovarian cancer is thought to be derived from the ovarian surface epithelium (OSE) but often goes undetected in the early stages, and as a result, the factors that contribute to its initiation and progression remain poorly understood." | ( Courville, K; Crane, CA; Garson, K; Laviolette, LA; Macdonald, EA; Senterman, MK; Vanderhyden, BC, 2010) |
| "Ovarian cancer is the most lethal gynecologic cancer mainly because of widespread peritoneal dissemination and malignant ascites." | ( Tang, MK; Wong, AS; Yam, JW; Zhou, HY, 2010) |
| "Ovarian cancer is a leading cause of cancer mortality in women." | ( Birrer, MJ; Bonome, T; Clauss, A; Drapkin, R; Hirsch, MS; Ligon, AH; Liu, J; Matulonis, U; Ng, V; Piao, H; Russo, M; Sheng, Q; Vena, N, 2010) |
| "Ovarian cancer is associated with high mortality due to its late onset of symptoms and lack of reliable screening methods for early detection." | ( Barton, JK; Craig, ZR; Davis, JR; Hoyer, PB; Marion, SL, 2010) |
| "Most of the ovarian cancers are environmental in origin and consequently, at least in principle avoidable." | ( Mathew, A; Murthy, NS; Pruthvish, S; Shalini, S; Suman, G, 2009) |
| "Ovarian cancer is known as the silent killer for being asymptomatic until late stages." | ( Allen, CJ; De Souza, R; Moriyama, EH; Piquette-Miller, M; Wilson, BC; Zahedi, P, 2010) |
| "Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world-wide." | ( Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Martinek, I; Morrison, J; Nicum, S, 2010) |
| "Ovarian cancer is tumour with high mortality." | ( Bienertová-Vasků, J; Chovanec, J; Dostálová, Z; Minár, L, 2009) |
| "Ovarian cancer is a lethal gynecologic malignancy that may benefit from new therapies that block key paracrine pathways involved in tumor-stromal interactions and tumor vascularity." | ( Agarwal, A; Balla, M; Covic, L; Kaimal, R; Kuliopulos, A; Lam, FH; Tressel, SL, 2010) |
| "Ovarian cancer is one of the most lethal types of female malignancy." | ( Balgley, BM; Davidson, B; Fang, X; Guo, T; Jinawath, A; Jinawath, N; Lee, CS; Shih, IeM; Vasoontara, C; Wang, TL; Wang, W; Yap, KL; Zhao, K, 2010) |
| "Ovarian cancer is the second most frequently diagnosed malignancy of the reproductive system and is the leading cause of gynecological cancer mortality." | ( Cicchillitti, L; Della Corte, A; Di Michele, M; Donati, MB; Rotilio, D; Scambia, G, 2010) |
| "Once breast or ovarian cancer is diagnosed, indications for (18)F-FDG-PET or PET-CT imaging are similar for high-risk patients and patients with sporadic cancer." | ( Even-Sapir, E; Inbar, M, 2010) |
| "Ovarian cancer is primarily treated with platinum-based chemotherapy, with ROS generation implicated in cytotoxicity." | ( Al-Attar, A; Chan, SY; Deen, S; Martin, SG; Shehata, M; Woolston, CM, 2010) |
| "Ovarian cancer is the leading cause of death among women with gynecologic malignancies in the United States." | ( Hoory, T; Hsueh, WT; Hung, CF; Kim, D; Monie, A; Pai, SI; Wu, A, 2010) |
| "Ovarian cancer is the most fatal gynecologic malignancies in the world." | ( Atmaca, H; Cakar, B; Karabulut, B; Karaca, B; Kisim, A; Muslu, U; Uslu, R; Uzunoglu, S; Varol, U, 2010) |
| "Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with approximately 15,000 deaths per year." | ( Liu, J; Matulonis, UA, 2010) |
| "Epithelial ovarian cancer is one of the most malignant cancers in women because metastasis occurs in the most of patients by the time of diagnosis." | ( Chen, M; Ning, Y; Xu, C; Yao, L; Zhu, P, 2010) |
| "Ovarian cancer is a gynecological malignancy with the highest mortality." | ( An, HJ; Chung, K; Huh, JH; Jung, SG; Kang, H; Kim, TH; Ko, JJ; Lee, DH; Song, JA, 2010) |
| "Ovarian cancer is of worldwide importance, and has a significantly high mortality rate due to therapy failure." | ( Chang, CC; Chao, KC; Wang, PH; Yen, MS, 2010) |
| "However, epithelial ovarian cancer is refractory to the inhibitory functions of TGF-β, and yet TGF-β induces metastasis or epithelial-mesenchymal transition (EMT) in advanced ovarian cancer." | ( Chan, MW; Chen, LY; Chou, JL; Lai, HC, 2010) |
| "Treatment of ovarian cancer is still challenging especially in recurrent platinum refractory cases." | ( Bauerschlag, DO; Egberts, JH; Jonat, W; Kalthoff, H; Maass, N; Meinhold-Heerlein, I; Schem, C; Tiwari, S; Weigel, MT, 2010) |
| "Ovarian cancer is a highly metastatic and lethal disease, making it imperative to find treatments that target late-stage malignant tumors." | ( Guo, P; Ho, SM; Shu, Y; Tarapore, P, 2011) |
| "Ovarian cancer is mainly confined in peritoneal cavity and its metastasis is often associated with the formation of malignant ascites." | ( Chen, H; Huang, S; Pan, ZK; Wu, X, 2010) |
| "Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies." | ( Baba, T; Berchuck, A; Fujii, S; Huang, Z; Iversen, ES; Konishi, I; Matsumura, N; Mori, S; Murphy, SK, 2011) |
| "Ovarian cancer is often diagnosed in women after menopause when the levels of the serum gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are increased because of the depletion of growing follicles within the ovary." | ( Devine, PJ; Ethier, JF; Laviolette, LA; Senterman, MK; Vanderhyden, BC, 2011) |
| "Ovarian cancer is a leading cause of cancer death for Kenyan women." | ( Busakhala, N; Nyangena, J; Orango, E; Rosen, B; Sterling, L; Strother, M; van Lonkhuijzen, L, 2011) |
| "Undoubtedly ovarian cancer is a vexing, incurable disease for patients with recurrent cancer and therapeutic options are limited." | ( Bhattacharya, R; Bhattacharyya, S; Jennings, NB; Lopez-Berestein, G; Mukherjee, P; Rodriguez-Aguayo, C; Sood, AK; Szabolcs, A; Wang, E, 2011) |
| "Epithelial ovarian cancer is an aggressive and deadly disease and understanding its invasion mechanisms is critical for its treatment." | ( Cukierman, E; Godwin, AK; Kwon, Y, 2011) |
| "Ovarian cancer is the most lethal gynecologic cancer in women." | ( Giri, S; Graham, RP; Maguire, JL; Rattan, R; Shridhar, V, 2011) |
| "Ovarian cancer is the second most common gynecological cancer, representing 5% of all cancers in women." | ( Poveda, A, 2011) |
| "Ovarian cancer is the leading cause of death from gynecologic cancers in the United States." | ( Goldberg, GL; Pellicciotta, I; Shahabi, S; Yang, CP, 2011) |
| "Recurrent ovarian cancer is resistant to conventional chemotherapy." | ( Alvero, AB; Chefetz, I; Holmberg, JC; Mor, G; Visintin, I, 2011) |
| "Ovarian cancer is the leading cause of death from gynecological malignancies." | ( Donahue, RN; McLaughlin, PJ; Zagon, IS, 2011) |
| "Bone involvement in ovarian cancer is relatively rare and even rarer in the sternum." | ( Ho, L; Kaushik, A; Wassef, H; Zhang, W, 2011) |
| "Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes." | ( Birrer, MJ; Bowtell, D; Ellard, SL; Gilks, CB; Gout, PW; Huntsman, DG; Kagami, T; Lopez-Berestein, G; McAlpine, JN; Miller, DM; Mok, SC; Ozbun, L; Sood, AK; Stany, MP; Stone, RL; Vathipadiekal, V; Vivas-Mejia, P; Wang, Y; Wang, YZ; Xue, H, 2011) |
| "Epithelial ovarian cancer is a deadly insidious disease because it typically remains asymptomatic until it has metastasized to vital abdominal organs." | ( Murdoch, WJ; Murphy, CJ; Shen, Y; Van Kirk, EA, 2010) |
| "Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis." | ( Brard, L; Brodsky, AS; Fischer, A; Hillenmeyer, S; Kim, KK; Miller, DH; Raphael, BJ; Ritz, A; Singh, RK; Stuckey, A, 2011) |
| "Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge." | ( Coleman, RL; Naumann, RW, 2011) |
| "Ovarian cancer is the most lethal gynecological malignancy affecting American women." | ( Burdette, JE; Fazleabas, AT; Hilliard, TS; Jaffe, RC; King, SM; Wu, LY, 2011) |
| "Late stage Ovarian Cancer is essentially incurable primarily due to late diagnosis and its inherent heterogeneity." | ( Joshi, S; Khatri, A; Nair, S; Russell, PJ; Singh, PP, 2011) |
| "Ovarian cancer is the number one cause of death from gynecologic malignancy." | ( Cao, K; Deng, HX; Li, J; Li, L; Lin, C; Liu, HY; Liu, L; Nie, CL; Wei, YQ; Yuan, Z; Zhao, XY, 2011) |
| "Ovarian cancer is the most lethal gynecological malignancy among US women." | ( Burdette, JE; Gaisin, AM; Gaisina, IN; Gallier, F; Hilliard, TS; Muehlbauer, AG, 2011) |
| "Ovarian cancer is a leading cause of death due to neoplasm of the female genital tract." | ( Chou, LC; Chung, JG; Huang, CH; Huang, LJ; Hung, MC; Kuo, SC; Lee, JC; Lee, KH; Way, TD, 2011) |
| "Epithelial ovarian cancer is the leading cause of cancer death from gynecological malignancies." | ( Grabiec, M; Sadłecki, P; Szymański, W; Walentowicz-Sadłecka, M, 2011) |
| "Ovarian cancer is a leading cause of cancer death among women in the United States and it has the highest mortality rate of all gynecologic cancers." | ( Aschebrook-Kilfoy, B; Cross, AJ; Gierach, GL; Hollenbeck, AR; Schatzkin, A; Sinha, R; Ward, MH, 2012) |
| "Ten percent of ovarian cancer is attributed to hereditary syndromes, most commonly to mutations in the BRCA1 or BRCA2 genes." | ( Adams, SF; Bradbury, AR; Daly, M; Elmasri, W; Halberstadt, S; Karlan, B; Marsh, EB; Rubin, SC; Sammel, MD; Vandecker, S, 2011) |
| "Ovarian cancer is the seventh most common cause of cancer death in women world-wide." | ( Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Morrison, J; Nicum, S, 2011) |
| "Ovarian cancer is the leading cause of death from gynecological cancer." | ( Baldassare, J; Bastow, M; Klein, C; Kriedt, CL; Shah, M, 2011) |
| "Ovarian cancer is the fifth most frequent cause of cancer death in women." | ( Allouche, S; Gauduchon, P; Guével, B; Lemoisson, E; Lincet, H; Pineau, C; Poulain, L, 2012) |
| "Ovarian cancer is the leading cause of reproductive cancer death in U." | ( Buckles, EL; Johnson, PA; Treviño, LS, 2012) |
| "Ovarian cancer is one of the three gynecologic cancers, and its mortality is the highest one of them." | ( Cao, R; Chen, J; Dou, A; Lu, X; Wang, Y; Xu, C; Xu, G; Zhao, S, 2011) |
| "Ovarian cancer is the most lethal gynecologic malignancy." | ( Enomoto, T; Kim, A; Naka, T; Ueda, Y, 2012) |
| "Ovarian cancer is the most lethal gynecologic cancer." | ( Alvarez, RD; Landen, CN; Ziebarth, AJ, 2012) |
| "AGR3 expression in ovarian cancer is independent of oestrogen-receptor expression, which is distinct from the oestrogen-receptor dependent expression of AGR3 in breast cancers." | ( Bouchalova, P; Gourley, C; Gray, TA; Hayward, L; Howie, J; Hrstka, R; Hupp, TR; Langdon, S; MacLaine, NJ; Maslon, MM; Michie, CO; Murray, E; Nenutil, R; Vojtesek, B, 2012) |
| "Ovarian cancer is among the deadliest in women." | ( Ascencio, M; Collinet, P; Guyon, L; Mordon, S, 2012) |
| "Ovarian cancer is the most lethal gynecologic malignancy in women." | ( Kim, JH; Park, S; Seo, JM, 2012) |
| "Epithelial ovarian cancer is diagnosed in 4500 women in the UK each year of whom 1700 will ultimately die of their disease." | ( Kitchener, HC; Lawrie, TA; Winter-Roach, BA, 2012) |
| "Ovarian cancer is routinely treated with surgery and platinum-based chemotherapy." | ( Abdel-Fatah, T; Chan, SY; Deen, S; Martin, SG; Safuan, S; Storr, SJ; Woolston, CM, 2012) |
| "Ovarian cancer is the most lethal gynecological cancer." | ( Bell, JK; Dumur, CI; Fang, X; Harikumar, KB; Lépine, S; Marion, JD; Roberts, CF; Schreiter, J; Spiegel, S; Van, DN, 2012) |
| "Ovarian cancer is the most common cause of death from gynecologic malignancy." | ( Cao, K; Deng, HX; Li, J; Li, L; Lin, C; Liu, HY; Liu, L; Liu, XY; Nie, CL; Tong, AP; Wan, Y; Wei, YQ; Yuan, Z; Zhao, XY, 2012) |
| "Ovarian cancer is the most lethal gynecological cancer in women in the western world with a 5-year survival of 49." | ( Boere, IA; van der Burg, ME, 2012) |
| "Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum- and taxane-based chemotherapy." | ( Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L, 2012) |
| "Advanced ovarian cancer is treated with cytoreductive surgery and combination platinum- and taxane-based chemotherapy." | ( Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Telleria, CM, 2012) |
| "Most ovarian cancers are estrogen-positive and hormonal treatments using anti-estrogens or aromatase inhibitors are under investigation for treating the tumors that are resistant to conventional therapies." | ( Badia, E; Balaguer, P; Busson, M; Cavailles, V; Docquier, A; Lapierre, M; Pujol, P, 2012) |
| "Ovarian cancer is a debilitating disease, which needs multi-pronged approach of targeted drug delivery and enhanced efficacy with the use of combination therapeutics." | ( Amiji, M; Denny, WA; Ganta, S; Garg, S; Kendall, J; Singh, A; Talekar, M, 2012) |
| "Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US." | ( Akalkotkar, A; Chablani, L; Chiriva-Internati, M; D'Souza, C; D'Souza, MJ; Selvaraj, P; Tawde, SA, 2012) |
| "Ovarian cancer is the most important cause of gynecological cancer-related mortality." | ( Bellati, F; Benedetti Panici, P; Boni, T; Gasparri, ML; Imperiale, L; Marchetti, C; Palaia, I; Pignata, S, 2012) |
| "Ovarian cancer is the leading cause of death from all gynecological cancers and conventional therapies such as surgery, chemotherapy, and radiotherapy usually fail to control advanced stages of the disease." | ( Chiang, AJ; Hung, CF; Kang, TH; Pomper, MG; Roden, RR; Tsai, HH; Wu, TC, 2012) |
| "Ovarian cancer is the most lethal gynaecological cancer." | ( Auranen, A; Bützow, R; Hietanen, S; Komulainen, M; Kuoppala, T; Leminen, A; Mäenpää, J; Puistola, U; Vuento, M; Vuorela, P; Yliskoski, M, 2012) |
| "Ovarian cancer is one of the leading causes of cancer death for women throughout the Western world." | ( Chen, YC; Jiang, B; Jiang, BH; Li, B; Li, Z; Luo, H, 2012) |
| "Ovarian cancer is a highly angiogenic tumor and a model for antiangiogenic research." | ( Berlin, S; Campos, SM; Horowitz, NS; Matulonis, U; Penson, RT; Pereira, L; Roche, M; Szymonifka, J; Tyburski, K; Whalen, C, 2013) |
| "Ovarian cancer is an important health concern worldwide." | ( Collinson, FJ; Perren, TJ; Seligmann, J, 2012) |
| "Ovarian cancer is the leading cause of cancer related deaths in women." | ( Gupta, P; Kandala, PK; Loganathan, S; Srivastava, SK, 2012) |
| "Ovarian cancer is frequently advanced at presentation when treatment is rarely curative." | ( Ferguson, MJ; Gourley, C; Herrington, CS; Ng, MT; Shepherd, L; Smith, G; Wolf, CR, 2012) |
| "Ovarian cancer is one of the most lethal malignancies in women, as it is frequently detected at an advanced stage, and cancers often become refractory to chemotherapy." | ( Arfuso, F; Dharmarajan, A; Saran, U; Zeps, N, 2012) |
| "Epithelial ovarian cancer is the most lethal gynecological malignancy in the Western world." | ( Berns, EM; Boersma, AW; Despierre, E; Helleman, J; Mathijssen, RH; Pothof, J; van Ijcken, WF; van Jaarsveld, MT; van Kuijk, PF; Vergote, I; Verweij, J; Wiemer, EA, 2013) |
| "Advanced ovarian cancer is characterized by peritoneal metastasis and the accumulation of ascites." | ( Kaneda, N; Konishi, H; Kurita, A; Matsuzaki, T; Takagi, A, 2012) |
| "Ovarian cancer is the most lethal gynecological malignancy and mainly occurs in older women." | ( Bahr, JM; Eilati, E; Hales, DB; Pan, L, 2012) |
| "Ovarian cancer is the fifth leading cause of cancer-related deaths among American women." | ( Bowman, BM; Cho, KR; Galbán, CJ; Galbán, S; Rehemtulla, A; Ross, BD; Vetter, K; Wang, H; Witte, A; Wu, R, 2013) |
| "Ovarian cancer is the number one killer among all the gynecological cancers." | ( Bhattacharya, C; Bhattacharya, N; Khanra, K; Mitra, AK; Panda, K; Sarkar, R, 2012) |
| "Ovarian cancer is the leading gynecologic malignancy with more than 22,000 new cases and 15,000 deaths estimated each year." | ( Kandala, PK; Srivastava, SK, 2012) |
| "Ovarian cancer is the leading cause of death from gynecological malignancies worldwide." | ( Gauduchon, P; Lheureux, S; Malzert-Fréon, A; Rault, S; Tomasina, J, 2013) |
| "Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance." | ( Cho, H; Kwon, GS; Lai, TC, 2013) |
| "Ovarian cancer is responsible for the largest proportion of deaths among patients with gynecologic cancer." | ( Blake, MA; Cronin, CG; McDermott, S; O'Connor, OJ; Prakash, P, 2013) |
| "Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system." | ( Chandran, S; Chennazhi, K; Lakshmanan, VK; Nair, SV; Pavithran, K; Praveen, G; Snima, KS, 2013) |
| "Ovarian cancer is the deadliest gynecological malignancy due to detection of cancer at a late stage when the disease has metastasized." | ( Burdette, JE; King, SM; Quartuccio, SM; Vanderhyden, BC, 2013) |
| "Epithelial ovarian cancer is the leading cause of death from gynaecologic cancers in the Western world." | ( Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L, 2013) |
| "Ovarian cancer is the leading cause of death from gynecological cancer." | ( Blanc-Fournier, C; Briand, M; Brotin, E; Dutoit, S; Giffard, F; Lheureux, S; Loussouarn, C; N'Diaye, M; Poulain, L; Simonin, K, 2013) |
| "Ovarian cancer is associated with systemic coagulation activation." | ( Amirkhosravi, A; Bigsby, G; Coll, E; Desai, H; Faust, P; Francis, JL; Langer, F; Meyer, T; Reyes, E; Rivera-Amaya, M; Robles-Carrillo, L; Waters, A, 2013) |
| "Most patients with ovarian cancer are diagnosed late in progression and often experience tumor recurrence and relapses due to drug resistance." | ( Agarwal, A; Aljumaily, R; Covic, L; Kaimal, R; Kim, YB; Kuliopulos, A; Pradhan, RV; Sharifi, S; Tressel, SL; Zarwan, C, 2013) |
| "Ovarian cancer is one human malignancy which has response portly to doxorubicin." | ( Wang, J; Yuan, Z, 2013) |
| "Ovarian cancer is a highly lethal disease among all gynecologic malignancies and is the fifth leading cause of cancer-related death in women." | ( Ngai, S; Wang, C; Zhan, Q, 2013) |
| "Ovarian cancer is a leading cause of cancer death in women in the United States." | ( Bauckman, KA; Flores, I; Haller, E; Nanjundan, M, 2013) |
| "Ovarian cancer is the leading cause of death from gynecologic malignancies in the United States." | ( Couch, J; Fleury, AC; Hill, MC; Kushnir, CL; Spirtos, NM, 2013) |
| "Ovarian cancer is the leading cause of gynecologic cancer deaths among women." | ( Chen, G; Chen, L; Feng, J; Gao, Q; Han, Z; Hong, Z; Ji, T; Li, W; Liao, S; Ma, D; Wang, S; Wang, X, 2013) |
| "Ovarian cancers are highly heterogeneous and while chemotherapy is the preferred treatment many patients are intrinsically resistant or quickly develop resistance." | ( Banerjee, N; Cutter, N; Dimitrova, N; Kamalakaran, S; Khan, S; Levine, DA; Lucito, R; Lum, E; Vigliotti, M; Wrzeszczynski, KO, 2013) |
| "Epithelial ovarian cancer is the most lethal gynecologic malignancy; it is highly aggressive and causes almost 125,000 deaths yearly." | ( Alder, H; Baldassarre, G; Belletti, B; Califano, D; Canzonieri, V; Chiappetta, G; Cirombella, R; Croce, CM; Giglio, S; Losito, S; Lovat, F; Onesti, EC; Pellegrini, P; Pignata, S; Sonego, M; Sorio, R; Stoppacciaro, A; Vecchione, A; Volinia, S; Wernicke, D, 2013) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Bahr, JM; Eilati, E; Hales, DB, 2013) |
| "Ovarian cancer is one of the most lethal female malignancies and epigenetic abnormalities are thought to play a vital role in the pathogenesis, development and progression of ovarian cancer." | ( Brewer, MA; Meng, F; Sun, G; Yu, Y; Zhong, M, 2013) |
| "Ovarian Cancer is the leading cause of death from gynecological malignancy." | ( Browne, A; Curry, E; El-Bahrawy, M; Gabra, H; Guney, T; Rama, N; Sriraksa, R; Stronach, E; Van Noorden, S, 2013) |
| "Ovarian cancer is the leading cause of mortality from gynecological malignancy despite advancements in novel therapeutics." | ( Berkowitz, RS; Crum, C; Gali, R; He, H; Liu, S; May, T; Ng, SK; Ng, SW; Shoni, M; Yang, J, 2013) |
| "Ovarian cancer is commonly treated with cisplatin/paclitaxel but many tumors become resistant." | ( Muldoon, LL; Neuwelt, AJ; Neuwelt, EA; Wu, YJ, 2013) |
| "Ovarian cancer is the leading cause of morbidity/mortality from gynecologic malignancy." | ( Chen, J; Clarke, B; Liu, TW; Macdonald, TD; Neel, BG; Shi, J; Stewart, JM; Wilson, BC; Zheng, G, 2013) |
| "Epithelial ovarian cancer is a major cause of mortality among women with gynecological malignancies." | ( Chen, Y; Du, F; Han, X; Hua, D; Jiang, L; Jin, J; Liu, Y; Ma, X; Mao, Y; Qi, X; Wang, T; Wu, X; Zhu, R; Zhu, Y, 2013) |
| "Ovarian cancer is the fifth-leading cause of cancer-related deaths among women as a result of late diagnosis." | ( Chung, HH; Jeong, MS; Kang, KW; Kim, JH; Kim, JS; Song, MR, 2013) |
| "Ovarian cancer is a difficult-to-treat cancer with a 5-year survival rate of only ∼45%, due to late diagnosis and therapy resistance." | ( de Groote, ML; Faas, MM; Huisman, C; Kazemier, HG; Rots, MG; van der Gun, BT, 2014) |
| "Ovarian cancer is the eighth most common cancer in women and it is usually diagnosed at an advanced stage." | ( Bryant, A; Cameron, A; Gray, E; Lawrie, TA; Morrison, J, 2013) |
| "Ovarian cancer is the most lethal gynaecologic cancer affecting women." | ( Duffy, MJ; Elia, G; Rudd, PM; Saldova, R; Struwe, WB; Wynne, K, 2013) |
| "Ovarian cancer is a prevalent gynecological malignancy with potent immune-suppression capabilities; regulatory T cells (Tregs) are significant contributors to this immune-suppression." | ( Flanagan, K; Govindaraj, C; Hallo, J; Madondo, M; Plebanski, M; Quinn, M; Scalzo-Inguanti, K, 2013) |
| "Prevention of ovarian cancer is the best approach for reducing the impact of this deadly disease." | ( Ansenberger Fricano, K; Eilati, E; Hales, DB; Hales, K; van Breemen, RB; Yu, R; Zhuge, Y, 2013) |
| "Ovarian cancer is the fifth leading cause of cancer-related mortalities for women in the United States and the most lethal gynecological cancer." | ( Alley, WR; Goetz, JA; Jacobson, SC; Mitra, I; Novotny, MV; Vasseur, JA, 2013) |
| "Ovarian cancer is the major cause of death from gynaecological malignancy with a 5year survival of only ∼30% due to resistance to platinum and paclitaxel-based first line therapy." | ( Barber, F; Bowtell, DD; Cameron, D; Chan, J; Christensen, JG; Cullinane, C; Ellul, J; Foo, J; Hannan, KM; Hannan, RD; Hicks, RJ; Johnstone, RW; Kinross, KM; Kleinschmidt, M; McArthur, GA; Neilsen, A; Ng, P; Pearson, RB; Phillips, WA; Sheppard, KE; Wall, M, 2013) |
| "Ovarian cancer is the most lethal gynaecological cancer and is often diagnosed in late stage, often as the result of the unavailability of sufficiently sensitive biomarkers for early detection, tumour progression and tumour-associated inflammation." | ( Berghmans, N; Galligan, MC; Harvey, DJ; Madden, SF; Opdenakker, G; Peracaula, R; Pérez-Garay, M; Piccard, H; Rudd, PM; Saldova, R; Struwe, WB, 2013) |
| "Ovarian cancer is known to display a particular association with venous thromboembolism (VTE) with reports up to 42% of patients developing thromboembolic complications." | ( Abu Saadeh, F; Gleeson, N; Langhe, R; Mohamed, BM; Norris, L; O'Leary, J; O'Toole, S, 2013) |
| "TF expression in ovarian cancer is significantly higher in patients who develop VTE." | ( Abu Saadeh, F; Gleeson, N; Langhe, R; Mohamed, BM; Norris, L; O'Leary, J; O'Toole, S, 2013) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Eilati, E; Hales, DB; Kurrey, NK; McGee, SR; Small, CC, 2013) |
| "Ovarian cancer is the leading cause of gynecological cancer deaths worldwide." | ( Colombo, N, 2013) |
| "Epithelial ovarian cancer is one of the most malignant cancers in women and resistant to chemotherapy is the major obstacle for the five-year survival rate." | ( Chen, M; Chen, S; Liang, J; Ning, Y; Wang, L; Xu, C; Yao, L; Zhang, H; Zhu, P, 2013) |
| "Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths." | ( Basal, E; Bhattacharya, R; Bhattacharyya, S; Cliby, W; Giri, K; Jennings, NB; Lanza, IR; Lopez-Berestein, G; Mukherjee, P; Nair, KS; Rodriguez-Aguayo, C; Saha, S; Sood, AK; Visscher, DW; Weaver, AL, 2013) |
| "Ovarian cancer is characterized by high rates of metastasis and therapeutic resistance." | ( Singh, G; Verschoor, ML, 2013) |
| "Ovarian cancer is a lethal gynecological malignancy largely due to the lack of biomarkers for early detection and treatment options." | ( Cao, X; Chen, X; Liu, M; Tao, G; Xie, W; Zhou, F, 2014) |
| "Ovarian cancer is the fourth most common cause of cancer deaths among women, and chronic alcoholism may exert co-carcinogenic effects." | ( Chuffa, LG; Fávaro, WJ; Fioruci-Fontanelli, BA; Martinez, FE; Martinez, M; Mendes, LO; Pinheiro, PF, 2013) |
| "Ovarian cancer is a cancerous growth arising from the ovary and with poor prognosis that usually have resistant to all currently available treatments." | ( Back, MK; Chang, HW; Cho, SH; Han, SB; Hong, JT; Jeong, HS; Kim, JH; Lee, HP; Park, MH; Sung, HC, 2014) |
| "Ovarian cancer is the deadliest of gynecologic cancers, largely due to the development of drug resistance in chemotherapy." | ( Guo, Y; Ma, JX; Mueller, MD; Remick, SC; Yan, BX; Yu, JJ; Zhang, J, 2014) |
| "Advanced ovarian cancer is a devastating disease." | ( Gui, L; Shi, J; Wang, X; Xu, G; Zhang, J; Zhang, Y, 2014) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Bugno, J; Burdette, JE; Hong, S; Lantvit, DD; Modi, DA; Sunoqrot, S, 2014) |
| "Ovarian cancer is the most lethal gynecologic disease due to delayed diagnosis, and ascites production is a characteristic of patients in advanced stages." | ( Cantú de León, D; Encarnación-Guevara, S; Gallardo-Rincón, D; Garibay-Cerdenares, OL; Hernández-Ortíz, M; Hernández-Ramírez, VI; Osorio-Trujillo, JC; Talamás-Rohana, P; Villegas-Pineda, JC, 2014) |
| "Ovarian cancer is the most lethal gynecological disease affecting women in the US." | ( Ahmed, RA; Burdette, JE; Cheng, W; King, SM; Ó hAinmhire, E; Quartuccio, SM, 2014) |
| "Ovarian cancer is the leading cause of death in women worldwide." | ( Hu, CF; Liu, M; Xu, NZ; Xu, Q; Zhang, X; Zhu, HX, 2014) |
| "Ovarian cancer is the leading cause of death among gynecological tumors." | ( Botta, C; Caraglia, M; Ciliberto, D; Fiorillo, L; Grimaldi, A; Lama, S; Salvino, A; Staropoli, N; Tagliaferri, P; Tassone, P, 2014) |
| "Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy." | ( Chan, DW; Liu, MX; Liu, SS; Ngan, HY; Siu, MK; Yam, JW, 2014) |
| "Ovarian cancer is the leading cause of death among women with gynecological malignancies." | ( He, C; Lin, W; Liu, D; Lu, K, 2014) |
| "Ovarian cancer is the deadliest of the gynecologic malignancies." | ( Anchoori, R; Bazzaro, M; Coughlin, K; Iizuka, Y; Lee, MK; MacNeill, L; Meints, J; Orlowski, RZ; Roden, RB; Vogel, RI, 2014) |
| "Ovarian cancer is associated with a leukocyte infiltrate and high levels of chemokines such as CCL2." | ( Brozovic, A; Chaturvedi, S; Doshi, P; Duran, GE; Francisco, EB; Moisan, F; Seetharam, S; Sikic, BI; Snyder, LA; Wang, YC, 2014) |
| "Ovarian cancer is the leading cause of death in gynecologic malignancies." | ( Fan, L; Ge, T; Guo, B; Hou, Y; Ke, C; Li, K; Lou, G; Wang, J; Yang, K; Zhang, F; Zhang, H, 2015) |
| "Ovarian cancer is a highly lethal disease in which the majority of patients eventually demonstrate multidrug resistance." | ( Amiji, MM; Cacaccio, J; Coleman, TP; Ferris, CF; Ganta, S; Kulkarni, P; Patel, NR; Rawal, Y; Singh, A, 2016) |
| "Ovarian cancer is 1 kind of a highly malignant gynecologic tumor, and current treatments have not achieved satisfactory effects." | ( Chen, X; Gou, L; Kang, T; Lai, Q; Li, J; Li, W; Wang, Y; Wu, Y; Xie, Y; Yang, J; Yao, Y; Yi, C; Yu, L; Zhou, Y, 2014) |
| "Ovarian cancer is the leading cause of death from gynecologic cancer, reflecting its often late diagnosis and its chemoresistance." | ( Habata, S; Iwasaki, M; Mariya, T; Osogami, H; Saito, T; Sugio, A; Suzuki, M; Tamate, M; Tanaka, R, 2014) |
| "Ovarian cancer is the deadliest of all gynecologic malignancies." | ( Dong, L; Liu, L; Qiu, W; Wang, X; Xu, S; Yang, L; Yang, Y, 2014) |
| "Ovarian cancer is one of the most aggressive malignant tumors in women." | ( Lisianskaia, AS, 2014) |
| "Ovarian cancer is the most lethal gynecologic malignancy among women worldwide and is presumed to result from the presence of ovarian cancer stem cells." | ( Kim, MK; Kim, TH; Song, YS; Suh, DH, 2014) |
| "Ovarian cancers are addicted to Bcl-xL and Mcl-1, antiapoptotic members of the Bcl-2 family." | ( Abeilard, E; Blanc-Fournier, C; Briand, M; Clarisse, B; Crouet, H; Dugué, AE; Dutoit, S; Giffard, F; Grellard, JM; Joly, F; Labiche, A; Lheureux, S; Martin, S; N'Diaye, M; Poulain, L, 2015) |
| "Ovarian cancer is the most common cause of death among all gynecologic malignancies and a result of complex interaction of multiple oncogenes and tumor suppressor genes." | ( Celik, C; Eser, M; Kanter, M; Karacan, M; Tavli, L; Turan, G; Usta, A; Usta, CS, 2014) |
| "Ovarian cancer is the first in mortalities among gynecologic cancers in the United States, often due to late diagnosis and/or acquired platinum-resistant recurrences." | ( Blanchard, Z; ElShamy, WM; Paul, BT; Ridgway, M, 2015) |
| "Ovarian cancer is a serious tumor which represents a great threat to women's health." | ( He, P; Nao, JF; Wang, JH; Zhang, M, 2014) |
| "Ovarian cancer is a major cause for death of gynecological cancer patients." | ( Chen, Y; Deng, H; Ge, R; Jin, L; Lian, Q; Mu, X, 2014) |
| "Ovarian cancer is the most lethal gynaecologic malignancy in the United States, and advanced serous ovarian adenocarcinoma is responsible for most ovarian cancer deaths." | ( Armaiz-Pena, GN; Balasubramanian, L; Birrer, MJ; Leung, CS; Liu, J; Lopez-Berestein, G; Mangala, LS; Mok, SC; Pradeep, S; Sood, AK; Wong, KK; Yeung, TL; Yip, KP, 2014) |
| "Ovarian cancer is the most deadly gynecological malignancy since most patients have metastatic disease at the time of diagnosis." | ( Carrasco, M; Cowden Dahl, KD; Dahl, R; Joseph, S; Li, J; Roy, L; Samyesudhas, SJ, 2014) |
| "Ovarian cancer is one of the most common and deadliest gynecologic cancer with about 75% of the patients presenting in advanced stages." | ( Karim, AA; Loh, XJ; Ye, H, 2014) |
| "Ovarian cancer is the number one cause of death from gynaecological malignancy." | ( Jo, SY; Lee, C; Lee, HY; Suh, YA, 2015) |
| "Ovarian cancer is the deadliest gynaecological cancer." | ( Brooks, SA; Caley, DP; Carter, DR; Massa, D; Pink, RC; Samuel, P, 2015) |
| "Ovarian cancer is a leading killer of women, and no cure for advanced ovarian cancer is available." | ( Ding, YH; Duan, W; Edelman, JL; Ha, CF; He, ZX; Pan, ST; Qiu, JX; Wang, D; Yang, T; Yang, YX; Zhang, X; Zhang, XY; Zhou, SF; Zhou, ZW, 2015) |
| "Ovarian cancer is the fifth most common cancer in the UK, and the fourth most common cause of cancer death." | ( Barton, S; Edwards, SJ; Thurgar, E; Trevor, N, 2015) |
| "Ovarian cancer is a dreadful disease estimated to be the second most common gynecologic malignancy worldwide." | ( De Rosa, G; Navarro, G; Salzano, G; Torchilin, VP; Trivedi, MS, 2015) |
| "Ovarian cancer is a life‑threatening disease in females worldwide." | ( Cai, DJ; Li, B; Zhang, Q, 2015) |
| "Ovarian cancer is recognized as the fourth leading cancer in Malaysia." | ( Abdul Wahab, SB; Chiu, LB; Keng, SL; Yusuf, A, 2015) |
| "The incidence of ovarian cancer is tenfold lower than that of breast cancer." | ( Burger, H; Gompel, A, 2015) |
| "Ovarian cancer is a common gynaecological malignancy still remaining a challenge to treat." | ( Grizas, S; Janciauskiene, R; Juozaityte, E; Jureniene, K; Liutkauskiene, S; Malonyte, R, 2015) |
| "Ovarian cancer is a gynecological malignancy with high mortality rates worldwide and novel diagnostic and prognostic markers and therapeutic targets are urgently required." | ( Jiang, L; Li, J; Liu, A; Liu, J; Wu, G; Wu, S; Zang, D; Zhang, X; Zhu, J, 2015) |
| "Ovarian cancer is among the most lethal cancers in women." | ( Bar, J; Bednarz-Misa, I; Choromańska, A; Dubińska-Magiera, M; Kulbacka, J; Marcinkowska, A; Rembiałkowska, N; Saczko, J, 2015) |
| "Ovarian cancer is one of the most lethal of woman cancers, and its clinical therapeutic outcome currently is unsatisfied." | ( Chen, XX; Gong, LH; Jiang, QW; Lin, F; Mei, XL; Pan, SS; Qin, WM; Qiu, JG; Shi, Z; Xie, FF; Xue, YQ; Yan, XJ; Zhang, WJ; Zhu, XJ, 2015) |
| "Ovarian cancer is known to be composed of distinct populations of cancer cells, some of which demonstrate increased capacity for cancer initiation and/or metastasis." | ( Buckanovich, RJ; Burgos-Ojeda, D; Chen, YC; Cho, KR; McLean, K; Talpaz, M; Wu, R; Yoon, E, 2015) |
| "Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world-wide." | ( Bryant, A; Cass, GK; Lawrie, TA; Morrison, J; Wiggans, AJ, 2015) |
| "Although ovarian cancer is a highly chemosensitive disease, it is only infrequently cured." | ( Abramian, A; Ayub, TH; Barchet, W; Debald, M; Kaiser, C; Keyver-Paik, MD; Kristiansen, G; Kübler, K; Kuhn, W; Rostamzadeh, B; Schröder, L; Thiesler, T, 2015) |
| "Ovarian cancer is a lethal gynecological disease that is characterized by peritoneal metastasis and increased resistance to conventional chemotherapies." | ( Batruch, I; Diamandis, EP; Karagiannis, GS; Musrap, N; Saraon, P; Tuccitto, A, 2015) |
| "Familial breast and ovarian cancer are often caused by inherited mutations of BRCA1." | ( Amoozgar, Z; Cong, Z; Goldberg, MS; Huang, J; Kiner, E; Matulonis, U; Orsulic, S; Wang, L; Xing, D, 2015) |
| "Ovarian cancer is not particularly responsive to immune checkpoint blockade, so combination with a complementary therapy may be beneficial." | ( Amoozgar, Z; Goldberg, MS; Huang, J; Orsulic, S; Saleh, MH; Wang, L; Xing, D, 2015) |
| "Ovarian cancer is a disease that seriously threatens the health of women and results in a high mortality rate." | ( He, X; Liang, X; Liu, X; Tang, Z; Yang, C, 2015) |
| "Ovarian cancer is the fourth most ordinary cause of cancer-related deaths in women." | ( Liu, E; Liu, Z; Zhou, Y, 2015) |
| "Ovarian cancer is the leading cause of death in women with gynecological malignancy worldwide." | ( Li, H; Shi, C; Sui, H; Yan, Z, 2015) |
| "Epithelial ovarian cancer is one of the increasingly incident malignancies that is notorious because of its evasiveness for early diagnosis and high mortality rates." | ( Bhagat, R; Chennagiri Srinivasamurthy, P; Gawari, R; Janardhan, B; Krishnamoorthy, L; Vaderhobli, S; Venketeshiah Reddihalli, P, 2015) |
| "Ovarian cancer is among the most lethal of all malignancies in women." | ( Gao, L; Gao, Y; Li, J; Shan, N; Wang, Y; Xu, F; Yi, Z; Yu, X; Zhao, C, 2015) |
| "Ovarian cancer is the seventh-most common cancer amongst women and the most deadly gynecologic cancer." | ( Hrstka, R; Karban, J; Koubkova, L; Ondrouskova, E; Pinkas, J; Vojtesek, B; Vyzula, R, 2015) |
| "Ovarian cancer is associated with poor long-term survival due to late diagnosis and development of chemoresistance." | ( Blackshields, G; Gallagher, MF; Martin, CM; McEvoy, LM; O'Leary, JJ; O'Toole, SA; Sheils, O; Spillane, CD; Stordal, B, 2015) |
| "Ovarian cancer is the most lethal gynecologic malignancy characterized by the frequent development of resistance to platinum chemotherapy." | ( Barham, W; Khabele, D; Saskowski, J; Wilson, AJ; Yull, F, 2015) |
| "Ovarian cancer is the most deadly gynecological malignancy." | ( Bulfamante, G; Chiaramonte, R; Colombo, M; De Simone, D; Falleni, M; Garavelli, S; Neri, A; Platonova, N; Todoerti, K; Tosi, D; Vigolo, E, 2015) |
| "Ovarian cancer is the most deadly gynecological cancer." | ( Badria, FA; Chauhan, SC; El-Senduny, FF; El-Waseef, AM; Halaweish, F, 2016) |
| "Ovarian cancer is one of the most common causes of mortality among all cancers in females and is the primary cause of mortality from gynecological malignancies." | ( Hui, LM; Zhao, GD; Zhao, JJ, 2015) |
| "Ovarian cancer is one of the most common lethal gynecological malignancies world-wide." | ( Kumar, L; Patel, S; Singh, N, 2015) |
| "Ovarian cancer is associated with increased expression of the pro-angiogenic chemokine interleukin-8 (IL-8, CXCL8), which induces tumor cell proliferation, angiogenesis, and metastasis." | ( Chen, ZS; Gatla, HR; Patel, A; Phyo, S; Singha, B; Vancurova, I, 2015) |
| "Serous ovarian cancer is the most common malignant ovarian tumour." | ( Gupta, SD; Iyer, V; Kalaivani, M; Khandakar, B; Kumar, L; Kumar, S; Mathur, SR, 2015) |
| "Epithelial ovarian cancer is the most common and lethal gynecological cancer in USA and around the world, causing major mortality annually." | ( Fang, B; Xia, H; Zhang, D; Zhang, W, 2016) |
| "Most ovarian cancers are highly invasive in nature and the high burden of metastatic disease make them a leading cause of mortality among all gynaecological malignancies." | ( Basu, M; Bhattacharya, R; Chatterjee, U; Mukhopadhyay, S; Ray, U; Roy, SS, 2015) |
| "Ovarian cancer is the most frequent cause of cancer-related death among all gynecological cancers." | ( Lai, D; Qi, C; Qian, L; Wang, W; Zhang, J; Zhang, Q, 2015) |
| "Ovarian cancer is the eighth most common malignancy among women and has a high mortality rate." | ( Alongi, P; Caobelli, F; Castello, A; Cocciolillo, F; Crivellaro, C; De Biasi, V; Dolci, C; Evangelista, L; Geatti, O; Kirienko, M; Laghai, I; Picchio, M; Popescu, CE; Quartuccio, N; Rensi, M; Saladini, G; Seghezzi, S, 2016) |
| "Ovarian cancer is the most fatal of gynaecological malignancies, usually detected at a late stage with intraperitoneal dissemination." | ( Gomez-Roman, N; McGregor, F; Plumb, JA; Wheate, NJ, 2015) |
| "Patients with ovarian cancer are at increased risk of SPM development." | ( Chao, Y; Chen, MH; Chen, TJ; Chiou, TJ; Hu, YW; Hung, YP; Li, CP; Liu, CJ; Yang, MH; Yeh, CM, 2015) |
| "Epithelial ovarian cancer is the fourth cause of death among cancer-bearing women and frequently associated with carboplatin resistance, underlining the need for more efficient and targeted therapies." | ( Annereau, JP; Bailly, C; Clement, E; Couderc, B; Delord, JP; Ferré, P; Guilbaud, N; Kruczynski, A; Meignan, S; Narducci, F; Thibault, B; Vandenberghe, I; Zorza, G, 2016) |
| "Ovarian cancer is the major cause of cancer death among female genital malignancies, and requires developing novel therapeutic measures." | ( Ino, K; Ishida, Y; Kimura, A; Kobayashi, A; Kondo, T; Kuninaka, Y; Minami, S; Nosaka, M; Tanizaki, Y; Toujima, S, 2015) |
| "Ovarian cancer is the fifth most common malignancy in the world's female population and with the highest lethality index among gynecological tumors." | ( Bláha, M; Diaz-Garcia, D; Filip, S; Kubeček, O, 2015) |
| "Ovarian cancer is a silent disease with a poor prognosis that urgently requires new therapeutic strategies." | ( Abelanet, S; Bellanger, D; Bieche, I; Garnier, C; Gruosso, T; Kieffer, Y; Lemesre, V; Marangoni, E; Mechta-Grigoriou, F; Mieulet, V; Sastre-Garau, X, 2015) |
| "Ovarian cancer is often diagnosed at an advanced stage with dissemination in the peritoneal cavity." | ( Albertsson, P; Andersson, H; Bäck, T; Bernhardt, P; Cederkrantz, E; Hultborn, R; Jacobsson, L; Jensen, H; Lindegren, S; Ljungberg, M; Magnander, T; Palm, S, 2015) |
| "During pregnancy, ovarian cancer is usually discovered at an early stage, which improves patients' prognosis." | ( Amitai, I; Drucker, L; Fishman, A; Lishner, M; Matalon, ST; Pomeranz, M; Shochet, GE, 2015) |
| "Epithelial ovarian cancer is characterized by nonspecific signs and clinical symptoms arising at late stages." | ( Bolstad, N; Gislefoss, RE; Langseth, H; Mørkrid, L; Nustad, K, 2015) |
| "Ovarian cancer is the 5th leading cause of cancer death among women in the United States." | ( Bae-Jump, VL; Gehrig, PA; Gilliam, TP; Guo, H; Han, X; Schointuch, MN; Sheng, X; Stine, JE; Zhou, C, 2016) |
| "Ovarian cancer is a highly lethal gynecological malignancy for which the overall prognosis has remained poor over the past few decades." | ( Xu, C; Zhang, X; Zou, M, 2016) |
| "Ovarian cancer is the third most common cause of cancer in Indian women." | ( Kumar, L; Patel, S; Singh, N, 2015) |
| "Ovarian cancer is burdened by the highest mortality rate among gynecological cancers." | ( Abdul Halim, T; Casorelli, A; Di Donato, V; Domenici, L; Gasparri, ML; Imperiale, L; Marchetti, C; Monti, M; Musella, A; Muzii, L; Palaia, I; Panici, PB; Pecorini, F; Ruscito, I; Salerno, L, 2015) |
| "Ovarian cancer is the most lethal gynecological malignancy, for which platinum- and taxane-based chemotherapy plays a major role." | ( Kitanaka, C; Kurachi, H; Kuramoto, K; Nagase, S; Ohta, T; Okada, M; Sakaki, H; Seino, M; Seino, S; Suzuki, S; Takeda, H; Watarai, H, 2016) |
| "Ovarian cancer is the most lethal gynecologic malignancy, with limited treatment options for chemoresistant disease." | ( Barham, W; Khabele, D; Saskowski, J; Wilson, AJ; Yull, F, 2015) |
| "Ovarian cancer is the most aggressive gynecological cancer." | ( Brooks, SA; Carter, DR; Pink, RC; Samuel, P, 2016) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Boratyn-Nowicka, A; Cholewa, H; Duda, K; Okopień, B; Łabuzek, K, 2015) |
| "Ovarian cancer is the most lethal gynecologic malignancy with an overall cure rate of merely 30%." | ( Deng, Y; Fan, J; Haydon, RC; He, TC; Liao, J; Liu, H; Lu, S; Luu, HH; Mohammed, MK; Qi, H; Qiao, M; Tang, L; Tang, S; Wang, J; Wang, X; Wang, Z; Wei, Q; Yan, Z; Ye, J; Zhang, F; Zhang, J; Zhao, L; Zou, Y, 2015) |
| "Epithelial ovarian cancer is diagnosed in over 200,000 women worldwide each year." | ( Heus, P; Kitchener, HC; Lawrie, TA; Winter-Roach, BA, 2015) |
| "Since ovarian cancer is the fifth cause of prevalence of women cancer in Chile and is usually of late diagnosis, i." | ( Araos, J; Beltrán, AR; Gutiérrez, J; Leiva, A; Naranjo, L; Pardo, F; Ramírez, MA; Salomon, C; Sanhueza, C; Sobrevia, L; Villalobos, R; Westermeier, F, 2016) |
| "Ovarian cancer is one of the most lethal of women cancers and lack potent therapeutic options." | ( Chen, J; Chen, X; Gong, L; Huang, X; Jiang, Q; Ou, R; Qiu, J; Shi, Z; Xie, F; Yan, X; Yang, Y; Zhang, W; Zheng, Z; Zhu, H, 2016) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Li, J; Li, Y; Liu, Z; Lu, S; Shao, C; Tian, X; Wang, Y; Wei, JJ; Xu, L; Zhang, X, 2016) |
| "Ovarian cancer is mostly diagnosed in the elderly woman who is likely to have comorbid disease and to take several comedications on a regular basis." | ( Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H, 2016) |
| "Ovarian cancer is the third most common gynaecological cancer worldwide, with an age-standardised incidence rate of 6." | ( Kietpeerakool, C; Laopaiboon, M; Lumbiganon, P; Supoken, A, 2016) |
| "Ovarian cancer is the deadliest gynecologic cancer, due in large part to the diagnosis of advanced stage disease, the development of platinum resistance, and inadequate treatment alternatives." | ( Casarez, EV; Dziegielewska, B; Dziegielewski, J; Gray, LS; Slack-Davis, JK; Yang, WZ, 2016) |
| "Ovarian cancer is a highly aggressive pathology, displaying a poor prognosis and chemoresistance to classical therapy." | ( Achimas-Cadariu, P; Berindan-Neagoe, I; Braicu, C; Braicu, OL; Budisan, L; Drigla, F; Gherman, C; Jurj, A; Maralani, M; Pileczki, V; Zanoaga, O, 2016) |
| "Ovarian cancer is commonly treated with cisplatin and paclitaxel combination chemotherapy; however, ovarian cancer cells often develop resistance to these drugs." | ( Li, XS; Meng, XN; Wu, DD; Yan, J; Zong, ZH, 2016) |
| "Epithelial ovarian cancer is a heterogeneous disease comprising several tumor types that each have multiple histopathological features and different biological behaviors." | ( Glowacka, E; Kielbik, M; Klink, M; Kulig, A; Nowak, M; Sulowska, Z, 2017) |
| "Ovarian cancer is the most cause of cancer death in gynecological malignancy." | ( Choi, KC; Hwang, KA; Jeon, SY, 2016) |
| "Ovarian cancer is the leading cause of death for gynecologic cancers, ranking fifth overall for cancer-related death among women." | ( Chang, JT; Huang, RS; Kao, CJ; Wang, F, 2016) |
| "Ovarian cancer is a silent killer." | ( Fathalla, MF, 2016) |
| "Ovarian cancer is responsible for the highest mortality among all gynecologic malignancies, and novel therapies are urgently needed to improve patient outcome." | ( Cai, MC; Di, W; Gao, WQ; Gu, Z; Ji, ZL; Jing, Y; Ma, P; Peng, H; Yan, Y; Zhang, M; Zhang, S; Zhang, Z; Zhuang, G, 2016) |
| "Ovarian cancer is a leading cause of cancer-related death in women and the most lethal gynecological malignancy in the developed world." | ( Greenshields, AL; Hoskin, DW; Shepherd, TG, 2017) |
| "Ovarian cancer is the leading cause of death due to gynecologic malignancies worldwide." | ( El-Sehemy, A; Fu, Y; Postovit, LM, 2016) |
| "While ovarian cancer is enriched with a population of tumors with known homologous recombination defects, investigations are underway to help identify pathways in other gynecologic cancers that may demonstrate susceptibility to PARPi through synthetically lethal mechanisms." | ( Liu, FW; Tewari, KS, 2016) |
| "Epithelial ovarian cancer is a heterogeneous disease with distinct histological subtypes characterized by different patterns of clinical behaviour." | ( Banerjee, S; Dumas, L; Lima, JP; McLachlan, J, 2016) |
| "Ovarian cancers are the leading cause for mortality among gynecologic malignancies with five-year survival rate less than 30%." | ( Chang, CW; Chen, Y; Huang, RY; Kuan, CH; Lin, CJ; Wang, LW; Wang, TW; Wu, HC, 2016) |
| "Epithelial ovarian cancer is chemotherapy responsive, and multiple lines of chemotherapy are often given." | ( Hoskins, P; Kumar, A; Le, N; Santos, J, 2018) |
| ": High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying defects in the important DNA repair pathway of homologous recombination." | ( Kennedy, RD; Parkes, EE, 2016) |
| "Ovarian cancer is the most lethal gynecological cancer among women worldwide." | ( Chen, YC; Gao, Y; Kim, E; Li, B; Rankin, GO; Tu, Y, 2016) |
| "Epithelial ovarian cancer is the most lethal gynecologic cancer worldwide and chemoresistance is one of the major causes of treatment failure." | ( Chang Chien, CC; Fu, HC; Huang, CC; Lin, H; Liu, JM; Liu, SC; Ma, YY; Ou, YC; Tsai, CC, 2016) |
| "Ovarian cancer is the most aggressive gynecological cancer and is often diagnosed in advanced stage." | ( Bilska, M; Bilski, M; Kotarski, J; Okła, K; Surówka, J; Tarkowski, R; Wertel, I, 2015) |
| "We found that ovarian cancer is not associated with an enhanced aggregation response of platelets to ADP or collagen, and plasma concentration of β-TG and PF-4 is not higher in patients with ovarian cancer compared to those in patients with benign ovarian tumors." | ( Afshar-Kharghan, V; Feng, S; Kroll, MH; Nick, AM; Sood, AK, 2016) |
| "Ovarian cancer is characterized by an increase in cellular energy metabolism, which is predominantly satisfied by glucose and glutamine." | ( Avril, N; Avril, S; DiFeo, A; Hudson, CD; Joseph, P; Nagaraj, AB; Savadelis, A, 2016) |
| "Ovarian cancer is currently the most lethal gynecologic malignancy with limited treatment options." | ( Choy, E; Duan, Z; Gao, Y; Hornicek, FJ; Liu, X; Mankin, H; Shen, J; Yang, W, 2016) |
| "Ovarian cancer is the second most common gynaecological malignancy and was diagnosed in over 7,000 women in 2011 in the UK." | ( Chudasama, D; Goumenou, A; Hall, M; Karteris, E; Pados, G; Rogers-Broadway, KR; Tsolakidis, D, 2016) |
| "Ovarian cancer is the fifth leading cause of cancer-related female deaths." | ( Edmondson, RJ; Lunec, J; Zanjirband, M, 2016) |
| "Ovarian cancer is the leading cause of death among gynecological malignancies, and high grade serous ovarian carcinoma is the most common and most aggressive subtype." | ( Bast, RC; Fang, Z; Gao, M; Li, Y; Liu, Y; Ma, Y; Sun, Y; Wan, L; Wang, X; Wei, Z; Zhang, L, 2016) |
| "Ovarian cancer is the first leading cause of death among gynecologic malignancies worldwide." | ( Chen, X; Chen, XP; Ding, CY; Huang, MQ; Li, T; Lu, JJ; Tang, ZH; Wang, YT; Xu, XH; Xu, YL; Yuan, XF; Zhang, LL, 2016) |
| "Ovarian cancer is the deadliest gynecologic malignancy in the United States with most patients diagnosed in the advanced stage of the disease." | ( Chan, DW; Levine, DA; Snyder, M; Yu, KH; Zhang, H; Zhang, Z, 2016) |
| "Epithelial ovarian cancer is recognized to be heterogeneous but is currently treated with a single treatment strategy." | ( Cross, PA; Curtin, NJ; Edmondson, RJ; Kaufmann, A; McCormick, A; O'Donnell, RL; Woodhouse, L, 2016) |
| "Ovarian cancer is seventh most common cancer in women worldwide." | ( Lane, G; Montes, A; Seshadri, S; Wuntakal, R, 2016) |
| "Ovarian cancer is amongst the most common types of cancer in women, with a relatively low overall cure rate of approximately 30%." | ( Carlier, C; Ceelen, W; Laforce, B; Tucoulou, R; Vekemans, B; Villanova, J; Vincze, L, 2016) |
| "Ovarian cancer is a deadly disease, largely because of relapse and chemotherapy resistance." | ( Müller, R; Strandmann, EPV, 2016) |
| "Epithelial ovarian cancer is most lethal in female reproductive carcinomas owing to the high chemoresistance and metastasis, so more efficient therapeutic agents are terribly needed." | ( Chang, B; Chen, Y; Gu, H; Li, S; Liang, F; Wang, H; Wang, J; Yang, G; Yang, L, 2016) |
| "Ovarian cancer is the most lethal gynecologic malignancy, and there is an unmet clinical need to develop new therapies." | ( Chen, L; Deng, Y; Fan, J; Haydon, RC; He, TC; Hu, X; Liao, J; Liu, H; Luu, HH; Qi, H; Qiao, M; Wang, J; Wang, Z; Wei, Q; Yan, Z; Yu, X; Zhang, F; Zhang, J; Zou, Y, 2016) |
| "Ovarian cancer is the most leading cause of cancer-related death in women ." | ( Paul, KB; Singh, SG; Singh, V; Vanjari, SRK, 2017) |
| "Cancer of the ovary is mostly discovered at a late stage and cannot be removed by surgery alone." | ( Däster, S; Delko, T; Droeser, RA; Güth, U; Kraljević, M; Mechera, R; Singer, G; Stadlmann, S; Terracciano, L; Weixler, B, 2016) |
| "Ovarian cancer is one of the most important malignancies, and the origin, detection, and pathogenesis of epithelial ovarian cancer remain elusive." | ( Gurunathan, S; Zhang, XF, 2016) |
| "Ovarian cancer is the most lethal gynecological malignancy due to its high metastatic ability." | ( Gao, SH; Hou, YF; Li, BY; Liu, LZ; Wang, P; Ye, MX; Zhang, HM; Zhang, ZL; Zhou, GM, 2016) |
| "Ovarian cancer is not a single disease and can be subdivided into at least five different histological subtypes that have different identifiable risk factors, cells of origin, molecular compositions, clinical features and treatments." | ( Fallowfield, L; Howitt, BE; Karlan, BY; Matulonis, UA; Sehouli, J; Sood, AK, 2016) |
| "Ovarian cancer is the most fatal gynecologic cancer with poor prognosis." | ( Dhanasekaran, DN; Gomathinayagam, R; Ha, JH; Husain, S; Jayaraman, M; Liu, J; Mukherjee, P; Reddy, EP; Song, YS; Yan, M, 2016) |
| "Ovarian cancer is the leading cause of death among all gynecological malignancies due to the development of acquired chemoresistance and disease relapse." | ( Chaudhuri, G; Farias-Eisner, R; Ramachandran, I; Ramadoss, S; Roy, S; Sen, S, 2017) |
| "Ovarian cancer is a complex disease with heterogeneity among the gene expression molecular subtypes (GEMS) between patients." | ( Antony, J; Choolani, M; Gabra, H; Huang, RY; Kelly, Z; Low, J; Recchi, C; Tan, TZ; Thiery, JP, 2016) |
| "Ovarian cancer is the most lethal gynecological malignant tumor because of its high recurrence rate." | ( Cao, G; Chen, Y; Deng, H; Liu, C; Qu, H; Xu, J; Zhang, Z, 2016) |
| "Ovarian cancer is a gynecological malignancy with high mortality rates all over the world." | ( Dai, J; Feng, JB; Li, R; Liu, PS; Wei, RJ; Yu, YL, 2016) |
| "Ovarian cancer is among the leading cause of cancer-related deaths in females." | ( Chen, X; Liu, Y; Lou, G; Tian, S; Zhang, M, 2016) |
| "Ovarian cancer is characterized by being highly metastatic, a feature that represents the main cause of failure of the treatment." | ( Abramovich, D; Accialini, P; Bechis, A; Irusta, G; Parborell, F; Pazos, MC; Tesone, M, 2017) |
| "Ovarian cancer is highly prevalent among European women, and is the leading cause of gynaecological cancer death." | ( Brown, R; Dória, ML; Ghaem-Maghami, S; Golf, O; McKenzie, JS; Mroz, A; Phelps, DL; Rosini, F; Speller, A; Strittmatter, N; Takats, Z; Veselkov, K, 2016) |
| "Epithelial ovarian cancer is prone to metastasizing at an early stage, but their mechanisms remain unclear." | ( Huang, Q; Liu, KJ; Shao, WY; Yan, H; Yang, YL; Zhang, S, 2017) |
| "Ovarian cancer is the most lethal gynecological cancer, with over 200,000 women diagnosed each year and over half of those cases leading to death." | ( Aoisa, C; Menzie, CJ; Paullin, TR; Powell, CD; Ubaldini, A; Westerheide, SD, 2016) |
| "Ovarian cancer is the highest mortality rate of all female reproductive malignancies." | ( Cai, G; Chen, B; Hua, W; Ma, X; Yang, H; Zou, W, 2017) |
| "Ovarian cancer is one of the most common cancer among women in the world, and chemotherapy remains the principal treatment for patients." | ( Chen, X; Guo, X; Hou, J; Ji, Y; Wang, J; Wei, S; Xue, P; Yang, F; Zhang, C, 2017) |
| "Ovarian cancer is the most lethal disease among gynecological malignancies." | ( Akiyama, M; Kitawaki, J; Sakai, T; Sowa, Y; Taniguchi, T; Watanabe, M; Yogosawa, S, 2017) |
| "Ovarian cancer is the most lethal gynecologic malignancy." | ( Anan, H; Fukagawa, S; Kato, K; Katsuda, T; Kiyoshima, C; Miyahara, D; Miyamoto, S; Miyata, K; Murata, M; Nam, SO; Shirota, K; Yagi, H; Yasunaga, S; Yotsumoto, F, 2017) |
| "Ovarian cancer is the most common malignant tumor in female reproductive system." | ( Bian, XH; Huang, Y; Huo, J; Miao, ZC; Song, LH, 2017) |
| "Ovarian cancer is one of the leading causes of death in the world, which is linked to its resistance to chemotherapy." | ( Adachi, K; Eguchi, S; Fujii, T; Fujimoto, A; Inoue, T; Kawana, K; Nagamatsu, T; Nakamura, H; Nishida, H; Oda, K; Ogishima, J; Osuga, Y; Sato, M; Taguchi, A; Tomio, K; Wada-Hiraike, O; Yamashita, A; Yoshida, M, 2017) |
| "Ovarian cancer is the seventh most common cancer among women worldwide, causing approximately 120,000 deaths every year." | ( Ferreira, A; Gabler, F; Oróstica, L; Romero, CA; Selman, A; Vega, M; Vera, CA, 2017) |
| "Ovarian cancer is a lethal malignancy that has not seen a major therapeutic advance in over 30 years." | ( Basuli, D; Brewer, M; Crum, CP; Deng, Z; Dyment, N; Hegde, P; Lynch, M; McKeon, F; Miller, LD; Ning, G; Paul, B; Tesfay, L; Torti, FM; Torti, SV; Wang, X; Xian, W; Yamamoto, Y, 2017) |
| "Prostate and ovarian cancers are major contributors to cancer-related deaths worldwide." | ( Burke, AJ; Garrido, P; Glynn, SA; Johnson, C; Sullivan, FJ, 2017) |
| "Ovarian cancer is the leading cause of death among gynecologic malignancies." | ( Christensen, IJ; Ekmann-Gade, AW; Hansen, A; Høgdall, C; Høgdall, E; Jensen, PB; Jensen, T; Karlsen, MA; Knudsen, S; Mirza, MR; Nedergaard, L; Novotny, GW; Prahm, KP, 2017) |
| "Ovarian cancer is the deadliest gynecological malignancy in women, and fifth leading cause of death." | ( Kalinovsky, T; Niedzwiecki, A; Rath, M; Roomi, MW, 2017) |
| "Ovarian cancer is particularly lethal due to late stage at presentation." | ( Jayalakshmi, P; Rhodes, A; Vallikkannu, N, 2017) |
| "Ovarian cancer is the most lethal gynecologic malignancy, and cisplatin is one of the first-line chemotherapeutic agents." | ( Bao, Z; Fan, L; Peng, Y; Shao, M; Tao, L; Wang, Q; Wu, W; Xiang, Y; Zhang, X; Zhang, Y, 2017) |
| "Ovarian cancer is one of the leading causes of death in gynecological malignancies, and the resistance to chemotherapeutic agents remains a major challenge to successful ovarian cancer chemotherapy." | ( Chan, HF; Chen, M; He, C; Lin, Z; Lu, H; Wang, S; Xu, Y, 2017) |
| "Ovarian cancer is most lethal among all gynecologic malignancies." | ( Dwivedi, A; Dwivedi, VN; Goyal, S; Jaiswar, SP; Kumar, V; Pal, MK; Pathak, AK; Ray, RS; Sankhwar, PL, 2017) |
| "Ovarian cancer is the leading cause of death for gynecological cancers and the 6th cause of women cancer death in developed countries." | ( Jean-Claude, B; Thibault, B, 2017) |
| "Ovarian cancer is a serious threat for women health and the early diagnosis of this cancer might improves the survival rate of patients." | ( Abedi, SM; Hosseinimehr, SJ; Khalaj, A; Noaparast, Z; Rahmanian, N; Sabzevari, O, 2017) |
| "High-grade serous ovarian cancer is the most common ovarian cancer type." | ( Carpén, O; Goodlett, DR; Huhtinen, K; Lahesmaa, R; Lund, RJ; Moulder, R; Nguyen, EV; Rantala, J; Salmi, J, 2017) |
| "Ovarian cancer is highly dependent on tumor microvessels and angiogenesis regulated by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) and angiopoietins (Ang) and their Tie receptors." | ( Anttila, M; Hämäläinen, K; Hytönen, E; Karvonen, A; Kosma, VM; Laakso, H; Liimatainen, T; Sallinen, H; Tuppurainen, L; Valkonen, E; Ylä-Herttuala, S, 2017) |
| "Ovarian cancer is the most lethal gynecological malignancy worldwide." | ( Choi, JH; Jang, DS; Kim, NJ; Lee, JY; Lee, KT; Preya, UH, 2017) |
| "Ovarian cancer is one of the major causes of death among females in worldwide." | ( Choi, BY; Jang, IS; Joo, JC; Lee, YK; Park, SJ; Park, YJ, 2017) |
| "Advanced ovarian cancer is very responsive to first line platinum therapy, however almost invariably it relapses with a resistant disease." | ( Broggini, M; Damia, G; Guffanti, F; Ricci, F, 2017) |
| "Ovarian cancer is the most lethal disease among all gynecological malignancies." | ( An, Q; Jin, Y; Qiu, S; Sun, L; Weng, C; Zheng, J, 2017) |
| "Ovarian cancer is the deadliest of all gynecologic cancers." | ( Curiel, T; Garcia, L; Kost, E; Li, R; Liu, J; Nair, BC; Rao Tekmal, R; Rao, MK; Sareddy, GR; Vadlamudi, RK; Viswanadhapalli, S; Zhou, M, 2017) |
| "Ovarian cancer is the most lethal gynecological malignancy in the world." | ( Lei, T; Liu, Y; Qi, P; Sun, M; Wang, H; Wang, Y; Zou, B, 2017) |
| "Most of the ovarian cancers are diagnosed at advanced stages." | ( Gulec, UK; Guzel, AB; Khatib, G; Vardar, MA, 2017) |
| "Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance." | ( Bao, HX; Gao, S; Gao, T; Hu, S; Johnston, RN; Li, QH; Li, T; Liu, H; Liu, J; Liu, SL; Liu, Y; Mastriani, E; Qi, Y; Shen, Z; Wang, H; Wang, S; Wang, X; Yu, M; Zeng, Z; Zhou, YJ, 2017) |
| "Ovarian cancer is the most common malignancy in women." | ( Cao, YL; Li, N; Li, Q; Xing, BH; Zhuang, T, 2017) |
| "Ovarian cancer is the most lethal gynecological cancer, with over 200,000 women diagnosed each year and over half of those cases leading to death." | ( Cheng, F; Hill, R; Martyniuk, CJ; Menzie, C; Paullin, T; Powell, C; Westerheide, SD, 2017) |
| "Ovarian cancer is gynecologic tumor with particularly high mortality because it is usually diagnosed in advanced stages." | ( Bukowski, A; Goss, PE; Nogueira Rodrigues, A; Paulino, E; St Louis, J; Strasser-Weippl, K, 2017) |
| "Ovarian cancer is a common cause of cancer death in women and is associated with the highest mortality rates of all gynecological malignancies." | ( Astilean, S; Craciun, AM; Imre-Lucaci, F; Licarete, E; Nagy-Simon, T; Potara, M; Suarasan, S, 2017) |
| "Ovarian cancer is the most lethal gynaecological cancer and the sixth most common cause of cancer related death among Western women." | ( Gao, G; Gao, J; Ma, X; Wan, H; Zhu, H; Zou, X, 2017) |
| "Ovarian cancer is one of most common malignancies in women and is associated with high reoccurrence rate and poor prognosis." | ( He, S; Liu, H; Yue, Q, 2017) |
| "Ovarian cancer is one of the most lethal gynecologic malignancies in women." | ( Guo, NL; Wu, JP; Xu, YH; Zhang, JX, 2017) |
| "Ovarian cancer is often diagnosed at later stages with poor prognosis." | ( Kang, L; Liu, H; Luan, X; Shi, Y; Sun, Y; Wang, M; Wang, S; Wang, T; Wang, Y; Zhang, J; Zhang, Y; Zhou, Z; Zou, Z, 2017) |
| "BACKGROUND Ovarian cancer is the most common gynecological malignancies in women, with high mortality rates worldwide." | ( Ding, H; Tian, B; Wang, Y; Zhao, Y, 2017) |
| "Ovarian cancer is deadliest of fifth leading cause of death in women worldwide." | ( Hugar, AL; Kanjikar, AP; Londonkar, RL, 2018) |
| "Ovarian cancer is the third most common cancer in the female reproductive organs and epithelial ovarian cancer has the highest lethality of all gynecological cancers." | ( Bao, HX; Dong, L; Gao, S; Gao, T; Hu, S; Johnston, RN; Li, QH; Li, T; Liu, H; Liu, SL; Liu, W; Liu, Y; Mastriani, E; Qi, Y; Shen, Z; Wang, H; Wang, S; Wang, X; Yu, M; Zeng, Z; Zhou, YJ, 2017) |
| "Ovarian cancer is the most common gynecological malignancy." | ( Dou, M; Gao, W; Guo, Y; Hu, K; Liu, Y; Su, J; Sun, L; Xie, Q; Xu, Y; Zhang, Y, 2018) |
| "Ovarian cancer is treated with cisplatin and various combinations, in 64% or paclitaxel in 54." | ( Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ, 2018) |
| "Ovarian cancer is the leading cause of gynecologic cancer deaths in the United States." | ( Aghajanian, C; Alvarez Secord, A; Carney, ME; Coleman, RL; Gray, HJ; Hanjani, P; Hu, W; Kehoe, SM; Landrum, LM; Lankes, HA; Pearl, ML; Richardson, DL; Sill, MW; Sood, AK; Van Le, L; Zhou, XC, 2018) |
| "Ovarian cancer is the most common and lethal type of gynecological malignancy, due to its invasiveness." | ( Hong, B; Yang, W; Zhang, J, 2018) |
| "Ovarian cancer is a highly metastatic disease." | ( Alfandari, A; Ashur-Fabian, O; Davis, PJ; Ellis, M; Hercbergs, A; Jenudi, Y; Moskovich, D; Tshuva, RY; Weingarten, C, 2018) |
| "Ovarian cancer is the fifth leading cause of cancer-related deaths in women." | ( Abramovich, D; Bocchicchio, S; Irusta, G; May, M; Parborell, F; Pazos, MC; Sequeira, G; Tesone, M, 2018) |
| "Ovarian cancer is the fourth leading cause of death in women in developed countries." | ( Allen, C; De Souza, R; Eetezadi, S; Evans, JC; Piquette-Miller, M; Shen, YT, 2018) |
| "Ovarian cancer is still a major cause of morbidity and mortality." | ( Behzadi, R; Ghassami, E; Jahanian-Najafabadi, A; Minaiyan, M; Noorbakhsh, A; Varshosaz, J, 2018) |
| "Ovarian cancer is one of the most common female malignancies, and cisplatin-based chemotherapy is routinely used in locally advanced ovarian cancer patients." | ( Huang, X; Jin, C; Jin, H; Lin, J; Teng, Y; Yu, R, 2018) |
| "Epithelixal ovarian cancer is the fourth cause of cancer death in developed countries with 77% of ovarian cancer cases diagnosed with regional or distant metastasis, with poor survival rates." | ( Ghassami, E; Hayati, E; Jahanian-Najafabadi, A; Minaiyan, M; Rajabi, P; Varshosaz, J, 2018) |
| "Breast and/or ovarian cancers are among the most common cancers in women across the world." | ( Agarwal, A; Aggarwal, S; Ahmed, R; Almel, S; Arora, N; Chakraborti, B; DadiReddy, PK; Deshwal, S; Dodagoudar, C; Ghosh, A; Ghosh, M; Hariharan, R; Joshi, A; Karaba, A; Katragadda, S; Kumar, A; Kumar, R; Mannan, AU; Mishra, DK; Mohan, P; Padhi, S; Raina, V; Rajappa, S; Sankaran, S; Sarin, R; Singh, J; Singh, S; Singhal, M; Smruti, BK; Sur, S; Thota, N; Veeramachaneni, V, 2018) |
| "Ovarian cancer is the most leading cause of death and the third most common gynecologic malignancy in women." | ( Feng, JB; Kong, BH; Li, L; Lu, ZJ; Song, K; Su, XT; Wang, K; Yan, S; Yao, S; Yuan, CZ, 2018) |
| "Ovarian cancer is one of the most common gynecologic cancers and one of the leading causes of cancer death in women." | ( Chondrogiannis, S; Marzola, MC; Rubello, D, 2018) |
| "Ovarian cancer is one of the most common malignancies with a high rate of mortality in women." | ( Lin, J; Liu, H; Liu, Y; Sun, C; Xu, C; Zhai, S; Zhou, H, 2018) |
| "Ovarian cancer is the main cause of gynecological cancer‑associated mortality around the world." | ( Chen, XG; Hua, F; Li, CH; Liu, XP, 2018) |
| "Ovarian cancer is a highly metastatic malignancy and a leading cause of cancer-related death in postmenopausal women." | ( Chen, Y; Diao, Y; Lv, T; Song, K; Wang, Y; Yao, Q, 2018) |
| "Ovarian cancer is a devastating disease due to its high incidence of relapse and chemoresistance." | ( Chen, G; Gao, Q; Jin, P; Li, X; Long, S; Ma, D; Sun, C; Wang, Y; Wei, X; Xu, S; Yang, X; Yang, Z; Zhang, T, 2018) |
| "Ovarian cancer is the most frequent cause of death resulting from malignant gynecological tumors." | ( Chen, L; Dong, Q; Jiang, T; Ju, X; Liang, D; Liu, X; Liu, Y; Yu, H, 2018) |
| "Ovarian cancer is the leading gynecologic cancer diagnosed in North America and because related symptoms are not disease specific, this often leads to late detection, an advanced disease state, and the need for chemotherapy." | ( Bartlett, JMS; Boutros, PC; Chong, T; Liao, L; Lyttle, N; Sarac, A; Spears, M; Yao, CQ, 2018) |
| "Ovarian cancer is a disease with a propensity to recur despite dramatic responses to initial treatment, which typically consists of a combination of cytoreductive surgery and platinum-based chemotherapy." | ( Longoria, TC; Tewari, KS, 2018) |
| "Ovarian cancer is a common and lethal cancer affecting women globally." | ( Chang, Y; Jiao, Y; Ren, Y; Shi, C; Shi, X; Song, X; Zhang, H, 2018) |
| "Ovarian cancer is one of the most common malignancies in women and characterized by a rapid progression to metastasis, which restricts effective treatment options." | ( Han, NZ; Liu, GL; Liu, SS, 2018) |
| "Ovarian cancer is one of the most serious disease in female reproductive system." | ( Chen, D; Chen, X; Lu, M; Xiang, J; Xiao, J; Yang, L, 2018) |
| "Ovarian cancer is the fifth leading cause of cancer-related deaths in females in the United States." | ( Arend, RC; Jones, BA; Varambally, S, 2018) |
| "Ovarian cancer is the most lethal gynecologic malignancy worldwide with extremely poor patient prognosis." | ( Marczak, A; Rogalska, A, 2018) |
| "Epithelial ovarian cancer is the sixth most common cancer among women worldwide and the first cause of death among gynecological malignancies." | ( Bogani, G; Lepori, S; Lorusso, D; Maltese, G; Raspagliesi, F; Sabatucci, I; Tripodi, E, 2018) |
| "BACKGROUND Ovarian cancer is the second most common malignant tumor of the female reproductive system and is the leading cause of death of gynecological malignancies, but at present there is no effective and safe therapy." | ( Liu, T; Liu, X; Xu, Y; Zhang, H; Zhang, L, 2018) |
| "Ovarian cancer is the second most common gynaecologic malignancy and the most common cause of death from gynaecologic cancer, especially due to diagnosis at an advanced stage, when a cure is rare." | ( Gouveia-Fernandes, S; Lopes-Coelho, F; Nunes, SC; Pereira, SA; Ramos, C; Serpa, J, 2018) |
| "Ovarian cancer is the most lethal gynecologic malignancy among women." | ( Gartung, A; Panigrahy, D; Serhan, K, 2018) |
| "Ovarian cancer is the second most common gynaecologic malignancy and the main cause of death from gynaecologic cancer, due to late diagnosis and chemoresistance." | ( Abreu, S; Brito, C; Félix, A; Gouveia-Fernandes, S; Guimarães, A; Lopes-Coelho, F; Nunes, SC; Pereira, SA; Ramos, C; Rodrigues, A; Santo, VE; Sequeira, CO; Serpa, J; Silva, F; Silveira, M, 2018) |
| "Ovarian cancer is the major cause of death from gynaecologic disease and the second most common gynaecologic malignancy worldwide." | ( Nunes, SC; Serpa, J, 2018) |
| "Ovarian cancer is the fifth common cancer in females." | ( Gao, H; Li, Q; Shi, J; Xu, X, 2018) |
| "Ovarian cancer is the most deadly gynecologic cancer, and the therapy is very difficult." | ( Liu, S; Shi, R; Sun, H; Xiao, M, 2018) |
| "Ovarian cancer is a common gynecologic malignancy with poor prognosis, requiring innovative new therapeutic strategies." | ( An, Y; Chen, D; Tang, Q; Wang, X; Yang, R; Yuan, C, 2018) |
| "Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it." | ( Arffman, M; Arima, R; Hautakoski, A; Hinkula, M; Ilanne-Parikka, P; Kangaskokko, J; Läärä, E; Marttila, M; Puistola, U; Sund, R; Urpilainen, E, 2018) |
| "Ovarian cancer is the deadliest gynecologic cancer due to lack of early effective diagnosis and development of resistance to platinum-based chemotherapy." | ( Brockmann, N; Hamacher, A; Kassack, MU; Stork, B; Sureechatchaiyan, P, 2018) |
| "Ovarian cancer is the most malignant gynecologic cancer among women worldwide." | ( Cao, Y; Chen, L; Cheng, X; Liu, F; Qi, Z; Wang, Z; Yang, Y, 2018) |
| "Ovarian cancer is a leading cause of death among gynecologic malignancies." | ( Besharat, RA; Besharat, ZM; Farooqi, AA; Ferretti, E; Gasparri, ML; Khalid, S; Mueller, MD; Panici, PB; Papadia, A; Sabato, C; Taghavi, K, 2018) |
| "Ovarian cancer is a most common lethal gynecological malignant tumor, with a gradual increasing incidence throughout the world." | ( Cai, J; Jin, M; Wang, X; Zhang, T; Zhao, Y, 2018) |
| "Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States." | ( Alvarez, RD; Arend, RC; Fehling, SC; Gamblin, TL; Katre, AA; Kreitzburg, KM; Landen, CN; Oliver, PG; van Waardenburg, RCAM; Vance, RB; Yoon, KJ, 2018) |
| "BACKGROUND Ovarian cancer is considered one of the lethal cancers responsible for high mortality and morbidity across the world." | ( Chen, H; Du, J; Wang, B; Yang, L; Zhang, F, 2018) |
| "Ovarian cancer is currently the most life‑threatening type of gynecological malignancy with limited treatment options." | ( Kan, SF; Sun, GX; Wang, J, 2018) |
| "Ovarian cancer is usually treated with transurethral resection or systemic chemotherapy in clinic." | ( Li, M; Lin, Y; Zhan, X; Zheng, W, 2018) |
| "Ovarian cancer is the major cause of death in women gynecological malignancy and gemcitabine (GEM) is commonly used in related chemotherapy." | ( Chen, X; Shen, N; Tang, Z; Wang, G; Yang, S; Zhang, D, 2019) |
| "Ovarian cancer is a highly fatal malignant neoplasm with few modifiable risk factors." | ( Barnard, ME; Curhan, GC; Eliassen, AH; Poole, EM; Rosner, BA; Terry, KL; Tworoger, SS, 2018) |
| "Ovarian cancer is the second most common and the most lethal gynecological malignancy in the western world." | ( Monga, DK; Patibandla, NS, 2019) |
| "Ovarian cancer is the leading cause of death from gynaecological cancer in developed countries." | ( Hoogendam, JP; Roze, JF; Scholten, RJ; Spijker, R; van de Wetering, FT; Veldhuis, WB; Verleye, L; Vlayen, J; Zweemer, RP, 2018) |
| "Breast and ovarian cancer are common malignancies among older adults, causing significant morbidity and mortality." | ( Baldini, C; Banerjee, S; Battisti, NML; Dumas, L; Kadambi, S; Lichtman, SM; Liposits, G; Loh, KP; Soto-Perez-de-Celis, E, 2019) |
| "Ovarian cancer is one of the most serious diseases worldwide and the fifth-most common cancer among women." | ( Ding, J; Li, X; Nie, S; Ren, S; Wang, H; Wang, L; Zhang, L, 2019) |
| "Resistance in ovarian cancer is driven by a range of mechanisms, some of which are therapy specific whereas others confer multidrug resistance." | ( Beach, JA; Bowtell, DDL; Christie, EL; Freimund, AE, 2018) |
| "Ovarian cancer is poorly immunogenic; however, increased major histocompatibility complex class II (MHCII) expression correlates with improved immune response and prolonged survival in patients with ovarian cancer." | ( Arend, RC; Buchsbaum, DJ; Forero, A; Katre, AA; Londono, AI; McCaw, TR; Meza-Perez, S; Norian, LA; Randall, TD; Smith, HJ; Straughn, JM; Yang, ES, 2018) |
| "Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat." | ( Binju, M; Cohen, PA; Kaur, P; Padilla, MA; Singomat, T; Suryo Rahmanto, Y; Yu, Y, 2019) |
| "Ovarian cancer is most frequently detected in the advanced stage." | ( Buczkowska, M; Głogowska-Gruszka, A; Janyga, S; Nowak, D; Nowak, P; Roczniak, W; Słomian, GJ; Słomian, SP, 2019) |
| "Ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer mortality in women." | ( Aoki, D; Banno, K; Kobayashi, Y; Kunitomi, H; Tominaga, E, 2019) |
| "Ovarian cancer is one of the deadliest gynecological malignancies in women." | ( Cui, Y; Fan, L; Qin, L; Tian, D; Wang, T; Wang, Z; Zhang, P, 2018) |
| "Ovarian cancer is the most lethal cancer of the female reproductive system." | ( Chan, MWY; Chang, CB; Chen, GCW; Chen, YC; Cheng, ASL; Cheng, FHC; Chou, JL; Chuang, YM; Huang, RL; Hwang, TW; Kuo, LW; Lai, HC; Li, C; Lin, CW; Lin, HY; Lin, JMJ; Lin, RI; Mai, SY; Tsai, JC; Wu, SF; Yang, W, 2019) |
| "Ovarian cancer is one of the most common and resistant cancers with poor prognosis among women, which scientists are trying to prepare new methods for improving their treatments outcomes in past decades." | ( Ajjoolabady, A; Alizadeh, L; Rahmati-Yamchi, M; Salehi, R; Zarebkohan, A, 2019) |
| "Ovarian cancer is the leading cause of gynaecology related cancer death worldwide." | ( Elayapillai, SP; Jagadeesan, A; Teekaraman, D; Viswanathan, MP, 2019) |
| "Ovarian cancer is the leading cause of gynecologic-related mortality worldwide." | ( An, HJ; Cho, HJ; Choi, HJ; Heo, JH; Jeong, JY; Kim, JS; Kim, SH; Moon, YW; Park, JY; Park, KS, 2019) |
| "Epithelial ovarian cancer is the most lethal gynecologic malignancy." | ( Gadducci, A; Guarneri, V; Peccatori, FA; Ronzino, G; Salutari, V; Scandurra, G; Zamagni, C; Zola, P, 2019) |
| "Ovarian cancer is the third most common type of gynecological tumor, in addition to being the most lethal." | ( Cao, W; Dai, L; Li, A; Liu, Z; Qin, S; Wang, P; Xie, F; Xiong, X; Yuan, W; Zhang, J, 2019) |
| "Ovarian cancer is often diagnosed at a late stage, when disease has spread to extra-pelvic regions such as the omentum." | ( Ford, CE; Henry, CE; Khine, YY; Lai, H; Lu, M; Stenzel, MH, 2019) |
| "Ovarian cancer is the most lethal of all gynecologic malignancies." | ( Gómora, MJ; Mendez, C; Morales-Vásquez, F; Pedernera, E; Pérez-Montiel, D, 2019) |
| "Ovarian cancer is commonly diagnosed only after it has metastasized to the abdominal cavity (stage III)." | ( Abidi, W; Aboody, KS; Aramburo, S; Batalla-Covello, J; Berlin, JM; Cornejo, YR; Dellinger, T; Flores, L; Gonzaga, J; Han, E; Kang, Y; Li, J; Mooney, R; Tiet, P; Tsaturyan, L, 2019) |
| "Ovarian cancer is a significant cancer-related cause of death in women worldwide." | ( Abanto, M; Brebi, P; Buchegger, K; Ili, C; Jofre, I; Parker, AC; Piccolo, SR; Riquelme, I; Roa, JC; Viscarra, T; Zanella, L, 2019) |
| "Ovarian cancer is one of the most common causes of morbidity related to gynecologic malignancies." | ( Asemi, Z; Reiter, RJ; Shafabakhsh, R; Zare, H, 2019) |
| "Ovarian cancer is a highly lethal cancer in females." | ( Hu, Y; Li, C; Xie, Y; Zeng, Q, 2019) |
| "Ovarian cancer is the most frequent cause of death in women among gynecological cancers in Poland." | ( Cybulski, M; Guz, M; Jeleniewicz, W; Kotarski, J; Marzec-Kotarska, B; Nowakowski, A; Stenzel-Bembenek, A; Stepulak, A, 2019) |
| "Ovarian cancer is the gynecological malignancy with the poorest prognosis, in part due to its high incidence of recurrence." | ( Joo, JC; Lee, YK; Lim, J; Park, SJ; Park, YJ; Yoon, SY, 2019) |
| "Recurrence of ovarian cancer is mainly due to multidrug resistance (MDR)." | ( Buluan, Z; Dongchen, W; Hui, Y; Jin, L; Jinhua, W; Wanzhou, Z; Xi, Y; Yinan, W; Yingchun, W; Zhujun, S, 2019) |
| "Ovarian cancer is a heterogeneous disease that can be divided into multiple subtypes with variable etiology, pathogenesis, and prognosis." | ( Anderson, WF; Anglesio, MS; Bodelon, C; Bowtell, DDL; Brinton, LA; Doherty, JA; Killian, JK; Lissowska, J; Matsuno, R; Ramus, SJ; Sampson, JN; Sherman, ME; Talhouk, A; Wentzensen, N, 2019) |
| "Ovarian cancer is one of the most lethal gynecologic malignancies due to its rapid proliferation, frequent acquisition of chemoresistance, and widespread metastasis within the peritoneal cavity." | ( Cohn, DE; Dwivedi, M; Dwivedi, P; Fan, R; Han, S; Hu, S; Huang, F; Khatik, R; Mangrio, F; Si, T; Sparreboom, A; Wu, Q; Xu, RX; Zhu, Z, 2019) |
| "Ovarian cancer is the leading cause of gynecologic cancer-related death, due in part to a late diagnosis and a high rate of recurrence." | ( Carnero, A; Domínguez-Piñol, J; Espinosa-Sánchez, A; Estevez-Garcia, P; Felipe-Abrio, B; García-Carrasco, M; García-Heredia, JM; Jiménez-García, MP; Marin, JJ; Muñoz-Galván, S; Navas, LE; Otero-Albiol, D; Quiroga, AG; Suarez-Martinez, E; Verdugo-Sivianes, EM, 2019) |
| "Ovarian cancer is a common type of fatal gynecological cancer worldwide." | ( Hao, J; Jiang, YM; Li, Y; Liu, Y; Zhang, SH, 2019) |
| "Ovarian cancer is the main cause of death among all reproductive cancers in females." | ( Asemi, Z; Shafabakhsh, R, 2019) |
| "Ovarian cancer is among the highest mortality gynecological cancers." | ( Aleem, AM; Ferorelli, S; Fortuna, CG; Iaselli, MC; Marnett, LJ; Miciaccia, M; Pati, ML; Perrone, MG; Scilimati, A, 2019) |
| "Ovarian cancer is associated with a high percentage of recurrence of tumors and resistance to chemotherapy." | ( Ding, F; Ding, J; Li, N; Li, X; Liu, R; Liu, W; Ning, Y; Ren, S; Wang, H; Zheng, H, 2019) |
| "Ovarian cancer is a common human malignancy of the female reproductive system." | ( Jia, F; Jiang, C; Li, Q; Liu, K; Mo, P; Sun, G; Wang, Y; Wei, M; Xu, X; Xu, Y; Zang, J; Zheng, H, 2019) |
| "Ovarian cancer is a common malignant cancer among women." | ( Cui, J; Gao, YM; Guo, YH; Hu, Y; Jiao, M; Liao, ZJ; Zhang, Q; Zhang, YB, 2019) |
| "Ovarian cancer is the second the most common gynaecological malignancy in developed countries." | ( Gray, S; Khor, XY; Yiannakis, D, 2019) |
| "Ovarian cancer is considered as one of the most lethal gynecological cancers, and cisplatin-based therapy has an important role as the first-line option for chemotherapy." | ( Mohammadzadeh, A; Molaparast, M; Sarkhosh-Inanlou, R; Shafiei-Irannejad, V, 2020) |
| "Ovarian cancer is the most lethal gynecological cancer of female reproductive system." | ( Abriata, JP; de Melo, SMG; Emery, FDS; Fumagalli, F; Lee, R; Luiz, MT; Marcato, PD; Marchetti, JM; Raspantini, GL; Swiech, K; Tofani, LB, 2019) |
| "Ovarian cancer is the third leading cause of death among gynecological cancers in women in China." | ( Feng, W; Tang, Z; Wang, Q; Yang, Y, 2019) |
| "Ovarian cancer is the main cause of death from gynecological cancer, with its poor prognosis mainly related to late diagnosis and chemoresistance (acquired or intrinsic) to conventional alkylating and reactive oxygen species (ROS)-generating drugs." | ( Antunes, AMM; Bonifácio, VDB; Fernandes, DGH; Hipólito, A; Mendes, C; Mota, P; Nunes, SC; Pereira, SA; Pires, RF; Ramos, C; Santos, I; Sequeira, CO; Serpa, J; Tomé, CS; Urso, D; Vicente, JB, 2019) |
| "Ovarian cancer is the deadliest gynecologic cancer." | ( Chi, JT; Ding, CC; Huang, Z; Murphy, SK; Wu, J; Yang, WH, 2020) |
| "IMPLICATIONS: Ovarian cancer is a malignancy with high mortality rates, with to date, no successful molecular characterization strategies." | ( Beiter, Y; Beyer, I; Braicu, EI; Brucker, S; Darb-Esfahani, S; Fehm, T; Gottstein, J; Hartkopf, AD; Honisch, E; Naskou, J; Neubauer, H; Niederacher, D; Rudelius, M; Schlensog, M; Sehouli, J; Staebler, A; Templin, MF; van Rensburg, R; Wallwiener, D; Walter, L, 2020) |
| "Ovarian cancer is the leading cause of gynecological cancer-related mortality." | ( Chen, T; Cui, Z; Li, X; Liu, Z; Tian, T; Wang, L; Yan, W; Zou, L, 2019) |
| "Ovarian cancer is the fifth leading cause of cancer-related deaths amongst women in the United States." | ( Kakar, SS; Straughn, AR, 2019) |
| "Ovarian cancer is the most lethal gynecologic malignancy in women with an increasing number of cases worldwide." | ( Liu, J; Tang, Q; Wang, SS; Yang, XS; Zheng, W; Zuo, Y, 2020) |
| "Ovarian cancer is the most lethal gynecological malignancy, often because of the frequent insurgence of chemoresistance to the drugs currently used." | ( Belluti, S; Costi, MP; D'Arca, D; Gozzi, G; Imbriano, C; Lauriola, A; Marverti, G; Ponterini, G, 2019) |
| "Ovarian cancer is a common malignancy in the female reproductive system with a high mortality rate." | ( Chen, FY; Dong, W; Fei, WD; Li, JQ; Wen, LJ; Yang, PL; Zhang, X; Zhang, XM; Zhao, MD; Zheng, CH, 2019) |
| "Ovarian cancer is the leading cause of death among gynecological malignancies." | ( Deng, L; Feng, D; Liang, H; Liang, J; Ling, B; Yan, K; Zhang, X, 2019) |
| "Epithelial ovarian cancers are insidious pathologies that give a poor prognosis due to their late discovery and the increasing emergence of chemoresistance." | ( Carreiras, F; Cosson, F; Giffard, F; Kellouche, S; Laurent-Issartel, C; Leroy-Dudal, J; Lubin-Germain, N; Uziel, J; Wambecke, A, 2019) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Amin, O; Baloch, T; Bithras, J; Kessous, R; Kogan, L; Laskov, I; López-Ozuna, VM; Wang, Q; Yasmeen, A, 2020) |
| "Ovarian cancer is the second-most lethal gynecological malignancy and the seventh-commonest cause of cancer-related death in women around the world." | ( Asano, H; Baghdadi, M; Daigo, Y; Endo, D; Endo, H; Hama, N; Ishikawa, K; Kato, H; Kato, T; Konno, Y; Miyagi, Y; Otsuka, R; Seino, KI; Suzuki, N; Takano, A; Tozawa, A; Wada, H; Watari, H; Yokose, T, 2020) |
| "Ovarian cancer is the most lethal gynecological malignancy, but the mechanisms of ovarian cancer progression and cisplatin resistance remain unclear." | ( Chen, C; Chen, M; Dong, X; Li, J; Shen, X; Yao, L; Yuan, L; Zhi, X; Zhu, C, 2020) |
| "Ovarian cancer is one of the most lethal gynecological malignancies throughout the world." | ( Dong, C; Illahi, GS; Lin, H; Lin, Q; Maswela, B; Shen, L; Wu, X, 2020) |
| "Ovarian cancer is the most lethal gynaecologic malignancy." | ( Jiang, H; Kong, B; Li, R; Li, Y; Ma, H; Sun, C; Wu, H; Yuan, C; Zhang, Z, 2019) |
| "Ovarian cancer is the major cause of mortality due to late stage diagnoses and lower survival rates, and the mechanism of cancer progression is not completely understood." | ( Li, F; Liu, Z; Xie, Y; Zhu, Y, 2020) |
| "Ovarian cancer is one of the most common and malignant cancers, partly due to its late diagnosis and high recurrence." | ( Carnero, A; Estevez-Garcia, P; Felipe-Abrio, B; Jiménez-García, MP; Muñoz-Galván, S; Perez, M; Suarez-Martinez, E; Verdugo-Sivianes, EM, 2020) |
| "Ovarian cancer is one of the most serious female malignancies worldwide." | ( Chen, J; Deng, Y; Guo, Y; Han, X; Hao, Y; Li, Q; Liao, W; Mao, L; Yuan, M; Zhang, R, 2020) |
| "The treatment of ovarian cancer is a big challenge for the present medicine." | ( Brzózka, Z; Flont, M; Jastrzębska, E, 2020) |
| "Ovarian cancer is the deadliest among gynecologic malignancies, which is connected with the development of chemoresistant forms of the disease in over 70% of patients after initial treatment regimen." | ( Antoszczak, M; Huczyński, A; Lach, MS; Michalak, M; Suchorska, WM, 2020) |
| "Ovarian cancer is a prominent disease that demonstrates high incidence rates in women and often presents multidrug resistance." | ( Cheng, ZG; Ma, LX; Peng, YB; Sun, Y; Ye, LL; Zou, MY, 2020) |
| "Epithelial ovarian cancer is still the leading cause of death in gynecology due to its resistance to platinum-based first-line chemotherapeutic drugs." | ( Akakuru, OU; He, Y; Jiang, Z; Li, A; Li, J; Wu, A; Xing, Y, 2020) |
| "Ovarian cancer is the fifth most common cause of cancer deaths among women with lesser prognostics." | ( Arul, S; Dayalan, H; Rajagopalan, H; Ravi, J, 2020) |
| "The epithelial ovarian cancer is one of the most lethal gynecological malignancy due to its late diagnostic and many relapses observed after first line of treatment." | ( Bellard, E; Chabot, S; Coustets, M; Ecochard, V; Ferron, G; Golzio, M; Ladurantie, C; Paquereau, L; Prat, M; Rols, MP, 2020) |
| "Ovarian cancer is prone to chemoresistance, leading to poor outcomes in patients." | ( Gao, X; Yu, JL, 2020) |
| "Ovarian cancer is the seventh most common cancer worldwide in women." | ( Baygar, T; Cavusoglu, T; Elbe, H; Ozgul Onal, M; Ozturk, F; Yigitturk, G, 2020) |
| "Ovarian cancer is the most lethal gynecologic malignancy worldwide with poor prognosis owing to chemotherapy resistance and cancer relapse." | ( Liu, J; Qiu, M; Su, Y; Wu, C; Zhao, B, 2020) |
| "Ovarian cancer is one of the most malignant tumors of the female reproductive system, with high invasiveness." | ( Jin, X; Li, D; Li, H; Ma, L; Ren, D; Sun, Y, 2020) |
| "Ovarian cancer is one of the most frequent types of gynaecological malignancy among women." | ( Adamek, D; Chmura, Ł; Grzelak, MM; Jach, R; Lankosz, M; Welter, E; Wróbel, PM, 2020) |
| "Ovarian cancer is the most deadly gynecologic cancer among women worldwide." | ( Guo, B; Wang, L; Zhou, S, 2020) |
| "Ovarian cancer is the leading cause of mortality among malignant gynecological tumors." | ( Castellanos-Mijangos, RD; Chávez-Munguía, B; González-Horta, C; Hernández-Ramírez, VI; Sánchez-Ramírez, B; Talamás-Rohana, P; Varela-Rodríguez, H; Varela-Rodríguez, L, 2020) |
| "Ovarian cancer is considered to be the most fatal reproductive cancers." | ( Feng, C; Mei, X; Shen, C; Wang, B; Wen, A; Zhang, X, 2020) |
| "Ovarian cancer is usually diagnosed at an advanced stage when five-year relative survival is <50%." | ( Dixon-Suen, S; Jordan, SJ; Majidi, A; Na, R; Webb, PM, 2020) |
| "Ovarian cancer is the most lethal gynecological cancer worldwide." | ( Chen, Y; Gu, WJ; Shen, JJ; Wang, ZF; Xu, J; Zhu, XF, 2020) |
| "Ovarian cancer is the most lethal gynecologic cancer." | ( Chen, H; Chen, Y; Gong, J; Lei, J; Li, Y; Wang, J; Wang, T; Wu, L; Yan, G; Zhang, J; Zhang, Q; Zhang, X; Zhao, H; Zhou, Y, 2020) |
| "Ovarian cancer is characterised by frequent recurrence due to persistent presence of residual cancer stem cells (CSCs)." | ( Chan, DW; Chan, KK; Cheung, AN; Jiang, YX; Leung, TH; Mo, XT; Ngan, HY; Siu, MK; Wang, JJ, 2020) |
| "BACKGROUND Ovarian cancer is one of the most common gynecological malignancies and mortality ranks the highest in cancer-associated death in females' worldwide." | ( Huang, P; Li, Q; Li, Y; Qi, B; Yao, H; Zhang, L, 2020) |
| "Ovarian cancer is difficult to diagnose early and has high rates of relapse and mortality." | ( Bae, H; Lee, JY; Lim, W; Song, G, 2020) |
| "Ovarian cancer is a highly aggressive disease which is treated by surgery and platinum chemotherapy." | ( Altaf, M; Ang, WH; Babak, MV; Ehsan, MA; Gushchin, AL; Isab, AA; Le, HV; Reichert, L, 2020) |
| "Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options." | ( Cai, S; Li, H; Sun, L; Wu, L; Yang, M; Zhang, X; Zhang, Y, 2020) |
| "Ovarian cancer is one of the leading causes of mortality in women worldwide." | ( Feng, Q; Li, X; Li, Z; Shan, C; Sheng, H; Sun, M; Sun, W; Xie, F; Zhang, S, 2020) |
| "Ovarian cancer is one of the most common malignant tumors in the female reproductive system with the highest mortality rate." | ( Duan, PJ; Xie, LL; Zhao, JH, 2020) |
| "Ovarian cancer is the most lethal malignant tumor of female reproductive system." | ( Chen, X; Chen, Y; Fang, L; Ge, X; Tan, X; Tian, H; Wang, P; Weng, L; Wu, Z; Zhang, J; Zhang, W; Zhao, L, 2021) |
| "Ovarian cancer is a serious threat to women's life and health, with a high mortality rate." | ( Han, B; Li, R; Lin, X; Liu, F; Tang, S; Xiao, J; Xu, H; Yang, M, 2020) |
| "Ovarian cancer is one of the most lethal cancer types in American women." | ( Chen, X; Fu, S; Lin, J; Xu, L; Zhang, R, 2020) |
| "Ovarian cancer is associated with high serum calcium and low serum albumin in clinical and epidemiologic studies." | ( Klug, MG; Robsahm, TE; Schwartz, GG; Tretli, S, 2020) |
| "Ovarian cancer is the most lethal gynaecological cancer, and resistance of platinum-based chemotherapy is the main reason for treatment failure." | ( Lou, G; Mi, W; Qi, R; Tian, S; Xing, L; Zhang, C; Zhang, Y, 2020) |
| "Ovarian cancer is the leading cause of cancer-related death among women." | ( Chou, PC; Huang, CF; Lee, MH; Lin, JH; Sung, PL; Wen, KC; Wu, ATH; Yeung, SJ, 2020) |
| "Ovarian cancer is prone to recurrence and chemotherapy resistance." | ( Hui, B; Shao, YW; Shi, X; Wang, S; Wang, Y; Xing, F; Zhang, J; Zhang, X, 2020) |
| "Ovarian cancer is the leading cause of death among gynecologic cancer patients." | ( Hou, HX; Kang, JK; Li, DR; Li, JY; Li, XX; Pang, HF; Tian, W; Wang, CM; Zhao, YH, 2020) |
| "Ovarian cancer is amongst the most common gynecological and lethal cancers in women affecting different age groups (20-60)." | ( Dodamani, S; Tendulkar, S, 2021) |
| "Ovarian cancer is a severe health threat for women with increased incidence and stymied development in diagnosis and therapy." | ( Dou, H; Su, S; Wang, Z; Zhang, Q, 2021) |
| "Ovarian cancer is one of the most common gynecological cancers with high morbidity and mortality, which seriously endangers women's health and quality of life." | ( Feng, D; Li, P; Lin, X; Lv, Y, 2020) |
| "High fatality in ovarian cancer is attributed to metastasis, propagated by the release of multi-cellular aggregates/spheroids into the peritoneal cavity and their subsequent mesothelial invasion of peritoneal organs." | ( Acar, H; Baghdasaryan, O; Gunay, G; Hamsici, S; Kamatar, A; Kirit, HA, 2020) |
| "Ovarian cancer is a malignant tumor that attacks reproductive organs of women." | ( Astuti, I; Haryana, SM; Martien, R; Sesotyosari, SL; Suardi, RB; Wardana, T; Ysrafil, Y, 2020) |
| "Ovarian cancer is the deadliest gynaecologic malignancy, and the five-year survival rate of patients is less than 35% worldwide." | ( Hao, L; Jiang, JY; Li, C; Liu, BQ; Qiao, HY; Wang, HQ; Wang, JM; Yan, J; Zhao, FY, 2021) |
| "Ovarian cancer is the second commonly seen cancer in the US, patients with ovarian cancer are commonly diagnosed in the advanced stage." | ( Cui, Y; Lv, Q; Ma, L; Shen, G, 2021) |
| "Ovarian cancer is a gynecological cancer that has the highest mortality rate and is often resistant to conventional treatments." | ( Cui, Y; Rong, F; Zhou, J, 2020) |
| "Ovarian cancer is one of the most common malignant tumors in women." | ( Chen, C; Chen, H; Chen, X; Li, R; Ma, B; Wu, J, 2020) |
| "Ovarian cancer is the most lethal cancer in the female reproductive system." | ( Guo, H; Li, F; Wang, H; Wang, T; Wang, Z; Wu, W; Zhang, S, 2020) |
| "Ovarian cancer is one of three malignant tumors of the female reproductive system." | ( Gao, J; Hu, X; Lin, S; Zhu, H; Zou, X, 2020) |
| "Ovarian cancer is a lethal disease with few modifiable risk factors." | ( Lin, S; Yang, H, 2021) |
| "Ovarian cancer is the fifth leading cause of cancer deaths." | ( Bandolik, JJ; Hamacher, A; Hansen, FK; Kassack, MU; Kurz, T; Rodrigues Moita, AJ, 2020) |
| "Ovarian cancer is a challenging disease." | ( Bhosale, P; Ganeshan, D; Gulati, AT; Iyer, R; Palmquist, S; Virarkar, M, 2021) |
| "Ovarian cancer is the leading cause of death from gynecologic malignancies." | ( Kulbacka, J; Piwowar, A; Roik, J; Saczko, J; Sawicka, E, 2020) |
| "Ovarian cancer is a common gynecological malignant tumor, second only to cervical cancer and uterine body cancer." | ( Du, X; Guo, J; Wang, Y; Yue, H, 2021) |
| "Ovarian cancer is a stubborn malignancy of gynecological system with a high mortality rate." | ( Cheng, Y; Hu, Y; Lin, Y; Ran, M; Wang, B; Zheng, S, 2020) |
| "Most epithelial ovarian cancers are characterized by a TP53 mutation causing dysfunction at the G1/S checkpoint, which makes tumor cells highly dependent on Chk1-mediated G/M phase cell-cycle arrest for DNA repair." | ( Cho, HY; Kim, YB; No, JH; Park, WH, 2021) |
| "Ovarian cancer is the first leading cause of death in gynecological cancers." | ( Jiang, Y; Li, J; Pei, M; Wu, L; Zhang, S, 2021) |
| "Ovarian cancer is a gynecological malignancy with high mortality." | ( Deng, X; Fan, L; Liu, Z; Sun, L; Wang, J; Zhang, Y; Zhao, L, 2021) |
| "Ovarian cancer is one of the most common gynecological malignancies in the world." | ( Ci, X; Fan, C; Fan, X; Li, J; Wei, Z; Xie, M; Zhang, S; Zhao, F; Zheng, H, 2021) |
| "More patients with ovarian cancer are being treated with poly(adenosine diphosphate-ribose) polymerase inhibitors because regulatory agencies have granted these drugs new approvals for a variety of treatment indications." | ( Fu, S; Giordano, SH; Harrison, RF; Lu, KH; Meyer, LA; Sun, CC; Zhao, H, 2021) |
| "Ovarian cancer is poorly treatable due, at least in part, to induced drug resistance to taxol- and cisplatin-based chemotherapy." | ( Chang, TC; Chao, CCK; Huang, SL; Sun, NK, 2021) |
| "Ovarian cancer is a known risk factor of venous thromboembolism (VTE)." | ( Aman, M; Asada, Y; Gi, T; Kawagoe, Y; Kuwahara, A; Onishi, J; Sameshima, H; Sato, Y; Yamashita, A, 2021) |
| "Ovarian cancer is the most lethal gynaecological malignancy." | ( Oehler, MK; Pitman, M; Pitson, SM, 2021) |
| "Ovarian cancer is the most deadly gynaecology related cancer due to its high metastasizing ability." | ( Arunakaran, J; Dhanaraj, T; Mohan, M, 2021) |
| "Ovarian cancer is one of the most common diseases of the female reproductive system." | ( Alexandrov, VA; Barakova, NV; Baranenko, DA; Bespalov, VG; Ermakova, ED; Semenov, AL; Tochilnikov, GV; Zhilinskaya, NT, 2021) |
| "Most patients with ovarian cancer are diagnosed at an advanced stage of the disease for the first time because of its insignificant early clinical symptoms." | ( Dong, D; Luo, H; Shen, L; Sun, L; Xia, M; Zhang, Y, 2021) |
| "Ovarian cancer is a disease with the highest mortality in gynecologic malignancies." | ( Jiao, W; Kong, D; Li, H; Liu, Y; Peng, X; Shao, J; Wang, R; Wang, W; Xu, Y, 2021) |
| "Ovarian cancer is the most lethal of the gynecologic malignancies." | ( Chan, HC; Chang, HW; Liao, YH; Liu, CH, 2021) |
| "Ovarian cancer is the most common reproductive system cancer and has a high mortality rate in women." | ( Fu, L; Gao, H; Jin, TW; Liu, S; Sang, C; Song, Y; Wang, Z; Zhang, S; Zhao, Y; Zou, X, 2021) |
| "Ovarian cancer is one of the highly prominent gynecological malignancies after breast cancer." | ( Qazi, S; Raza, K, 2021) |
| "Ovarian cancer is a chemoresponsive tumor with very high initial response rates to standard therapy consisting of platinum/paclitaxel." | ( Fang, F; Nephew, KP; Ozes, A; Wang, W, 2021) |
| "Ovarian cancer is a deadly gynecologic cancer, and the majority of patients with ovarian cancer experience relapse after traditional treatment." | ( Chen, J; Cui, M; Liu, J; Peng, Y; Shangguan, M; Tan, W; Zhang, L; Zhao, B; Zhao, J; Zhao, S, 2021) |
| "Ovarian cancer is one of the most common cancers of the reproductive organs." | ( Cymbaluk-Płoska, A; Kozłowski, M; Nowak, K, 2021) |
| "Ovarian cancer is the most lethal gynecologic malignancy due to the tumor's acquisition of chemoresistance to platinum-based chemotherapy." | ( Hasegawa-Minato, J; Ishibashi, M; Kitatani, K; Misawa, T; Shigeta, S; Toyoshima, M; Yaegashi, N, 2021) |
| "Ovarian cancer is highly metastatic, with a high frequency of relapse, and is the most fatal gynecologic malignancy in women worldwide." | ( Chen, HJ; Chen, IU; Cheng, CM; Cheng, TL; Cheng, YA; Ho, KW; Huang, BC; Huang, MY; Lai, HW; Li, CC; Lin, WW; Liu, HJ; Lu, YC, 2021) |
| "Ovarian cancer is the most fatal gynecologic malignancy in the United States." | ( Braley, C; Connor, EV; Crean-Tate, KK; DeBernardo, R; Dey, G; Esakov, E; Lathia, J; Michener, CM; Reizes, O; Rose, PG; Saygin, C; Silver, DJ; Trestan, A; Turaga, SM, 2021) |
| "Ovarian cancer is the most deadly gynecological malignant tumor in the world today." | ( Chunfang, W; Jia, J; Jing, B; Ruitao, Z; Ruixia, G; Weiwei, Z; Wenwen, W; Ya, X, 2021) |
| "Ovarian cancer is the fifth most common cause of cancer deaths among American women." | ( Li, C; Lin, J; Roque, DM; Yang, X; Zhang, R, 2021) |
| "Because most ovarian cancers are BRCA wild-type, it is necessary to extend the usage of PARPis." | ( Lin, J; Wang, T; Zhang, R, 2021) |
| "Both breast and ovarian cancer are hormone dependent cancers, meaning they cannot grow without the presence of hormones." | ( Blanton, HL; Guindon, J; McHann, MC, 2021) |
| "Advanced stage ovarian cancer is challenging to treat due to widespread seeding of tumor spheroids throughout the mesothelial lining of the peritoneal cavity." | ( Azarin, SM; Choi, Y; Ferry, VE; Geller, MA; Jones, VO; Kim, DW; Lee, HR, 2021) |
| "Ovarian cancer is the most lethal gynecologic malignant cancer, frequently due to its late diagnosis and high recurrence." | ( Huyan, LY; Jiang, JY; Li, C; Liu, BQ; Wang, HQ; Wang, JM; Yan, J; Zhang, Q; Zhao, FY, 2021) |
| "Ovarian cancer is the most frequent cause of gynecologic malignancies associated death." | ( Gao, Q; Hao, L; Huyan, LY; Jiang, JY; Li, C; Liu, BQ; Wang, HQ; Wang, JM; Yan, J; Zhang, Q, 2021) |
| "Ovarian cancer is the leading cause of death among all gynecological cancers." | ( Jiang, L; Jiao, J; Luo, Y, 2021) |
| "Ovarian cancer is one of the most common malignancies often resulting in a poor prognosis." | ( Gao, S; Wang, L, 2021) |
| "Ovarian cancer is the third most common cancer and the second most common cause of gynecologic cancer death in women." | ( Chen, C; Haydon, RC; He, F; He, TC; Huang, L; Liu, Q; Luu, HH; Ni, N; Reid, RR; Shen, L; Shi, D; Tang, L; Wagstaff, W; Wang, H; Zhang, J; Zhao, L, 2021) |
| "Ovarian cancer is a lethal gynaecologic malignancy with poor diagnosis and prognosis." | ( Gu, W; Han, X; Jin, Z; Wu, Y, 2021) |
| "Ovarian cancer is known as one of the most common malignancies of the gynecological system, whose treatment is still not satisfactory because of the unclear understanding of molecular mechanism." | ( Huang, J; Li, W; Liu, N; Yan, L; Zhu, D, 2021) |
| "Epithelial ovarian cancer is a lethal gynecological cancer." | ( Elzarkaa, AA; Malik, E; Soliman, AA, 2021) |
| "Ovarian cancer is the most lethal gynecological malignancy, with serous histotype as the most prevalent epithelial ovarian cancer (EOC)." | ( Alves, PCM; da Silva, RF; de Souza-Araújo, CN; Derchain, S; Fernandes, LGR; Guimarães, F; Mazzola, TN; Tonetti, CR; Yoshida, A, 2021) |
| "Ovarian cancer is a lethal type of cancer which is initiated to the ovaries and affects 1 out of every 75 women." | ( Asemi, Z; Hallajzadeh, J; Mansournia, MA; Sadoughi, F; Yousefi, B, 2022) |
| "Ovarian cancer is the deadliest gynecological malignancy worldwide." | ( Ahn, J; Cha, H; Jeong, HS; Kang, YJ; Koo, HS; Lee, D; Yoon, MJ, 2021) |
| "Ovarian cancer is the most malignant gynecologic cancer." | ( Chen, Q; Gong, G; He, L; Wang, Y; Wu, D; Wu, X, 2021) |
| "Ovarian cancer is the leading cause of gynecological malignancy-related deaths, due to its widespread intraperitoneal metastases and acquired chemoresistance." | ( Dorigo, O; Eggold, JT; Enejder, A; Fuh, KC; Heilshorn, SC; Hubka, KM; Krishnan, V; LeSavage, BL; Ma, C; Natarajan, S; Qian, J; Rankin, EB; Xiao, Y, 2021) |
| "Ovarian cancer is associated with poor prognosis." | ( Chia, CS; Hendrikson, J; Liu, Y; Nadarajah, R; Ng, G; Ng, WH; Ong, CJ; Ong, XS; Shannon, NB; Soo, KC; Tan, GHC; Tan, JW; Tan, LLY; Tan, QX; Teo, MCC; Wong, JSM, 2021) |
| "Ovarian cancer is characterized by aberrant activation of the mitogen-activated protein kinase (MAPK), highlighting the importance of targeting the MAPK pathway as an attractive therapeutic strategy." | ( Bei, JX; Chan, JY; Chen, J; Chen, JP; Chen, R; Deng, P; Guan, P; Hong, JH; Kang, T; Koh, J; Lai, X; Liang, W; Liu, H; Liu, J; Liu, S; Lu, H; Sun, Y; Tan, J; Teh, BT; Wang, B; Xiao, R; Xiong, Y; Yao, X; Yin, J; Yu, Q; Yu, Z; Zou, Q, 2021) |
| "Ovarian cancer is the most lethal gynecologic malignancy worldwide." | ( Chen, Y; Gu, X; Hu, W; Li, M, 2021) |
| "Ovarian cancer is the major cause of death in gynecologic diseases worldwide." | ( Chao, H; Li, D; Zhang, M, 2021) |
| "In 2021, ovarian cancer is predicted to be responsible for ≈ 43,770 deaths in Europe and the USA combined." | ( Lee, A, 2021) |
| "Epithelial ovarian cancer is a gynecological cancer with the highest mortality rate, and it exhibits resistance to conventional drugs." | ( Choe, HS; Choi, KU; Kim, DK; Kim, JH; Kwon, SG; Lee, H; Shin, MJ, 2021) |
| "Recurrent ovarian cancer is characterized by high tumor heterogeneity; therefore, it is susceptible to epigenetic therapy in classic 2D tissue culture and rodent models." | ( Aikins, JK; Bilbao, M; Hunter, K; Kass, SL; Katz, C; Ostrovsky, O; Smith, D; Warshal, D, 2021) |
| "Ovarian cancers are among the fatal malignancies affecting women globally, mainly due to their metastatic and chemoresistant nature." | ( Choudhary, B; Koroth, J; Manjunath, M; Narayan, S; Ravindran, F, 2021) |
| "Most women with ovarian cancer are treated with chemotherapy before or after surgery." | ( Condello, M; Gallo, FR; Meschini, S; Multari, G; Pellegrini, E; Vecchiotti, D; Zazzeroni, F, 2022) |
| "Ovarian cancer is the most lethal gynecologic cancer." | ( Beyer, S; Burges, A; Chen, F; Czogalla, B; Hester, A; Jeschke, U; Kolben, T; Kolben, TM; Mahner, S; Mayerhofer, A; Mayr, D; Meister, S; Schmoeckel, E; Trillsch, F, 2022) |
| "Ovarian cancer is a devastating gynecological malignancy and frequently presents as an advanced carcinoma with disseminated peritoneum metastasis." | ( Huang, T; Liu, Y; Pan, Y; Tang, Y; Tian, M, 2021) |
| "Ovarian cancer is one of the most lethal gynecologic malignancies." | ( He, Y; Wu, S; Xiang, J; Zhou, L, 2021) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Januchowski, R; Jopek, K; Kazmierczak, D; Nowicki, M; Rucinski, M; Sterzynska, K, 2022) |
| "Ovarian cancer is one of the most common gynecologic malignancies in women and has a poor prognosis." | ( Cicka, D; Doyle, S; Du, Y; Fan, D; Fu, H; Ivanov, AA; Mo, X; Niu, Q; Qian, K; Shu, C; Wuhafu, A; Zheng, X, 2022) |
| "Ovarian cancer is the most lethal gynecological malignancy in women." | ( Albert, I; Gopalan, L; Praul, CA; Ramachandran, R; Sebastian, A, 2021) |
| "Ovarian cancer is the deadliest gynecologic cancer, with a 5-year survival rate of 30%, when the disease has spread throughout the peritoneal cavity." | ( Anastasia, A; Baakza, H; Bani, MR; Cadogan, EB; Chiorino, G; Dellavedova, G; Ghilardi, C; Giavazzi, R; James, N; Ramos-Montoya, A; Russo, M; Wilson, J, 2022) |
| "Ovarian cancer is the second leading cause of cancer-related deaths in women, with low five-year survival rates." | ( Hu, X; Li, G; Wu, J; Wu, T; Wu, Y; Xiao, D; Xu, S; Yan, X; Yang, X, 2022) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Chen, J; Chen, Z; Chu, R; Dou, Z; Kong, B; Li, R; Liu, C; Liu, P; Qiu, C; Song, K; Wang, K; Wang, Z; Yao, S; Zhang, X; Zhao, C, 2022) |
| "Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases were diagnosed in 2018, with 184,799 deaths." | ( Clamp, A; Cook, A; Goh, BC; Goh, RM; Huang, RY; James, E; Ngoi, NY; Soon, YY; Syn, NL; Tan, DS, 2022) |
| "Ovarian cancer is one of the fatal gynecological cancers around the world." | ( Chen, J; Ni, D; Qiu, C; Wu, F; Xiao, Z; Xu, C; Zhang, J; Zhang, T; Zhang, X; Zheng, P; Zhu, J; Zou, P, 2022) |
| "Ovarian cancer is initially responsive to frontline chemotherapy." | ( Binder, PS; Buchanan, T; Cripe, J; Hashim, YM; Hawkins, WG; Mutch, DG; Powell, MA; Spitzer, D; Vangveravong, S; Zamorano, A, 2022) |
| "Ovarian cancer is the most lethal gynecological cancer type in the United States." | ( Lin, J; Reader, J; Roque, DM; Zhang, R, 2022) |
| "Ovarian cancer is the fifth most common cause of cancer-related death in women." | ( Akasu-Nagayoshi, Y; Akiyama, T; Hayashi, T; Kawabata, A; Nakato, R; Okamoto, A; Shimizu, N; Shirahige, K; Yamada, A; Yokota, N, 2022) |
| "Ovarian cancer is a very common gynecological malignant tumor." | ( Han, B; Jiang, W; Lan, J; Li, H; Li, R; Lin, X; Liu, F; Su, B; Xu, H; Yang, D; Yang, M, 2022) |
| "Ovarian cancer is the most lethal malignancy with depressive 5-year survival rate, mainly due to patients with advanced stages experience tumor recurrence and resistance to the current chemotherapeutic agents." | ( Gao, T; He, J; He, S; Li, L; Liang, S; Liu, Y, 2022) |
| "Ovarian cancer is the deadliest gynecological malignancy, usually not detected until the late stages." | ( Eren, CY; Gurer, HG; Gursoy, OO; Sezer, CV, 2022) |
| "Epithelial ovarian cancers are among the most aggressive forms of gynecological malignancies." | ( Brezenger, ME; Burkhard, K; Crochran, DE; Fermanich, W; Geza, IA; Horst, EN; Mehta, G; Mehta, P; Novak, CM; Schlautman, DC; Snyder, CS; Tran, LA; Verma, R, 2022) |
| "Platinum-resistant ovarian cancer is one of the most common and refractory gynecologic cancers around the world." | ( Gou, W; Guo, J; Hou, W; Li, Y; Liu, Q; Ning, H; Shang, H; Sun, X; Wei, H, 2022) |
| "Ovarian cancer is a common gynecologic malignancy with a high fatality rate." | ( Chen, J; Chen, Y; Huang, X; Li, B; Liu, P; Pan, Y; Qian, ZR; Qiu, M; Wang, Q; Zhang, S; Zhao, J, 2022) |
| "Ovarian cancer is one of the lethal gynecologic cancers." | ( Abbady, AQ; Alghamian, Y; Murad, H; Soukkarieh, C, 2022) |
| "Ovarian cancer is a gynaecological tumour has high incidence and mortality rates." | ( Ding, P; Liu, X; Liu, Y; Wang, C; Wang, H, 2022) |
| "Ovarian cancer is the most common type of gynecological cancer, which often remains undiagnosed until the later stages of the disease or until cancer has metastasized towards the peritoneum and omentum, compelling it to be a deadly disease complicating the prognosis and therapeutics." | ( Dhingra, A; Kumar, A; Kumar, P; Sharma, D; Singh, S, 2022) |
| "Ovarian cancer is the fifth leading cause of cancer-related deaths in women." | ( Amoresano, A; Carpentieri, A; Fiaschi, T; Gamberi, T; Magherini, F; Massai, L; Melchiorre, C; Messori, L; Modesti, A, 2022) |
| "Ovarian cancer is the most lethal gynecologic malignancy, and a major barrier to effective treatment is resistance to platinum-based chemotherapy." | ( Fenton, SE; Rickard, BP; Rizvi, I; Tan, X, 2022) |
| "Ovarian cancer is a disease with significant impact, because more than half of cases exhibit recurrence despite platinum therapy." | ( Aoki, Y; Arakaki, Y; Kudaka, W; Nakamoto, T; Nakasone, T; Ooyama, T; Shimoji, Y; Taira, Y, 2022) |
| "Ovarian cancer is the eminent gynecological malignancy and chemoresistance remains a major reason for poor in ovarian cancer patients." | ( Feng, Q; Quan, Q; Sheng, H; Sheng, X; Zhang, P, 2022) |
| "Ovarian cancer is a serious threat to female health, although the incidence of it is relatively low, its mortality rate remains high due to its intense invasion and metastasis." | ( Liu, XX; Tan, S; Tang, L; Yang, XD; Zou, ZW, 2023) |
| "Ovarian cancer is one of the most serious problems in modern oncological gynecology." | ( Chudecka-Glaz, AM; Kukla, A; Misiek, M; Piotrowska, K, 2022) |
| "Ovarian cancer is one of the three major gynecological malignancies." | ( Cao, X; Ge, H; Guo, T; He, C; Huang, A; Qian, H; Wang, X; Yu, H; Yuan, D; Zhao, Y; Zhu, D, 2022) |
| "Ovarian cancer is the most lethal gynecologic malignancy." | ( Guo, X; Jia, J; Liu, R; Miao, D; Pei, J; Shen, Y; Tang, H; Xie, Y; Zheng, Y; Zhu, M, 2022) |
| "Ovarian cancer is the leading cause of death in gynecological malignancies worldwide." | ( Sun, H; Zhang, H; Zheng, Y, 2022) |
| "Ovarian cancer is a carcinoma that affects women and that has a high mortality rate." | ( Bae, S; Hong, J; Jang, SK; Jin, HO; Kim, G; Kim, YJ; Lee, JH; Park, IC, 2022) |
| "Ovarian cancer is one of the leading causes of cancer-related mortality in women, and is often associated with drug resistance." | ( Abdullah, N; Ahmed, I; Al Bahlani, S; Al Balushi, N; Al Dhahli, B; Burney, IA; Dobretsov, S; Hassan, SI; Tamimi, Y; Tsang, BK, 2022) |
| "Ovarian cancer is one of the deadliest epithelial malignancies in women, owing to the multidrug resistance that restricts the success of conventional chemotherapy, carboplatin and paclitaxel." | ( Decaudin, D; Idlas, P; Jaouen, G; Ladaycia, A; Lepeltier, E; Némati, F; Passirani, C; Pigeon, P, 2022) |
| "The hallmark of ovarian cancer is its high mortality rate attributed to the existence of cancer stem cells (CSCs) subpopulations which result in therapy recurrence and metastasis." | ( Fang, H; Gao, Z; Jiang, Q; Li, C; Li, G; Li, N; Li, X; Nie, S; Ren, S; Wang, Z; Zhang, J, 2022) |
| "Ovarian cancer is one of the most common and lethal gynecological malignancies." | ( Jiang, X; Liu, Q; Liu, Y, 2022) |
| "Ovarian cancer is one of the deadliest cancers in women, due to its heterogeneity and usually late diagnosis." | ( Kallay, E; Piatek, K; Schepelmann, M, 2022) |
| "Ovarian cancer is the seventh most common cancer globally, and the second most common cancer among women with significant mortality." | ( AlAlikhan, A; Ebrahimi, S; Ghahremanloo, A; Hashemy, SI; Javid, H, 2022) |
| "Ovarian cancer is the most common malignancy in females." | ( Huang, L; Wu, X; Zhang, J, 2022) |
| "Oovarian cancer is a common lethal gynecological malignancy with a high occurrence and dismal prognosis on account of its drug resistance." | ( Li, N; Liu, Y; Wang, P; Wang, X; Yu, Y; Zhang, F; Zhang, J; Zhao, H, 2022) |
| "Ovarian cancer is the second most common cancer to cause large death among gynecological tumors." | ( Gao, Y; Meng, Y; Qu, N; Wang, C, 2023) |
| "Ovarian cancer is the fifth leading cause of cancer, followed by front line is mostly platinum agents and PARP inhibitors, and very limited option in later lines." | ( Park, JY; Park, SG; Seo, MD; Sim, YH; Um, YJ, 2022) |
| "Ovarian cancer is a highly fatal gynecologic malignancy worldwide." | ( Cai, X; He, L; Li, G; Ling, M; Liu, Q; Mai, Z; Sun, R; Wang, X; Xiao, Y; Yang, W; Yu, K; Yu, Z; Zhong, M, 2022) |
| "Ovarian cancer is one of the most dangerous gynecologic cancers worldwide, showing a high fatality rate and recurrence due to diagnosis at an advanced stage of the disease and the occurrence of chemoresistance, which weakens the therapeutic effects of the chemotherapeutic treatments." | ( Tossetta, G, 2022) |
| "Breast and ovarian cancers are the most common cancer types in females worldwide and in India." | ( Joshi, CG; Joshi, MN; Pandit, RJ; Pandya, S; Patel, PS; Puvar, A; Shah, FD; Sheth, H; Tarapara, B; Vora, H; Waghela, BN, 2023) |
| "Breast and ovarian cancers are the most common cancer types in females worldwide and in India." | ( Joshi, CG; Joshi, MN; Pandit, RJ; Pandya, S; Patel, PS; Puvar, A; Shah, FD; Sheth, H; Tarapara, B; Vora, H; Waghela, BN, 2023) |
| "Breast and ovarian cancers are the most common cancer types in females worldwide and in India." | ( Joshi, CG; Joshi, MN; Pandit, RJ; Pandya, S; Patel, PS; Puvar, A; Shah, FD; Sheth, H; Tarapara, B; Vora, H; Waghela, BN, 2023) |
| "Epithelial ovarian cancer is the most lethal gynaecological cancer worldwide." | ( Ahmed, N; Goonetilleke, L; Kadife, E; Kannourakis, G; Leung, D; Lokman, NA; Oehler, MK; Price, ZK; Ricciardelli, C; Wang, W, 2022) |
| "Epithelial ovarian cancer is the most lethal gynaecological cancer worldwide." | ( Ahmed, N; Goonetilleke, L; Kadife, E; Kannourakis, G; Leung, D; Lokman, NA; Oehler, MK; Price, ZK; Ricciardelli, C; Wang, W, 2022) |
| "Ovarian cancer is currently the most lethal gynecological cancer." | ( Chen, F; Gui, A; Huang, X; Liu, W; Qiu, S; Yan, Y; Yang, L; Zhu, S; Zuo, J, 2022) |
| "Ovarian cancer is currently the most lethal gynecological cancer." | ( Chen, F; Gui, A; Huang, X; Liu, W; Qiu, S; Yan, Y; Yang, L; Zhu, S; Zuo, J, 2022) |
| "Ovarian cancer is the most lethal in gynecologic malignancies." | ( Murata, T; Ramos, JW; Yamaguchi, M, 2023) |
| "Ovarian cancer is the leading cause of cancer deaths in female patients." | ( Chaudhari, BP; Gajbhiye, V; Kumar, P; Salve, R, 2023) |
| "Ovarian cancer is a serious threat to women's health, and resistance to chemotherapeutic drugs constitutes one of the principal reasons for ovarian cancer recurrence and the low overall survival rate." | ( Liu, C; Mai, Z; Xia, C; Xu, L; Yin, S, 2023) |
| "Breast and ovarian cancers are two common malignancies in women and a leading cause of death globally." | ( Alemi, M; Aminzade, Z; Bayanati, M; Noori, S; Nourbakhsh, M; Zarghi, A, 2023) |
| "Ovarian cancer is a gynecological malignancy characterized with increasing death rate in the world." | ( Chen, Y; Huang, S; Liang, K; Pan, X, 2023) |
| "Ovarian cancer is the second cause of death among gynecological malignancies." | ( Bao, H; Chen, H; Guo, X; Liu, R; Lv, Z; Miao, D; Pei, J; Ren, Z; Shen, Y; Tang, H; Wang, S; Xie, Y; Zhang, Y; Zheng, Y; Zhu, M, 2023) |
| "Ovarian cancer is one of leading causes of cancer death in gynecological tumor." | ( Lei, J; Xiao, D; Xie, Z; Xu, J; Yu, J, 2023) |
| "Ovarian cancer is a gynecological tumor with a poor prognosis." | ( Chen, S; Huang, C; Huang, Q; Qin, L, 2023) |
| "Ovarian cancer is a lethal reproductive tumour affecting women worldwide." | ( Abd Aziz, NHB; Atallah, GA; Chew, KT; Kampan, NC; Md Zin, RR; Mohd Mokhtar, N; Shafiee, MNB, 2023) |
| "Ovarian cancers are hallmarked by chromosomal instability." | ( Crosbie, EJ; Edmondson, RJ; Faraahi, ZF; Gavrielides, N; Hawarden, A; Jones, DM; McCormick, A; Price, MJ; Roberts, C; Russell, B; Tyagi, S; Waddell, CA; Walker, TDJ; Whalley, B; Woodhouse, LC, 2023) |
| "High-grade serous ovarian cancer is unique in expressing unusually high levels of LGR5 and LGR6 mRNA." | ( Barth, EI; Gately, D; Howell, SB; Mulero, MC; Rice, C; Shang, X; Tikle, S; Wang, K; Wong, C, 2023) |
| "Epithelial ovarian cancer is the most lethal gynecological malignancy, owing notably to its high rate of therapy-resistant recurrence in spite of good initial response to chemotherapy." | ( Carmona, E; Leclerc-Desaulniers, K; Lheureux, S; Mes-Masson, AM; Oza, AM; Provencher, DM; Radulovich, N; Rottapel, R; Sauriol, A; Udaskin, ML, 2023) |
| "Ovarian cancer is the most lethal gynecological malignancy." | ( Bi, B; Chen, G; Chen, P; Chen, Y; Chen, ZY; He, Y; Huang, X; Pan, Y; Qiu, M; Zeng, L; Zhao, J, 2023) |
| "Ovarian cancer is the most lethal gynecologic malignancy." | ( Cainap, C; Cainap, SS; Havasi, A; Havasi, AT, 2023) |
| "Ovarian cancer is the most lethal cancer in gynaecology." | ( Abdallah, Y; Abdel-Rasheed, M; Moawad, R; Mousa, AB; Zaher, AMA, 2023) |
| "Ovarian cancer is the leading cause of death among gynecological malignancies." | ( Gao, Q; Huang, S; Jiang, Y; Jin, L; Li, B; Li, T; Lin, Y; Mao, X; Nowialis, P; Song, L; Song, Q; Xing, C; Zheng, G, 2023) |
| "Ovarian cancer is one of the most common malignant tumors in gynecology with a high incidence." | ( Gao, M; Gong, X; Liu, Y; Lv, X; Wu, Y; Yang, Y; Yao, Q, 2023) |
| "Ovarian cancers are subdivided into histological subtypes that have significant molecular and clinical differences, with high-grade serous carcinoma representing the most common and aggressive subtype." | ( Beynon, AL; Das, N; Edwards, K; Francis, LW; Garcia, J; Gonzalez, D; Harker, NR; James, DW; Lutchman-Singh, K; Margarit, L; Prinjha, RK; Quintela, M; Rioja, I; Steven Conlan, R, 2023) |
| "Ovarian cancer is a fatal gynecological malignancy." | ( Li, W; Xie, J; Zhang, G; Zhang, R; Zhao, X, 2023) |
| "Ovarian cancer is one of the most common gynecological cancers with high mortality rate." | ( Dai, X; Li, J; Li, L; Li, M; Mao, H; Wang, C; Xu, H; Yan, X, 2023) |
| "Ovarian cancer is the deadliest gynecological malignancy of the reproductive organs in the United States." | ( Bae-Jump, V; Deng, B; Emanuele, MJ; Fan, Y; Huang, Y; Pierce, SR; Shen, X; Staley, A; Sun, W; Suo, H; Tucker, K; West, L; Yin, Y; Zhang, X; Zhao, Z; Zhou, C, 2023) |
| "Ovarian cancer is one of the most dangerous gynecological cancers." | ( Dzik, R; Kabała-Dzik, A; Kleczka, A, 2023) |
| "Ovarian cancer is the leading cause of death linked to gynecological cancers." | ( Chen, Y; Guo, C; Li, H; Liang, L; Liu, X; Mo, J; Yang, L, 2023) |
| "Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and is initially very responsive to platinum-based chemotherapy." | ( Konstantinopoulos, PA; Matulonis, UA, 2023) |
| "Ovarian cancer is known as the second leading cause of gynecologic cancer-associated deaths in women worldwide." | ( Chen, J; Feng, M; Guo, A; Lin, J; Lin, X; Wang, L; Zhong, P, 2023) |
| "Ovarian cancer is a gynecological malignancy with a poor prognosis." | ( Asano, F; Haruna, Y; Kobayashi, Y; Matsumoto, H; Momomura, M; Morisada, T; Shibuya, H; Tsushima, K, 2023) |
| "Ovarian cancer is one of the most frequent and deadly gynaecological cancers, often resistant to platinum-based chemotherapy, the current standard of care." | ( Denel-Bobrowska, M; Klink, M; Kowalewicz-Kulbat, M; Krawczyk, KT; Locht, C; Olejniczak, AB; Rykowski, S; Szulc-Kielbik, I, 2023) |
| "Ovarian cancer is one of the most frequent and deadly gynaecological cancers, often resistant to platinum-based chemotherapy, the current standard of care." | ( Denel-Bobrowska, M; Klink, M; Kowalewicz-Kulbat, M; Krawczyk, KT; Locht, C; Olejniczak, AB; Rykowski, S; Szulc-Kielbik, I, 2023) |
| "Ovarian cancer is the second leading cause of gynecologic cancer-associated deaths." | ( Lin, YB; Xu, BH, 2023) |
| "Ovarian cancer is the fifth leading cause of cancer-related death in women." | ( Çil, N; Mete, GA; Önder, E; Seçme, M, 2024) |
| "Ovarian cancer is the leading cause of gynecologic cancer-related death, and PARP inhibitors (PARPis) are becoming a promising treatment option, as demonstrated by recent clinical trials." | ( Chai, R; Dai, Y; Gao, Y; Kang, Y; Lu, C; Xu, C; Xu, J; Yu, B, 2023) |
| "Ovarian cancer is one of the most common cancers in women and the most concerning issues in gynecological oncology in recent years." | ( Kozieł, MJ; Piastowska-Ciesielska, AW, 2023) |
| "Ovarian cancer is commonly associated with a poor prognosis due to metastasis and chemoresistance." | ( Chen, K; Lu, W; Shen, Z; Shi, Y; Tang, S; Wang, F; Wang, S; Wu, Y; Xia, D; Yuan, X; Zheng, F; Zhong, J, 2023) |
| Excerpt | Reference |
|---|
| "Twenty-one patients with advanced ovarian cancer proven resistant to standard alkylating chemotherapy were evaluated in a prospective study of Hexamethylmelamine." | ( Bender, RA; Chabner, BA; DeVita, VT; Fisher, RI; Johnson, BL; Young, RC, 1978) |
| "19 patients with advanced ovarian cancer (FIGO-stages IIb-IV) were treated by ultra-high doses of VM26 partly according to positive oncobiograms during Multiple-drug-stoss-therapy." | ( Jankowski, RP; Vahrson, H, 1977) |
| "45 patients with ovarian cancer stage III and IV were treated with melphalan, which was injected intravenously over a time period of six hours." | ( Beller, FK; Möhlen, KH, 1979) |
| "Twenty-seven patients with advanced ovarian cancer were treated with a total of 80 courses of cis-dichlorodiammine platinum (II) (cisplatin)." | ( Fox, RM; Stewart, JF; Tattersall, MH; Woods, RL, 1979) |
| "Chromosome abberations in cells of 4 ovarian cancer patients have been studied prior to and during the treatment with ThioTEPA." | ( Aĭnbinder, NM; Gnilevskaia, ZU; Neĭshtadt, EL, 1975) |
| "In 22 cases with advanced ovarian cancer, chemotherapy with Adriamycin was employed." | ( Vahrson, H; Wolf, A, 1977) |
| "The treatment of breast and ovarian cancer brought the best results, improved by a synchronisation therapy." | ( Siebner, H; Weber, W, 1976) |
| "To treat ovarian cancer of stage III-IV the authors have used an antimetabolite-fluorafur." | ( Gutman, EKh; Osman, VI; Plaude, RK; Purinia, IZh; Tabachnik, BI, 1975) |
| "The results of the treatment of 1022 ovarian cancers were reviewed and the problems of prophylactic chemotherapy, a second look operation and the maintenance of the remission were studied." | ( Pfleiderer, A, 1976) |
| "The survival of ten stage-III ovarian cancer patients, who received chemoradiotherapy and were evaluable for assessment of treatment efficacy, was retrospectively compared with the survival of 11 stage-III patients who received chemotherapy only." | ( Heydarfadai, M; Lahousen, M; Petru, E; Pickel, H, 1992) |
| "Results of Carboplatin treatment of ovarian cancer were presented." | ( Koralewski, P; Pawlicki, M, 1992) |
| "A group of 18 patients with ovarian cancer, who participated in an earlier randomized study with placebo or Org 2766, together with cisplatin and cyclophophamide, were thereafter prospectively followed up to 2 years after discontinuation of treatment to monitor the development of neurological signs and symptoms and vibration perception threshold (VPT)." | ( Hovestadt, A; van der Burg, ME; van Putten, WL; Vecht, CJ; Verbiest, HB, 1992) |
| "For the recurrent ovarian cancer patients at present there are no definite strategy to treat the recurrent cases." | ( Kudo, R; Sagae, S, 1992) |
| "Among ovarian cancer cell lines tested, the enhancement of the activity of HuIFN by dipyridamole for HAC-2 and SHIN-3 cells was equivalent to or greater than that for 3 chemotherapy agents (adriamycin, vincristine, and a camptothecin derivative)." | ( Fukazawa, I; Inaba, N; Isogai, E; Oiwa, Y; Saito-Ebihara, M; Sekiya, S; Sugano, I; Suzuki, N; Takakubo, Y; Yoshida, J, 1992) |
| "The standard approach for epithelial ovarian cancer has been maximum cytoreductive surgery followed by combination therapy." | ( Hatae, M; Hokanishi, H; Kume, H; Maeda, Y; Nakagawa, S; Onishi, Y, 1992) |
| "For 109 patients with advanced ovarian cancer treated with various doses and schedules, an overall response rate of 12% was reported." | ( Splinter, TA; van der Gaast, A, 1992) |
| "Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate, administered intravenously." | ( Buchler, D; Bulkowski, D; Goldstein, D; Hannon, C; Knudsen, C; Smalley, RV; Tuttle, RL, 1992) |
| "10 patients with ovarian cancer, whose disease had progressed while receiving platinum-based therapy, were entered onto a phase II clinical trial of the antiproliferative agent suramin." | ( Bostick-Bruton, F; Cooper, MR; LaRocca, RV; Myers, CE; Reed, E, 1992) |
| "A patient with liver metastasis from ovarian cancer was treated by intra-arterial infusion chemotherapy (well differentiated adenocarcinoma--CDDP 50 mg/body, ADR 30 mg/body, CPA 500 mg/body (iv))." | ( Kitada, H; Kobayashi, O; Kohyama, A; Kuwae, C; Minami, T; Otsuka, H; Sudo, H; Yorinaga, Y, 1992) |
| "Seventy-seven ovarian cancer patients were evaluated for auditory toxicity following low-dose, slow-infusion cisplatin therapy." | ( Hallmark, RJ; Jusenius, K; Snyder, JM; Tamimi, HK, 1992) |
| "40 patients with advanced ovarian cancer were treated with immediate debulking followed by sequential cisplatin and doxorubicin every 4 weeks, followed by second-look laparotomy (SLL)." | ( Cady, J; Couturier, JY; de Gramont, A; Delfau, S; Demuynck, B; Lagadec, B; Louvet, C; Marpeau, L; Pigne, A; Varette, C, 1992) |
| "Fourteen patients with relapsing ovarian cancer were treated with Mitomycin C (Mit C) and 5 Fluorouracil (5-FU)." | ( Covens, A; Mazurka, J; O'Connell, G; Rusthoven, J, 1992) |
| "In patients with residual ovarian cancer after standard platinum-based induction, dose intensification was achieved by intraperitoneal administration of cisplatin 90 mg/m2 with intravenous Na thiosulphate and increasing dosages of etoposide." | ( Boonstra, H; Bouma, J; de Vries, EG; Mulder, NH; Sleijfer, DT; Willemse, PH, 1992) |
| "In a phase I study, ten ovarian cancer patients with extensive metastatic disease despite chemotherapy were immunized three to eight times subcutaneously with the synthetic form of the immunodominant disaccharide (beta Gal1----3 alpha GalNAc) of the Thomsen-Friedenreich antigen conjugated to KLH (TF alpha-KLH) plus DETOX adjuvant." | ( Bowen-Yacyshyn, MB; Jerry, M; Koganty, R; MacLean, GD; Meikle, A; Nation, J; Poppema, S; Samuel, J; Stuart, G; Wong, T, 1992) |
| "Chemotherapy for ovarian cancer is frequently limited by cisplatin (CDDP) resistance." | ( Hamilton, TC; Handel, LM; Perez, RP, 1992) |
| "Sixty-one patients with epithelial ovarian cancer were treated with intensive high-dose, short-course chemotherapy that consisted of cisplatin (120 mg/m2) and doxorubicin (70 mg/m2) every 3 weeks for four cycles." | ( Bokhari, F; Dillon, MB; Fitzgerald, TJ; Griffin, TW; Hunter, RE; Reale, FR; Roman, LD; Rose, PG; Stevens, S; Tak, WK, 1991) |
| "A total of 15 patients with residual ovarian cancer confined to the peritoneal cavity after first-line systemic chemotherapy were treated with triethylene-thiophosphoramide (thioTEPA) in a phase I study." | ( Cassidy, J; Cordiner, J; Kaye, SB; Kerr, DJ; Lawson, N; Lewis, C; MacLean, AB; Morrison, G; Rankin, EM, 1990) |
| "Six patients with ovarian cancer received 25 mg of HMFG1 monoclonal antibody coupled with 90Y-DOTA (doses of radioactivity, 15 to 25 mCi), administered i." | ( Courtenay-Luck, NS; Epenetos, AA; Gooden, CS; Kosmas, C; McCall, MJ; Meares, CF; Snook, D, 1992) |
| "Thirty advanced ovarian cancer patients have been treated with sequential multimodality treatment including primary surgery, cisplatin or carboplatin-based polichemotherapy, second-look laparotomy followed by abdominopelvic irradiation (moving strip or open-field technique)." | ( Bruzzone, M; Chiara, S; Conte, PF; Franzone, P; Orsatti, M; Repetto, L; Rosso, R; Scarpati, D; Vitale, V, 1991) |
| "Four patients with ovarian cancer were treated with a 20mg injection of sizofiran, a MW 450,000 beta-1,3-glucan, intramuscularly one day before and 4,7,11,14,18 and 21 days after second look laparotomy and with the administration of 2 million units of interferon gamma intraperitoneally at 0,4,7,11,14,18 and 21 days after second look laparotomy." | ( Chen, JT; Hasumi, K; Masubuchi, K, 1991) |
| "In cases of advanced ovarian cancer, intermittent CDDP therapy (ICDDPT) was applied after the first operation and induction chemotherapy, and its efficacy and limit were studied." | ( Kawabata, M; Matsumoto, Y; Nakano, M; Sugawa, T; Tsuda, K; Umesaki, N; Yamamoto, A, 1991) |
| "The lack of decisive progress in ovarian cancer chemotherapy in recent years led the ARTAC "Ovary" group to initiate a study based on the hypothesis of collateral sensitivities." | ( Coiffier, B; Facchini, T; Filippi, MH; Goudier, MJ; Goupil, A; Mignot, L; Pinel, MC; Pinon, G; Roullet, B; Tresca, P, 1991) |
| "Thirty female patients with ovarian cancer of poor prognosis were included in a chemotherapy trial using high dose IV carboplatin--800 mg/m2 every 5 weeks." | ( Chazard, M; George, M; Goupil, A; Guastalla, JP; Héron, JF; Kerbrat, P; Lenaz, L; Lhomme, C; Rey, A; Toussaint, C, 1991) |
| "Twelve FIGO stage III-IV ovarian cancer patients progressing or relapsing after primary cisplatin-containing combination chemotherapy were treated with ifosfamide and etoposide." | ( Bottero, G; Bruzzone, M; Campora, E; Donadio, M; Ferrari, I; Giudici, S; Iskra, L; Merlini, L; Ragni, N, 1991) |
| "105 patients with advanced ovarian cancer previously treated with cisplatin or carboplatin were entered into a study of iproplatin as second-line therapy." | ( Alberts, DS; Baker, LH; Goodwin, JW; Green, S; Hanson, K; Hines, HE; Pierce, HI; Thigpen, JT; Weiss, G, 1991) |
| "We conclude Lupron's effect on ovarian cancer cell proliferation is independent of gonadotropin and steroid, involves a cell cycle regulatory event, and duration of benefit observed in vivo for some patients may be related to total tumor volume at the time of treatment." | ( Adelson, MD; Kaufman, LM; Thompson, MA, 1991) |
| "As a single agent in the treatment of ovarian cancer, altretamine demonstrates a response rate similar to other active agents in this disease (21-39 percent)." | ( Hansen, LA; Hughes, TE, 1991) |
| "A total of 24 previously untreated ovarian cancer patients were given a combination of 250-500 mg/m2 carboplatin and 500 mg/m2 cyclophosphamide every 4 weeks for 4 months." | ( Jakobsen, A; Jakobsen, P; Strömgren, A; Sørensen, BT, 1991) |
| "CA125 released from ovarian cancer tissues increased time-dependently following phosphatidylinositol-specific phospholipase C (PI-PLC) treatment, concomitant with the release of tissue-unspecific alkaline phosphatase." | ( Fujimoto, M; Hirota, N; Komoda, T; Nagata, A; Sakai, T, 1991) |
| "Seventy-two patients with advanced ovarian cancer received CAP chemotherapy followed by laparotomy and 'second-effort' surgery." | ( Alonso-Muñoz, MC; Alvárez-López, I; Badía-Serra, J; de Andrés-Basauri, L; Delgado-Latre, E; López-López, JJ; Ojeda-González, MB, 1991) |
| "Of 13 patients with ovarian cancer who had a baseline serum magnesium determination obtained prior to the initiation of a second-line cisplatin-based chemotherapy regimen, 9 (69%) were found to be hypomagnesemic (serum magnesium less than 1." | ( Almadrones, L; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markmann, M; Reichman, B; Rothman, R; Rubin, S, 1991) |
| "The survival of 10 Stage III ovarian cancer patients who received chemoradiotherapy and were evaluable for assessment of treatment efficacy was retrospectively compared with the survival of 11 Stage III patients who received chemotherapy only." | ( Arian-Schad, K; Hackl, A; Heydarfadai, M; Lahousen, M; Petru, E; Pickel, H; Stettner, H, 1991) |
| "Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug." | ( Larson, JE; Lyter, JA; MacNeill, C; Manetta, A; Podczaski, ES; Scheffler, B; Schein, P, 1990) |
| "Twenty nine patients with ovarian cancer of common epitherial origin who had no evidence of disease proved by computed tomography after the initial operation and chemotherapy were studied." | ( Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K; Yokosuka, K, 1990) |
| "Treatment options for patients with ovarian cancer who have failed systemic and intraperitoneal (ip) cisplatin-based chemotherapy are limited." | ( Howell, SB; Kirmani, S; Loo, D; McVey, L, 1990) |
| "All patients with ovarian cancer and 87% of those with cervical cancer had had prior platinum-based therapy." | ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
| "In a cohort of 24 ovarian cancer patients treated with single-agent cisplatin or carboplatin, we retrospectively assessed the relationship between disease response, platinum-DNA adducts in WBC DNA, and each of eight prognostic variables by both univariate analysis and multivariate analysis." | ( Ostchega, Y; Ozols, RF; Poirier, MC; Reed, E; Steinberg, SM; Young, RC; Yuspa, SH, 1990) |
| "Thirty-one ovarian cancer patients with minimal residual disease after intravenous cisplatin combination chemotherapy were treated with intraperitoneal carboplatin (IP-Ca)." | ( Bennedbaek, O; Bertelsen, K; Pfeiffer, P, 1990) |
| "Strategy for the treatment of advanced ovarian cancer would be continued until the development of new drugs which are effective comparable with cisplatin and have no cross resistance with cisplatin." | ( Hirabayashi, K, 1990) |
| "The current treatment for ovarian cancer introduced the improvement of survival rate by the chemotherapy based on cisplatin and maximum debulking surgery." | ( Murae, M; Niimi, S; Ochiai, K; Sasaki, H; Terashima, Y; Yokoyama, S, 1990) |
| "A 67-year-old woman with recurrent ovarian cancer, who had carcinomatous peritonitis and large abdominal cystic lesions, was treated by daily oral etoposide at a dose of 50 mg/day for 21 consecutive days at 2-week intervals in the outpatient department." | ( Fujita, H; Ito, R; Okada, H; Yamamoto, T, 1990) |
| "A 2780 human ovarian cancer cells, obtained from an untreated patient, have been exposed to a relatively low, clinically maintainable dose (10 nmol/l) of the anthracycline doxorubicin (DX) to derive a low-degree (5-fold) drug-resistant subline (A2780-DX1)." | ( Mazzoni, A; Nicolin, A; Russo, P; Rustum, YM; Trave, F, 1990) |
| "Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4'deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks." | ( Beckman, EM; Beller, U; Colombo, N; Green, MD; Muggia, FM; Speyer, JL; Wernz, JC, 1990) |
| "In 84 patients with advanced ovarian cancer, the measured 24-hr urinary creatinine clearance and a calculated creatinine clearance were compared prior to cis-platinum-based chemotherapy." | ( Chambers, JT; Chambers, SK; Schwartz, PE, 1990) |
| "Fifty-two patients with ovarian cancer (post surgical residual tumor) were treated with the combination of platinum + epirubicin (PE) (P 50mg/m2, E 60 mg/m2) alternated with cyclophosphamide + 5-fluorouracil (CF) (C 800 mg/m2, F 600 mg/m2)." | ( Bellucco, A; Canova, N; Ercolino, L; Lelli, G; Martoni, A; Pannuti, F, 1990) |
| "A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy." | ( Alama, A; Conte, PF; Repetto, L; Rosso, R, 1990) |
| "In 13 patients with ovarian cancer who had been treated with remission induction chemotherapy, we measured the levels of platelet PT, APTT, Hepa T, ATIII, alpha 2PI and FDP, and we also measured such molecular markers as fibrinopeptide A(FPA), fibrinopeptide B beta 1-42(FPB beta 1-42), and fibrinopeptide B beta 15-42 (FPB beta 15-42) before and after chemotherapy." | ( Nakanishi, M; Narumiya, H; Noguchi, M; Sawaguchi, K; Yabushita, H, 1990) |
| "A 49-year-old woman with stage III ovarian cancer (undifferentiated adenocarcinoma), who refused combination chemotherapy for postoperative residual tumor, were successfully treated with daily oral etoposide in the outpatient clinic." | ( Kinoshita, K; Kojima, T; Sakamoto, S; Takada, S; Takeda, S, 1990) |
| "Two human ovarian cancer cell lines were established from a patient before (PEO1) and after (PEO4) the onset of resistance to 5-fluorouracil (5-FU)/cisplatin-based chemotherapy." | ( Allegra, CJ; Chu, E; Lai, GM; Zinn, S, 1990) |
| "Since ovarian cancer remains confined to the peritoneal cavity for the majority of its natural history, it provides us with a unique opportunity to explore the possibility of administering chemotherapeutic agents in direct contact with the tumor." | ( Howell, SB; McClay, EF, 1990) |
| "Eleven untreated patients with advanced ovarian cancer were studied for tolerance and response to combination treatment with fixed doses of adriamycin (45 mg/m2) and cyclophosphamide (600 mg/m2) + escalating doses of carboplatin." | ( Bentivoglio, G; Bruzzone, M; Carnino, F; Chiara, S; Conte, PF; Foglia, G; Giaccone, G; Guercio, E; Ragni, N; Rosso, R, 1988) |
| "Thirty-six patients with epithelial ovarian cancer, incompletely resected at primary laparotomy, were treated with one of two intensive cis-platinum-based combination chemotherapy regimens." | ( Blackledge, G; Chan, KK; Lawton, FG; Luesley, DM; Redman, CW, 1989) |
| "About 8 months ago, she suffered from ovarian cancer disseminated in pleura and peritoneum, and was treated successfully with CAP therapy only (Cis-platin, Adriamycin and Cyclophosphamide)." | ( Aiba, T; Koyama, M; Miyazawa, N; Watanabe, T, 1989) |
| "This regimen is active in advanced ovarian cancer that has not responded to prior treatment and warrants further study combination with other active drugs as a first-line regimen for ovarian cancer." | ( Buxton, J; Chetiyawardana, A; Crawford, M; Lawton, F; Mould, J; O'Brien, M; Patterson, M; Redman, C; Stuart, N; Sykes, V, 1989) |
| "In four ovarian cancer patients with malignant ascites, 10 KE of OK-432 was intraperitoneally administered four times every other day for priming, and 40 KE of OK-432 in a single dose by the same route on day 13 for triggering." | ( Itoh, N; Mori, H; Tamaya, T, 1989) |
| "Two hundred fifty-nine patients with ovarian cancers were treated with the combination of CDDP, aclarubicin and tegafur." | ( Hiroi, M; Maki, M; Nishiya, I; Saito, Y; Sato, A; Shinagawa, S; Suzuki, M; Wada, Y; Yajima, A, 1989) |
| "Patients with refractory ovarian cancer were treated intra-peritoneally with interferon-gamma." | ( Dapunt, O; Daxenbichler, G; Flener, R; Gastl, G; Herold, M; Hetzel, H; Huber, C; Marth, C; Mull, R; Steiner, E, 1989) |
| "To four ovarian cancer patients with malignant ascites, 10 KE of OK-432 was intraperitoneally administered four times at 2 day intervals for priming, and 40 KE of OK-432 was given on the 13th day after the first injection for triggering." | ( Itoh, N; Mori, H; Tamaya, T; Yamada, Y, 1989) |
| "Six patients with recurrent ovarian cancer who had prior chemotherapy were studied for the clinical efficacy of CDDP-ACR treatment." | ( Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K; Yokosuka, K, 1989) |
| "In 20 ovarian cancer patients treated by cisplatin-based chemotherapy quantitative investigations of the vibration and the thermoperception were performed." | ( Elderson, A; Gerritsen van der Hoop, R; Gispen, WH; Haanstra, W; Jennekens, FG; Neijt, JP, 1989) |
| "Forty two ovarian cancer patients with residual disease after the first laparotomy were treated with the combination of cisplatin (80 mg/m2 day 1), adriamycin (50 mg/m2 i." | ( Bullon, F; Diaz-Rubio, E; Escudero, M; Gonzalez-Larriba, JL; Herraiz, MA; Lopez Vega, JM; Martin-Jimenez, M; Vidart, JA, 1989) |
| "Eleven patients with persistent ovarian cancer after remission-induction chemotherapy were treated with high-dose cyclophosphamide and etoposide followed by autologous bone marrow transplantation (ABMT)." | ( Aalders, JG; de Vries, EG; Mulder, NH; Mulder, PO; Sibinga, CT; Sleijfer, DT; Willemse, PH, 1989) |
| "Twenty-five patients with stage Ic-II ovarian cancer (8 stage Ic and 17 stage IIb-c) were treated with total tumor removal followed by six cycles of chemotherapy consisting of cyclophosphamide, doxorubicin, and cisplatin (CAP-1) i." | ( van Geuns, H; Wils, J, 1989) |
| "Consequently, SLO in the treatment of ovarian cancer is considered to be effective in the extirpation of residual cancer and in the early detection of cancer recurrence." | ( Yuzawa, H, 1989) |
| "Twenty-three previously untreated ovarian cancer patients were treated, from January 1986 to March 1987, with combination chemotherapy consisting of cisplatin, cyclophosphamide and cytarabine (DAC regimen)." | ( Bianco, AR; De Placido, G; De Placido, S; Frasci, G; Iaffaioli, RV; Lombardi, D; Mastrantonio, P; Montemagno, U; Palmieri, G, 1989) |
| "Eighty-nine patients with advanced ovarian cancer have been treated with a combination of cis-platinum (50 mg/m2) + an anthracycline (adriamycin 50 mg/m2 in 26 patients, or epirubicin 60 mg/m2 in 63 patients)." | ( Bellucco, A; Canova, N; Martoni, A; Pannuti, F, 1989) |
| "A patient with ovarian cancer recurrent in the pelvis showed partial response to consecutive intraarterial (IA) cisplatin (CDDP) combined with continuous IA 5FU treatment and received third look operation in which the recurrent tumor could not be completely removed." | ( Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Masubuchi, K; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K, 1989) |
| "Patients with ovarian cancer often respond well to combination chemotherapy initially but the majority eventually relapse when, with further treatment, the initially successful regimen proves ineffectual." | ( Lee, FY; Siemann, DW; Sutherland, RM, 1989) |
| "We studied the effect of ovarian cancer and its chemotherapy on the urinary excretion of prostacyclin (PGI2) and thromboxane A2 (TxA2) hydration and metabolic products." | ( Aitokallio-Tallberg, A; Viinikka, L; Ylikorkala, O, 1989) |
| "This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome." | ( Chambers, JT; Chambers, SK; Chopyk, RL; Duffy, TP; Schwartz, PE, 1989) |
| "Sixty-five patients had Stage III ovarian cancer, 34 with six courses of therapy and 31 with nine courses of therapy." | ( Alaverdian, V; Latino, F; Pretorius, G; Semrad, N; Watring, W, 1989) |
| "A 66-year-old woman with ovarian cancer which had metastasized was receiving chemotherapy with cisplatin and cyclophosphamide while undergoing haemodialysis for chronic renal failure." | ( Ehninger, G; Sanwald, R; Sturn, W, 1989) |
| "Twenty-seven patients with ovarian cancer who had failed combination chemotherapy were offered intraperitoneal (IP) fluorouracil (5-FU) as salvage therapy in an attempt to ascertain the efficacy of such a therapeutic method." | ( Blessing, JA; Homesley, HD; Walton, LA, 1989) |
| "We used the recently developed ovarian cancer model in rats, which is produced by treatment of pregnant rats with N-nitrosobis(2-oxopropyl)amine (BOP), following which a high incidence of ovarian tumors are induced in the offspring." | ( Paz-Bouza, JI; Pour, PM; Redding, TW; Schally, AV, 1988) |
| "Forty-one patients with advanced ovarian cancer (FIGO stage III or IV) who had relapsed following conventional treatment were treated with long acting depot preparation of D-Trp-6-LH-RH once a month." | ( Lightman, SL; Parmar, H; Phillips, RH; Rustin, G; Schally, AV, 1988) |
| "Nineteen previously treated refractory ovarian cancer patients, including 17 who had received standard-dose cisplatin regimens, were treated in a phase II trial with high-dose cisplatin (40 mg/m2 daily for five days with cycles administered every 28 to 35 days)." | ( Myers, CE; Ostchega, Y; Ozols, RF; Young, RC, 1985) |
| "However, cancers such as ovarian cancer that form huge tumor masses cannot be cured completely with chemotherapy alone." | ( Yakushiji, M, 1987) |
| "For 129 ovarian cancer patients failing prior chemotherapy, overall clinical response rates were: 21% with cisplatin, 36% with cisplatin plus doxorubicin, 52% with cyclophosphamide added to the two drugs, and 44% with hexamethylmelamine added to the three drugs." | ( Bruckner, HW; Cohen, CJ; Feuer, E; Holland, JF; Kabakow, B; Wallach, RC, 1987) |
| "Fifty-five ovarian cancer patients receiving platinum drug-based chemotherapy have been studied prospectively to determine the extent of formation of the bidentate intrastrand adducts of diammineplatinum covalently attached to the N7 positions of adenosine and/or guanosine in leukocyte DNA." | ( Ozols, RF; Poirier, MC; Reed, E; Tarone, R; Yuspa, SH, 1987) |
| "A human ovarian cancer cell line, A2780, derived from an untreated ovarian cancer patient and relatively sensitive to cisplatin was treated by stepwise incubation with cisplatin to produce a cisplatin-resistant variant, 2780CP." | ( Fojo, A; Hamilton, TC; Lai, GM; Masuda, H; Ozols, RF; Rothenberg, M, 1988) |
| "One hundred cases of ovarian cancer were studied at autopsy to determine the effect of morphologic and clinical factors on survival time, the primary cause of death, and tumor/treatment-related morbidity." | ( Angel, C; Beecham, JB; Bonfiglio, TA; Dvoretsky, PM; Rabinowitz, L; Richards, KA, 1988) |
| "Responders were patients with stage III ovarian cancer, small residual disease of less than or equal to 1 cm (primarily less than or equal to 5 mm), and patients who previously had responded to cisplatin-based IV chemotherapy." | ( Baker, TR; Emrich, LJ; Hartman, AB; Lele, SB; Marchetti, DL; Piver, MS, 1988) |
| "Of 267 patients with ovarian cancer FIGO stages III and IV, 157 underwent second-look laparotomy after combination chemotherapy consisting of cis-platinum and cyclophosphamide with and without doxorubicin." | ( Andersen, JE; Bertelsen, K; Hansen, MK; Jacobsen, M; Larsen, G; Nyland, M; Pedersen, PH, 1988) |
| "Iproplatin is an active drug in ovarian cancer; the results achieved in patients previously treated with cisplatin strongly suggest that the two drugs are cross-resistant." | ( Cavalli, F; Kaye, S; Pinedo, H; Renard, J; Sessa, C; Smith, D; ten Bokkel Huinink, W; Vermorken, J, 1988) |
| "Five patients with intraabdominal ovarian cancer, 4 of whom with concomitant ascites, refractory to cisplatin-containing combination chemotherapy were treated with intraperitoneal cisplatin." | ( Campora, E; Civalleri, D; Collecchi, P; Esposito, M; Falcone, A; Fulco, RA; Gogioso, L; Nobile, MT; Repetto, M; Simoni, GA, 1988) |
| "A 49-year-old woman with recurrent ovarian cancer clear cell carcinoma was treated by etoposide." | ( Sou, S; Wakisaka, T, 1988) |
| "In 73 CAP-1 treated stage III and IV ovarian cancers, the prognostic significance of morphometric features and cellular DNA content has been evaluated in comparison with histologic type, grade of differentiation and a number of clinical characteristics." | ( Baak, JP; Bosman, FT; Ceelen, T; Schipper, NW; van Geuns, H; Wils, J; Wisse-Brekelmans, EC, 1988) |
| "Fifty-five ovarian cancer patients treated with melphalan during 1968-1978 were followed during 309 person years and studied with cytogenetic analyses." | ( Einhorn, N; Eklund, G; Lambert, B, 1988) |
| "Serial specimens from two ovarian cancer patients undergoing chemotherapy had elevated FHp associated with increased amounts of tumour." | ( Thompson, S; Turner, GA, 1987) |
| "These results indicated that ovarian cancer containing ER, even though it originated from germ cells, would be responsible for antiestrogen therapy." | ( Isonishi, S, 1987) |
| "Fifty-one patients with ovarian cancer were entered in a randomised trial comparing treatment with cisplatin + adriamycin + cyclophosphamide (PAC) to cisplatin + 4'epi-adriamycin + cyclophosphamide (PEC)." | ( Bezwoda, WR, 1986) |
| "Thirty previously treated refractory ovarian cancer patients, all of whom received prior therapy with cisplatin, were treated in a phase II trial with high-dose carboplatin (800 mg/m2 per cycle with cycles administered every 35 days)." | ( Curt, G; Ostchega, Y; Ozols, RF; Young, RC, 1987) |
| "Eight patients with refractory ovarian cancer were treated on a pilot protocol of verapamil plus Adriamycin (Adria Laboratories, Columbus, OH)." | ( Cunnion, RE; Hamilton, TC; Klecker, RW; Ostchega, Y; Ozols, RF; Parrillo, JE; Young, RC, 1987) |
| "Eighty-three patients with ovarian cancer who had undergone radiation therapy, chemotherapy, or both were evaluated." | ( Cormier, WJ; Jazy, FK; Meyer, RL; Shehata, WM, 1987) |
| "Three patients with stage III ovarian cancer had brain metastases following aggressive chemotherapy with Platinol and Adriamycin, and negative second-look surgery." | ( Beck, D; Brandes, J; Deutsch, M; Manor, D, 1987) |
| "Seventy-five patients with epithelial ovarian cancers received cisplatin-based chemotherapy as a post-surgical treatment in the 1980s." | ( Kaku, T; Kamura, T; Matsukuma, K; Matsuyama, T; Suenaga, T; Tsukamoto, N, 1987) |
| "Thirty-six patients with stage III-IV ovarian cancer, bulky disease, were treated with adriamycin and cyclophosphamide administered in two different dosages." | ( Brandi, M; De Lena, M; De Leonardis, A; Lorusso, V; Marzullo, F; Traversa, A, 1986) |
| "Eight patients with advanced ovarian cancer were treated with polyinosinic-polycytidylic lysine carboxymethylcellulose (poly(ICLC]." | ( Berman, ML; DiSaia, PJ; Rettenmaier, MA, 1986) |
| "Twelve patients with advanced ovarian cancer with ascites were treated by intraperitoneal immunotherapy with OK-432 in combination with surgery and systemic immunochemotherapy." | ( Kawagoe, K; Masuda, H, 1986) |
| "Clinically patients with ovarian cancer were divided into two groups; OK-432 treated group and no immunotherapy groups." | ( Kano, T; Nishida, Y; Ohta, M; Sakakibara, K; Tomoda, Y, 1986) |
| "While the treatment of ovarian cancer has made remarkable progress in recent years, the chemotherapy of ovarian germ cell tumor has not as yet been fully established and remains to be improved." | ( Dozono, H; Fujiya, S; Inui, H; Murae, M; Nakabayashi, Y; Nakata, H; Ochiai, K; Takahashi, S; Yasuda, M; Yoshioka, M, 1986) |
| "Seventy-six patients with advanced ovarian cancer treated with cyclophosphamide, doxorubicin, and cisplatin (CAP) at 3-week intervals were tested for the response of their tumors to treatment with CAP in the subrenal capsule tumor implant assay." | ( Berman, ML; Braly, PS; DiSaia, PJ; Dobashi, K; Kucera, PR; Micha, JP; Rettenmaier, MA; Stratton, JA, 1986) |
| "Twenty patients with epithelian ovarian cancer treated with DDP (cis-diammine-dichloroplatinum II) 50 mg/m2 were followed for 24 weeks in order to assess the nephrotoxicity of the drug." | ( Assael, BM; Cavanna, G; Colombo, N; Mangioni, C; Tirelli, AS, 1985) |
| "Eleven women with advanced ovarian cancer treated postoperatively with combination chemotherapy (cytoxan, hexamethylmelamine, Adriamycin, and cis-platinum) had disease-free intervals of 5 to 46 months (mean: 22 months) and subsequently developed recurrent carcinoma." | ( Kaplan, B; Seltzer, V; Vogl, S, 1985) |
| "Treatment of patients with advanced ovarian cancer who have failure of first-line chemotherapy is rarely effective." | ( Howell, SB; Lucas, WE; Markman, M, 1985) |
| "Up to 30% of ovarian cancer patients with minimal residual disease may achieve a complete remission with intraperitoneal cisplatin therapy." | ( Aartsen, E; Dubbelman, R; Franklin, H; McVie, JG; ten Bokkel Huinink, WW, 1985) |
| "These human ovarian cancer xenografts may offer a reliable screening model for selection of a cisplatin analog with a higher therapeutic index or without cross-resistance for treatment in ovarian cancer." | ( Boven, E; Elferink, F; Nauta, MM; Pinedo, HM; Schluper, HM; van der Vijgh, WJ, 1985) |
| "Thus, the HTSCA for advanced ovarian cancer appears to have a similar predictive accuracy rate to the estrogen receptor assay for predicting the response to hormonal therapy for disseminated breast cancer." | ( Alberts, DS; Chen, HS; Meyskens, FL; Moon, TE; Salmon, SE; Surwit, EA; Young, L, 1981) |
| "In the clinical treatment of ovarian cancer, we employed the regimen based on results of experimental chemotherapy using heterotransplanted human tumors of the ovary." | ( Matsui, Y; Okudaira, Y; Sawada, M, 1983) |
| "Six patients with ovarian cancer who had a relapse after treatment with standard dose cisplatin regimens were treated with high-dose cisplatin and three partial responses were seen." | ( Corden, BJ; Jacob, J; Ostchega, Y; Ozols, RF; Wesley, MN; Young, RC, 1984) |
| "Samples of 21 ovarian cancers were assayed for oestrogen receptor (ER) and progesterone receptor (PR) content, and the response in vitro to treatment with a combination of doxorubicin, diacetyldian hydrogalactitol and cisplatin was determined." | ( Grönroos, M; Kangas, L; Mäenpää, J; Paul, R; Vanharanta, R, 1984) |
| "Thirty-eight women with advanced ovarian cancer resistant to alkylating-agent chemotherapy were treated with a combination of hexamethylmelamine and cisplatin." | ( Arseneau, JC; Davis, TE; Einhorn, N; Kaplan, BH; Pagano, M; Tunca, JC; Vogl, SE, 1982) |
| "Thus our data suggest that residual ovarian cancer is accompanied by increased production of PG1(2) and TxA2, and that prostaglandins have no role in the acute side effects of cancer chemotherapy." | ( Kauppila, A; Viinikka, L; Ylikorkala, O, 1983) |
| "Two patients with persistent minimal ovarian cancer after conventional polychemotherapy were treated with high doses of cyclophosphamide and VP 16-213 followed by autologous bone marrow infusion." | ( Aalders, JG; Bouma, J; Mulder, NH; Postmus, PE; Sleijfer, DT; Vriesendorp, R; Willemse, PH, 1984) |
| "Clinical investigation of epithelial ovarian cancer must involve the precise definition of the lesion, careful application of new techniques, the objective evaluation of such techniques, the comparison of results in a randomized fashion with prior forms of therapy, careful pathological evaluation of the tumour, and the evaluation of toxicity to the patient." | ( Decker, DG, 1983) |
| "Since the incidence of ovarian cancer is increasing, the development of appropriate methods for early diagnosis and treatment of this carcinoma is eagerly awaited." | ( Fukazawa, I; Fukuda, K; Hayashi, K; Masubuchi, K; Masubuchi, S; Miyata, R; Okajima, H; Yokosuka, K, 1984) |
| "Eighteen women with bulky ovarian cancer at the start of chemotherapy were brought to second laparotomy after 6 months of combination chemotherapy in an effort to resect previously unresectable tumor masses." | ( Calanog, A; Camacho, F; Greenwald, E; Kaplan, BH; Moukhtar, M; Seltzer, V; Vogl, SE, 1984) |
| "In patients with advanced ovarian cancer, initial treatment with combination chemotherapy, including cyclophosphamide and cis-platinum diamminedichloride (cis-platinum), produces response and progression-free survival results which are superior to those achieved with alkylating single-agent chemotherapy." | ( Neijt, JP; Pinedo, HM; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vriesendorp, R, 1984) |
| "Repeated tumor sampling in ascitic ovarian cancer has been exploited to study tumor cell kinetic recruitment following treatment with the alkylating agent iphosphamide (IFX)." | ( Alama, A; Conte, PF; Favoni, R; Nicolin, A; Rosso, R; Trave, F, 1984) |
| "Thirty-one patients with refractory ovarian cancer and other malignancies principally confined to the abdominal cavity were treated with an intraperitoneal combination-chemotherapy regimen consisting of cisplatin (100 to 200 mg/m2), cytosine arabinoside (10(-4) to 10(-3) mol/L) and doxorubicin (2 to 18 mumol/L)." | ( Green, MR; Howell, SB; Lucas, WE; Markman, M; Pfeifle, CE, 1984) |
| "Fifty-four patients with advanced ovarian cancer have been treated with combination chemotherapy using cyclophosphamide, adriamycin and cis-platinum." | ( Barr, W; Calman, K; Cordiner, J; Cunningham, D; Kaye, S; Kennedy, J; Milsted, R; Sangster, G; Soukop, M; Soutter, W, 1984) |
| "Thirty-two patients with advanced ovarian cancer were treated with a combination of 4'-epi-doxorubicin, a new analog of doxorubicin, and cisplatin at a dose of 60 and 50 mg/m2, respectively, every 28 days." | ( Farabegoli, G; Fruet, F; Martoni, A; Pannuti, F; Tomasi, L, 1984) |
| "Eleven women with advanced ovarian cancer were treated with a sequential and combined hormonal regimen designed to induce and bind tumor progesterone receptors." | ( Freedman, RS; Jolles, CJ; Jones, LA, 1983) |
| "Twenty-five patients with advanced ovarian cancer were treated with Cis-dichlorodiammneplatinum (CD-DP) 50 mg/m2 as single agent or CDDP 50 mg/m2 in combination with adriamycin (ADM) 50 mg/m2." | ( Hagio, Y; Inoue, T; Kato, T; Nishimura, H; Tsunawaki, A; Yakushiji, M; Yamada, T, 1983) |
| "Twenty-three ovarian cancer patients refractory to first-line chemotherapy consisting of cis-dichlorodiamminoplatinum used as a single agent (50 mg/m2 IV every 4 weeks) were admitted to this study." | ( Colombo, N; D'Incalci, M; Mangioni, C; Pecorelli, G; Sessa, C, 1983) |
| "A 53-year-old woman with recurrent ovarian cancer sustained an intracerebral hemorrhage after the 4th course of a chemotherapy regimen which included cis-platinum (DDP)." | ( Brunner, K; Goldhirsch, A; Joss, R; Markwalder, TM; Studer, H, 1983) |
| "Twenty-seven patients with advanced ovarian cancer were treated with CAPF therapy consisting of CPA, ADM, CPDD, and 5-FU." | ( Aiba, K; Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Komyo, M; Kubo, H; Miyamoto, H; Ogawa, M, 1983) |
| "A 40-year-old female with ovarian cancer being treated with daily oral cyclophosphamide developed fatal interstitial pneumonitis." | ( Imachi, M; Kamura, T; Kashimura, M; Matsukuma, K; Matsuyama, T; Tsukamoto, N; Uchino, H, 1984) |
| "Among the 95 cases of ovarian cancer treated by us between May, 1975 and August, 1978, only 33 were suitable for complete resection." | ( Hanyu, T; Higashiiwai, H; Igarashi, N; Kinii, H; Mori, T; Moritsuka, T; Nagasawa, K; Nakano, M; Sato, A; Sato, S; Suzuki, K; Suzuki, M; Watanabe, M; Yajima, A, 1980) |
| "Thirty-seven patients with advanced ovarian cancer were treated with futraful (FT-207) and esquinone (CQ)." | ( Fukuda, O; Inoue, S; Maeyama, M; Nakayama, M; Tajima, C; Tokunaga, T, 1982) |
| "Thirty-eight patients with an advanced ovarian cancer (FIGO stage III and IV) were randomly allocated to treatment, either with melphalan (M) or a combination of adriamycin, 5-fluorouracil and cyclophosphamide (CAF) to determine the effect on survival." | ( Adams, M; James, KW; Johansen, KA; Rocker, I, 1982) |
| "Thirty-seven patients with advanced ovarian cancer were treated in a prospective, randomised trial comparing chlorambucil with a combination of cyclophosphamide and cis-diamminedichloroplatinum (cis DDP)." | ( Bell, DR; Fox, RM; Levi, JA; Tattersall, MH; Woods, RL, 1982) |
| "A patient with inoperable advanced ovarian cancer with metastases and ascites who had received several courses of radiotherapy and chemotherapy is presented." | ( Miyashita, T; Nakamura, A; Sashida, T; Soma, H; Yoshida, M, 1980) |
| "Patients with advanced epithelial ovarian cancer were treated with first-line carboplatin (AUC = 7, using the 51Cr EDTA [edetic acid] clearance method) and escalating doses of paclitaxel." | ( Bailey, NP; Boddy, A; Calvert, AH; Chapman, F; Gumbrell, L; Hughes, A; Humphreys, A; Robson, L; Siddiqui, N; Thomas, H, 1995) |
| "The combined use of rG-CSF in ovarian cancer chemotherapy prevents a decrease in the number of neutrophils and promotes their recovery." | ( Adachi, T; Hoshino, T; Okabe, K; Suzuki, Y; Takayama, M, 1993) |
| "Recurrent ovarian cancer after frontline chemotherapy is incurable; however, palliation of focal lesions often is needed to alleviate symptoms." | ( Boente, M; Corn, BW; Hunter, WM; Ladazack, J; Lanciano, RM; Ozols, RF, 1994) |
| "Between 1987 and 1993, 33 patients with ovarian cancer were irradiated at 47 sites with palliative intent after failing cisplatin-based chemotherapy regimens." | ( Boente, M; Corn, BW; Hunter, WM; Ladazack, J; Lanciano, RM; Ozols, RF, 1994) |
| "Durable palliation of patients with ovarian cancer that recurs after cisplatin-based chemotherapy can be achieved with local radiotherapy, especially among patients with high performance status." | ( Boente, M; Corn, BW; Hunter, WM; Ladazack, J; Lanciano, RM; Ozols, RF, 1994) |
| "Six women with ovarian cancer and chemotherapy-induced leukopenia received 300 micrograms Filgrastrim (r-metHuG-CSF, Neupogen 30; AMGEN, Germany) daily for 10 days." | ( Böhme, M; Morenz, J; Radke, J; Schmidt, D; Weise, W, 1994) |
| "A total of 22 patients with recurrent ovarian cancer previously treated with cisplatin-containing chemotherapy were treated with Fazarabine." | ( Blessing, JA; Look, KY; Manetta, A, 1995) |
| "A new therapeutic strategy for advanced ovarian cancer is to administer ultra-high doses of anticancerous drugs, followed by peripheral blood stem cell transplantation (PBSCT) to recover normal marrow functions." | ( Chiba, T; Fujioka, T; Hiura, M; Murakami, J; Nogawa, T; Shigemasa, K; Shimokawa, T; Yokoyama, T, 1995) |
| "Patients with advanced breast or ovarian cancer that overexpressed HER-2/neu were eligible for treatment." | ( Deo, Y; Fisher, JL; Graziano, R; Guyre, PM; Kaufman, PA; Lewis, LD; Memoli, V; Meyer, L; Mrozek-Orlowski, M; Valone, FH, 1995) |
| "Full details of the treatment for ovarian cancer were sought for both cases and for controls." | ( Bell, J; Day, NE; Kaldor, JM; Karjalainen, S; Kittelmann, B; Langmark, F; Neal, F; Pedersen, D; Pettersson, F; Prior, P, 1995) |
| "Platinum is a key drug in ovarian cancer chemotherapy." | ( Hayakawa, S; Sato, S; Yajima, A, 1995) |
| "Seventy-one patients with epithelial ovarian cancer stage III (n = 56) or IV (n = 15) were treated with carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 400 mg/m2 every fourth week." | ( Akesson, M; Andersson, H; Friberg, LG; Horvath, G; Johansson, O; Westberg, R, 1995) |
| "Thirty-three patients with ovarian cancers refractory to platinum and taxane therapy were treated with single-agent carboplatin reinduction once the disease progressed on a taxane." | ( Edwards, C; Fishman, A; Freedman, R; Gonzalez de Leon, C; Hord, M; Kavanagh, J; Kudelka, A; Mante, R; Tresukosol, D, 1995) |
| "A total of 485 patients with epithelial ovarian cancer and residual masses more than 1 cm following surgery (stage III presentation) or any stage IV presentation were randomly assigned to receive either standard therapy (cyclophosphamide 500 mg/m2 and cisplatin 50 mg/m2 intravenously every 3 weeks for eight courses) or intense therapy (cyclophosphamide 1,000 mg/m2 and cisplatin 100 mg/m2 intravenously every 3 weeks for four courses)." | ( Ball, H; Berek, JS; Berman, ML; Brady, MF; Creasman, WT; Homesley, HD; Hoskins, WJ; McGuire, WP; Woodward, J, 1995) |
| "implants of human ovarian cancer (IGROV) cells were treated 3 days later with i." | ( Cowherd, R; Eshhar, Z; Hwu, P; Rosenberg, SA; Shafer, GE; Treisman, J; Yang, JC, 1995) |
| "In the treatment of advanced-stage ovarian cancer, it is common practice to treat elderly patients in a less aggressive fashion than young patients." | ( Adamo, DO; Bicher, A; Chabner, BA; Davis, P; Jacob, J; Kohn, E; Reed, E; Sarosy, G, 1993) |
| "We conclude that the French ovarian cancer protocol may represent a significant advance and that glucose potentiation may be more widely applicable as an adjunct to cancer chemotherapy." | ( Lin, JY; Scheim, DE, 1993) |
| "Fourteen patients with advanced ovarian cancer who failed chemotherapy received a long-acting LHRH agonist." | ( Chaitchik, S; Inbar, MJ; Merimsky, O; Ron, IG; Wigler, N, 1995) |
| "In conclusion, advanced ovarian cancer patients with macroscopically complete remission at second-look have a substantial risk of relapse after aggressive treatment." | ( Bruzzi, P; Campora, E; Chiara, S; Conte, PF; Lionetto, R; Merlini, L; Oliva, C; Rosso, R, 1995) |
| "Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy." | ( Balat, O; Burk, K; Edwards, CL; Finnegan, MB; Franklin, JL; Freedman, RS; Hord, M; Kavanagh, JJ; Loechner, S; Tresukosol, D, 1995) |
| "Primary chemotherapy for ovarian cancer has evolved over the past 30 years from the use of single alkylating agent to several combination regimens." | ( Colombo, N; Maggioni, A; Mangioni, C; Parma, G; Vignali, M, 1994) |
| "Advanced epithelial ovarian cancer is a highly chemosensitive solid tumor with response rates of 70-80% to first-line chemotherapy, including a high proportion of complete responses." | ( Christian, MC; Trimble, EL, 1994) |
| "Major improvements in survival from ovarian cancer will likely result from a combined effort in prevention, diagnosis, screening, and treatment." | ( Ozols, RF, 1994) |
| "Patients with platinum-refractory ovarian cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3, at least three prior chemotherapy regimens, adequate hepatic and renal function, and no significant cardiac history were eligible." | ( Adams, JD; Canetta, R; Christian, MC; Fisherman, JS; Friedman, MA; Hawkins, MJ; Hayn, R; Onetto, N; Trimble, EL; Vena, D, 1993) |
| "Many ovarian cancer patients will after treatment of the recurrence with cisplatin based therapy enter phase I or II studies with new drugs." | ( Eisenhauer, EA; Hansen, HH; Hansen, M; Neijt, JP; Piccart, MJ; Sessa, C; Thigpen, JT, 1993) |
| "A group of 298 patients with epithelial ovarian cancer were treated with combination chemotherapy between July 1979 and January 1986 at the Tokai Ovarian Tumor Study Group." | ( Arii, Y; Hattori, S; Kawai, M; Kikkawa, F; Ohta, M; Tomoda, Y, 1994) |
| "21 untreated ovarian cancer patients with stage III and minimal tumour size, were given weekly intraperitoneal (i." | ( Cardone, A; Conforti, S; Facchini, G; Frasci, G; Iaffaioli, RV; Mastrantonio, P; Persico, G; Tortoriello, A, 1994) |
| "Women diagnosed with early stage ovarian cancer may be considered for adjuvant therapy." | ( McGowan, L, 1994) |
| "A significant proportion of ovarian cancer patients do not achieve a complete response to chemotherapy, due mainly to the evolution of clones resistant to cytotoxic drugs." | ( Bar-Shira Maymon, B; Holzinger, M; Leibovici, J; Maymon, R; Tartakovsky, B, 1994) |
| "One of the major problems in treating ovarian cancers at present is how to cure patients with platinum-resistant tumors." | ( Fujiwara, K; Kohno, I, 1994) |
| "In patients with ovarian cancer receiving chemotherapy we compared the creatinine clearance measured in the usual way with the calculation of the creatinine clearance according to the formulas of Jelliffe and Cockroft." | ( Haller, U; Köchli, OR; Küng, F; Seifert, B, 1994) |
| "Data from women with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III or IV) were analyzed to evaluate the pharmacokinetic/pharmacodynamic relationships of carboplatin-based combination chemotherapy." | ( Burroughs, JN; Canetta, RM; Egorin, MJ; Jodrell, DI; Novak, MJ; Pater, JL; Reyno, LM; Sridhara, R; Swenerton, KD, 1994) |
| "Twenty-eight patients with ovarian cancer refractory to or relapsing within 12 months after cisplatin-containing chemotherapy were treated with etoposide 50 mg/m2 daily for 21 days, followed by a 7-day break." | ( de Wit, R; Logmans, A; Stoter, G; van den Gaast, A; van der Burg, ME; Verweij, J, 1994) |
| "We established two human ovarian cancer cell lines (KK and MH) from the ascites of patients who did not respond to cisplatin (CDDP)-based combination chemotherapy." | ( Hiramatsu, H; Hirata, J; Ishii, K; Kikuchi, Y; Kita, T; Kudoh, K; Nagata, I, 1994) |
| "A total of 25 patients with epithelial ovarian cancer were treated with second-line carboplatin, etoposide, and ifosfamide (ICE) following failure of first-line cisplatin-based combination chemotherapy." | ( Fanning, J; Hilgers, RD; Hutson, E, 1994) |
| "Chemotherapy for advanced ovarian cancer remains suboptimal." | ( Hamilton, TC; Ozols, RF; Perez, RP; Young, RC, 1993) |
| "A patient with ovarian cancer under long-term hemodialysis was treated with carboplatin at 240 mg/m2 via intravenous drip infusion for 30 min." | ( Cho, T; Ikarashi, H; Kaneko, T; Kodama, S; Kurata, H; Suzuki, E; Suzuki, K; Tanaka, K; Yoshiya, N; Yoshizawa, H, 1994) |
| "Twenty-one patients with metastatic ovarian cancer with minimal residual disease confined to the peritoneal cavity, were treated with intraperitoneal-administered carboplatin." | ( Beijnen, JH; Dubbelman, AC; McVie, JG; ten Bokkel Huinink, WW; van Warmerdam, LJ, 1994) |
| "A human ovarian cancer cell line designated "MH" was established from ascites of a patient with ovarian serous cystadenocarcinoma treated with cisplatin." | ( Aida, S; Hirata, J; Hisano, A; Ishii, K; Kikuchi, Y; Nagata, I; Sasa, H; Senoo, A; Sugita, M; Tamai, S, 1993) |
| "In 23 patients with treated ovarian cancer, 24 magnetic resonance (MR) examinations of the abdomen and pelvis were performed before and after administration of an oral superparamagnetic contrast medium." | ( Haugen, I; Imhof, H; Kainz, C; Koelbl, H; Kramer, J; Poelzleitner, D; Prayer, L; Schima, W; Stiglbauer, R; Wimberger, D, 1993) |
| "Intraperitoneal disseminated ovarian cancer has a poor prognosis and its treatment is difficult." | ( Demukai, H; Hirashima, Y; Kobayashi, T; Kubota, T; Shimura, T; Suzuki, A; Tanaka, Y, 1993) |
| "Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial." | ( Dhokia, B; Epenetos, AA; Hird, V; Lambert, HE; Maraveyas, A; Mason, P; Meares, C; Snook, D; Soutter, WP; Stewart, JS, 1993) |
| "Forty-one ovarian cancer patients with less than 2 cm residual disease after systemic cisplatin-based chemotherapy received 4 courses of an ip regimen including cisplatin (75 mg/m2), mitoxantrone (20 mg/m2), and interferon-alpha 2b (30 mil IU/m2)." | ( Cardone, A; Conforti, S; Facchini, G; Frasci, G; Iaffaioli, RV; Mastrantonio, P; Persico, G; Tortoriello, A, 1993) |
| "Eighteen women with epithelial ovarian cancer and small-volume disease within the peritoneal cavity at reassessment laparotomy after initial treatment with platinum-based regimens received treatment with a combination of intraperitoneal (ip) carboplatin and etoposide administration." | ( Chen, SC; Curtin, J; Groshen, S; Jeffers, S; Morrow, CP; Muggia, FM; Russell, C; Schlaerth, J, 1993) |
| "Results were found to be negligible in ovarian cancer patients, most of them being refractory to previous chemotherapy containing an anthracyclin compound." | ( Armand, JP; Cappelaere, P; Chauvergne, J; Chevallier, B; de Forni, M; Fumoleau, P; Kerbrat, P; Lhommé, C; Metz, R; Roche, H, 1993) |
| "25 patients with residual or recurrent ovarian cancer were treated with the new platinum complex zeniplatin (CL 286,558) and 23 patients were evaluable for response." | ( Birkhofer, M; Bouma, J; de Vries, EG; Gietema, JA; Meijer, S; Mulder, NH; Rastogi, RB; Sleijfer, DT; Willemse, PH, 1993) |
| "In this study, ovarian cancer cells (SHIN-3) were continuously exposed to low-dose etoposide in vitro to determine the optimum schedule for CDDP administration." | ( Adachi, S; Imamura, K; Ito, K; Kiyozuka, Y; Murakami, F; Nishimura, H; Noda, T; Shintani, M; Tamori, N; Yakushiji, M, 1993) |
| "The chromosomes of 111 ovarian cancer patients were studied in G- and C-banded slides from peripheral blood lymphocyte (PBL) cultures for chromosome damage caused by chemotherapy and radiotherapy and for asymmetry of the constitutive heterochromatin of chromosomes 1, 9, and 16." | ( Friberg, LG; Granberg, S; Islam, MQ; Köpf, I; Levan, A; Levan, G, 1993) |
| "Twenty-two patients with ovarian cancer stage III and IV received combination chemotherapy with CDDP, adriamycin (ADM) and cyclophosphamide (CPM), and were studied for response and side-effects." | ( Chen, JT; Hasumi, K; Hirai, Y; Tatsuki, Y, 1993) |
| "24 patients with advanced epithelial ovarian cancer, who demonstrated a clinical complete or partial response to the induction of intravenous chemotherapy, underwent implantation of a subcutaneous semipermanent port-and-catheter system (Port-A-Cath) for intraperitoneal chemotherapy, which consisted of carboplatin 300 mg/m2 every 4 weeks." | ( Bauer, J; De Grandi, P; Delaloye, JF; Leyvraz, S; Tran, L, 1993) |
| "Sixty-six patients with ovarian cancer were treated with low-dose consecutive CP (LDC-CP) consisting of cyclophosphamide (CPM: 500 mg/m2, day 1) and CDDP (10 mg/m2, days 1-7)." | ( Fujimoto, I; Hasumi, K; Hirai, Y; Shimizu, Y; Takeshima, N; Umezawa, S; Yamauchi, K, 1993) |
| "Thirty-five patients with stages II-IV ovarian cancer with refractory cancer at second look or recurrent disease were treated second line with intraperitoneal (ip) combination chemotherapy of high-dose cisplatin (100-200 mg/m2) plus etoposide (350 mg/m2) in 1-6 cycles." | ( Malmström, H; Rasmussen, S; Simonsen, E, 1993) |
| "From 1982 to 1992 103 patients with ovarian cancer stage FIGO III have been treated." | ( Anderl, H; Dettmar, P; Hölscher, M; Jänicke, F; Kuhn, W; Pache, L; Schattenmann, G; Schmalfeldt, B; Schüle, G; Siewert, JR, 1993) |
| "A patient with ovarian cancer had been treated with carboplatin based chemotherapeutic agent for about a month before surgery." | ( Nosaka, S; Sakai, T; Takenoshita, M; Yoshikawa, K, 1993) |
| "Thirty-three patients with residual ovarian cancer following standard chemotherapy were entered onto this phase I trial." | ( Francis, P; Hakes, T; Hoskins, W; Markman, M; Rowinsky, E; Schneider, J, 1995) |
| "27 patients with ovarian cancer FIGO stages IIc-IV were treated with carboplatin 7 x (glomerular filtration rate + 25) mg given intravenously on day 1 and hexamethylmelamine (HMM) 150 mg/m2 orally on days 2-15, every 28 days." | ( Baekelandt, M; Kristensen, GB; Tropé, C; Vergote, IB, 1995) |
| "Estrogen receptor positive ovarian cancer is often refractile to antiestrogen therapy." | ( Christianson, T; Clinton, GM; Hua, W; Rochefort, H; Rougeot, C, 1995) |
| "20 patients with stage III-IV ovarian cancer were submitted to induction chemotherapy (ICT) (40 mg/m2 cisplatin, days 1-4; 1." | ( Baiocchi, G; Benedetti-Panici, P; Foddai, ML; Greggi, S; Laurelli, G; Menichella, G; Pierelli, L; Salerno, MG; Scambia, G; Serafini, R, 1995) |
| "In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival." | ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996) |
| "Adjuvant cisplatin treatment in early ovarian cancer significantly prevents relapse in comparison to 32P in stage IC patients or to no immediate treatment in earlier stage women." | ( Bolis, G; Bonazzi, C; Chiari, S; Colombo, N; Favalli, G; Mangili, G; Marsoni, S; Pecorelli, S; Presti, M; Torri, V, 1995) |
| "121 patients with advanced ovarian cancer resistant to or relapsing following platinum-based chemotherapy participated in this prospective randomised multicenter study." | ( Dose, J; Freitag, K; Graeff, H; Jänicke, F; Kuhn, W; Pache, L; Schmalfeldt, B; Ulm, K, 1996) |
| "Among advanced ovarian cancer, OCCA has worse prognosis compared with serous cystadenocarcinoma because of its poor sensitivity to CDDP-based chemotherapy (CTX)." | ( Hasumi, K; Shimizu, Y; Umezawa, S, 1996) |
| "This second-line chemotherapy for ovarian cancer is effective as salvage treatment in potentially responsive patients with late recurrent tumors, while paclitaxel is the drug of choice for patients who have developped primary or secondary resistance to platin therapy." | ( Chauvergne, J; Chinet-Charrot, P; Stöckle, E; Thomas, L; Toulouse, C, 1996) |
| "In 33 patients with primary ovarian cancer who had not received any chemotherapy before surgery, expression of glutathione S-transferase pi (GST-pi) was studied immunohistochemically in relation to the response to chemotherapy with CDDP, and furthermore it was examined whether numerical aberration of chromosome 11 was available as a prognostic indicator." | ( Fukushi, Y; Kunugi, T; Maruyama, H; Saito, Y; Sato, S; Yokoyama, Y, 1996) |
| "Nineteen patients with progressive ovarian cancer following a cisplatin-based induction chemotherapy were treated with continuous infusion ifosfamide with mesna at 1 g/m2/d and 400 mg/m2/d, respectively, for seven days every 28 days." | ( Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Mosseri, V; Palangié, T; Pouillart, P; Sastre, X; Scholl, S; Soussain, C, 1996) |
| "Epithelial ovarian cancer patients with bulky residual tumor have a poor response to therapy and limited survival." | ( Christian, M; Davis, P; Jacob, J; Kohn, EC; Link, CE; Ognibene, FP; Premkumar, A; Reed, E; Sarosy, GA; Sindelar, WF; Steinberg, SM, 1996) |
| "The standard treatment for ovarian cancer is cytoreductive surgery followed by platinum-based combination chemotherapy." | ( Chang, C; Imamura, K; Nishimura, H, 1996) |
| "Sixteen patients with advanced ovarian cancer, not previously treated, were randomly divided into two groups: every patient in group I received intraperitoneal administration of DDP (100mg/m2) and those in group II received the same dose of DDP by intravenous route." | ( Deng, C; Huang, R; Lian, L, 1996) |
| "Patients with advanced clear cell ovarian cancer have a poor response to conventional platinum-based chemotherapy and overall prognosis is poor." | ( Cain, JM; Ek, M; Fleischhacker, D; Fuller, AF; Goff, BA; Greer, BE; Muntz, HG; Nikrui, N; Rice, LW; Sainz de la Cuesta, R; Tamimi, HK, 1996) |
| "Six human epithelial ovarian cancer cell lines were treated with media (control) for 24 hr, G-CSF for 24 hr, cisplatin for 24 hr, simultaneous cisplatin and G-CSF for 24 hr, media (control) for 48 hr, cisplatin for 24 hr and sequential media for 24 hr, cisplatin for 24 hr, and sequential G-CSF for 24 hr." | ( Fanning, J; Hilgers, RD; Kane, C; Medrano, C, 1996) |
| "For a model of advanced ovarian cancer, mice received tumor cell injections on day 0 and did not begin drug treatment until tumors were palpable (0." | ( Capizzi, RL; Johnson, CS; Lopez, MH; Paine, GD; Taylor, CW, 1996) |
| "Twelve ovarian cancer patients who failed chemotherapy entered a Phase I trial of intraperitoneal 177Lu-CC49 antibody." | ( Alvarez, RD; Grizzle, WE; Khazaeli, MB; Liu, T; LoBuglio, AF; Meredith, RF; Partridge, EE; Plott, G; Russell, CD; Schlom, J; Wheeler, RH, 1996) |
| "Paclitaxel is effective in the treatment of cancer of the ovary and cancer of the breast, as well as other malignancies." | ( Bitton, R; Kohn, E; Reed, E; Sarosy, G, 1996) |
| "Thirty-eight women with epithelial ovarian cancer were treated with gemcitabine, a new antimetabolite." | ( Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V, 1996) |
| "A case of primary ovarian cancer responding favorably to EP therapy is reported." | ( Arai, Y; Inoue, K; Kubo, T; Nishida, M; Sasaki, J; Sato, Y, 1996) |
| "A group of 104 chemotherapy-naive ovarian cancer patients, scheduled for at least three cycles of combination chemotherapy including cisplatin (50 mg/m2), were randomly allocated to receive either dexamethasone or placebo in addition to ondansetron." | ( Avall-Lundqvist, E; Börjeson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Lomberg, H; Peterson, C; Steineck, G, 1996) |
| "Twelve chemonaive patients with ovarian cancer were treated with paclitaxel followed by a 30-min infusion of carboplatin." | ( Bailey, NP; Boddy, AV; Calvert, AH; Lind, MJ; Robson, L; Siddiqui, N; Thomas, HD, 1997) |
| "Advanced chemotherapy-resistant ovarian cancer has a poor prognosis, thus requiring new therapeutic modalities." | ( Alavi, A; Goldenberg, DM; Hanley, D; Herskovic, T; Juweid, M; Pereira, M; Rubin, AD; Sharkey, RM; Swayne, LC, 1997) |
| "Eighteen patients with advanced ovarian cancer were treated in this study." | ( Aghajanian, C; Crown, JP; Curtin, JP; Fennelly, DW; Hoskins, WJ; O'Connor, K; O'Flaherty, C; Shapiro, F; Spriggs, DR, 1997) |
| "Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody." | ( Alvarez, RD; Austin, M; Grizzle, WE; Khazaeli, MB; Kilgore, L; Liu, T; LoBuglio, AF; Meredith, RF; Partridge, EE; Plott, G; Russell, CD; Schlom, J, 1997) |
| "The successful outcome of ovarian cancer therapy with alkylating agents and cisplatin is seriously hampered by the development of acquired drug resistance." | ( Iqbal, MP; Malik, IA; Mehboobali, N, 1997) |
| "Chemotherapy drugs for advanced ovarian cancer with novel mechanisms of action include topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I inhibitor." | ( Dunton, CJ, 1997) |
| "Strategies for treatment of ovarian cancer would be improved by identification of patients likely to respond to hormonal therapy." | ( Clinton, GM; Hua, W, 1997) |
| "Early ovarian cancers have a good prognosis after comprehensive staging, complete surgery and adjuvant chemotherapy." | ( Cady, J; de Gramont, A; Drolet, Y; Faivre, S; Krulik, M; Lavoie, A; Louvet, C; Marpeau, L; Ouellet, P; Raymond, E; Rioux, E; Tessier, C, 1997) |
| "One approach in the treatment of ovarian cancer patients involves the infusion of autologous T lymphocytes coupled with a bispecific monoclonal antibody MOv18/anti-CD3 (biMAb OC/TR), which recognizes a 38-kDa glycoprotein expressed on ovarian carcinomas and the CD3 T cell receptor." | ( Arienti, F; Bogni, A; Bombardieri, E; Botti, C; Canevari, S; Crippa, F; Lombardo, C; Maffioli, L; Massaron, S; Negri, DR; Nerini-Molteni, S; Pascali, C; Ramakrishna, V; Remonti, F; Seregni, E, 1997) |
| "Although, in ovarian cancer, CA-125 provides a unique opportunity in identifying those patients requiring further treatment, this concept could be applied to other forms of cancer as other prognostic indicators become available." | ( Bernacki, RJ; Sharma, A, 1997) |
| "With current standard-dose chemotherapy ovarian cancer is a chemosensitive but not chemocurable disease in the majority of cases." | ( Carlsson, K; Grenman, S; Hóglund, M; Kauppila, M; Oberg, G; Pelliniemi, TT; Rajamäki, A; Rantanen, V; Remes, K; Salmi, T; Simonson, B; Tholander, B, 1997) |
| "A total of 34 patients with advanced ovarian cancer, who relapsed 1-72 months after at least one first-line cisplatin-based chemotherapy protocol, were treated with carboplatin, 350 mg/m2 q 4 weeks, with the adjunct of primary prophylactic granulocyte colony stimulating factor (G-CSF; filgrastim), 300 or 480 microg daily, days 5-9." | ( Lalisang, F; van Geuns, H; Vreeswijk, J; Wals, J; Wils, JA, 1997) |
| "Forty-two previously untreated ovarian cancer patients were included in the study." | ( Hansen, HH; Hansen, M; Lund, B; Strauss, G, 1997) |
| "The German Ovarian Cancer Study Group (GOCA) performed a prospective randomized trial in a subgroup of patients specified by a successful cytoreductive operation before the start of chemotherapy." | ( Kühnle, H; Meerpohl, HG; Pfleiderer, A; Sauerbrei, W; Schumacher, M, 1997) |
| "Forty patients with stage I epithelial ovarian cancer treated from 1985 to 1990, were divided into two groups and retrospectively analyzed." | ( Huo, R; Wang, W, 1996) |
| "All patients with ovarian cancer were given cytoreductive surgery followed by systemic and intraabdominal chemotherapy." | ( Huang, X; Li, M, 1996) |
| "The prognosis of ovarian cancer following cytoreductive surgery is influenced by residual tumor, and the number of courses of chemotherapy." | ( Huang, X; Li, M, 1996) |
| "The treatment of advanced ovarian cancer with taxol is hindered by the development of drug resistance." | ( Burkhart, CA; Haber, M; Horwitz, SB; Kavallaris, M; Kuo, DY; Norris, MD; Regl, DL, 1997) |
| "Of the 62 patients with ovarian cancer or primary peritoneal carcinoma with carbohydrate antigen-125 levels > or = 60 U/mL before the initiation of chemotherapy, 74% exhibited a > or = 90% decline in the tumor marker following treatment." | ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1997) |
| "To characterize treatments for ovarian cancer, to determine if recommended staging and treatment were provided, and to determine factors that influence receipt of recommended staging and treatment." | ( Harlan, LC; Muñoz, KA; Trimble, EL, 1997) |
| "Human 2780 ovarian cancer cells were inoculated subcutaneously while paclitaxel and amifostine were administered intraperitoneally." | ( Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM, 1997) |
| "Thirty-one patients with ovarian cancer who had failed chemotherapy were treated, 24 at the MTD." | ( Baldwin, P; Buckner, CD; Greco, FA; Hainsworth, JD; Lewis, M; Schwartzberg, L; Weaver, CH; West, WH; Wittlin, F; Zhen, B, 1997) |
| ""Optimal" chemotherapy for advanced ovarian cancer has constantly evolved over the last 2 decades through the conduct of prospective randomized clinical trials." | ( Nogaret, JM; Piccart, MJ, 1997) |
| "Treatment options for epithelial ovarian cancers are under constant evolution." | ( Benjamin, I; Rubin, SC, 1998) |
| "Recurrent ovarian cancer patients initially treated with paclitaxel-based chemotherapy frequently responded to salvage treatment." | ( Alvarez, R; Austin, JM; Barnes, MN; Kilgore, LC; Niwas, S; Partridge, EE; Robertson, MW; Roland, PY, 1998) |
| "nodules of human ovarian cancer after administration of human monoclonal IgMlambda (AC6C3-2B12), labeled with 111In or 90Y." | ( Borchardt, PE; Freedman, RS; Quadri, SM; Vriesendorp, HM, 1998) |
| "Human ovarian cancer cells were evaluated to determine whether combination treatment with mild hyperthermia and cisplatin could inhibit repair of sublethal radiation damage." | ( Miao, J; Ng, CE; Raaphorst, GP; Stewart, D, 1998) |
| "A total of 30 patients with advanced ovarian cancer (24 patients), primary carcinoma of the peritoneum (four patients), or fallopian tube cancer (two patients) who previously had received paclitaxel administered on either a 3-hour or 24-hour schedule were treated with the agent delivered as a 96-hour infusion (30 to 35 mg/m2/d x 4 days) on an every 3-week program." | ( Belinson, J; Fluellen, L; Fusco, N; Horowitz, IR; Jones, E; Kennedy, A; Kulp, B; Markman, M; McGuire, WP; Peterson, G; Rose, PG; Webster, K, 1998) |
| "In patients with ovarian cancer who have shown resistance to shorter paclitaxel infusion schedules, ninety-six hour infusional paclitaxel is an inactive treatment strategy." | ( Belinson, J; Fluellen, L; Fusco, N; Horowitz, IR; Jones, E; Kennedy, A; Kulp, B; Markman, M; McGuire, WP; Peterson, G; Rose, PG; Webster, K, 1998) |
| "Primary therapy of advanced ovarian cancer is standardized, the therapy in relapsed ovarian cancer however is still controversial." | ( Canzler, E; Graeff, H; Janicke, F; Kroner, M; Kuhn, W; Nöschel, H; Pache, L; Renziehausen, K; Richter, B; Schmalfeldt, B; Späthe, K; Tilch, G; Ulm, K, 1998) |
| "Patients with recurrent epithelial ovarian cancer previously treated with no more than two separate regimens of chemotherapy, one of which had to be platinum-containing, were randomized to either topotecan 1." | ( Beare, S; Bryson, P; Capstick, V; Drouin, P; Eisenhauer, E; Grimshaw, R; Hoskins, P; Roy, M; Stuart, G; Zee, B, 1998) |
| "Twenty-one chemotherapy naive ovarian cancer patients with stage III and minimal residual tumor were treated with cisplatin 75 mg/m2 and mitoxantrone 15 mg/m2 (1st day) by intraperitoneal (i." | ( Aydmer, A; Bengisu, E; Berkman, S; Saip, P; Salihoğlu, Y; Topuz, E, 1998) |
| "Patients with epithelial ovarian cancer must receive optimal surgical care and state-of-the-art chemotherapy in the primary treatment setting." | ( Sabbatini, P; Spriggs, D, 1998) |
| "Three patients presented with ovarian cancer that was initially treated with paclitaxel and platinum-based compounds." | ( Carlson, JA; Dunton, CJ; Neufeld, J, 1998) |
| "Sixteen patients with ovarian cancer treated with 2 to 6 courses of cisplatin-containing chemotherapy and abdomino-pelvic radiation therapy received filgrastim for neutrophil counts <2 x 10(9)/L." | ( Fyles, AW; Levin, W; Manchul, L; Robertson, JM; Sturgeon, J; Tsuji, D, 1998) |
| "One patient with recurrent ovarian cancer who received 16 courses of therapy experienced complete resolution of her ascites, near normalization of CA-125 levels, and improved quality of life; two patients with high-risk tumors receiving "adjuvant" therapy are disease-free at 3 and 6 years after treatment; other patients experienced transient clearing of ascites." | ( Akman, S; Carroll, M; Chow, W; Coluzzi, P; Doroshow, JH; Hamasaki, V; Klevecz, R; Leong, L; Longmate, J; Margolin, K; McGonigle, K; Morgan, RJ; Newman, EM; Paz, B; Raschko, J; Shibata, S; Somlo, G; Tetef, M; Vasilev, S; Wagman, L; Yen, Y, 1998) |
| "Women undergoing chemotherapy for ovarian cancer received selenium during three months at a daily dose of 200 micrograms." | ( Sieja, K, 1998) |
| "Forty-eight patients with ovarian cancer were treated with cyclophosphamide and randomized to receive filgrastim 5 microg/kg alone or filgrastim 5 microg/kg plus SCF." | ( Chang, J; Collins, CD; Crowther, D; de Wynter, E; Dexter, TM; Gill, C; Jenkins, B; Lind, M; Pettengell, R; Radford, JA; Testa, NG; Weaver, A; Wilkinson, PM; Woll, PJ; Wrigley, E, 1998) |
| "Human ovarian cancer cell lines with different p53 status were investigated for p53-dependency of cell cycle arrest upon treatment with cytostatic drugs." | ( Brandner, G; Hess, RD; Merlin, T, 1998) |
| "An animal model of human epithelial ovarian cancer was established in nude mice using the serous ovarian adenocarcinoma cell lines Ov-ca-2774, then mice were treated by ADV/RSV-Tk and GCV, or GCV and HSV-tk respectively." | ( Gu, M; Sei, W; Tong, X, 1997) |
| "As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH)." | ( Akiya, T; Gray, JW; Iwabuchi, H; Kawasaki, K; Kikuchi, Y; Kunugi, T; Muroya, T; Sakamoto, H; Sakamoto, M; Sakunaga, H; Suehiro, Y; Sugishita, T; Tanaka, T; Tenjin, Y; Umayahara, K, 1998) |
| "Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine." | ( Pawlicki, M; Rolski, J; Rychlik, U; Wiczyńska, B, 1998) |
| "47 patients with advanced ovarian cancer after routine treatment were treated with tamoxifen." | ( Pawlicki, M; Rolski, J, 1998) |
| "An increase in gene transfer to ovarian cancer cells of 2 to 3 orders of magnitude was demonstrated by the vector, suggesting that recombinant Ad containing fibers with an incorporated RGD peptide may be of great utility for treatment of neoplasms characterized by deficiency of the primary Ad type 5 receptor." | ( Belousova, N; Curiel, DT; Dmitriev, I; Kashentseva, E; Krasnykh, V; Mikheeva, G; Miller, CR; Wang, M, 1998) |
| "Epithelial ovarian cancer is a major cause of cancer-related mortality in women, making the search for new treatment modalities essential." | ( Abbruzzese, JL; Ferrandina, G; Freedman, RS; Loercher, A; Melichar, B; Verschraegen, CF, 1998) |
| "Patients with advanced epithelial ovarian cancer treated with salvage therapy using new combinations of systemic chemotherapy, radiation therapy, and systemic immunotherapy have had limited success." | ( Alvarez, RD; Berek, JS; Blessing, JA; DiSaia, PJ; Feun, LG; Major, FJ, 1998) |
| "In advanced ovarian cancer, first-line regimens based on paclitaxel have been reported to be more effective than standard therapy based on cyclophosphamide + cisplatin." | ( Messori, A; Trippoli, S, 1998) |
| "Platinum-based treatment of ovarian cancer increases the risk of secondary leukemia." | ( Andersson, M; Bergfeldt, K; Curtis, RE; Hall, P; Holowaty, EJ; Kohler, BA; Lynch, CF; Pukkala, E; Stovall, M; Sturgeon, J; Travis, LB; Wiklund, T, 1999) |
| "Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment." | ( Bell, D; Bugat, R; Campbell, L; Friedlander, M; Harnett, P; Kayitalire, L; Millward, MJ; Moreno, JA; Ripoche, V; Varette, C, 1998) |
| "Epithelial ovarian cancer (EOC) has a high mortality rate, which is due primarily to the fact that early clinical symptoms are vague and nonspecific; hence, this disease often goes undetected and untreated until in its advanced stages." | ( Balasubramaniam, S; Baron, AT; Boardman, CH; Lafky, JM; Maihle, NJ; Podratz, KC; Suman, VJ, 1999) |
| "Forassessing activity of therapy for ovarian cancer, these data show that precise 50% or 75% CA-125 response criteria are as sensitive as standard response criteria." | ( Bridgewater, JA; Gore, ME; Hoskins, WJ; McGuire, WP; Nelstrop, AE; Rustin, GJ, 1999) |
| "Patients with progressive ovarian cancer who underwent a remission-induction therapy in our department; intermittent chemotherapy (IC) of CDDP was performed every 3 months, and good outcome has been obtained." | ( Muso, H, 1998) |
| "Brain metastasis from ovarian cancer, a rare and highly dismal event, develops mostly during or after postoperative chemotherapy." | ( Imai, A; Matsunami, K; Noda, K; Takagi, H; Tamaya, T, 1999) |
| "Patients with stage Ic-IV ovarian cancer were randomized to receive either epirubicin 100 mg/m2 plus cisplatin 75 mg/m2 q 4 weeks or cyclophosphamide 500 mg/m2 plus epirubicin 75 mg/m2 plus cisplatin 50 mg/m2 q 4 weeks, which we considered the reference treatment based on our previous experience." | ( Bergmans, M; Boschma, F; Bron, H; de Pree, N; de Rooy, C; Degen, J; Erdkamp, F; Haest, J; Iding, R; Lalisang, F; Schepers, J; Schouten, L; Smeets, J; Snijders, M; Stoot, J; van Erp, J; van Geuns, H; Vreeswijk, J; Wals, J; Werter, M; Wetzels, L; Wils, J, 1999) |
| "Twenty-one advanced ovarian cancer patients, all pretreated with cisplatin and paclitaxel, were treated with 1." | ( Bleuzen, P; Buthaud, X; Cvitkovic, E; Goldwasser, F; Gross, M; Jasmin, C; Misset, JL; Romain, D; Voinea, A, 1999) |
| "Because the options available to ovarian cancer patients for second-line therapy are limited, and knowing that mechanistic differences exist between cisplatin and paclitaxel, we assessed the efficacy of combination drug therapy on cisplatin-resistant (cisplatinR) ovarian cancer cells." | ( Fowler, WC; Gehrig, PA; Haskill, JS; Judson, PL; Watson, JM, 1999) |
| "We treated the human ovarian cancer cell lines OVCAR-3 and SKOV-3 for 5 or 7 days and sex-matched SCID mice with GnRH agonist for 29 days." | ( Choi, YK; Jung, JK; Kim, DH; Kim, JH; Kim, JW; Lew, YO; Lim, YA; Namkoong, SE; Park, DC, 1999) |
| "A 57-year-old woman with metastasizing ovarian cancer and chronic renal failure was admitted for morphine treatment of an acute lumbospinal pain syndrome, ambulant treatment with analgesics having failed provide adequate pain relief." | ( Caduff, B; Dubs, A; Wiedemeier, P, 1999) |
| "Patients with ovarian cancer that is clinically resistant to cisplatin-based chemotherapy have little hope of a cure of their disease." | ( Duska, LR; Hamblin, MR; Hasan, T; Miller, JL, 1999) |
| "A 64-year-old female with advanced ovarian cancer and pleural effusion underwent 4 courses of combination chemotherapy with CP." | ( Asaoka, K; Ishitani, K; Iwasaki, K; Komuro, Y; Masumoto, N, 1999) |
| "Twenty-three primary ovarian cancer cell (CSOC) cultures established from solid ovarian carcinomas were treated with TGF-beta1 and assayed for growth response by MTT assay." | ( Baldwin, RL; Karlan, BY; Yamada, SD, 1999) |
| "Forty-three patients with ovarian cancer were entered on this trial and treated with intravenous (iv) cyclophosphamide (C) and doxorubicin (A), and intraperitoneal (ip) cisplatin (DDP), every 21 days for eight cycles." | ( Braly, P; Cecchi, G; Cho, J; Coluzzi, P; Doroshow, JH; Johnson, D; Kogut, N; Leong, L; Longmate, J; Margolin, K; McNamara, M; Morgan, RJ; Nagasawa, S; Najera, L; Parker, P; Raschko, J; Schinke, S; Shibata, S; Smith, E; Somlo, G; Stein, A; Womack, E, 1999) |
| "This retrospective study of ovarian cancer aimed to elucidate whether expression of apoptosis-related proteins, bcl-2, p53 or MDM-2, is associated with resistance to chemotherapy, especially cisplatin (CDDP) based chemotherapy." | ( Hirata, J; Ishii, K; Kikuchi, Y; Kita, T; Mano, Y; Nagata, I; Tode, T; Yamamoto, K, 1999) |
| "HER-2/neu-overexpressing human ovarian cancer cells and treated with both paclitaxel and E1A gene therapy survived significantly longer than did mice treated only with paclitaxel or E1A gene therapy." | ( Andreeff, M; Anklesaria, P; Bartholomeusz, C; Estrov, Z; Herrmann, JL; Hung, MC; Paul, RW; Price, J; Shao, R; Ueno, NT; Yu, D, 2000) |
| "Among gynecologic cancers, ovarian cancer is treated with chemotherapy as a routine practice." | ( Ochiai, K, 2000) |
| "Paclitaxel is a frontline therapy for ovarian cancer." | ( Haskill, JS; Hellendall, RP; Lee, LF; Matsushima, K; Mukaida, N; Ting, JP; Wang, Y, 2000) |
| "We have therefore established a human ovarian cancer cell line differing only in p53 status and characterized its response after treatment with different platinum complexes." | ( Hobbs, SM; Kelland, LR; Pestell, KE; Titley, JC; Walton, MI, 2000) |
| "Patients with recurrent ovarian cancer after one or two prior chemotherapy regimens and in whom the interval between prior platinum therapy and the initiation of protocol therapy was greater than 6 months were treated with topotecan 1." | ( Blessing, JA; Bookman, MA; Dunton, CJ; Lentz, SS; McGuire, WP, 2000) |
| "Treatment of ovarian cancer HEY cells with 500 nM 5alpha-dihydrotestosterone (DHT), but not estradiol-17beta or progesterone, for 60 h down-regulated the expression of mRNA for TGF-beta receptors I and II (TbetaR-I and TbetaR-II), betaglycan, and endoglin but had no effect on TGF-beta1 mRNA levels." | ( Brown, TJ; Evangelou, A; Jindal, SK; Letarte, M, 2000) |
| "Despite the relatively favorable ovarian cancer patient population treated in this trial (platinum-sensitive recurrent disease), the response rate was disappointingly low." | ( Alvarez, RD; Blessing, JA; Hall, K; Hanjani, P; Markman, M; Waggoner, S, 2000) |
| "Twenty-four patients with ovarian cancer were entered on this trial and treated with intraperitoneal (ip) cisplatin (DDP) and ip 5-fluorouracil, every 3 weeks for eight cycles." | ( Braly, P; Doroshow, JH; Johnson, D; Kogut, N; Leong, L; Longmate, J; Margolin, K; McNamara, M; Morgan, RJ; Nagasawa, S; Najera, L; Raschko, J; Schinke, S; Shibata, S; Somlo, G, 2000) |
| "Fifty-eight patients with stage III ovarian cancer and 22 patients with stage IV received PEC as primary treatment (41 patients), or for residual disease after surgery (37 patients), or for relapsed disease after primary surgery (2 patients)." | ( Alessandroni, P; Antognoli, S; Bascioni, R; Bracci, R; Cellerino, R; Ciavattini, A; De Nictolis, M; Massacesi, C; Piga, A; Scartozzi, M, 2000) |
| "Patients with recurrent ovarian cancer were treated with a replication-deficient recombinant adenovirus containing the herpes simplex virus thymidine kinase gene administered intraperitoneally (i." | ( Aguilar-Cordova, E; Hasenburg, A; Kaplan, A; Kaufman, RH; Kieback, CC; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW, 2000) |
| "We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up." | ( Goldwasser, F; Gross, M; Hiesse, C; Kriaa, F, 1999) |
| "Cisplatin is in common use in ovarian cancer therapy, although it is also implicated in cytotoxicity in normal tissue." | ( Amsterdam, A; Dantes, A; Hosokawa, K; Kotsuji, F; Tajima, K; Yoshida, Y, 2000) |
| "Thirty-two patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who failed paclitaxel-based chemotherapy received either 100 or 75 mg/m(2) of docetaxel every 3 weeks." | ( Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M, 2000) |
| "Most trials of hormonal treatment in ovarian cancer have been retrospective, involved only limited numbers of patients, and lacked important patient-related data and information pertaining to tumor characteristics." | ( Makar, AP, 2000) |
| "The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined." | ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kiamouris, C; Kosmidis, P; Papadimitriou, C; Papakostas, P; Pavlidis, N; Sikiotis, K; Skarlos, DV, 2000) |
| "Forty-eight had epithelial ovarian cancer and all received prior treatment with cisplatin and paclitaxel: 27 received two to six prior regimens, 44 were platinum resistant, 21 patients had measurable disease, and 27 had evaluable disease only." | ( Burnett, A; Garcia, AA; Israel, VP; Jeffers, S; Muderspach, L; Muggia, FM; Roman, L, 2000) |
| "A case report of a patient with ovarian cancer extensively treated with platinum-based chemotherapy and aggressive surgery is presented." | ( Markman, M, 2000) |
| "Forty women (29 with ovarian cancer, 7 with uterine cancer, 3 with cervical cancer, and 1 with choriocarcinoma) were treated with cyclosporin A, 4 mg/kg intravenously, 6 hours before and 18 hours after the specific chemotherapeutic agent, to which the tumor had developed drug resistance." | ( Anderson, B; Buller, RE; Skilling, JS; Sood, AK; Sorosky, JI; Squatrito, RC, 1999) |
| "Forty-seven ovarian cancer cases in which 20 were previously treated with cisplatin (cisPt) based chemotherapy, were checked for in vitro chemosensitivity using MTT assay." | ( Adwankar, MK; Juvekar, AS; Tongaonkar, HB, 2000) |
| "Ongoing trials in ovarian cancer are examining the clinical utility of this approach as a second-line treatment option in carefully defined paclitaxel-resistant disease and as a consolidation strategy in high-risk, early stage disease following initial therapy with a carboplatin/paclitaxel combination regimen." | ( Markman, M, 2000) |
| "Similarly, chemotherapy-sensitive ovarian cancer cells A2780 and PA-1, possessing wild-type p53, and their respective chemotherapy-resistant clones A2780/200CP, lacking p53 function, and PA-1/E6, permanently expressing the HPV E6 gene, were equally sensitive to HSV oncolysis." | ( Albelda, SM; Coukos, G; Kang, EH; Makrigiannakis, A; Molnar-Kimber, KL; Rubin, SC, 2000) |
| "Patients had epithelial ovarian cancer that either progressed on or recurred within 6 months of completion of platinum and paclitaxel chemotherapy." | ( Gordon, AN; Granai, CO; Hainsworth, J; Lopez, A; Rosales, R; Rose, PG; Sharpington, T; Weissman, C, 2000) |
| "In patients with advanced ovarian cancer, first-line therapy with oxaliplatin/cyclophosphamide achieved an objective response rate which did not differ significantly from that of cisplatin/cyclophosphamide (33 vs 42%)." | ( Clemett, D; Culy, CR; Wiseman, LR, 2000) |
| "A reduced vigilance in patients with ovarian cancer prior to chemotherapy compared to healthy controls was observed (clearly demonstrated by an attenuated total power, a decrease in fast alpha and slow beta activity, an increase in delta and theta activity as well as a deceleration of the centroid of the total power spectrum)." | ( Anderer, P; Bodner, K; Bodner-Adler, B; Hefler, L; Kaider, A; Kainz, C; Leodolter, S; Mayerhofer, K; Saletu, B, 2000) |
| "A group of 32 patients with epithelial ovarian cancer were treated with intraperitoneal (i." | ( Fujiwara, K; Fujiwara, M; Ishikawa, H; Kohno, I; Suzuki, S; Tanaka, Y; Yamauchi, H, 2001) |
| "35 consecutive patients with advanced ovarian cancer, not previously treated with chemotherapy were treated with paclitaxel at a dose of 135 mg/m(2) intravenously (i." | ( Caporusso, L; Catino, A; Crucitta, E; De Lena, M; Fanizza, G; Gargano, G; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D, 2001) |
| "Nude mice with highly metastatic human ovarian cancer were treated with CD3 McAB activated killer cells (CD3AK) from human ovarian cancer draining lymph node lymphocytes." | ( Mou, H; Qian, L; Xu, S, 1998) |
| "Women with epithelial ovarian cancer FIGO Stage II--IV who had a complete or partial response to first-line treatment with cisplatin or carboplatin-based regiments and subsequently progressed or relapsed more than 6 months after discontinuation of first-line treatment were eligible for the study." | ( Bolis, G; Franchi, M; Giardina, G; Mangili, G; Melpignano, M; Parazzini, F; Presti, M; Scarfone, G; Tateo, S; Villa, A, 2001) |
| "Pretreatment of ovarian cancer cells and their whole cell lysate with tetrapeptide inhibitors of caspases in vitro significantly decreased Akt cleavage induced by cisplatin and exogenous active caspase-3." | ( Asselin, E; Mills, GB; Tsang, BK, 2001) |
| "Standard chemotherapy for advanced ovarian cancer currently includes a platinum agent (usually carboplatin) and paclitaxel." | ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 2001) |
| "The treatment of ovarian cancer has evolved over the past two decades from one of palliation to one where patients can achieve prolonged remission and cure." | ( Christian, J; Thomas, H, 2001) |
| "23 patients with stage III ovarian cancer were treated with second-line chemotherapy of PTXL and carboplatin (CRB) with the doses of 175 mg/m2, 3 h and AUC 5 mg/ml x min, respectively." | ( Bagaméri, A; Lehoczky, O; Pulay, T; Udvary, J, 2001) |
| "BG-1 human ovarian cancer cells were treated with various concentrations of nedaplatin to simulate the pharmacokinetics of administration in a clinical setting." | ( Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Nakamura, K; Yamamoto, J; Yoshinouchi, M, 2001) |
| "Fifteen patients with advanced ovarian cancer were enrolled and were administered paclitaxel in a 3-h infusion at dosing levels of 135 mg/m2, 175 mg/m2, and 235 mg/m2." | ( Fu, Q; Li, DK; Shen, K; Ye, M; Zhu, Z, 2000) |
| "The data suggest that almost all the ovarian cancer cells, which are resistant to chemotherapy, are also resistant to TRAIL." | ( Cuello, M; Ettenberg, SA; Lipkowitz, S; Nau, MM, 2001) |
| "Despite advances in treatment, ovarian cancer remains the number one gynecologic killer in the Western world." | ( Ozols, RF, 2001) |
| "In one case of ovarian cancer, chemotherapy was applied with CBDCA and TXL." | ( Arimoto, Y; Hayashi, S; Komura, H; Kunishige, I; Okuno, Y; Otsuki, Y; Shimoya, K, 2001) |
"We could not show that ovarian cancer patients with residual disease of | ( Heintz, AP; Mol, BW; Roovers, JP; Sijmons, EA; Slee, PH; van Leeuwen, JH; Witteveen, PO, 2001) | |
| "Thirty-six patients with ovarian cancer were accrued for the study, their selection being based on their progression following different systemic therapies with anti-neoplastic (multiple chemotherapy-resistant or -refractory) agents." | ( Dziambor, H; Hager, ED; Höhmann, D; Mühe, N; Strama, H, 2001) |
| "In the setting of ovarian cancer, high-dose chemotherapy should be administered only as part of well-designed clinical trials." | ( Aleman, AS; Bast, RC; Bevers, MW; Bodurka-Bevers, D; Burke, TW; Champlin, RE; Donato, ML; Freedman, RS; Gajewski, JL; Gershenson, DM; Ippoliti, CM; Levenback, CF; Wharton, JT; Wolf, JK, 2001) |
| "Thus, melatonin may improve ovarian cancer chemotherapy." | ( Futagami, M; Saito, Y; Sakamoto, T; Sato, S; Yokoyama, Y, 2001) |
| "Most advanced ovarian cancer which was fatal before introduction of cisplatin have become to be treated for cure by combination chemotherapy containing cisplatin and its analogues." | ( Kikuchi, Y, 2001) |
| "The SKOV-3 human ovarian cancer cell line was tested for uPA secretory responses (enzyme immunoassay of conditioned media) after treatments with sex steroids, human menopausal gonadotropins (hMG), or gonadotropin-releasing hormone (GnRH)." | ( McDonnel, AC; Murdoch, WJ, 2001) |
| "In seven patients with ovarian cancer, Epo and haemoglobin concentration (c(Hb)) were measured before, 24h and 7 days after administration of the first three courses of chemotherapy." | ( Herrero, J; Künzel, W; Pedain, C, 2001) |
| "To this aim, human ovarian cancer SKOV3 cells were treated once with vehicle or various concentrations of TGFbeta1 for 24 h." | ( Chen, L; Huang, CJ; Hwang, JJ; Ip, MM; Ke, FC; Lee, MT; Lee, PP; Lin, SW, 2000) |
| "Patients with recurrent or persistent ovarian cancer confined to the abdominal cavity after first line therapy, Karnofsky performance status > 60, adequate liver, renal and hematologic function, and tumor that reacted with CC49 antibody were enrolled." | ( Alvarez, RD; Austin, JM; Grizzle, WE; Khazaeli, MB; Kilgore, LC; Lin, CY; LoBuglio, AF; Macey, DJ; Meredith, RF; Partridge, EE; Schlom, J, 2001) |
| "This article reviews the treatment of ovarian cancer and looks at the place of Caelyx as a new second-line treatment option." | ( Johnston, SR; Kaye, S, 2001) |
| "Women with relapsing ovarian cancer more than 6 months after first-line treatment were eligible for the study." | ( Bolis, G; Guarnerio, P; Parazzini, F; Polverino, GP; Rosa, C; Scarfone, G; Sciatta, C, 2001) |
| "Patients with recurrent ovarian cancer were treated intraperitoneally (ip) with a replication-deficient recombinant adenovirus (ADV) containing the herpes simplex virus thymidine kinase gene." | ( Aguilar-Cordova, E; Fischer, DC; Hasenburg, A; Kaplan, AL; Kaufman, RH; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW, 2001) |
| "Chemotherapy for advanced ovarian cancer has evolved over the past 25 years from the initial use of alkylating agents such as melphalan." | ( du Bois, A, 2001) |
| "Caelyx is a new treatment for advanced ovarian cancer, which delivers doxorubicin encapsulated in long-circulating Stealth liposomes, resulting in a prolonged circulation and enhanced tumour targeting of the drug, together with a markedly different safety profile compared with native doxorubicin." | ( Gore, ME; Johnston, SR, 2001) |
| "Although the results of treatment of ovarian cancer have improved over the past 20 years with the introduction of platinum and more recently taxoid-based chemotherapy, the majority of patients still die of this disease." | ( Kaye, SB, 2001) |
| "Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5-30 mg/m(2)) for pharmacokinetic analysis." | ( Aalders, JG; Beijnen, JH; Bos, AM; de Vries, EG; Hofstra, LS; Mulder, NH; Rosing, H; van der Zee, AG; Willemse, PH, 2001) |
| "The outcome of patients with advanced ovarian cancer is poor despite aggressive therapy including surgery and multiagent chemotherapy." | ( Caspari, C; Hepp, H; Hillemanns, P; Kapsner, T; Kimmig, R; Wimberger, P, 2002) |
| "Patients with recurrent ovarian cancer who experienced a progression-free interval of greater than 6 months after response to platinum-based chemotherapy are defined as platinum sensitive by the GOG and were eligible for this trial." | ( Blessing, JA; Bookman, MA; Creasman, WT; Plaxe, SC, 2002) |
| "In early-stage epithelial ovarian cancer, a meticulous staging procedure should be performed to aid in determining patients who require appropriate adjuvant therapy and patients who can be monitored." | ( Im, DD; McGuire, WP; Rosenshein, NB, 2001) |
| "The treatment of ovarian cancer has rapidly evolved in the past decade." | ( Wadler, S, 2001) |
| "Despite its proven efficacy in treating ovarian cancer, chemotherapy seems to be used less among patients over age 65, especially those who are nonwhite and/or in the oldest age groups." | ( Grann, VR; Hershman, D; Jacobson, JS; Neugut, AI; Sundararajan, V, 2002) |
| "A total of 30 patients with ovarian cancer who had initially undergone chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide (CAP) and exhibited measurable lesions were entered in the study." | ( Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N, 2001) |
| "Eighteen patients with ovarian cancer received two consecutive courses of chemotherapy (16 cases, CAP therapy and two cases, CP therapy) at 4-week intervals." | ( Akada, S; Hatake, K; Morikawa, H; Saito, S; Teranishi, A, 2002) |
| "Apoptosis was observed in primary ovarian cancer cell culture treated with COX-2 inhibitor." | ( Barnes, MN; Grizzle, WE; Myers, RB; Oelschlager, DK; Partridge, EE; Rodríguez-Burford, C; Talley, LI, 2002) |
| "Furthermore, this ovarian cancer survival model was used to evaluate the in vivo efficacy of cationic lipid mediated pOSP1-HSVtk gene delivery followed by GCV treatment." | ( Bao, R; Hamilton, TC; Selvakumaran, M, 2002) |
| "In advanced ovarian cancer, gemcitabine is a candidate for combination chemotherapy due to its unique mechanism of action, favorable toxicity profile, and proven activity." | ( Hansen, SW, 2002) |
| "Forty-two women with relapsed, advanced ovarian cancer were treated with cisplatin 60 mg/m2 on days 1, 8, 15, 29, 36 and 43 and oral etoposide 50 mg given from day 1-14 and day 29-43." | ( Mahmoudi, M; Meyer, T; Nelstrop, AE; Rustin, GJ, 2001) |
| "Eighteen ovarian cancer patients who had received cytoreductive operation 1 to 3 times and 8 to 18 courses of chemotherapy but still failed in DDP-based(86." | ( Li, H; Liu, L; Zhang, W, 2001) |
| "inoculation with OVCAR-3 ovarian cancer cells, mice were treated i." | ( Hofmann, J; Hu, L; Jaffe, RB; Lu, Y; Mills, GB, 2002) |
| "We investigated 48 women: 17 with ovarian cancer untreated before, 16 with benign ovarian cysts and 15 healthy controls." | ( Maciołek-Blewniewska, G; Malinowski, A; Małafiej, E; Nowak, M; Oszukowski, P; Szpakowski, A; Szpakowski, M; Wieczorek, A; Wierzbicka, E; Wilczyński, JR, 2001) |
| "The majority of patients with ovarian cancer are not cured by first-line treatment." | ( Bauknecht, T; Costa, S; du, BA; Emon, G; Jackisch, C; Lück, HJ; Meier, W; Moebus, V; Olbricht, S; Richter, B; Schroeder, W; Wagner, U, 2002) |
| "Patients with ovarian cancer progressing during platinum-paclitaxel containing first-line therapy or experiencing relapse within 6 months were eligible." | ( Bauknecht, T; Costa, S; du, BA; Emon, G; Jackisch, C; Lück, HJ; Meier, W; Moebus, V; Olbricht, S; Richter, B; Schroeder, W; Wagner, U, 2002) |
| "Our goal was to determine whether ovarian cancer cells isolated from patient ascites fluid were growth inhibited by TGF beta 1 treatment and further characterize the expression and activity profile of TGF beta/Smad signaling components in human ovarian cancer cells." | ( Dunfield, LD; Dwyer, EJ; Nachtigal, MW, 2002) |
| "To analyze detailed mechanisms, the ovarian cancer cell lines (2774, PA-1, OVCAR-3, and SKOV-3) were treated with IFN-gamma." | ( Kim, EJ; Lee, JM; Namkoong, SE; Park, JS; Um, SJ, 2002) |
| "A mouse model of human ovarian cancer was used to investigate the effect of adenovirus-mediated thymidine kinase gene therapy (gt) in combination with chemotherapy." | ( Aguilar-Cordova, E; Engehausen, DG; Fischer, DC; Kieback, DG; Oehler, MK; Sauerbrei, W; Tong, XW, 2002) |
| "Patients with recurrent measurable ovarian cancer who had up to two prior chemotherapy regimens for the management of their disease participating in this phase II trial were to receive topotecan at a dose of 1." | ( Hanjani, P; Nolte, S; Shahin, MS, 2002) |
| "All clinically early-stage ovarian cancer patients should be considered for comprehensive staging surgery prior to further treatment recommendations." | ( Adolph, A; Heywood, MS; Krepart, GV; Le, T; Lotocki, R, 2002) |
| "Much improvement in the treatment of ovarian cancer has been achieved since the introduction of platinum compounds in the 1980s, with the result that single-agent platinum-based therapy following primary surgery is now the standard treatment for advanced ovarian cancer." | ( Chakraborti, PR; Garner, CM; Hubbold, LM, 2002) |
| "Twenty five recurrent ovarian cancer patients were treated between March, 1999 and March, 2001." | ( Bagaméri, A; Lehoczky, G; Lehoczky, O; Pulay, T, 2002) |
| "Treatment of primary human ovarian cancer cells and human ovarian cancer cell lines EFO-21 and EFO-27 with LHRH agonist triptorelin (100 nM) resulted in an increase in G(0/1) phase and a decrease in G(2/S) phase of cell cycle." | ( Emons, G; Gründker, C; Günthert, AR; Hollmann, K, 2002) |
| "Although early stage ovarian cancer can be effectively treated with surgery and chemotherapy, the majority of cases present with advanced disease, which remains essentially incurable." | ( Auersperg, N; Birrer, MJ; Choi, YH; Dayton, M; Dent, P; Gardner, GJ; Kinoshita, I; Manzano, RG; Montuenga, LM; Nguyen, P; Trepel, J; Vicent, S, 2002) |
| "Xenograft tumors of human ovarian cancer NIH-OVCAR-3 cells were established in athymic nude mice, and tumor growth was monitored after treatment with NO-Cbl and IFN-beta, both individually and concomitantly." | ( Bauer, JA; Carnevale, KA; Dabney, S; Drazba, J; Gamero, AM; Grane, RW; Jacobs, BS; Lindner, DJ; Morrison, BH; Seetharam, B; Smith, DJ, 2002) |
| "As a single agent in advanced ovarian cancer patients previously treated with a platinum agent, docetaxel at 100 mg/m2 every 3 weeks yields a 30% overall response rate and a 6-month duration of response." | ( Kavanagh, JJ, 2002) |
| "Clinical trials of gene therapy for ovarian cancer have explored the feasibility of delivering a variety of agents as well as highlighted problems with the delivery of therapeutic constructs." | ( Jenkins, AD; Wolf, JK, 2002) |
| "Relapsed ovarian cancer and small cell lung cancer are frequently treated with topotecan (Hycamtin), for which the standard dose and schedule are 1." | ( Rowinsky, EK, 2002) |
| "Up to 80% of patients with advanced ovarian cancer will recur following first-line platinum containing chemotherapy." | ( Beshara, N; Faught, W; Fung Kee Fung, M, 2002) |
| "Most patients with ovarian cancer need cytotoxic chemotherapy." | ( Gore, M; Harries, M, 2002) |
| "Most patients with ovarian cancer respond to first-line chemotherapy, but many relapse within 18 to 22 months." | ( Herzog, TJ, 2002) |
| "Treatment of ovarian cancer cells with alendronate resulted in inactivation of Rho, changes of cell morphology, loss of stress fiber formation, and focal adhesion assembly, and the suppression of phosphorylation of myosin light chain and tyrosine phosphorylation of focal adhesion proteins, which are essential processes for cell migration." | ( Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sawada, K; Tahara, M; Tasaka, K, 2002) |
| "Women with relapsed epithelial ovarian cancer after platinum and paclitaxel treatment were eligible to participate in this trial." | ( Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D, 2002) |
| "Recurrent ovarian cancer after front-line chemotherapy is incurable." | ( Kawano, Y; Miyakawa, I; Narahara, H; Nasu, K; Takai, N; Utsunomiya, H, 2002) |
| "A total of 31 patients with recurrent ovarian cancer in a multiple centers clinical trial were treated with Topotecan 1." | ( Bian, ML; Cui, Y; Guan, ZZ; Huang, CJ; Li, JD; Liu, FY; Liu, JH; Song, L; Xin, XY; Zhou, QH, 2002) |
| "In a clinical trial, 43 ovarian cancer patients were treated with low doses of MTX." | ( Boiocchi, M; Corona, G; Innocenti, F; Mini, E; Russo, A; Sartor, F; Toffoli, G; Tumolo, S, 2003) |
| "Previously treated ovarian cancer patients with measurable disease and/or elevated cancer antigen 125 (CA-125) received (as second-line or third-line therapy) weekly 30-min bolus IV topotecan starting at 2 mg/m(2) combined with weekly paclitaxel starting at a dose of 60 mg/m(2)." | ( Benigno, B; Homesley, H; Vaccarello, L; Williams, J, 2002) |
| "We treated an ovarian cancer patient in whom low-dose CDDP intratumoral injection with CPT-11 therapy was very effective." | ( Inoue, S; Kagawa, M; Kusanishi, H; Watanabe, Y, 2002) |
| "Chemoresistance of ovarian cancer can be overcome by co-administration of retinoids, albeit clinical proof of this hypothesis is pending." | ( Grunt, TW, 2003) |
| "Seventeen patients with advanced ovarian cancer were treated with neoadjuvant chemotherapy based on the extent of disease on computer tomography." | ( Chan, YM; Ng, TY; Ngan, HY; Wong, LC, 2003) |
| "Furthermore, the 5-year survival of ovarian cancer patients treated with a drug found sensitive in vitro is significantly higher than that for patients treated with a drug found resistant in vitro (p = 0." | ( Sargent, JM, 2003) |
| "The standard therapy for recurrent ovarian cancer has not been confirmed." | ( Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T, 2003) |
| "A total of 7 patients with recurrent ovarian cancer were treated with weekly paclitaxel (TXL)." | ( Fujiyoshi, K; Ishimatsu, J; Kawagoe, H; Kawata, T; Nishio, S; Shimomura, T; Tsunawaki, A, 2003) |
| "Most patients with ovarian cancer undergo cytoreductive therapy." | ( Das, SK; Dey, SK; DuBois, RN; Gupta, RA; Morrow, JD; Tejada, LV; Tong, BJ, 2003) |
| "Patients affected by ovarian cancer, and with progressive disease after treatment with platinum/paclitaxel-based chemotherapy, were enrolled into this phase II study." | ( Amant, F; Berteloot, P; D'Agostino, G; Scambia, G; Vergote, I, 2003) |
| "Fifty-nine advanced-stage ovarian cancer patients who were treated with platinum-based chemotherapy were studied." | ( Barassi, F; Bosari, S; Buttitta, F; Coggi, G; Cosio, S; Felicioni, L; Gadducci, A; Marchetti, A; Martella, C; Pellegrini, C; Salvatore, S, 2003) |
| "We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m(2) body-surface area (BSA)) given as 3-25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation." | ( Bojko, P; Dirsch, O; Hilger, RA; Ruehm, SG; Scheulen, ME; Seeber, S, 2003) |
| "Re-expression of HSulf-1 in ovarian cancer cell lines resulted in diminished HSPG sulfation, diminished phosphorylation of receptor tyrosine kinases that require sulfated HSPGs as co-receptors for their cognate ligands, and diminished downstream signaling through the extracellular signal-regulated kinase pathway after treatment with fibroblast growth factor-2 or heparin-binding epidermal growth factor." | ( Avula, R; Chien, J; Greene, EL; Kaufmann, SH; Lai, J; Matthews, TA; Roberts, LR; Shridhar, V; Smith, DI; Staub, J, 2003) |
| "Five patients with recurrent ovarian cancer who had a previous documented hypersensitivity reaction to carboplatin and a good clinical indication for continuing treatment with platinum were retreated following cisplatin desensitisation." | ( Friedlander, M; Jones, R; Ryan, M, 2003) |
| "Epithelial ovarian cancer is moderate sensitivity to chemotherapy; the survival has been improved by aggressive cytoreductive surgery followed by combination chemotherapy with cisplatin-based regimen." | ( Huang, MN; Li, N; Liu, LY; Wang, GX; Wu, LY; Zhang, R, 2003) |
| "Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment." | ( Brown, D; Flick, M; Hanczaruk, B; Kamsteeg, M; Mor, G; Rutherford, T; Sapi, E; Shahabi, S, 2003) |
| "30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine." | ( Aapro, MS; Beex, LV; Guastalla, JP; Kobierska, A; Namer, M; Rosso, R; Splinter, TE; ten Bokkel Huinink, W; van der Burg, ME; van Wijk, FH; Vergote, I; Vermorken, JB, 2003) |
| "The Scottish Randomized Trial in Ovarian Cancer (SCOTROC) trial randomly assigned 1,077 patients with International Federation of Gynecology and Obstetrics stage Ic to IV disease to six cycles of docetaxel plus carboplatin (DC) or paclitaxel plus carboplatin (PC) as primary chemotherapy." | ( Vasey, PA, 2003) |
| "When ovarian cancer recurs, chemotherapy is continued when patients respond to therapy." | ( Karlen, JR; von Gruenigen, VE; Waggoner, SE, 2003) |
| "A woman with advanced ovarian cancer was treated with cytoxan and cisplatin chemotherapy after having surgical cytoreduction." | ( Karlen, JR; von Gruenigen, VE; Waggoner, SE, 2003) |
| "Sixteen patients with epithelial ovarian cancer were given paclitaxel (175 mg/m(2), 3 hours) and carboplatin (area under the curve of 5) every three weeks, and the CPT values were measured at two sites on the day before and several times after administration." | ( Araki, T; Doi, D; Konishi, H; Ota, Y; Yoneyama, K, 2003) |
| "Data of four Hungarian Ovary Cancer Treatment Center was collected, evaluated and presented here as a preliminary retrospective study." | ( Mayer, A; Pete, I; Pulay, T; Szánthó, A; Thurzó, L, 2003) |
| "Patients whose ovarian cancer actually demonstrated growth during platinum-combination treatment or no objective evidence of regression following four to six cycles of therapy were considered to have clinically defined platinum-resistant disease." | ( Aufman, K; D'Angelo, G; Edwards, R; Ferrell, R; Godfrey, TE; Gooding, W; Kanbour-Shakir, A; Makhija, S; Raja, S; Sit, A; Weiss, H, 2003) |
| "Patients with ovarian cancer who had failed a platinum and paclitaxel-containing therapy were enrolled." | ( Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D, 2003) |
| "In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel." | ( Baergen, R; Bundy, BN; Burger, RA; Clarke-Pearson, D; DeGeest, K; Fowler, JM; Greer, BE; Hartenbach, EM; Mannel, RS; Ozols, RF, 2003) |
| "This suggests that ovarian cancers that overexpress MDM2 may be amenable to treatment with platinum compounds." | ( Mi, RR; Ni, H, 2003) |
| "The potential of OVS1 MAb in ovarian cancer treatment was studied by evaluating the induction of cytotoxicity and apoptosis of SKOV3 ovarian cancer and BT549 breast cancer cell lines induced by OVS1." | ( Jongsomboonkusol, S; Junnu, S; Kaslungka, S; Kosem, N; Moongkarndi, P; Neungton, N; Theptaranon, Y, 2003) |
| "Primary chemotherapy for advanced ovarian cancer includes the administration of a platinum agent (carboplatin or cisplatin) and a taxane (paclitaxel or docetaxel)." | ( Markman, M, 2003) |
| "This approach is actively pursued in ovarian cancer, which allows local, intraperitoneal drug administration." | ( de Vries, EG; Willemse, PH, 2003) |
| "Ovary function impairment may occur in ovarian cancer patient treated by one side ovarectomy followed by chemotherapy." | ( Huang, HF; Lang, JH; Shen, K; Sun, ZY, 2003) |
| "Improvements in ovarian cancer management mean that it may now be a long-term disease for which treatment must be carefully considered." | ( Spriggs, D, 2003) |
| "Thus, treatment of ovarian cancer with paclitaxel might be less effective in the setting of postoperative estrogen replacement therapy." | ( Arimoto-Ishida, E; Kimura, A; Mabuchi, S; Murata, Y; Nishio, Y; Ohmichi, M; Tasaka, K; Yada-Hashimoto, N, 2004) |
| "Twenty patients with recurrent ovarian cancer previously treated with two (30%) or three lines (70%) of chemotherapy were entered into the trial." | ( Amiconi, G; Carta, G; Cesta, A; De Filippis, S; Rea, S; Recchia, F; Saggio, G, 2003) |
| "The mainstay of treatment for advanced ovarian cancer is the multimodality approach of debulking surgery and paclitaxel--platinum chemotherapy." | ( van der Burg, ME; Vergote, I, 2003) |
| "In these patients (full cousins) the ovarian cancers were noted for their aggressive development and rapid recurrence after surgical debulking and during regular multichemotherapy including Cisplatin." | ( Lutgens, LC; Marcelis, CL; Moog, U; Tops, C; van der Putten, HW, 2001) |
| "The study recruited 44 women with ovarian cancer or primary peritoneal cancer previously treated with platinum therapy and paclitaxel and with progressive disease after, or intolerance to, topotecan administered as the most recent therapy." | ( Carson, L; Clarke-Pearson, D; Douglass, EC; Holloway, R; Kao, MS; Moore, M; Rader, JS; Wiznitzer, I, 2003) |
| "A 59-year-old woman with advanced ovarian cancer complained of massive refractory ascites after 2 years' history of chemotherapy." | ( Fujimoto, S; Kobayashi, K; Mutou, T; Ogasawara, T; Ohtsuka, Y; Takahashi, M; Toyosawa, T, 2003) |
| "The therapeutic principle of ovarian cancer was cytoreductive surgery assisting with chemotherapy." | ( Liu, SL; Peng, ZL; Qian, XL, 2003) |
| "A total of 28 patients with epithelial ovarian cancer in stages III and IV who were primarily treated in our ward from 1993 were examined retrospectively." | ( Baba, T; Goto, M; Nonogaki, T; Tamai, A; Ueda, M; Utsunomiya, Y, 2003) |
| "We have successfully treated an ovarian cancer patient with Parkinson's disease by paclitaxel/CBDCA combined chemotherapy after surgery." | ( Date, K; Egawa, M; Fujitoh, N; Fujiwara, H; Furukawa, M; Mizunoe, T; Sakashita, T; Ueda, K; Urabe, S; Urabe, T, 2003) |
| "Nude mice bearing OVCAR-3 human ovarian cancer xenografts were treated intravenously with doxorubicin (8 mg x kg(-1)) alone or preceded by PC-SOD 20000 or 80000 U x kg(-1) weekly x 2 and appropriate controls were included." | ( Bast, A; Boven, E; den Hartog, GJ; Haenen, GR; van der Vijgh, WJ, 2004) |
| "Patients with epithelial ovarian cancer (EOC) who relapse more than 6 months following completion of platinum-based primary chemotherapy are considered platinum-sensitive, and can be effectively retreated with cisplatin or carboplatin." | ( Aravantinos, G; Briassoulis, E; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, C; Moulopoulos, LA; Papadimitriou, CA, 2004) |
| "In total, 43 patients with advanced ovarian cancer and >1 cm residual disease were treated with sequential carboplatin (area-under-the-curve (AUC) 5 days 1 and 22), paclitaxel (175 mg m(-2) days 43 and 64) and topotecan (1." | ( Agarwal, R; Foster, T; Guppy, AE; Nelstrop, AE; Rustin, GJ; Seckl, MJ, 2004) |
| "Current treatment of ovarian cancer entails a combination of surgery and chemotherapy." | ( Eltabbakh, GH, 2004) |
| "Patients with histologically proven ovarian cancer who relapsed after platinum- and paclitaxel-containing therapy were enrolled." | ( Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D, 2004) |
| "Three ovarian cancer cell lines, platinum-sensitive A2780, and platinum-resistant A2780/CP70 and OvCar-3, were exposed to their respective IC(50) dose of cisplatin for 1 h with or without a 24-h pretreatment with harringtonine." | ( Guo, Y; Miller, MR; Yu, JJ; Yunmbam, MK, 2004) |
| "Treatment of well-established FMa human ovarian cancer xenografts with intravenous injection of DOX-GA3 (500 mg/kg) resulted in a tumor volume-doubling time of 23." | ( Boven, E; de Graaf, M; Gerritsen, WR; Haisma, HJ; Oosterhoff, D; Pinedo, HM; van der Meulen-Muileman, IH, 2004) |
| "For this reason, ovarian cancer now is considered a chronic disease with treatment aimed at control of disease, palliation of symptoms, and quality-of-life maintenance." | ( Almadrones, LA, 2003) |
| "Pretreatment of the ovarian cancer cells with the pertussis toxin completely inhibited lysophosphatidic acid-stimulated production of interleukin-6, interleukin-8 and tumor necrosis factor-alpha." | ( Furui, T; Imai, A; Sugiyama, M; Tamaya, T, 2004) |
| "We treated a patient with recurrent ovarian cancer with cancerous peritonitis by weekly paclitaxel (w-TXL) therapy (65 mg/m2)." | ( Date, K; Egawa, M; Fujitou, N; Fujiwara, H; Mizunoe, T; Sakashita, T; Ueda, K; Urabe, S; Urabe, T, 2004) |
| "Most women with epithelial ovarian cancer (EOC) will develop disease progression or recurrence with resistance to platinum therapy." | ( Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P, 2004) |
| "As single agent, in advanced ovarian cancer patients previously treated with platinum agents, docetaxel 100 mg/m(2) every 3 weeks yields a 30% overall response rate and 6 months duration of response." | ( Ray-Coquard, I, 2004) |
| "The patients with ovarian cancer undergoing chemotherapy and receiving Se showed a significant increase in the activity of GSH-P(x) in erythrocytes after 2 months' (P < 0." | ( Sieja, K; Talerczyk, M, 2004) |
| "A 62-year-old patient with ovarian cancer reported vaginal burning associated with dyspareunia, which emerged 3-5 days after her initial chemotherapy and persisted throughout her treatment." | ( Aghajanian, CA; Carter, J; Castiel, M; Dizon, DS; Krychman, ML, 2004) |
| "Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak." | ( BogoviC, J; Douwes, F; Douwes, O; Grote, C; Migeod, F, 2004) |
| "Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak." | ( BogoviC, J; Douwes, F; Douwes, O; Grote, C; Migeod, F, 2004) |
| "Thirteen patients with stage III and IV ovarian cancer treated with carboplatin and paclitaxel were studied." | ( Flick, MB; Hao, XY; Kacinski, BM; Kamsteeg, M; Mor, G; O'Malley, D; Rodov, S; Rutherford, T; Schwartz, P, 2004) |
| "In contrast, ovarian cancer cell lines OVCAR4 and OVCAR5, which have low basal levels of AKT activity, did not show increased cisplatin-induced apoptosis when pretreated with LY294002." | ( Altomare, DA; De Rienzo, A; Godwin, AK; Klein-Szanto, AJ; Skele, KL; Testa, JR; Wang, HQ, 2004) |
| "The UGT1A1*28 distribution among an ovarian cancer patient (OCP) population of 217 mono-institutional individuals was investigated to clarify its possible involvement in the pathogenesis and chemotherapy of ovarian cancer." | ( Boiocchi, M; Campagnutta, E; Cecchin, E; Corona, G; Martella, L; Russo, A; Toffoli, G, 2004) |
| "In this study we found that in ovarian cancer cells, CHK2 kinase is activated by irofulven while CHK1 kinase is not activated even when treated at higher concentrations of the drug." | ( Burks, J; Cunningham, C; Mikell, C; Reed, E; Van Laar, ES; Wang, J; Wang, W; Wang, Y; Waters, SJ; Wiltshire, T, 2004) |
| "The treatment of recurrent ovarian cancer with the combination of gemcitabine and cisplatin chemotherapy has recently been shown to be an active regimen." | ( Burger, RA; Falkner, CA; Hunter, M; Monk, BJ; Tewari, D, 2004) |
| "In second-line chemotherapy of ovarian cancer, patients demonstrating SD have a survival benefit compared to patients with PD measured by the WHO tumor response criteria." | ( Christensen, IJ; Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C, 2004) |
| "With a negative randomized trial of ovarian cancer in front-line treatment that included an adenovirus p53 plus chemotherapy, we feel that further refinement of gene therapy is required before additional trials are undertaken." | ( Bodurka, DC; Deavers, M; Gano, JB; Gershenson, DM; Levenback, C; Ramirez, PT; Ramondetta, L; Wolf, JK, 2004) |
| "Patients with epithelial ovarian cancer that recurred after or failed to respond to first-line platinum-based chemotherapy were randomized to receive pegylated liposomal doxorubicin 50 mg/m(2) every 28 days (n = 239) or topotecan 1." | ( Gordon, AN; Rackoff, W; Sun, S; Tonda, M, 2004) |
| "Three ovarian cancer cell lines, HO-8910, HO-8910PM and SKOV3, were treated with TGF-beta1 and assayed for growth response by MTT assay." | ( Fu, SB; Li, P; Li, X; Sui, LH; Wang, Q; Zhang, YY, 2004) |
| "Using a human ovarian cancer cell line (A2780) that expresses both Bcl-2 and MGMT, we show that cells treated with active dose levels of either oblimersen (but not control reverse sequence or mismatch oligonucleotides) or PaTrin-2 are substantially sensitized to temozolomide." | ( Barvaux, VA; Gillum, AM; Lorigan, P; Margison, GP; McElhinney, RS; McMurry, TB; Ranson, M, 2004) |
| "We used IGROV1 ovarian cancer cells loaded with CFSE at the time of seeding; 24 h later cells were treated with an anticancer drug (topotecan)." | ( Lupi, M; Matera, G; Ubezio, P, 2004) |
| "Animal models of ovarian cancer are crucial for understanding the pathogenesis of the disease and for testing new treatment strategies." | ( Babb, JS; Bao, R; Gruver, BN; Hamilton, TC; Klein-Szanto, A; Koutroukides, T; Ochman, AR; Patriotis, C; Pinnola, AD; Querec, TD; Stewart, SL; Wong, TS, 2004) |
| "Fifty-eight patients with ovarian cancer treated from January 1990 to December 2000 were retrospectively reviewed." | ( Chen, GL; Lin, YZ; Xie, R, 2004) |
| "A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment." | ( Herzog, TJ, 2004) |
| "Following cytoreductive surgery, 26 ovarian cancer patients received primary chemotherapy with carboplatin (AUC = 5, day 1), paclitaxel (175 mg/m(2) over 1 h, day 1), and gemcitabine (800 mg/m(2), day 1 day 8), with treatment repeated every 21 days x 6 cycles." | ( Bader, K; Brown, JV; Goldstein, BH; Graham, C; Markman, M; Mattison, JA; Micha, JP; Rettenmaier, MA, 2005) |
| "To estimate the risk of ovarian cancer after a primary diagnosis of breast cancer among women with a BRCA1 or BRCA2 mutation and to identify host and treatment-related factors that might modify the risk." | ( Eisen, A; Foulkes, WD; Ghadirian, P; Lynch, HT; McLennan, J; Metcalfe, KA; Narod, SA; Olivotto, IA; Olopade, O; Sun, P; Tung, N; Warner, E; Weber, B, 2005) |
| "Data on the first-line treatment of ovarian cancer in special centers of Hungary 2002 and 2003 are presented, involving 283 and 416 patients, respectively." | ( Baki, M; Bodoky, G; Cseh, J; Csejtei, A; Csömör, S; Dank, M; Erfán, J; Esik, O; Faluhelyi, Z; Hernádi, Z; Izsó, J; Kammerer, K; Kásler, M; Krommer, K; Magyar, T; Mayer, A; Megyery, E; Moskovits, K; Pécsi, L; Pikó, B; Pintér, T; Pulay, T; Ruzsa, A; Szánthó, A; Szántó, I; Szántó, J; Szucs, M; Tálos, Z; Thurzó, L, 2004) |
| "Following treatment with LPA, ovarian cancer cells showed significant rapid reduction of Fas presentation on the cell surface." | ( Fishman, DA; Kang, S; Meng, Y; Reierstad, S; So, J, 2005) |
| "Current treatment options for ovarian cancer, which is one of the most widespread gynecological malignancies, are limited, mainly because patients with advanced-stage disease often develop resistance to chemotherapeutics." | ( Abuharbeid, S; Aigner, A; Apel, J; Czubayko, F; Gilbert, S; Knabbe, C; Sander, M; Zugmaier, G, 2005) |
| "Analysis of BG-1(LT) ovarian cancer cells isolated after 5 months of long-term treatment with 4-OH TAM revealed both a significantly reduced apoptotic and antiproliferative effect of this drug." | ( Horn, F; Ortmann, O; Treeck, O; Zhou, R, 2005) |
| "In 91 patients with epithelial ovarian cancer and 95 healthy women matched for age, weight, and height, levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines, leptin, reactive oxygen species (ROS), and antioxidant enzymes were assessed at diagnosis before treatment." | ( Gramignano, G; Lusso, MR; Macciò, A; Madeddu, C; Mantovani, G; Massa, D; Melis, GB; Mudu, MC; Serpe, R, 2005) |
| "Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only approximately 20% achieve long-term disease-free survival." | ( Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J, 2005) |
| "Patients with ovarian cancer respond to initial platinum-based chemotherapy, such as cisplatin." | ( Aghajanian, C, 2004) |
| "Mucinous epithelial ovarian cancer (mEOC) representing about 10% of all EOC are known to be possibly resistant to platinum-based chemotherapy and bear a poorer prognosis with respect to other subtypes of EOC." | ( Aravantinos, G; Briasoulis, E; Dimopoulos, MA; Economopoulos, T; Efstathiou, E; Farmakis, D; Fountzilas, G; Kalofonos, HP; Pectasides, D; Salamalekis, E; Skarlos, D, 2005) |
| "Most patients with advanced epithelial ovarian cancer experience objective responses to paclitaxel/platinum-based chemotherapy, but responses are generally short-lived and the clinical outcome is still unsatisfactory." | ( Conte, PF; Cosio, S; Gadducci, A; Genazzani, AR, 2005) |
| "Many patients with ovarian cancer are at high risk of recurrence especially in the 2 years following first-line therapy." | ( De Iaco, P; Erba, P; Fanti, S; Farsad, M; Mariani, G; Nanni, C; Rampin, L; Rubello, D; Sansovini, M, 2005) |
| "Not all patients with relapsed ovarian cancer (EOC) benefit from further treatment and thus treatment should be selectively applied." | ( Hoskins, PJ; Le, N, 2005) |
| "Successful treatment of relapsed ovarian cancer has not been solved." | ( Bagaméri, A; Lehoczky, O; Pulay, T; Sárosi, Z; Thurzó, L; Udvary, J, 2005) |
| "Sixteen patients with relapsed ovarian cancer, premedicated with steroids, were given docetaxel-carboplatin chemotherapy at a dose of 75 mg/m2 and AUC 5 in 94 courses at the Gynecological Dept." | ( Bagaméri, A; Lehoczky, O; Pulay, T; Sárosi, Z; Thurzó, L; Udvary, J, 2005) |
| "All epithelial ovarian cancer patients requiring chemotherapy to manage their disease were recruited from university based gynecologic oncology clinics." | ( Hopkins, L; Kee Fung, MF; Le, T, 2005) |
| "The majority of patients with ovarian cancer, especially those who present with stages IIIC and IV, will relapse soon after completion of platinum-based induction treatment." | ( Blank, SV; Chang, R; Muggia, F, 2005) |
| "Cultured human epithelial ovarian cancer cell line A2780 and its platinum(DDP)-resistance cell line A2780/DDP were divided into three groups as control, treatment with DDP, and treatment with Taxol Expression of mdr1 and survivin genes in each group was detected by using reverse transcription-polymerase chain reaction (RT-PCR)." | ( Wang, H; Wang, Z; Xie, Y, 2005) |
| "Recurrent ovarian cancer is refractory and resistant to treatment in most patients, and no effective treatment for it has been established." | ( Maeda, M; Ozawa, T; Takekuma, M; Torizuka, T; Yasumi, K, 2005) |
| "Among patients with epithelial ovarian cancer in whom initial treatment achieved remission between April 1998 and December 2003, those patients in whom the cancer-related antigen (CA)125 level was increased during the subsequent follow-up period, or those who showed abnormal computed tomography (CT)/magnetic resonance imaging (MRI) findings despite normal CA125 levels, were examined by 18F-fluoro-2-deoxyglucose - positron emission tomography (FDG-PET)." | ( Maeda, M; Ozawa, T; Takekuma, M; Torizuka, T; Yasumi, K, 2005) |
| "Patients with unfavourable ovarian cancer responding to intravenous liposomal doxorubicin and whole abdomen hyperthermia maintained above average QoL during therapy." | ( Blivin, JL; Dewhirst, MW; Hahn, CA; Jones, EL; Prosnitz, LR; Sanders, LL; Secord, AA; Yu, D, 2005) |
| "This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin." | ( Bolis, G; Cipriani, S; Parazzini, F; Polverino, G; Scarfone, G; Stellato, G, 2005) |
| "This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival." | ( Bolis, G; Cipriani, S; Parazzini, F; Polverino, G; Scarfone, G; Stellato, G, 2005) |
| "The majority of ovarian cancer patients are treated with platinum-based chemotherapy, but the emergence of resistance to such chemotherapy severely limits its overall effectiveness." | ( Langdon, SP; Lawrie, S; Macleod, K; Miller, E; Mullen, P; Rabiasz, G; Sewell, J; Smyth, JF, 2005) |
| "Survivin gene is highly expressed in ovarian cancer cell line SKOV3 and drug-resistant cell line SKOV3/ADM, and is an ideal target of gene therapy for ovarian cancer." | ( Chen, WX; Chen, Y; Deng, KX; He, H; Jiang, MX; Zhong, L, 2005) |
| "All patients with ovarian cancer not enrolled in clinical studies and treated in 2001 in the participating centres were documented retrospectively and compared with patients enrolled in clinical trials at the same institutions during the same time period." | ( Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K, 2005) |
| "These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25-dihydroxyvitamin D3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells." | ( Bai, W; Bao, J; Enkemann, SA; Li, P; Nicosia, SV; Wang, H; Zhang, X, 2005) |
| "Most patients with advanced ovarian cancer achieve a clinical complete remission following cytoreductive surgery and chemotherapy with paclitaxel plus carboplatin." | ( Ozols, RF, 2005) |
| "Almost all patients with epithelial ovarian cancer receive chemotherapy and, concurrently, the synthetic steroid hormone dexamethasone to alleviate the side effects." | ( Brüning, A; Runnebaum, IB, 2005) |
| "Bcl-2 is overexpressed in ovarian cancer and participates in chemoresistance; we hypothesized that Bcl-2 inhibits E1A-induced apoptosis leading to resistance to E1A gene therapy." | ( Bartholomeusz, C; Esteva, FJ; Hung, MC; Itamochi, H; Terakawa, N; Ueno, NT; Wood, CG; Yuan, LX, 2005) |
| "Women with ovarian cancer who experience disease progression during or within 6 months of first-line treatment with platinum-based anticancer drugs are considered to have platinum-resistant tumors." | ( Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG, 2006) |
| "Although ovarian cancer is very responsive to multiple chemotherapeutic agents, with objective response rates of up to 80% with the standard platinum and taxane doublets, 75% of patients relapse within 2 years of primary therapy and become candidates for treatment of recurrent disease." | ( McGuire, WP; Tummala, MK, 2005) |
| "Epithelial ovarian cancer often develops resistance to standard treatments, which is a major reason for the high mortality associated with the disease." | ( Chang, Y; del Carmen, MG; Hasan, T; Moor, AC; Oliva, E; Pogue, B; Rizvi, I; Sherwood, M, 2005) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of M344, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2006) |
| "Human ovarian cancer cell parental line A2780s and a derivative cisplatin-resistant line A2780cp were given cisplatin treatment before a single acute dose irradiation or concurrently during a pulsed-dose irradiation sequence." | ( Leblanc, JM; Raaphorst, P, 2005) |
| "Nearly all women diagnosed with ovarian cancer receive combination chemotherapy including cis- or carboplatin." | ( Collins, S; Drescher, CW; Hood, L; Lin, B; Stewart, JJ; Urban, ND; White, JT; Yan, X, 2006) |
| "Standard first-line treatment of ovarian cancer (OC) consists of platinum-taxane combined chemotherapy." | ( Poveda, A, 2005) |
| "Sixteen patients with advanced ovarian cancer, previously treated with surgery and chemotherapy were enrolled in this study." | ( Corso, S; D'Incalci, M; Frapolli, R; Fruscio, R; Lissoni, AA; Mangioni, C; Zucchetti, M, 2006) |
| "Patients with recurrent ovarian cancer and documented platinum-resistant disease were treated with weekly intravenous paclitaxel (60-80 mg/m(2)) continuously for up to 24 weeks over an 18-month period." | ( Al Hayki, M; Baines, KA; Hopkins, L; Kee Fung, MF; Le, T; Rambout, L, 2006) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of Scriptaid, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2006) |
| "The treatment of ovarian cancer cells with 5-ADC contributed to the following results: the inhibition of DNA promoter methylation, the reactivation of FANCF mRNA expression and protein, and the subsequent reduction in the proliferation of tumor cells both in vitro and in vivo." | ( Li, M; Lu, S; Wang, H; Wang, Z; Zhang, Y, 2006) |
| "OVCAR-3 and SK-OV-3 ovarian cancer cells, HEC-1A endometrial adenocarcinoma cells and MCF-7 breast cancer cells were treated with different concentrations of mTOR inhibitor RAD001 alone or in combination with 4-OH tamoxifen." | ( Haus, U; Ortmann, O; Treeck, O; Wackwitz, B, 2006) |
| "Twenty-two women with epithelial ovarian cancer stage III-IV previously treated with platinum-based combinations who had achieved complete remission evidenced by symptoms, pelvic examination, computerized tomography and serum CA-125, were assigned to the study protocol consisting of: carboplatin of AUC=6, three cycles every 2 months, followed by two cycles once every 3 months for a total of five courses over 1 year." | ( Barak, N; Inbar, MJ; Kovner, F; Ron, IG; Safra, T, 2006) |
| "Salvage chemotherapy in advanced ovarian cancer is not yet standardized." | ( Baur, M; Dittrich, C; Fazeny-Doerner, B; Hudec, M; Salzer, H; Sevelda, P, 2006) |
| "Treatment of ovarian cancer cells with LPA leads to transcriptional activation of the GROalpha gene promoter and robust accumulation of GROalpha protein in culture supernatants." | ( Bast, RC; Fang, X; Lee, Z; Liang, Y; Liu, S; Lu, KH; Mills, GB; Swaby, RF; Yu, S, 2006) |
| "86 patients with ovarian cancer of stage I-IV were treated with the combination with paclitaxel (175 mg/m2, 3 hours) and carboplatin (AUC 5) at the Gynecological Department, National Institute of Oncology, Budapest." | ( Lehoczky, O; Pulay, T, 2005) |
| "Epithelial ovarian cancer patients who underwent tumor debulking surgery and received platinum plus cyclophosphamide as adjuvant chemotherapy at Vajira Hospital from January 1995 to December 2003 were identified." | ( Leelahakorn, S; Mamusirinitaya, S; Pataradool, K; Sittidilokratna, K; Suekwatana, P; Tangjitgamol, S; Thawaramara, T, 2005) |
| "Treatment of the ovarian cancer cell lines with L-NAME significantly reduced vascular endothelial growth factor levels production and completely inhibited angiogenesis." | ( Diamond, MP; Malone, JM; Munkarah, AR; Saed, GM; Sokol, RJ, 2006) |
| "Patients with recurrent ovarian cancer after surgery and adjuvant chemotherapy with platinum and taxane compounds were eligible to participate in this multi-institutional phase II study." | ( Camara, O; Heinrich, G; Hindenburg, HJ; Klare, P; Kühne, J; Lichtenegger, W; Mertens, H; Oskay-Ozcelik, G; Schmalfeldt, B; Sehouli, J; Stengel, D, 2006) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of CBHA, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | ( Kusumoto, M; Matsuda, K; Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2006) |
| "A human ovarian cancer cell line, which migrates to mouse ovaries and establishes peritoneal carcinomatosis, was used to evaluate the cooperative effect of an antiangiogenic gene therapy combined with chemotherapy." | ( Blazar, BR; Bui Nguyen, TM; Ramakrishnan, S; Subramanian, IV; Tolar, J; Truskinovsky, AM, 2006) |
| "Current systemic therapy for ovarian cancer consists of a combination of carboplatin and paclitaxel." | ( Ozols, RF, 2006) |
| "The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy." | ( Ledermann, JA; Pfisterer, J, 2006) |
| "Advanced ovarian cancers are initially responsive to chemotherapy with platinum drugs but develop drug resistance in most cases." | ( Calogero, R; Coltella, N; Crispi, S; Di Cunto, F; Di Renzo, MF; Olivero, M; Rasola, A; Ruggiero, T; Saviozzi, S, 2006) |
| "Chemotherapy (CT) resistance in ovarian cancer is related to multiple factors, and assessment of these factors is necessary for the development of new drugs and therapeutic regimens." | ( Bachvarov, D; Bachvarova, M; L'Espérance, S; Patten, N; Plante, M; Popa, I; Têtu, B; Wu, L, 2006) |
| "E2 promoted OSE and ovarian cancer cell growth, whereas simultaneous treatment with E2 and PEDF abrogated the estrogenic growth stimulation of these cells." | ( Au, SC; Auersperg, N; Cheung, AN; Cheung, LW; Ngan, HY; Tombran-Tink, J; Wong, AS, 2006) |
| "Because ovarian cancers tend to acquire chemoresistance, we used real-time PCR to measure the mRNA expression of multidrug resistance protein 1, multidrug resistance-related protein 1, and breast cancer resistance protein after treatment." | ( Baker, B; Buchholz, S; Engel, JB; Halmos, G; Heinrich, E; Hohla, F; Keller, G; Koester, F; Schally, AV, 2006) |
| "Most of the patients with advanced ovarian cancer will recur after first-line platinum-based chemotherapy and need additional treatment." | ( Arcuri, C; Galligioni, E; Griso, C; Sorio, R, 2006) |
| "Standard therapy for the treatment of ovarian cancer is radical surgery followed by radiation and/or chemotherapy using cisplatin and paclitaxel." | ( Götz, C; Harlozinska, A; Kartarius, S; Montenarh, M; Touma, R, 2006) |
| "In an animal model of ovarian cancer, we explored whether a survival advantage exists utilizing icodextrin rather than PBS as a delivery solution for an infectivity enhanced virotherapy approach." | ( Alvarez, RD; Curiel, DT; Lu, B; Makhija, S; Numnum, MT; Rivera, AA; Rocconi, RP; Stoff-Khalili, M; Wang, M; Zhu, ZB, 2006) |
| "Women with stage III ovarian cancer and with < or = 2 cm residual tumour were randomly assigned to receive either conventionally dosed chemotherapy (group A) or HDCT (group B)." | ( Grénman, S; Helenius, H; Itälä, M; Jalkanen, J; Joensuu, H; Kuoppala, T; Kuronen, A; Lehtovirta, P; Leminen, A; Mäenpää, J; Puistola, U; Salmi, T; Vuento, M; Vuolo-Merilä, P; Wiklund, T; Yliskoski, M, 2006) |
| "Lung and ovarian cancer cells were propagated in medium acutely depleted of folate and subsequently treated with cisplatin." | ( Bushell, TM; Johanning, GL; Piyathilake, CJ; Whiteside, MA, 2006) |
| "Forty-eight patients with untreated ovarian cancer were entered in a multicenter phase I/II trial of multicycle HDCT." | ( Berdel, WE; Frickhofen, N; Haas, R; Heimpel, H; Hinke, A; Hossfeld, DK; Kreienberg, R; Kuhn, W; Möbus, V; Opri, F; Sandherr, M; Schneeweiss, A; Thomssen, C, 2006) |
| "Advanced ovarian cancer (OC) is not curable by surgery alone and chemotherapy is essential for its treatment." | ( Brard, L; Dizon, DS; Kalkunte, S; Swamy, N, 2006) |
| "Twenty-two naive patients with ascitic ovarian cancer were treated with escalating doses of 4-HPR at 0, 400, 600, and 800 mg/d for 1 to 4 weeks before surgery." | ( Argusti, A; Baglietto, L; Cantù, MG; Cavadini, E; Colombo, N; Decensi, A; Formelli, F; Gasco, M; Guerrieri-Gonzaga, A; Montironi, R; Parma, G; Santinelli, A; Viale, G, 2006) |
| "This suggests adding SAHA to ovarian cancer chemotherapy could increase efficacy and that sequencing of agents is important." | ( Cooper, AL; Greenberg, VL; Lancaster, PS; Modesitt, SC; van Nagell, JR; Zimmer, SG, 2007) |
| "Chemonaive advanced ovarian cancer showed a high response rate to combined gemcitabine and carboplatin chemotherapy." | ( Ilanchadran, A; Tan, TY; Tay, SK, 2006) |
| "Most patients with advanced epithelial ovarian cancer (EOC) achieve a clinical complete response (CR) or have no clinical evidence of disease after aggressive cytoreductive surgery and 6 cycles of platinum-/taxane-based chemotherapy." | ( Pectasides, D; Pectasides, E, 2006) |
| "Current virotherapy strategies for ovarian cancer have been hampered by limitations in target cell infectivity and nonspecific tissue replication." | ( Alvarez, RD; Curiel, DT; Lu, B; Makhija, SK; Rivera, AA; Rocconi, RP; Stoff-Khalili, M; Wang, M; Zhu, ZB, 2007) |
| "The major obstacle in treating ovarian cancer is the rapid development of platinum resistance during therapy." | ( Concin, N; Hofstetter, G; Marth, C; Müller-Holzner, E; Reimer, D; Sadr, S; Stadlmann, S; Wiedemair, A; Zeimet, AG, 2007) |
| "To improve the treatment of women with ovarian cancer, we are investigating the modulation of a prominent DNA-damaging agent, temozolomide, by manipulating the DNA base excision repair (BER) pathway via BER inhibitor, methoxyamine, and overexpression of N-methylpurine DNA glycosylase (MPG)." | ( Fishel, ML; He, Y; Kelley, MR; Smith, ML, 2007) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of apicidin, and the effects on cell growth, cell cycle, apoptosis and related measurements were investigated." | ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2007) |
| "A panel of 13 ovarian cancer cell lines was treated with heregulin beta1 (HRGbeta1) or transforming growth factor-alpha, and cell proliferation was assessed." | ( Cameron, DA; Hasmann, M; Langdon, SP; Mullen, P; Smyth, JF, 2007) |
| "In a large phase III trial ovarian cancer patients in complete clinical remission with FIGO stage Ic-IV were randomized between standard treatment plus a single IP (90)Y-labeled muHMFG1 versus standard treatment alone after negative second-look laparoscopy." | ( Benigno, BB; Epenetos, AA; Lopes, A; Massuger, LF; Oei, AL; Seiden, MV; Soper, JT; Verheijen, RH, 2007) |
| "Advanced ovarian cancers are initially responsive to combinatorial chemotherapy with platinum drugs and taxanes but, in most cases, develop drug resistance." | ( Bardella, C; Coltella, N; Dettori, D; Di Renzo, MF; Mazzone, M; Olivero, M, 2007) |
| "Nine epithelial ovarian cancer cell lines isolated from ascites or ovarian tissue were treated with increasing concentrations of Topotecan (5-500 ng/ml) with or without Phenoxodiol pretreatment (10 microg/ml) for 24 h and cell viability was measured using CellTiter 96 AQueous One Solution Cell Proliferation Assay." | ( Alvero, AB; Brown, D; Matthews, M; Montagna, M; Mor, G, 2007) |
| "In advanced ovarian cancer, IPHC using paclitaxel or carboplatin during secondary surgery could be a candidate for regional consolidation therapy to prolong survival and hinder disease progression." | ( Ahn, WS; Bae, JH; Hur, SY; Lee, JM; Lee, YS; Namkoong, SE; Park, YG; Ryu, KS, 2007) |
| "Their serum concentrations in ovarian cancer patients may help in good monitoring of remission or progression during chemotherapy treatment." | ( Ahmetović, B; Fatusić, Z; Iljazović, E; Ljuca, D, 2007) |
| "Newly diagnosed ovarian cancer patients receiving the initial IPHC at the MTD defined above completed standard systemic chemotherapy with six courses of systemic chemotherapy." | ( Kucera, GL; Lentz, SS; Levine, EA; Miller, BE, 2007) |
| "The present treatment standards for ovarian cancer are based on the association of debulking surgery with platinum-based chemotherapy." | ( Chauffert, B; Combe, M; Delroeux, D; Guardiola, E; Heyd, B; Hoizey, G; Kantelip, JP; Montange, D; Pivot, X; Royer, B, 2008) |
| "Treatment of ovarian cancer cell lines with the methyltransferase inhibitor 5-aza-2-deoxycytidine and the histone deacetylase inhibitor trichostatin A resulted in significant synergistic induction of betaglycan message levels and increased betaglycan protein expression, indicating that epigenetic silencing may play a role in the loss of betaglycan expression observed in ovarian cancer." | ( Blobe, GC; Dong, M; Fields, TA; Hempel, N; How, T; Murphy, SK, 2007) |
| "Patients with advanced ovarian cancer were treated with topotecan, 1 mg/m(2) IV, days 1 to 5, and UCN-01 70 mg/m(2) on day 1 of the first cycle, and 35 mg/m(2) on day 1 of all subsequent cycles." | ( Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S, 2007) |
| "The underlying causes of epithelial ovarian cancer (EOC) are unclear, and treatment options for patients with advanced disease are limited." | ( Chakrabarty, A; Daikoku, T; Dey, SK; Dubois, RN; Khabele, D; Morrow, JD; Orsulic, S; Tranguch, S; Wang, D, 2007) |
| "The selective inhibition of ovarian cancer cell growth, apoptosis induction, and G2 arrest provide in vitro evidence for further studies of DHA as a possible anticancer drug in the clinical treatment of ovarian cancer." | ( Cao, JP; Fan, SJ; Ge, CM; Jiao, Y; Meng, QH; Tong, J, 2007) |
| "Xenografted nude mice models of human ovarian cancer were established, and then randomly allocated to treatment or control group, which was administered with either Celecoxib at the dosage of 10, 25, 50 mg/kg or distilled water alone (control) orally daily for 56 d." | ( Liu, XQ; Lou, JY; Luo, FM; Peng, ZL; Wang, HJ; Yang, KX, 2007) |
| "Corresponding mRNA in ovarian cancer cell lines treated with 17beta-estradiol (E2) was measured by quantitative RT-PCR." | ( Cameron, DA; Langdon, SP; MacLeod, K; Smyth, JF; Walker, G; Williams, AR, 2007) |
| "Four epithelial ovarian cancer cell lines (MDAH-2774, SKOV3, OVCAR and CaOV-3) were treated with the specific cyclooxygenase-2 inhibitor NS398 (10 or 100 mumol/l) and docetaxel (0." | ( Ali-Fehmi, R; Elhammady, E; Jiang, JZ; Malone, JM; Munkarah, AR; Saed, GM, 2007) |
| "Forty-two patients with advanced ovarian cancer underwent complete resection plus platinum/paclitaxel as first-line adjuvant chemotherapy." | ( He, SR; Wei, FH; Yang, L; Zhang, Y; Zhao, XD, 2007) |
| "Although ovarian cancer is one of the most chemotherapy-sensitive solid tumors, cure after radical surgery and chemotherapy is uncommon." | ( Bengala, C; Champion, K; Frickhofen, N; Hinke, A; Kimmig, R; Ledermann, JA; Möbus, V; Ostermann, H; Wandt, H, 2007) |
| "Patients with recurrent ovarian cancer were treated with intravenous bevacizumab 10 mg/kg every other week plus oral cyclophosphamide 50 mg daily until disease progression or undue toxicity." | ( Carson, LF; Chura, JC; Downs, LS; Judson, PL; Van Iseghem, K, 2007) |
| "Inhibition of glycolysis in ovarian cancer with resveratrol or other compounds may be effective therapy for ovarian cancer." | ( Choi, M; Griffith, KA; Huang, J; Kueck, A; Liu, JR; Opipari, AW; Tan, L; Wahl, H, 2007) |
| "Tumour cells isolated from 50 ovarian cancer patients were treated ex vivo with 100 microM cisplatin for 1 h and crosslink formation and repair (unhooking) measured." | ( Hartley, JA; Ledermann, JA; Mould, TA; Newton, C; Olaitan, A; Wynne, P, 2007) |
| "We treated five ovarian cancer cell lines using PTX combined with MEK inhibitor (PD98059 [PD]) and PI3K inhibitor (LY294002 [LY]), then assessed cell viability, apoptosis, and expression of phosphorylated (p) MEK and pAkt." | ( Itamochi, H; Kanamori, Y; Kawaguchi, W; Kigawa, J; Oishi, T; Sato, S; Shimada, M; Shimogai, R; Terakawa, N, 2007) |
| "Standard therapy for advanced ovarian cancer consists of a platinum agent in combination with a taxane, which has a 5-year survival rate of approximately 45%." | ( Brown, R; Gifford, G; King, CR; Marsh, S; McLeod, HL; Paul, J, 2007) |
| "However, ovarian cancer was found and therefore a surgical resection and chemotherapy were performed." | ( Amenomori, M; Eguchi, K; Fujiwara, E; Ito, M; Kishikawa, T; Migita, K; Miyashita, T; Niino, D; Osumi, M; Osumimoto, H; Shimomura, O; Yasuhi, I, 2007) |
| "It was evident that MyD88 expression in ovarian cancer cells accurately predicts a poor response to paclitaxel chemotherapy as shown by a short progression-free interval and overall survival." | ( Alvero, AB; Azodi, M; Chen, R; Fu, HH; Illuzzi, J; Kelly, M; Mor, G; Rutherford, T; Schwartz, P; Silasi, DA, 2006) |
| "Current treatment for epithelial ovarian cancer involves a combination of surgery and chemotherapy with platinum- and taxane-based chemotherapy." | ( Han, ES; Monk, BJ, 2007) |
| "Moreover, treatment of mouse ovarian cancer cells with a combination of SP600125 and paclitaxel, an established chemotherapeutic agent used in the treatment of ovarian cancer, or with MIS enabled inhibition of cell proliferation at a lower dose than with each treatment alone." | ( Donahoe, PK; O'Neill, FH; Pieretti-Vanmarcke, R; Renlund, N; Teixeira, J; Zhang, L, 2008) |
| "The treatment for ovarian cancer has continued to improve, resulting in disease recurrence associated with previously unusual locations." | ( Brown, JV; Epstein, HD; Goldstein, BH; Micha, JP; Rettenmaier, MA; Zusman, D, 2007) |
| "In 2003 she developed ovarian cancer metastatic to the breast and was treated with additional chemotherapy." | ( Brown, JV; Epstein, HD; Goldstein, BH; Micha, JP; Rettenmaier, MA; Zusman, D, 2007) |
| "190 epithelial ovarian cancer patients were given chemotherapy in the Gynecological Department at the National Institute of Oncology, Hungary." | ( Lehoczky, O; Pulay, T, 2007) |
| "Chemotherapy for ovarian cancer causes severe anemia (hemoglobin level < 10 g/dL) in one third of patients." | ( Lehoczky, O; Pulay, T, 2007) |
| "The effective treatment of ovarian cancer is hampered by the development of drug resistance, which may be mediated by members of the Bcl-2 family of apoptosis regulators." | ( De-Haven-Brandon, AK; Eccles, SA; Kaye, SB; Richardson, A; Valenti, MR; Vidot, S; Witham, J, 2007) |
| "Current firstline chemotherapy for ovarian cancer consists of carboplatin combined with either paclitaxel or docetaxel." | ( DeLoia, JA; Gallion, HH; Jones, JM; Kelley, JL; Strychor, S; Zamboni, WC, 2008) |
| "Furthermore, ascites from ovarian cancer patients or conditioned medium from ovarian cancer cells induced expression of alpha-SMA and phosphorylation of Smad2, and pretreatment of the cells with Ki16425 or SB431542 abrogated the expression of alpha-SMA and phosphorylation of Smad2." | ( Chang, CL; Cho, M; Jeon, ES; Jung, JS; Kim, JH; Kim, YM; Lee, MJ; Moon, HJ; Song, HY; Suh, DS; Yoon, MS, 2008) |
| "TPL actions on human ovarian cancer cells were investigated in vitro and in vivo with a nude mouse model to monitor tumor burden both in the absence or presence of other chemotherapy agents." | ( Nilsson, EE; Skinner, MK; Westfall, SD, 2008) |
| "Ginger treatment of cultured ovarian cancer cells induced profound growth inhibition in all cell lines tested." | ( Fogoros, S; Griffith, KA; Huang, J; Liu, JR; Rhode, J; Wahl, H; Zick, S, 2007) |
| "A 44-year-old woman with ovarian cancer and normal renal function developed gross hematuria after carboplatin therapy." | ( Krishnan, SG; Shah, HH; Singhal, PC; VanderBrink, B; Weiss, G, 2007) |
| "Current approaches to the treatment of ovarian cancer are limited because of the development of resistance to chemotherapy." | ( Gregory-Bass, RC; Liu, D; Matthews, R; Olatinwo, M; Stiles, JK; Thomas, K; Thompson, WE; Tsang, B; Xu, W, 2008) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of beta-HIVS, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2008) |
| "Obese patients with epithelial ovarian cancer do not have a poorer prognosis, provided that they receive optimal doses of chemotherapy based on measured GFR and actual body weight." | ( Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA, 2008) |
| "Chemotherapy (CT) resistance in ovarian cancer (OC) is broad and encompasses diverse unrelated drugs, suggesting more than one mechanism of resistance." | ( Bachvarov, D; Bachvarova, M; L'Espérance, S; Mes-Masson, AM; Tetu, B, 2008) |
| "Twenty-two patients with advanced stage ovarian cancer not suitable for debulking were treated with a neoadjuvant platinum/taxanes chemotherapy." | ( Capizzi, E; De Iaco, P; Fiorentino, M; Gabusi, E; Grigioni, AD; Rosati, M; Zamagni, C, 2008) |
| "Furthermore, the treatment of ovarian cancer cells with LMB revealed a reduction in COX-2 expression." | ( Buckendahl, AC; Denkert, C; Dietel, M; Koch, I; Niesporek, S; Noske, A; Röske, A; Sehouli, J; Weichert, W, 2008) |
| "The viability of ovarian cancer cell lines (SKOV-3, OVCAR-3) in comparison to pancreatic and prostate cancer cell lines, primary fibroblast and immortalized trophoblasts after treatment with 7Me-IEITC was analyzed." | ( Brard, L; Kim, KK; Lange, TS; Shaw, SK; Singh, RK, 2008) |
| "A patient with radically operated ovarian cancer FIGO stage IIIc was treated in a prospective clinical trial with WAI to a total dose of 30 Gy in 1." | ( Debus, J; Dinkel, J; Eichbaum, M; Harms, W; Herfarth, K; Jensen, A; Rochet, N; Schneeweiss, A; Schubert, K; Sohn, C; Sterzing, F, 2008) |
| "Control of ovarian cancer (OC) ascites remains a major objective in post-surgical treatment." | ( Allen, BJ; Apostolidis, C; Beretov, J; Bruchertseifer, F; Morgenstern, A; Perkins, A; Qu, CF; Raja, C; Rizvi, SM; Song, EY, 2008) |
| "Combining multiple therapies to treat ovarian cancer is an effective strategy." | ( Kong, BH; Sun, P, 2008) |
| "For women with early stage ovarian cancer (ESOC), comprehensive staging is the standard of care and studies suggest that these patients may not require further treatment." | ( Brard, L; Charbonneau, N; Disilvestro, P; Dizon, DS; Granai, CO; Hughes, T; Legare, R; Lomme, M; Restivo, A; Weitzen, S, 2008) |
| "Obese ovarian cancer patients treated with carboplatin experience substantially less toxicity than normal weight women." | ( Fujiwara, K; Herzog, TJ; Mutch, DG; Nagao, S; Powell, MA; Tian, C; Wright, JD, 2008) |
| "It is well recognized that ovarian cancer patients who are documented to experience an initial response to platinum-based chemotherapy but where the disease recurs approximately 6 or more months following the completion of primary therapy, may have another clinically meaningful response (both objective and subjective) to a second platinum-based strategy." | ( Markman, M, 2008) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of bufalin, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2008) |
| "Eighteen women with ovarian cancer that had recurred within 6 months after standard carboplatin and paclitaxel therapy were eligible for enrollment." | ( Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E, 2008) |
| "The cornerstone of therapy for advanced ovarian cancer is cytoreductive surgery (CRS) followed by platinum based chemotherapy." | ( Fong, DN; Landrum, LM; Mannel, RS; McMeekin, DS; Moore, KN; Moxley, KM; Myers, TK; Reid, MS; Walker, JL, 2008) |
| "Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses." | ( Aslan, Y; Buyukberber, S; Camci, C; Kalender, ME; Sevinc, A, 2009) |
| "Women with relapsed ovarian cancer after primary surgery and platinum-based chemotherapy were randomly assigned to topotecan monotherapy 1." | ( Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG, 2008) |
| "SK-OV-3 ovarian cancer cells were treated with various doses of I3C, RE or I3C+RE." | ( Abd Elmageed, ZY; Azam, GA; Braley, P; Fathi, IM; Gaur, RL; Nguyen, L; Ouhtit, A; Raj, MH; Rao, PN; Zhou, J, 2008) |
| "Imatinib mesylate blocks the growth of ovarian cancer cells in vitro and may enhance the activity of chemotherapy." | ( Baldridge, LA; Breen, T; Emerson, RE; Johnson, CS; Matei, D; McClean, J; Menning, N; Schilder, J; Stephens, D; Sutton, G; Whalen, C, 2008) |
| "The group of 32 patients with ovarian cancer was treated with pegylated liposomal doxorubicin (LPD) in Klinika Onkologii Klinicznej Centrum Onkologii Branch Gliwice between the years 2004 and 2007." | ( Kaleta, B; Mrochen-Domin, I; Nowara, E, 2008) |
| "Serum cystatin C level in patient with ovarian cancer is both the poor marker of GFR and has not prognostic value in the course of cancer after surgery with further primary chemotherapy." | ( Bodnar, L; elichowski, G; Raczka, A; Szczylik, C; Wańkowicz, Z; Wcisło, GB, 2008) |
| "We investigated whether epithelial ovarian cancer patients participating in a randomized phase III trial comparing single intraperitoneal (IP) administration of yttrium-90-labeled murine HMFG1 ((90)Y-muHMFG1) plus standard treatment (AT) vs." | ( Massuger, LF; Moreno, M; Oei, AL; Sweep, FC; Thomas, CM; Verheijen, RH; von Mensdorff-Pouilly, S, 2008) |
| "Long-term survival of patients with ovarian cancer remains poor and therapy disappointing despite decades of experience with various chemotherapies, including the current gold standard, carboplatin/paclitaxel (TC)." | ( Konishi, I; Sugiyama, T, 2008) |
| "The main strategy for recurrent ovarian cancer is to find the gene related to drug resistance, then treat the cancer based on its molecular biology." | ( Konishi, I; Sugiyama, T, 2008) |
| "In a panel of five ovarian cancer cell lines, simultaneous treatment with the IGF-IR/InsR inhibitor, BMS-536924 and BMS-599626, resulted in a synergistic antiproliferative effect." | ( Attar, RM; Carboni, JM; Erlichman, C; Gottardis, MM; Haluska, P; Hou, X; Sagar, M; TenEyck, C; Wong, TW; Yu, C, 2008) |
| "Although therapy for ovarian cancer has been greatly improved in the past 20 years, the overall survival for patients with advanced ovarian cancer has not changed significantly." | ( Kumar, S; Liang, SL; Liu, H; Liu, W; Weyman, CM; Zhou, A, 2009) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of ErPC, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | ( Narahara, H; Nasu, K; Takai, N; Ueda, T, 2008) |
| "DAC treatment of ovarian cancer cell lines increased the expression of 11 of 12 CTA genes tested including MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, NY-ESO-1, TAG-1, TAG-2a, TAG-2b, and TAG-2c." | ( Adair, SJ; Hogan, KT, 2009) |
| "Retrospective analysis of pre-treated ovarian cancer patients, i." | ( Alba, E; Alonso, L; Jurado García, JM; Jurado, JM; Pajares, B; Pérez, E; Sánchez, A, 2008) |
| "Our results indicate that ovarian cancer drug resistance is associated with a distinct miRNA fingerprint, and miRNA microarrays could represent a prognostic tool to monitor the chemotherapy outcome." | ( Addario, A; Ferlini, C; Liu, CG; Peschle, C; Scambia, G; Sorrentino, A, 2008) |
| "The standard of care for ovarian cancer includes platinum-based chemotherapy." | ( Balleine, RL; Brand, A; Byth, K; Chiew, YE; deFazio, A; Guminski, AD; Harnett, PR; Kennedy, C; Lei, Y; Pryor, K; Rizos, H; Scurr, LL; Sharma, R; Wain, GV, 2008) |
| "Treatment with aspirin did not decrease ovarian cancer incidence." | ( Giles, JR; Johnson, PA; Urick, ME, 2009) |
| "Nelfinavir sensitized ovarian cancer cells to treatment with an apoptosis-inducing TRAIL receptor antibody due to upregulation of the TRAIL receptor DR5 as shown by RT-PCR and FACScan analysis." | ( Brüning, A; Burger, P; Burges, A; Friese, K; Gingelmaier, A; Lenhard, M; Rahmeh, M; Vogel, M, 2008) |
| "We then treated SKOV3 and 3AO ovarian cancer cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc)." | ( Cui, J; Shen, L; Yu, H; Zhang, A; Zhang, H; Zhang, S, 2008) |
| "Heavily pretreated ovarian cancer received at least two cycles of topotecan (median 6, range 2-6) with prior chemotherapy lines (median 3, range 3-7)." | ( Bodnar, L; Gasowska-Bodnar, A; Nasilowska, A; Smoter, M; Szarlej-Wcislo, K; Szczylik, C; Wcislo, G, 2009) |
| "Patients with stage III to IV ovarian cancer with preoperatively elevated CA-125 and objectively defined characteristics were randomly assigned 4 to 12 weeks after front-line carboplatin and paclitaxel chemotherapy to maintenance monoimmunotherapy in a fully blinded protocol." | ( Berek, J; McGuire, W; Nicodemus, CF; Schultes, B; Smith, LM; Taylor, P, 2009) |
| "Since the prognosis of recurrent ovarian cancer patients is still poor, we need to establish a useful treatment strategy to achieve their long-term survival." | ( Ebina, Y; Hosaka, M; Mitamura, T; Moriwaki, M; Ohba, Y; Sakuragi, N; Takeda, M; Todo, Y; Watari, H, 2008) |
| "Sensitivity testing in ovarian cancer to individualize therapy remains an active area of interest and this has been renewed recently by results from several groups." | ( Cree, IA, 2009) |
| "A panel of ovarian cancer cell lines was treated with saquinavir." | ( Daudi, S; Liu, JR; McLean, K; Sorenson, DR; VanDeVen, NA, 2009) |
| "DMBA induction of ovarian neoplasms was greater in those rats treated with VCD." | ( Barton, JK; Bedrnicek, JB; Brewer, MA; Christian, PJ; Davis, JR; Hoyer, PB; Marion, SL, 2009) |
| "10 platinum-resistant ovarian cancer patients were treated under compassionate use." | ( Alberola Candel, V; Esteban González, E; Gasent Blesa, JM; Martín Algarra, S; Provencio Pulla, M, 2009) |
| "SKOV-3 ovarian cancer cells treated with PACs exhibited classic apoptotic changes." | ( Brard, L; Kim, KK; Nussbaum, R; Satyan, KS; Singh, AP; Singh, RK; Torres, M; Vorsa, N, 2009) |
| "Long-term follow-up of early stage ovarian cancer patients showed lasting GI morbidity in the survivors treated with adjuvant radiotherapy, which has therefore become obsolete." | ( de Vries, EGE; Engelen, MJA; Gietema, JA; Pras, E; Schaapveld, M; Snel, BJ; van der Zee, AGJ; Willemse, PHB, 2009) |
| "Survival of ovarian cancer patients is largely dictated by their response to chemotherapy, which depends on underlying molecular features of the malignancy." | ( Baba, T; Barnett, JC; Berchuck, A; Chang, JT; Fujii, S; Gray, JW; Gusberg, AH; Huang, Z; Kuo, WL; Lee, PS; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS, 2009) |
| "To report the results of ovarian cancer treatment, where a regimen of intravenous cyclophosphamide followed by intraperitoneal cisplatin or carboplatin was administered as second line treatment." | ( Emerich, J; Klasa-Mazurkiewicz, D; Kobierski, J; Milczek, T, 2009) |
| "The goal of treating recurrent ovarian cancer is disease control while minimizing toxicity." | ( Argenta, PA; Carson, LF; Downs, LS; Geller, MA; Ghebre, R; Jonson, AL; Judson, PL; Thomas, SG, 2009) |
| "The first-line treatment of ovarian cancer is based on cytoreductive surgery and the use of anticancer drugs." | ( Grènman, S; Miettinen, S; Ylikomi, T, 2009) |
| "We treated two ovarian cancer cell lines ES-2 and SKOV3 with 17beta-estradiol, methoxyprogesterone acetate (MPA) only, or hormone combined with and Akt, MAPK pathway inhibitor, or transefected with siRNA targeting Akt sequenced with hormone." | ( Cao, Q; Din, J; Feng, W; Feng, Y; Hua, K; Huang, Y; Yao, L; Zhang, Y; Zhao, Y, 2009) |
| "We treated A2780 ovarian cancer cells by weekly cycles of cisplatin over a period of 6 months and unveiled that enhanced insulin-like growth factor I receptor (IGF-IR) expression and autocrine IGF-I are associated with hyperactivation of the IGF-IR and phosphatidylinositol-3-OH kinase (PI3K) pathways in cisplatin-resistant cells." | ( Beier, M; Budczies, J; Denkert, C; Dietel, M; Eckstein, N; Hamacher, A; Hildebrandt, B; Kassack, MU; Napierski, I; Pölitz, A; Royer, HD; Royer-Pokora, B; Servan, K; von Jonquières, G; Wolf-Kümmeth, S, 2009) |
| "Human ovarian cancer cell line COC1 cells were treated with different nanomolar of NSC606985 with or without CDDP, and cell growth and apoptosis were evaluated, respectively, by MTT assay and annexin-V assay on flow cytometry." | ( Chen, G; Di, W; Xia, L; Yu, Y; Zhang, H; Zhang, N; Zheng, Y; Zhu, Y, 2009) |
| "The treatment of epithelial ovarian cancer in the older adult presents many challenges." | ( Steer, CB, 2009) |
| "Epithelial ovarian cancer's response to platinum retreatment depends on the duration of response to first-line platinum therapy." | ( Ansari, J; Buckley, L; Fernando, I; Tanguay, JS, 2009) |
| "More than half of heavily pretreated ovarian cancer patients may benefit from 3-day topotecan." | ( Angioli, R; Arrivi, C; Basile, S; Bellati, F; Calcagno, M; Palaia, I; Panici, PB; Pastore, M; Plotti, F; Sansone, M, 2009) |
| "Co-treatment of human ovarian cancer cells with TSA and TRAIL synergistically inhibited cell proliferation and induced apoptosis." | ( Bae, JH; Kang, CD; Kim, HB; Kim, MJ; Kim, SH; Park, SJ; Sohn, HY, 2009) |
| "Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P)." | ( Andras, M; Dabby, R; Fishman, A; Gadoth, N; Karmon, Y; Levavi, H; Levi, T; Loven, D; Sabach, G; Zart, R, 2009) |
| "Women with ovarian cancer treated with chemotherapeutic platinum agents frequently develop hypersensitivity reactions (HSRs)." | ( Banerji, A; Hesterberg, PE; Krasner, CN; Oren, E; Penson, RT; Seiden, MV; Wong, JT, 2009) |
| "The poor prognosis associated with ovarian cancer is primarily the result of delayed diagnosis and the lack of an effective treatment for advanced disease." | ( Anwer, K; Brunhoeber, E; Fewell, JG; Lewis, DH; Matar, MM; Pence, C; Rice, JS; Slobodkin, G; Worker, M, 2009) |
| "Thirty-five subjects with epithelial ovarian cancer (EOC) treated by platinum-based chemotherapy were recruited." | ( Chaudhry, P; Patel, FD; Srinivasan, R, 2009) |
| "Cisplatin resistant ovarian cancer cell line SKOV3/DDP cells were treated by staurosporine (a kind of PKC inhibitors)." | ( Li, X; Liao, QP, 2009) |
| "The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0." | ( Domchek, S; Isaacs, C; Kauff, ND; Lubinski, J; Lynch, HT; Narod, SA; Rosen, B; Sun, P; Tung, N; Vicus, D, 2009) |
| "Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1." | ( Debus, J; Dinkel, J; Eichbaum, MH; Harms, W; Herfarth, KK; Jensen, AD; Rochet, N; Schneeweiss, A; Schubert, K; Sohn, C; Sterzing, F, 2010) |
| "Loss of HLA class I is important in ovarian cancer prognosis but its role as a prognostic indicator in relation to therapy remains unproven." | ( Al-Attar, A; Chan, S; Deen, S; Durrant, LG; Mukherjee, A; Shehata, M, 2009) |
| "A total of 157 primary ovarian cancers were assessed for HLA class I immunohistochemically and linked to a comprehensive database of clinicopathological variables, treatment details, and platinum sensitivity." | ( Al-Attar, A; Chan, S; Deen, S; Durrant, LG; Mukherjee, A; Shehata, M, 2009) |
| "Intraperitoneal (IP) chemotherapy in ovarian cancer has been studied since 1978." | ( Ozols, RF, 2004) |
| "Advanced ovarian cancer has a high rate of recurrence and mortality despite relative chemosensitivity at the time of initial treatment." | ( Baba, T; Berchuck, A; Cory Barnett, J; Fujii, S; Kondoh, E; Konishi, I; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS; Yamaguchi, K, 2010) |
| "Data were collected from 1077 ovarian cancer patients treated from 1996 to 2003 in a random sample of 18 Dutch hospitals." | ( Heintz, AP; van der Graaf, Y; Vernooij, F; Verweij, E; Witteveen, PO, 2009) |
| "In the first-line ovarian cancer treatment the combination of PLD with carboplatin assures a prolonged interval to progression and produces less toxicity when compared to carboplatin with paclitaxel schedule." | ( Nowak-Markwitz, E, 2009) |
| "Chemotherapy resistance in ovarian cancer has been studied thoroughly and several non-overlapping single genes, gene profiles and copy number alterations have been suggested as potential markers." | ( Delle, U; Horvath, G; Levan, K; Olsson, B; Osterberg, L; Partheen, K; Sundfeldt, K, 2009) |
| "SKOV3 and Hey ovarian cancer cell lines were treated for 24 h with paclitaxel, then re-treated with SAHA or paclitaxel for an additional 48 h." | ( Craven, R; DeSimone, CP; Dietrich, CS; Greenberg, VL; Modesitt, SC; van Nagell, JR; Zimmer, SG, 2010) |
| "Blood samples from each ovarian cancer patient were obtained before (S(0)) and at day 5-7 (S(1)), day 12-14 (S(2)) and day 25-28 (S(3)) after chemotherapy in 13 patients." | ( DI, W; Feng, QM; Wu, X, 2009) |
| "We reviewed the records of women with ovarian cancer and optimal surgical debulking who underwent IP chemotherapy at our institution." | ( Goff, BA; Gray, HJ; Shah, CA; Swensen, RE; Tamimi, HK, 2010) |
| "The thesis that MDR in ovarian cancer is acquired through therapy itself and not present ab initio is supported by these findings." | ( Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R, 2010) |
| "Epithelial ovarian cancer (EOC) recurrence is common following treatment with cytoreductive surgery and adjuvant chemotherapy." | ( Leath, CA; Phippen, NT, 2009) |
| "In a group of 6 BRCA-related ovarian cancer patients presenting with clinical relapse, paclitaxel-carboplatin (TC) in a dose-dense regimen was administered to evaluate the response and tolerability compared with those of the sporadic group and of the patients using a regimen administered every 3 weeks." | ( Amant, F; Berteloot, P; Cadron, I; Legius, E; Leunen, K; Neven, P; Van Gorp, T; Vergote, I, 2009) |
| "Most patients with ovarian cancer are candidates for second-line or salvage treatments often for prolonged periods." | ( Daniele, A; Ferrero, A; Fuso, L; Logrippo, V; Perotto, S; Spanu, PG; Zola, P, 2009) |
| "In vitro treatment of ovarian cancer cell lines with gedunin alone produced up to an 80% decrease in cell proliferation (P < 0." | ( Apte, S; Chen, N; Cragun, J; Humphrey, M; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y, 2009) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of PK11195 alone or in combination with chemotherapeutic drugs (cisplatin, paclitaxel), and its effect on cell growth, the cell cycle, apoptosis and related measurements was investigated." | ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2010) |
| "In patients with epithelial ovarian cancer who have a complete pathologic response, HIPEC with paclitaxel should be considered as a consolidation treatment option." | ( Hur, SY; Kim, JH; Kim, SJ; Lee, JM; Lee, KH; Lee, SH; Lee, YS; Park, YG; Ryu, KS, 2010) |
| "Serum from 143 consecutive ovarian cancer patients referred for first line platinum/paclitaxel treatment were analyzed for serum VEGF levels using commercially available enzyme-linked immunosorbent assay (ELISA)." | ( Brandslund, I; Jakobsen, A; Steffensen, KD; Waldstrøm, M, 2010) |
| "FBXO32 methylation was observed in ovarian cancer cell lines displaying constitutive TGF-beta/SMAD4 signaling, and epigenetic drug treatment restored FBXO32 expression in ovarian cancer cell lines regardless of FBXO32 methylation status, suggesting that epigenetic regulation of this gene in ovarian cancer may be a common event." | ( Chan, MW; Chao, TK; Chen, LY; Chou, JL; Davuluri, RV; Deatherage, DE; Hartman-Frey, C; Hsiao, SH; Huang, TH; Huang, YW; Kuo, CT; Lai, HC; Lai, YH; Liao, YP; Lin, HJ; Nephew, KP; Su, HY; Tai, CK; Yan, PS; Yang, HW, 2010) |
| "Hereditary ovarian cancer mostly from maternal lineage are featuring in early age of onset, serous adenocarcinoma, advanced stage (stage III), and better prognosis after the comprehensive treated by cytoreductive surgery plus with chemotherapy." | ( Chen, YT; Gao, R; Liu, NF; Ma, YB; Ma, ZF; Sheng, XG; Sun, L; Wang, YY; Zhong, Y, 2009) |
| "The treatment of ovarian cancer cells with luteinizing hormone, follicle-stimulating hormone, and estrogen induced a significant upregulation of SEMA3B, whereas SEMA3F was upregulated only by estrogen." | ( Ho, SM; Joseph, D; Syed, V, 2010) |
| "One hundred seventy-seven women with ovarian cancer who received IP chemotherapy for a 10-year period at a regional cancer center were followed, and demographic and treatment data were collected." | ( Beyer, J; Robinson, WR, 2010) |
| "In SKOV-3 ovarian cancer cells HNTMB treatment led to chromatin fragmentation and activation of the extrinsic and intrinsic pathways of apoptosis with specific down-regulation of Bcl-2." | ( Brard, L; Kim, KK; Lange, TS; Singh, RK, 2010) |
| "Patients affected by advanced ovarian cancer with complete pathological response after standard treatment were enrolled in this study." | ( Angioli, R; Bellati, F; Benedetti Panici, P; Graziano, M; Manci, N; Palaia, I, 2010) |
| "Seventeen patients with ovarian cancer who had disease progression after a carboplatin and taxane front-line regimen were treated with VRL 30 mg/m(2) IV over 10 min followed by GEM 1,200 mg/m(2) IV over 30 min on days 1 and 15 of each 28 days cycle." | ( Amarantidis, K; Chamalidou, E; Chatzaki, E; Dimopoulos, P; Kakolyris, S; Karakitsos, P; Neanidis, K; Pitsiava, D; Tentes, A; Xenidis, N, 2011) |
| "Patients with pathologically proven ovarian cancer, who underwent cytoreductive surgery and 3-6 cycles of adjuvant chemotherapy, were included in this study." | ( Chen, YK; Huang, LW; Lee, SL; Pan, HS, 2011) |
| "Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery." | ( Fujiwara, H; Hatae, M; Inoue, I; Katabuchi, H; Kodama, S; Kotera, K; Kudo, Y; Masuzaki, H; Onishi, Y; Sueyoshi, K; Suzuki, M; Tajima, A; Tanaka, K; Tashiro, H; Yahata, T; Yoshihara, K, 2010) |
| "Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays." | ( Fujiwara, H; Hatae, M; Inoue, I; Katabuchi, H; Kodama, S; Kotera, K; Kudo, Y; Masuzaki, H; Onishi, Y; Sueyoshi, K; Suzuki, M; Tajima, A; Tanaka, K; Tashiro, H; Yahata, T; Yoshihara, K, 2010) |
| "We studied 93 Caucasian women with ovarian cancer treated with paclitaxel and carboplatin." | ( Bergmann, TK; Brasch-Andersen, C; Brosen, K; Damkier, P; Friberg, LE; Gréen, H; Karlsson, MO; Keldsen, N; Mirza, M; Nielsen, F; Pedersen, RS; Peterson, C; Skougaard, K; Vach, W; Wihl, J, 2011) |
| "Patients with BRCA1/2-mutated ovarian cancer were treated with olaparib within a dose-escalation and single-stage expansion of a phase I trial." | ( A'Hern, R; Ashworth, A; Boss, DS; Carden, CP; Carmichael, J; de Bono, JS; De Greve, J; Fong, PC; Gourley, C; Kaye, SB; Lubinski, J; Mergui-Roelvink, M; Messiou, C; Schellens, JH; Shanley, S; Stone, J; Tutt, A; Yap, TA, 2010) |
| "Patients with Stage III/IV ovarian cancer on Gynecologic Oncology Group Protocols 152 and 172 who underwent surgery followed by intravenous paclitaxel and cisplatin completed the Functional Assessment of Cancer Therapy-Ovarian." | ( Armstrong, DK; Cella, D; Gibbons, HE; Gil, KM; Huang, HQ; Monk, BJ; Rose, PG; von Gruenigen, VE; Wenzel, L, 2010) |
| "In patients with relapsed ovarian cancer, the objectives of salvage therapy are considered to be maintenance of quality of life and prolongation of patient survival." | ( Etoh, T; Hoshiai, H; Koike, E; Mizuno, Y; Wang, WM; Watanabe, Y, 2010) |
| "Chemotherapy resistance in ovarian cancer remains an unsolved problem in caring for women with this disease." | ( Belinson, JL; Ganapathi, R; Michener, CM; Sengupta, S; Vaziri, S; Wang, C, 2010) |
| "Adult women with histologically proven ovarian cancer who were randomised to treatment groups which either compared DNA-repair pathway inhibitors with no treatment or DNA-repair pathway inhibitors together with conventional chemotherapy compared with conventional chemotherapy alone." | ( Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Martinek, I; Morrison, J; Nicum, S, 2010) |
| "The toxicity data of 19 primary ovarian cancer patients (IP group) who underwent carboplatin-based IP and intravenous (IV) combination chemotherapy (IP carboplatin AUC 5 on day 1, IV paclitaxel 175mg/m² on day 2, and IP paclitaxel 60mg/m² on day 8) after primary debulking surgery were retrospectively analyzed and compared to 34 patients (IV group) who were treated with standard platinum-based IV chemotherapy during the same period." | ( Kim, JH; Kim, SH; Kim, SW; Kim, YT; Nam, EJ; Paek, J, 2010) |
| "Resistance to chemotherapy in ovarian cancer is poorly understood." | ( Brenton, JD; Cooke, SL; Garcia, MJ; Hardcastle, T; Huntsman, D; Langdon, S; Melnyk, N; Ng, CK; Temple, J, 2010) |
| "In advanced ovarian cancer patients who achieve a CCR following induction chemotherapy, optimal cytoreduction may confer a greater clinical benefit from a maintenance approach compared to suboptimal cytoreduction." | ( Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Markman, M; Micha, JP; Rettenmaier, MA, 2011) |
| "SKOV3, OVCAR5 and IGROV1 human ovarian cancer cell lines were treated with cisplatin, LY294002 and a combination of both drugs." | ( Dorigo, O; Eng, C; Fekete, M; Karam, AK; Santiskulvong, C; Zabih, S, 2010) |
| "Treatment of epithelial ovarian cancer patients relapsing with a short treatment-free interval (TFI) after prior chemotherapy is unsatisfactory." | ( Bertelsen, K; Christensen, RD; Keldsen, N; Lindegaard, JC; Lund, B; Mellemgaard, A; Mirza, MR, 2010) |
| "Advanced ovarian cancers are difficult to cure with the current available chemotherapy, which has many associated systemic side effects." | ( Hoory, T; Hsueh, WT; Hung, CF; Kim, D; Monie, A; Pai, SI; Wu, A, 2010) |
| "MA-148 ovarian cancer cells were treated with paclitaxel (43 pg/mL) and carboplatin (5 microg/mL) alone or in combination." | ( Bui-Nguyen, TM; Geller, MA; Ramakrishnan, S; Rogers, LM, 2010) |
| "Chemotherapy induction of MCP-1 in ovarian cancer suggests this chemokine plays an important role in the immune response occurring after chemotherapy exposure." | ( Bui-Nguyen, TM; Geller, MA; Ramakrishnan, S; Rogers, LM, 2010) |
| "Treatment of human epithelial ovarian cancer cell line (SKOV-3, an ovarian adenocarcinoma derived from the ascites of an ovarian cancer patient) with the prodrugs 5-fluorocytosine (5-FC) or camptothecin-11 (CPT-11) in the presence of HB1." | ( Choi, KC; Jeung, EB; Kim, KY; Kim, SU; Leung, PC, 2010) |
| "OCSCs and mature ovarian cancer cells (mOCCs) were treated with increasing concentrations of EriB." | ( Alvero, AB; Cheng, YC; Fu, HH; Holmberg, JC; Leizer, AL; Mor, G; Rutherford, T; Silasi, DA, 2011) |
| "Norepinephrine (NE) treatment of ovarian cancer cells resulted in a 250-300% increase in IL8 protein and 240-320% increase in its mRNA levels." | ( Arevalo, JM; Armaiz-Pena, GN; Bar-Eli, M; Bottsford-Miller, J; Cole, SW; Jennings, NB; Lee, JW; Lopez-Berestein, G; Lu, C; Lutgendorf, SK; Moreno-Smith, M; Nishimura, M; Shahzad, MM; Sood, AK; Stone, RL; Vivas-Mejia, P, 2010) |
| "In vivo uptake of (18)F-FLT in human ovary cancer xenografts in mice (A2780) was studied at various time points after Top216 treatment (50 mg/kg i." | ( Björkling, F; Erichsen, KD; Højgaard, L; Jensen, MM; Jensen, PB; Kjær, A; Madsen, J; Sehested, M, 2010) |
| "Treatment of ovarian cancer is still challenging especially in recurrent platinum refractory cases." | ( Bauerschlag, DO; Egberts, JH; Jonat, W; Kalthoff, H; Maass, N; Meinhold-Heerlein, I; Schem, C; Tiwari, S; Weigel, MT, 2010) |
| "Women with ovarian cancer have a low survival rate and develop resistance to chemotherapy, so new approaches to treatment are needed." | ( Booth, CJ; Dannies, PS; Fariña, JB; Hodsdon, ME; Llabrés, M; Meshack, S; Oliva, A; Patel, S; Santoveña, A; Zhu, Y, 2010) |
| "A phase I study of CRM197 for advanced ovarian cancer has already begun, which is the first approved trial of ErbB-ligand-targeted therapy." | ( Hikita, S; Kuroki, M; Miyamoto, S; Tsujioka, H; Ueda, T; Yotsumoto, F, 2011) |
| "In human ovarian cancer epithelial A2780 cells, gamma-synuclein overexpression improved cell adhesion and microtubule structure upon paclitaxel treatment." | ( Cartledge, D; Godwin, AK; Kouadio, A; Zhang, H, 2011) |
| "This study enrolled 47 women (26 with ovarian cancers and 21 with endometrial cancers) who underwent surgical treatment, with or without platinum-based adjuvant chemotherapy, according to established protocols between 2007 and 2009." | ( Fujishiro, N; Fujiwara, S; Maruoka, R; Ohmichi, M; Sekijima, T; Tanabe, A; Terai, Y; Yamashita, Y; Yu, S; Yuguchi, H, 2011) |
| "Most ovarian cancers recur after first-line treatment." | ( Andreopoulou, E; Blank, S; Chen, T; Curtin, J; Hochster, H; Liebes, L; Muggia, F; Wallach, R, 2011) |
| "Patients with platinum-resistant ovarian cancer were treated with pegylated liposomal doxorubicin (PLD) 50 mg/m(2) on day 1 (and repeated every 4 weeks) in combination with escalating doses of atrasentan once daily." | ( Groenewegen, G; Kronemeijer, RH; Los, M; van der Mijn, KJ; Voest, EE; Witteveen, PO, 2010) |
| "Patients with recurrent ovarian cancer and prior treatment with platinum- and taxane-based chemotherapy were included." | ( Alba, E; Alonso-Carrión, L; de Velasco, G; Ghanem, I; Jurado, JM; Mendiola, C; Pérez-Ruiz, E; Quero-Blanco, C; Rodríguez-Sánchez, CA; Sánchez-Muñoz, A, 2010) |
| "Docetaxel was used extensively in ovarian cancer treatment in the combination with platinum compound." | ( Chen, L; Li, Y; Lin, L; Zhang, P; Zhang, Z, 2010) |
| "Human ovarian cancer cells 3AO, SKOV(3), SKOV(3) /ADR, HO-8910 and HO-8910PM were subjected to a drug or sonochemotherapy (a drug followed by nonlethal insonation but in 3AO cells)." | ( He, H; Yu, T; Zhang, Y, 2012) |
| "Patients treated for ovarian cancer are usually referred for 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT) in case of increased Carcinoma Antigen 125 (CA125) but negative conventional imaging." | ( Al-Nahhas, A; Allegri, V; Ambrosini, V; Castellucci, P; Fanti, S; Grassetto, G; Montini, GC; Nanni, C; Palomar, A; Pettinato, C; Rubello, D; Soriano, A, 2012) |
| "We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA." | ( Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y, 2011) |
| "Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks." | ( Balkissoon, J; Chaplin, DJ; Hassan, B; Jayson, GC; Ledermann, J; Lu, SP; Osborne, R; Poupard, L; Reed, NS; Rustin, GJS; Shreeves, G; Zweifel, M, 2011) |
| "The 182 patients previously treated for ovarian cancer with carboplatin and paclitaxel in either the AGO-OVAR-9 or the NSGO-OC9804 trial in Denmark or Sweden were eligible for this study." | ( Bergmann, TK; Brasch-Andersen, C; Brosen, K; Damkier, P; du Bois, A; Gréen, H; Herrstedt, J; Hølund, B; Mirza, MR; Peterson, C; Vach, W, 2011) |
| "Patients with ovarian cancer were randomized to receive either TCM or placebo in addition to standard chemotherapy." | ( Chan, KK; Jones, B; Lau, SK; Leung, CY; Ma, FK; Ngan, HY; Yao, TJ; Yip, MW; Zhao, JF, 2011) |
| "We present a case of advanced ovarian cancer, diagnosed at week 28 of gestational age, treated with 2 cycles of paclitaxel/cisplatin (TC) chemotherapy during pregnancy, with no serious toxicity." | ( Jassem, J; Serkies, K; Węgrzynowicz, E, 2011) |
| "Women with ovarian cancer recurring within 6 months of end of last platinum-containing treatment received sagopilone 16 mg/m(2) as a 3- or 0." | ( Adams, M; Calvert, H; Essapen, S; Giurescu, M; Gore, M; Jayson, GC; Kaye, S; Ledermann, JA; Lind, M; Perren, T; Persic, M; Poole, C; Reed, N; Rustin, G; Stredder, C; Wagner, A, 2011) |
| "Forty-two women (38 with ovarian cancer, 1 with fallopian tube cancer, 3 with peritoneal cancer) whose cancer had progressed within 12 months of their last treatment with both a platinum agent and paclitaxel were treated with docetaxel (70 mg/m(2), day 1) and carboplatin (area under the curve of 4-6, day 1)." | ( Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T, 2012) |
| "To compare survival of ovarian cancer patients treated with neoadjuvant chemotherapy followed by intraperitoneal (IP) versus intravenous (IV) chemotherapy after optimal interval debulking." | ( Faught, W; Fung, MF; Hopkins, L; Jolicoeur, L; Latifah, H; Le, T; Weberpals, J, 2011) |
| "Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modulators of tumor cell survival, such as endothelin receptor (ETR) antagonist." | ( Brantley, E; Fidler, IJ; He, J; Kim, JS; Kim, SJ; Kim, SW; Lehembre, F; Maya, M; Regenass, U; Wu, Q; Yun, SJ; Zhang, F, 2011) |
| "While PPX is active in ovarian cancer, it is unclear at present whether it offers significant benefit in terms of its side-effect profile or outcomes over a standard taxane-based regimen as first-line therapy, or what role it will have in maintenance therapy as studies are ongoing." | ( Galic, VL; Herzog, TJ; Lewin, SN; Wright, JD, 2011) |
| "Treatment of the mouse ovarian cancer cell line HM-1 with recombinant TGF-β1 promoted invasiveness, cell motility and cell attachment while these were suppressed by treatment with A-83-01, an inhibitor of the TGF-β signaling pathway." | ( Abiko, K; Baba, T; Hamanishi, J; Huang, Z; Kang, HS; Konishi, I; Mandai, M; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S, 2012) |
| "Epithelial ovarian cancer is an aggressive and deadly disease and understanding its invasion mechanisms is critical for its treatment." | ( Cukierman, E; Godwin, AK; Kwon, Y, 2011) |
| "A2780 ovarian cancer cells were injected intraperitoneally in nude mice; A2780-induced tumors in nude mice, when treated with metformin in drinking water, resulted in a significant reduction of tumor growth, accompanied by inhibition of tumor cell proliferation (as assessed by immunohistochemical staining of Ki-67, Cyclin D1) as well as decreased live tumor size and mitotic cell count." | ( Giri, S; Graham, RP; Maguire, JL; Rattan, R; Shridhar, V, 2011) |
| "Specifically, we show that treatment of ovarian cancer cells with cisplatin caused Bim phosphorylation and subsequent degradation and that its degradation is associated with cisplatin resistance." | ( Wang, J; Wu, GS; Zhou, JY, 2011) |
| "Because ovarian cancer cells are dependent upon glucose for growth and survival, treatment with AMPK activators that mimic glucose deprivation may result in broad clinical benefits to ovarian cancer patients." | ( He, G; Kueck, A; Kwok, R; Liu, JR; Opipari, A; Priebe, A; Tan, L; Wahl, H, 2011) |
| "Sixty-two patients with ovarian cancer admitted in Beijing Obstetrics and Gynecology Hospital from January 2002 to December 2007, using TC regimen, a total of 196 cycles of chemotherapy, were divided into two groups by the doses of carboplatin [area under concentration-time curve (AUC) 4 - 6 for low-dose, AUC > 6 - 7 for hight-dose, the carboplatin dose calculated with AUC] or by the doses of paclitaxel (135- < 150 mg/m(2) low-dose, 150 - 175 mg/m(2) hight-dose)." | ( Ding, D; Kong, WM, 2011) |
| "Chemosensitive ovarian cancer cell lines (OV2008 and A2780s) and chemoresistant cells (C13(*) and A2780cp) were treated with cisplatin and whole cell and mitochondrial p53 contents were determined by Western blot." | ( Wang, HM; Wang, SY; Yang, XK; Zhou, Y, 2011) |
| "Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy, with a limited prognosis." | ( Ammerpohl, O; Arnold, N; Bauerschlag, DO; Bräutigam, K; Hilpert, F; Lin, Q; Maass, N; Meinhold-Heerlein, I; Schem, C; Wagner, W; Weigel, MT, 2011) |
| "Eighty percent of ovarian cancer patients initially respond to platinum-based combination therapy but most return with recurrence and ultimate demise." | ( Abubaker, K; Ahmed, N; Castrechini, N; Dobill, F; Findlay, JK; Kumar, J; Latifi, A; Liongue, C; Quinn, MA; Thompson, EW; Ward, AC, 2011) |
| "Recurrent ovarian cancer is resistant to conventional chemotherapy." | ( Alvero, AB; Chefetz, I; Holmberg, JC; Mor, G; Visintin, I, 2011) |
| "The treatment of ovarian cancer has traditionally been intractable, and required novel approaches to improve therapeutic efficiency." | ( Chen, J; Geng, F; Kong, B; Song, K; Xing, JZ; Yan, S; Yang, Q; Yuan, C, 2011) |
| "High grade epithelial ovarian cancers are relatively sensitive to DNA damaging platinum-based chemotherapy, suggesting that the dependencies of ovarian tumors on DNA damage response pathways can be harnessed for therapeutic purposes." | ( Bhaskara, S; Fass, DM; Haggarty, SJ; Hiebert, SW; Holson, E; Khabele, D; Schreiber, SL; Wagner, F; Wilson, AJ; Zhang, YL, 2011) |
| "In two different orthotopic ovarian cancer models, treatment with anti-human Jagged1 siRNA-CH reduced growth by 54." | ( Alvarez, RD; Coleman, RL; Goodman, B; Han, HD; Katre, AA; Landen, CN; Lopez-Berestein, G; Nick, AM; Sood, AK; Steg, AD; Stone, RL, 2011) |
| "Clear cell ovarian cancer is an epithelial ovarian cancer histotype that is less responsive to chemotherapy and carries poorer prognosis than serous and endometrioid histotypes." | ( Birrer, MJ; Bowtell, D; Ellard, SL; Gilks, CB; Gout, PW; Huntsman, DG; Kagami, T; Lopez-Berestein, G; McAlpine, JN; Miller, DM; Mok, SC; Ozbun, L; Sood, AK; Stany, MP; Stone, RL; Vathipadiekal, V; Vivas-Mejia, P; Wang, Y; Wang, YZ; Xue, H, 2011) |
| "Treatment of HER2-overexpressing ovarian cancer cells with magnolol down-regulated the HER2 downstream PI3K/Akt signaling pathway, and suppressed the expression of downstream target genes, vascular endothelial growth factor (VEGF), matrix metalloproteinase 2 (MMP2) and cyclin D1." | ( Cheng, YT; Chuang, TC; Fang, GS; Hsu, SC; Ou, CC; Shao, WS; Wang, V; Wu, K, 2011) |
| "These studies on mPR signaling in ovarian cancer lay the foundation for future work aimed at understanding how progesterone exerts its anti-tumorigenic effects in the ovary and suggest that pharmacologic activation of mPRs, abundantly expressed in ovarian cancers, may provide a new treatment option for patients with advanced stage disease." | ( Charles, NJ; Lange, CA; Thomas, P, 2010) |
| "Seven patients with 12 isolated ovarian cancer metastases to the liver were treated with CT-HDRBT." | ( Braicu, IE; Collettini, F; Denecke, T; Gebauer, B; Hamm, B; Poellinger, A; Schnapauff, D; Sehouli, J; Wust, P, 2011) |
| "Although ovarian cancer is often a chemosensitive malignancy, patients who are resistant to platinum-based chemotherapy represent a therapeutic challenge." | ( Coleman, RL; Naumann, RW, 2011) |
| "Epithelial ovarian cancer (EOC) patients with BRCA mutations (BRCA +) benefit from platinum-based treatment more than noncarriers." | ( Borgato, L; Boyd, L; Curtin, J; Donach, ME; Gabizon, A; Geva, R; Grenader, T; Lai, WC; Muggia, F; Nicoletto, MO; Novetsky, A; Pelles-Avraham, S; Rolnitzky, L; Safra, T, 2011) |
| "Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy." | ( Aitini, E; Brandes, A; Breda, E; Del Medico, P; Di Maio, M; Febbraro, A; Ferrandina, G; Ferro, A; Frigerio, L; Gallo, C; Gebbia, V; Greggi, S; Legge, F; Lombardi, AV; Lorusso, D; Morabito, A; Musso, P; Natale, D; Perrone, F; Pignata, S; Pisano, C; Ravaioli, A; Salutari, V; Savarese, A; Scaltriti, L; Scambia, G; Scollo, P; Sorio, R; Tamberi, S; Valerio, MR, 2011) |
| "91 patients were enrolled (65 with ovarian cancer and 26 breast cancer) and 90 were treated between July 8, 2008, and Sept 24, 2009." | ( Carmichael, J; Clemons, M; Gelmon, KA; Gilks, B; Hirte, H; Huntsman, D; Mackay, H; Macpherson, E; Oza, A; Robidoux, A; Swenerton, K; Tischkowitz, M; Tonkin, K; Yerushalmi, R, 2011) |
| "We present two cases of advanced ovarian cancer treated with neoadjuvant chemotherapy with standard tri-weekly carboplatin and paclitaxel." | ( Bellati, F; Di Donato, V; Marchetti, C; Musella, A; Napoletano, C; Nuti, M; Panici, PB; Perniola, G; Pignata, S, 2012) |
| "Hereditary epithelial ovarian cancers (EOCs) not expressing functional BRCA1 protein are characterized by defects in homologous recombination DNA repair, rendering such tumors more sensitive to DNA damaging agents and synthetic lethality, that is, poly-ADP-ribose-polymerase inhibitor treatment." | ( Camara, O; Diebolder, H; Dürst, M; Häfner, N; Jansen, L; Mothes, A; Radosa, MP; Runnebaum, IB; Winzer, H, 2011) |
| "Epithelial ovarian cancers with negative BRCA1 protein expression were identified in younger patients, showed a significantly better overall survival, prolonged treatment intervals and a tendency for an extended progression free time interval." | ( Camara, O; Diebolder, H; Dürst, M; Häfner, N; Jansen, L; Mothes, A; Radosa, MP; Runnebaum, IB; Winzer, H, 2011) |
| "Two human ovarian cancer cell lines, SKOV-3 and TOV-21G, were treated with A." | ( Chen, MJ; Hu, DN; Huang, YW; Liu, FS; Yang, PY, 2011) |
| "Many women with ovarian cancer eventually develop resistance to conventional chemotherapy drugs, and so novel agents are being developed to target specific molecular pathways." | ( Bryant, A; Gaitskell, K; Kehoe, S; Martinek, I; Morrison, J; Nicum, S, 2011) |
| "Treatment of patients with recurrent ovarian cancer remains a challenge, and there is a need for new and more effective agents." | ( Amant, F; Breda, E; Cannella, L; Hernes, K; Leunen, K; Lorusso, D; Pignata, S; Pisano, C; Rasch, W; Scambia, G; Sorio, R; Vergote, I, 2011) |
| "A total of 22 patients with cervical or ovarian cancer, who underwent chemotherapy consisting of NDP and irinotecan (CPT-11), were examined in this study." | ( Fujiwara, H; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y, 2012) |
| "A patient with metastatic ovarian cancer was treated with liposomal doxorubicin and carboplatin." | ( Brüggemann, RJ; Graaf, WT; Lesterhuis, WJ; Vos, FY, 2012) |
| "The standard treatment for ovarian cancer in advanced stages is post-surgery treatment with taxane-platin chemotherapy." | ( Bergmann, TK; Brasch-Andersen, C; Brøsen, K; Damkier, P; Gréen, H; Keldsen, N; Mirza, MR; Peterson, C; Skougaard, K; Vach, W; Wihl, J, 2012) |
| "PDT is an effective therapy for ovarian cancer cells." | ( Dong, R; Geng, F; Kong, B; Li, J; Li, L; Qu, X; Song, K; Yang, Q; Zhang, P, 2011) |
| "AR expression in primary epithelial ovarian cancer was investigated before and after chemotherapy using paired histological samples which had been incorporated into a tissue microarray." | ( Cross, P; Edmondson, RJ; Elattar, A; Freer, RM; Mukhopadhyay, A; Plummer, ER; Robson, CN; Shaheen, F; Warburton, KG, 2012) |
| "In the chemotherapy for ovarian cancer, cell apoptosis induced by cisplatin was dependent on the NLK expression." | ( Cheng, C; He, F; He, S; Huang, Y; Liu, R; Peng, C; Shen, A; Wang, Y; Wu, G; Yang, S; Yuan, Q; Zhang, Y, 2011) |
| "Epithelial ovarian cancer (EOC) usually spreads into the peritoneal cavity, thereby providing an opportunity for intraperitoneal adoptive immunotherapy with Vγ9Vδ2 T lymphocytes, a T cell subpopulation endowed with high lytic properties against tumor cells." | ( Bansard, JY; Bauville, E; Bouet-Toussaint, F; Burtin, F; Cabillic, F; Catros, V; Daniel, P; de La Pintière, CT; Dessarthe, B; Foucher, F; Henno, S; Lavoué, V; Levêque, J; Thedrez, A; Toutirais, O, 2012) |
| "In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, lapatinib/PTX nanocolloids mediated an enhanced cell growth inhibition in comparison with the PTX-only treatment." | ( Bellomo, C; Leporatti, S; Lorusso, V; Lvov, YM; Maffia, M; Rinaldi, R; Tinelli, A; Vergara, D; Vergaro, V; Zhang, X, 2012) |
| "Two human epithelial ovarian cancer cell lines, A2780 and its cisplatin-resistant form (A2780(cisR)) were treated with binary combinations of cisplatin and oxaliplatin with quercetin and thymoquinone using three sequences of administration." | ( Beale, P; Chan, C; Huq, F; Nessa, MU; Yu, JQ, 2011) |
| "Patients with stage III ovarian cancer on Gynecologic Oncology Group protocol #172 completed the Functional Assessment of Cancer Therapy-General (FACT-G) and were then randomly assigned to either intravenous (IV) or intraperitoneal (IP) chemotherapy." | ( Armstrong, DK; Frasure, HE; Gil, KM; Huang, HQ; von Gruenigen, VE; Wenzel, LB, 2012) |
| "Patients with ovarian cancer with elevated serum levels of CA-125 after primary treatment were immunized four times with the p53-SLP vaccine." | ( Bart, J; Daemen, T; Drijfhout, JW; Hamming, IL; Hollema, H; Hoogeboom, BN; Leffers, N; Melief, CJ; Molmans, BH; Nijman, HW; Oostendorp, J; Reyners, AK; van der Burg, SH; van der Zee, AG; Vermeij, R; Wolf, R, 2012) |
| "Epithelial ovarian cancer has a poor prognosis owing to late diagnosis and frequent relapse after first-line therapy." | ( Broggini, M; Caiola, E; Fruscio, R; Giuliani, D; Marabese, M; Milani, R; Porcu, L; Torri, V, 2013) |
| "I3C sensitised ovarian cancer cell lines to bortezomib treatment through potent synergistic mechanisms." | ( Agadjanian, H; Guo, X; Karlan, BY; Kwon, S; Miller, C; Nassanian, H; Orsulic, S; Taylor-Harding, B; Walsh, CS, 2012) |
| "In this ovarian cancer cohort, the patients with type II diabetes who used metformin had longer progression-free survival, despite receiving similar treatment for ovarian cancer." | ( Karrison, T; Lengyel, E; McCormick, A; McEwen, KA; Pannain, S; Park, S; Romero, IL; Yamada, SD, 2012) |
| "Patients had CC49 antibody-reactive ovarian cancer confined to the abdominal cavity after primary debulking and chemotherapy." | ( Alvarez, R; Grizzle, W; LoBuglio, A; Meredith, R; Partridge, E; You, Z, 2012) |
| "Patients with metastatic ovarian cancer continue to have a dismal prognosis, emphasizing the need for new strategies to identify and develop new molecular targets for therapy." | ( Lewin, SA; Luker, GD; Luker, KE; Mihalko, LA; Ray, P; Schmidt, BT, 2011) |
| "We evaluated Bcl-x(L) levels in ovarian cancer tumor tissue from 40 patients (20 taxane responsive and 20 with poor response to taxane) and found that patients with high Bcl-x(L) were less sensitive to taxane treatment (10 of 12) Bcl-x(L) positive patients, P = 0." | ( Belmont, LD; Fairbrother, WJ; Peale, FV; Tan, N; Wong, M; Yue, P; Zha, J, 2012) |
| "Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum." | ( Enomoto, T; Kim, A; Naka, T; Ueda, Y, 2012) |
| "(1)Serous type ovarian cancer cell line OVCA429 with platelet-activating factor receptor (PAFR) positive and mucinous type cell line RMUG-L (PAFR negative) were treated with 100 nmol/L of the PAF, cell invasion ability was determined by transwell cell migration assay." | ( Cong, Q; Jiang, W; Li, MJ; Wang, YS; Xu, CJ; Ye, B, 2011) |
| "Advanced-stage epithelial ovarian cancer remains a highly lethal malignancy, despite effective cytoreductive surgery and primary chemotherapy." | ( Bookman, MA, 2012) |
| "Forty-seven patients with suspected ovarian cancer recurrence after total ablative or cytoreductive surgery, as well as neoadjuvant or adjuvant chemotherapy, who had undergone (18)F-FDG PET/CT imaging were recruited for the present study." | ( Bakir, B; Has, D; Iyibozkurt, C; Mudun, A; Ozel, S; Sanli, Y; Topuz, S; Turkmen, C; Unal, SN; Yavuz, E; Yilmaz, E, 2012) |
| "Patients with recurrent ovarian cancer have limited options, especially in the context of relapse less than six months from primary platinum-based therapy." | ( Blessing, JA; Disilvestro, PA; Dizon, DS; Drake, RD; Fader, AN; Johnston, CM; Penson, RT; Walker, JL, 2012) |
| "Recurrent platinum-resistant ovarian cancer usually has a poor outcome with conventional chemotherapeutic therapy and new treatment modalities are warranted." | ( Bauerschlag, D; Baumann, KH; Canzler, U; Dewitz, T; du Bois, A; Hanker, LC; Hasenburg, A; Hillemanns, P; Hilpert, F; Kurzeder, C; Meier, W; Rau, J; Richter, B; Sehouli, J; Wagner, U; Wimberger, P; Wollschlaeger, K, 2012) |
| "Our studies of SKOV3 cells and ovarian cancer xenografts in nude mice indicate that shRNA targeting survivin has potential for the treatment of ovarian cancer." | ( Cai, Y; Guo, J; Jia, CR; Wang, Y; Xing, J, 2012) |
| "Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue." | ( Brennan, D; Fennelly, D; Flannelly, G; Foley, M; Lenehan, P; Shireen, R, 2012) |
| "Twelve ovarian cancer patients undergoing carboplatinum-containing chemotherapy were assessed using validated tests for olfactory, gustatory, and hearing functions before, during, immediately after, and 3 months after chemotherapy." | ( Berktold, S; Böhner, C; Harbeck, N; Hundt, W; Schmalfeldt, B; Steinbach, S; Wolf, P, 2012) |
| "In this study, human ovarian cancer cell lines (SKOV3 and CAOV3) were treated with different concentrations of GB alone or in combination with Cis-diaminodichloroplatinum (CDDP)." | ( Cong, Q; Jiang, W; Wang, Y; Xu, C; Ye, B, 2014) |
| "The current therapy for ovarian cancer has advanced from alkylating agents, to a combination of carboplatinum and paclitaxel offering increased survival." | ( Iannone, A; Maffia, M; Tinelli, A; Vergara, D, 2012) |
| "Mucin-16 (MUC16) is the established ovarian cancer marker used to follow the disease during or after treatment for epithelial ovarian cancer." | ( Delerue-Matos, C; Rani, C; Viswanathan, S, 2012) |
| "Preclinical in vitro platinum-resistant ovarian cancer cell survival, RNR activity, and DNA damage assays were done after cisplatin or cisplatin plus 3-AP treatments." | ( Abdul-Karim, FW; Abulafia, O; Bonebrake, AJ; Fanning, J; Kunos, C; Radivoyevitch, T; Usha, L, 2012) |
| "In serous ovarian cancer treated with platinum-based chemotherapy, higher levels of N(tAI) forecast a better initial response." | ( Birkbak, NJ; Bowman-Colin, C; Eklund, AC; Garber, JE; Greene-Colozzi, A; Iglehart, JD; Kim, JY; Li, Q; Li, Y; Richardson, AL; Ryan, PD; Silver, DP; Szallasi, Z; Tian, R; Tung, N; Wang, ZC, 2012) |
| "Advanced stage ovarian cancer is treated both surgically and with chemotherapy, but despite initial high response rates of 60- 75%, many women experience disease recurrence with a dismal prognosis, 5 year overall survival for FIGO stage IIIc and IV disease being only 32 and 18%." | ( Boere, IA; van der Burg, ME, 2012) |
| "Patients with relapsed ovarian cancer (N = 58), previously treated with platinum (100%) and taxane (95%), received bortezomib, 1." | ( Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A, 2012) |
| "The elevated risk of non-mucinous ovarian cancer in users of EPT ≥ 5 years does not depend on progestin type, mode or route of administration of EPT." | ( Koskela-Niska, V; Lyytinen, H; Pukkala, E; Riska, A; Ylikorkala, O, 2013) |
| "Advanced ovarian cancer is treated with cytoreductive surgery and combination platinum- and taxane-based chemotherapy." | ( Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Telleria, CM, 2012) |
| "Most ovarian cancers are estrogen-positive and hormonal treatments using anti-estrogens or aromatase inhibitors are under investigation for treating the tumors that are resistant to conventional therapies." | ( Badia, E; Balaguer, P; Busson, M; Cavailles, V; Docquier, A; Lapierre, M; Pujol, P, 2012) |
| "We treated 7 ovarian cancer cell lines with CDDP alone or with CDDP and either a PI3K inhibitor (LY294002), a MEK inhibitor (PD98059), or a MEK/ERK activator (phorbol 12-myristate 13-acetate [PMA]) and assessed cell viability, expression of MEK/ERK and PI3K/Akt, cell cycle distribution, and apoptosis." | ( Harada, T; Itamochi, H; Kawaguchi, W; Kigawa, J; Kudoh, A; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K, 2012) |
| "Gynecologists decided to treat her ovarian cancer with chemotherapy, and we were initially planning to provide treatment for breast cancer after that was completed." | ( Aruga, T; Honda, Y; Horiguchi, K; Kitagawa, D; Kuroi, K; Nako, Y; Shigekawa, T; Yamashita, T, 2012) |
| "Treatment of ovarian cancer cell lines with combination therapy acted synergistically to induce cell death, thus required a lower dose of cisplatin to achieve the same therapeutic effect." | ( Fong, MY; Jala, VR; Kakar, SS, 2012) |
| "Treatment of various ovarian cancer cells by different concentrations of diindolylmethane (DIM), an active ingredient of cruciferous vegetables, reduced the anoikis resistance in a concentration-dependent manner." | ( Kandala, PK; Srivastava, SK, 2012) |
| "MR-1S is highly expressed in ovarian cancer cells and tissues, and it may be a promising biomarker for diagnosis and a new target for ovarian cancer therapy." | ( Gao, X; Guo, L; Lu, RQ; Sun, M, 2012) |
| "The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy." | ( Clynes, M; Gillet, JP; Gottesman, M; Hamon, M; McEneaney, V; O'Leary, JJ; Roche, S; Stordal, B, 2012) |
| "BRCA-mutated ovarian cancer often presents at an advanced stage, however, tend to have better response to platinum-based chemotherapy as compared with sporadic cases of epithelial ovarian cancer (EOC)." | ( Cohn, DE; Eisenhauer, E; Hideg, K; Kuppusamy, P; McCann, GA; Selvendiran, K; Sudhakar, M; Tierney, BJ, 2012) |
| "Treatment of epithelial ovarian cancer is based on the combination of surgery and chemotherapy." | ( Auranen, A; Bützow, R; Hietanen, S; Komulainen, M; Kuoppala, T; Leminen, A; Mäenpää, J; Puistola, U; Vuento, M; Vuorela, P; Yliskoski, M, 2012) |
| "Treatment of various epithelial ovarian cancer cell lines (A2780, A2780/CP70 and CaOV3) with combination of WFA and Dox (WFA/DOX) showed a time- and dose-dependent synergistic effect on inhibition of cell proliferation and induction of cell death, thus reducing the dosage requirement of Dox." | ( Fong, MY; Gupta, R; Jin, S; Kakar, SS; Rane, M; Singh, RK, 2012) |
| "Three of nine women with ovarian cancer received taxane-based treatment during pregnancy." | ( Bhat, A; Cardonick, E; Gilmandyar, D; Somer, R, 2012) |
| "Human ovarian cancer SKOV3 cells (parental SKOV3) were treated with paclitaxel (1μM) for 2days, and the morphologic changes in the cells were monitored for more than 4months." | ( Bast, RC; Jia, L; Li, X; Liu, J; Mercado-Uribe, I; Ye, Y; Zhang, S, 2012) |
| "Small cell ovarian cancer of the hypercalcemic type (OSCCHT) is a very rare and highly aggressive disease which mainly affects young women, while optimal treatment guidelines have not yet been defined." | ( Braicu, EI; Darb-Esfahani, S; Fotopoulou, C; Pietzner, K; Sehouli, J; Woopen, H, 2012) |
| "Most ovarian cancer patients present at an advanced clinical stage and develop resistance to standard of care platinum/taxane therapy." | ( Patel, NR; Perche, F; Torchilin, VP, 2012) |
| "Treatment of ovarian cancer remains challenging despite the high complete response rate seen after maximal surgical debulking surgery and platinum-combination chemotherapy." | ( Chopra, N; Ledermann, JA; Raja, FA, 2012) |
| "After human ovarian cancer cell line HO-8910PM was treated with C3G, cell growth was determined by the Cell Counting Kit-8 (CCK-8) assay and apoptosis was evaluated by flow cytometry analysis stained with Annexin V-FITC/PI." | ( Gao, J; Zeng, L; Zhang, R, 2012) |
| "Mice engrafted with 5×10(6) SKOV-3 ovarian cancer cells were treated with cisplatin, FK228 or the combination, and tumor weights and volumes were measured." | ( Khabele, D; Lalani, AS; Saskowski, J; Wass, E; Wilson, AJ, 2012) |
| "In patients with advanced ovarian cancer, it can be challenging to evaluate response to neoadjuvant chemotherapy on computed tomography (CT) due to disseminated small volume disease and serosal disease." | ( Avril, N; Munari, A; Rockall, A, 2012) |
| "Patients with untreated stage IC-IV ovarian cancer received six cycles of carboplatin area under the curve 6 (AUC 6) 3 weekly either with no dose modification except for toxicity (Arm A) or with dose escalations in cycles 2-6 based on nadir neutrophil and platelet counts (Arm B)." | ( Banerjee, S; Gabra, H; Gilby, E; Goss, G; Hall, M; Harper, P; Hindley, A; Hogg, M; Kaye, SB; Kipps, E; Lamont, A; Lewsley, LA; Paul, J; Pledge, S; Rustin, G; Skailes, G; Vasey, P; Williams, C, 2013) |
| "The treatment of ovarian cancer cells with CDDP boosted the expression and the nuclear translocation of IRF-1, which in turn modulated the expression of putative IRF-1 target genes." | ( Corà, D; Di Renzo, MF; Olivero, M; Pavan, S, 2013) |
| "Human endometrial and ovarian cancer cells were treated with various concentrations of cucurbitacin D, and its effects on cell growth, the cell cycle, apoptosis, and their related measurements were investigated in vitro." | ( Ishii, T; Kira, N; Narahara, H; Yoshida, T, 2013) |
| "Treatment of endometrial and ovarian cancer cells with glycolysis inhibitor 2DG resulted in a significant decrease of cell viability and a significant increase of apoptosis." | ( Emons, G; Gründker, C; Reutter, M, 2013) |
| "In platinum-sensitive relapsed ovarian cancer, paclitaxel plus carboplatin is a standard second-line treatment." | ( Bagnato, A; Baumann, K; Cognetti, F; Colombo, N; Harter, P; Mari, E; McIntosh, S; Nathan, F; Pemberton, K; Savarese, A; Scambia, G; Sehouli, J; Sorio, R; Wimberger, P, 2013) |
| "195 patients with primary advanced ovarian cancer and treated by adjuvant chemotherapy were included in our study." | ( Kai, L; Miao, J; Tang, QL; Wang, XY; Zhang, X, 2012) |
| "Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection." | ( Cho, H; Kwon, GS; Lai, TC, 2013) |
| "A total of 82 patients with epithelial ovarian cancer treated at Sun Yat-sen University Cancer Center from January 1999 to December 2005 were enrolled along with 25 patients with benign ovarian lesions; 20 normal ovarian tissues served as controls." | ( Chen, C; Huang, YW; Li, JD; Xiao, J; Xu, MM; Zhu, XF, 2013) |
| "Notably, pretreatment of ovarian cancer cells expressing moderate to low levels of NKG2DLs with the histone deacetylase inhibitor sodium valproate (VPA) upregulated NKG2DL cell surface expression and consequently enhanced their immune recognition by chimeric NKG2D CAR T cells." | ( Best, A; Fang, C; Powell, DJ; Santoro, S; Song, DG; Ye, Q, 2013) |
| "ES-2, OVCAR-3, and SKOV-3 ovarian cancer cell lines were treated with doxorubicin-topotecan combinations by exposing the cells to drugs from 1 to 72 hours." | ( Bally, MB; Osooly, M; Patankar, NA; Pritchard, J; van Grinsven, M, 2013) |
| "Although great efforts in anti-ovarian cancer therapy have been made in the past 4 decades, the 5-year survival rates for ovarian cancer patients are still poor, and effective drugs to cure ovarian cancer patients are absent." | ( Bao, M; Cao, Z; Fu, S; Guo, P; Pan, Y; Shang, B; Tu, J; Yang, P; Yu, D; Zhang, G; Zhou, Q, 2013) |
| "Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease." | ( Gore, M; Gourley, C; Hall, M; Jayson, G; Kaye, S; Ledermann, J; McNeish, I; Perren, T; Rustin, G, 2013) |
| "Patients with metastatic ovarian cancer continue to experience high recurrence rates and significant morbidity from standard treatments." | ( Mutch, D; Wilkinson-Ryan, I, 2013) |
| "Platinum-resistant human ovarian cancer cell line (SKOV-3) was treated with gambogic acid, doxorubicin, or the combination of both to investigate cell proliferation and apoptosis." | ( Wang, J; Yuan, Z, 2013) |
| "Our study also found that treatment of ovarian cancer cells with genistein caused an inhibition of ovarian cancer cell growth and migration." | ( Li, P; Shen, J; Sun, Q; Wang, X; Xiang, J; Xu, L; Yin, Y; Zhai, S; Zou, X, 2013) |
| "Despite advances in treatment, ovarian cancer is the most lethal gynecologic malignancy." | ( Bae, I; Cha, SD; Cho, CH; Kwon, SH; Lee, GH; Lee, HG; Parajuli, B; Shin, SJ, 2013) |
| "CTR expression in ovarian cancer tissues resected from patients treated by platinum-based chemotherapy was evaluated immunohistochemically." | ( Fukuda, T; Honda, K; Ishiko, O; Sumi, T; Teramae, M; Yamauchi, M; Yasui, T; Yoshida, H, 2013) |
| "Treatment of advanced stage ovarian cancer continues to be challenging due to acquired drug resistance and lack of early stage biomarkers." | ( Anur, P; Kodigepalli, KM; Nanjundan, M; Sims, PJ; Spellman, P, 2013) |
| "Human ovarian cancer SKOV-3 cells were treated by various concentrations of Chitosan oligosaccharide." | ( Gao, ZH; Huo, GH; Lv, YF, 2012) |
| "The levels of Fas protein on surface of ovarian cancer cells and FasL protein on surface of CIK cells after Curcumin treatment were determined by Western blot." | ( Cui, LF; Cui, MH; Shan, YH, 2013) |
| "Tissues of 92 patients with ovarian cancer meeting the inclusion criteria with complete follow-up data were enrolled and divided into chemotherapy resistant group and sensitive group." | ( Gao, J; Gao, S; Hou, R; Hu, Z; Lin, B; Liu, C; Liu, D; Liu, J; Zhang, D; Zhang, S, 2013) |
| "For advanced-stage ovarian cancer treated during the platinum-taxane era, the proportions of patients left with no gross residual disease and receiving intraperitoneal chemotherapy are independently significant factors associated with the most favorable cohort survival time." | ( Bristow, RE; Chang, J; Chang, SJ; Hodeib, M, 2013) |
| "Older women with ovarian cancer have increased cancer-related mortality and chemotherapy toxicity." | ( Feng, T; Gajra, A; Gross, CP; Hurria, A; Klepin, HD; Lichtman, SM; Mohile, S; Owusu, C; Tew, WP; Won, E, 2013) |
| "Among older women with ovarian cancer, abnormal CA125 was associated with poor pretreatment functional status and an increased probability of chemotherapy toxicity and dose reduction." | ( Feng, T; Gajra, A; Gross, CP; Hurria, A; Klepin, HD; Lichtman, SM; Mohile, S; Owusu, C; Tew, WP; Won, E, 2013) |
| "Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy." | ( del Carmen, MG; Foley, OW; Rauh-Hain, JA, 2013) |
| "Proliferation of ovarian cancer cells under treatment of DZNep was assessed by MTT and apoptosis by flow cytometry." | ( Cui, J; Liu, PS; Ma, YH; Pang, YX; Shen, L, 2013) |
| "Women with relapsed epithelial ovarian cancer (EOC) often have a reduced performance status with a limited life expectancy, therefore maintaining quality of life with effective symptom control is the main purpose of treatment." | ( Bryant, A; Cameron, A; Gray, E; Lawrie, TA; Morrison, J, 2013) |
| "Patients with epithelial ovarian cancer, who underwent primary surgery and platinum-based first-line chemotherapy, were included." | ( Graeser, MK; Jaenicke, F; Mahner, S; Mathey, S; Milde-Langosch, K; Müller, V; Trillsch, F; Woelber, L; Zu Eulenburg, C, 2013) |
| "After the treatment of 5-Aza-dC, ovarian cancer cell lines(SKOV-3 and HEY) significantly increased HOXA10 expression." | ( Cheng, W; Chu, Y; Jiang, Y; Tang, W; Wan, Y; Zhang, L, 2014) |
| "Patients with stage II-IV ovarian cancer were randomly assigned to receive conventional treatment (carboplatin area under the curve [AUC] 6 mg/mL per min and paclitaxel 180 mg/m(2) on day 1) or dose-dense treatment (carboplatin AUC 6 mg/mL per min on day 1 and paclitaxel 80 mg/m(2) on days 1, 8, and 15)." | ( Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M, 2013) |
| "Due to frequent diagnosis of ovarian cancer at an advanced clinical stage, in most cases surgical debulking is followed by chemotherapy." | ( Maciejczyk, A; Surowiak, P, 2013) |
| "Mice bearing intraperitoneally spread ovarian cancer were treated with 20 or 50 mg/kg/day Pao by i." | ( Chen, Q; Yu, J, 2014) |
| "We conclude that different ovarian cancer cell lines show characteristic (31)P MRS fingerprints and specific metabolic changes in response to cytotoxic drug treatment." | ( Abramov, Y; Anteby, SO; Carmi, S; Ringel, I, 2013) |
| "We also examined HA serum levels in ovarian cancer patients prior to and following chemotherapy and assessed its prognostic relevance." | ( Lokman, NA; Oehler, MK; Pyragius, CE; Ricciardelli, C; Tan, IA; Ween, MP, 2013) |
| "HA production in ovarian cancer cells was increased in cancer tissues collected following chemotherapy treatment and at recurrence." | ( Lokman, NA; Oehler, MK; Pyragius, CE; Ricciardelli, C; Tan, IA; Ween, MP, 2013) |
| "Most women with ovarian cancer relapse and undergo further chemotherapy however evidence regarding the benefits of this for women with platinum-resistant disease is limited." | ( Beesley, VL; Butow, PN; Clavarino, AM; deFazio, A; Green, AC; Horwood, KR; O'Rourke, P; Price, MA; Webb, PM; Wockner, LF; Wyld, DK, 2014) |
| "Patients with ovarian cancer (OC) may be treated with surgery, chemotherapy and/or radiation therapy, although none of these strategies are very effective." | ( Banerjee, S; Banerjee, SK; De, A; Haque, I; Hentges, S; Papasian, C, 2013) |
| "G-1 treatment also induces apoptosis of ovarian cancer cells." | ( Davis, JS; He, C; Hua, G; Lv, X; Tsai, MY; Wang, C, 2013) |
| "Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first-line management." | ( Lawrie, TA; Morrison, J; Rabbie, R; Thoma, C, 2013) |
| "For effective ovarian cancer gene therapy, systemic administrated tumor-targeting siRNA/folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate (FA-PEG-COL) nanoparticles is vital for delivery to cancer site(s)." | ( Honke, K; Li, TS; Yawata, T, 2014) |
| "We describe 3 ovarian cancer patients who were successfully retreated with carboplatin via hyperthermic intraperitoneal chemotherapy following hypersensitivity reaction." | ( Bechtol, KA; Goldstein, BH; Gray, CM; Lopez, KL; Rettenmaier, MA, 2014) |
| "Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered." | ( Colombo, N, 2013) |
| "Epithelial ovarian cancer is one of the most malignant cancers in women and resistant to chemotherapy is the major obstacle for the five-year survival rate." | ( Chen, M; Chen, S; Liang, J; Ning, Y; Wang, L; Xu, C; Yao, L; Zhang, H; Zhu, P, 2013) |
| "A total of 152 ovarian cancer patients who had undergone therapy were evaluated." | ( Chen, T; Chen, YM; Shi, YP; Tong, LJ; Wan, LR; Zee, CS, 2014) |
| "Women presenting with epithelial ovarian cancer should be treated in centers with both aggressive surgical and chemotherapy teams prepared to confront the modifiable factors, which can optimize the patient's outcome." | ( Walker, JL, 2013) |
| "Furthermore, ovarian cancer cells treated with WP 631 showed a higher mean level of basal DNA damage in comparison to DOX." | ( Bukowska, B; Denel, M; Gajek, A; Marczak, A; Rogalska, A, 2014) |
| "Four ovarian cancer cell lines were cultured and treated with the DNA demethylation agent 5-aza-2'-deoxycytidine (5-AZA) for restoring OPCML expression." | ( Cao, X; Chen, X; Liu, M; Tao, G; Xie, W; Zhou, F, 2014) |
| "In vivo uptake of FLT and FDG in human ovarian cancer xenografts in mice (A2780) was determined before treatment with carboplatin and paclitaxel (CaP) and repeated day 1, 4 and 8 after treatment start." | ( Björkling, F; Erichsen, KD; Højgaard, L; Jensen, PB; Kjær, A; Madsen, J; Munk Jensen, M; Sehested, M, 2013) |
| "First, ovarian cancer cell lines exhibited constitutively active NF-κB, and treatment with butenal abolished this activation as indicated by DNA binding activity." | ( Back, MK; Chang, HW; Cho, SH; Han, SB; Hong, JT; Jeong, HS; Kim, JH; Lee, HP; Park, MH; Sung, HC, 2014) |
| "All patients with epithelial ovarian cancer treated with neoadjuvant chemotherapy were retrospectively reviewed from 2007 to 2009." | ( Al Mutairi, NJ; Le, T, 2014) |
| "Recent studies suggested that the ovarian cancers with negative excision repair cross-complementation group 1 enzyme (ERCC1) expression have a better response to platinum-based chemotherapy than those with positive ERCC1 expression." | ( Li, FY; Ren, XB; Xie, XY; Zhang, J, 2013) |
| "Transarterial treatment for ovarian cancer achieves a high local response and good symptom control, and significantly contributes to survival for patients with local control after multiple relapses." | ( Hori, A; Hori, S; Seki, A; Sueyoshi, S, 2014) |
| "Treating PBMCs obtained from ovarian cancer patients with GX15 also resulted in increased CD8(+):Treg and CD4(+):Treg ratios." | ( Donahue, RN; Farsaci, B; Grenga, I; Gulley, JL; Jochems, C; Kim, PS; Schlom, J; Tsang, KY, 2014) |
| "Human epithelial ovarian cancer cells (A2780 and A2780/CP70) were treated with cisplatin ± 20 μM NaAsO2 at 37 or 39°C for 1 h." | ( Helm, CW; Muenyi, CS; States, JC; Trivedi, AP, 2014) |
| "The standard treatment of ovarian cancer with chemotherapy often leads to drug resistance and relapse of the disease, and the need for development of novel therapy alternatives is obvious." | ( Andersson, Y; Bideli, H; Flatmark, K; Fodstad, O; Wiiger, MT, 2014) |
| "Immunotherapy against ovarian cancer is a promising strategy to develop from animal-based cancer research." | ( Choi, BS; Chung, YH; Hung, CF; Hur, DY; Jang, MJ; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Park, GB, 2014) |
| "Women with FIGO stage IC-IV ovarian cancer, an ECOG performance status of 2 or lower, and who had never received chemotherapy were randomly allocated in a 1:1 ratio to receive either carboplatin (AUC 6 mg/mL per min) plus paclitaxel (175 mg/m(2)) every 3 weeks for six cycles or carboplatin (AUC 2 mg/mL per min) plus paclitaxel (60 mg/m(2)) every week for 18 weeks." | ( Bologna, A; Breda, E; Cavazzini, MG; Cinieri, S; Cormio, G; De Placido, S; Di Maio, M; Ferrandina, G; Gallo, C; Greggi, S; Katsaros, D; Lauria, R; Lorusso, D; Marchetti, C; Murgia, V; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Pujade-Lauraine, E; Raspagliesi, F; Ricci, C; Sacco, C; Salutari, V; Scambia, G; Selvaggi, L; Signoriello, S; Sorio, R; Weber, B, 2014) |
| ""Platinum resistant" ovarian cancer was historically defined as disease recurrence within 6months of completion of first-line platinum-based chemotherapy, although this is now more broadly applied to also include patients progressing within 6months after multiple lines of chemotherapy." | ( Davis, A; Friedlander, M; Tinker, AV, 2014) |
| "In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard." | ( Bamias, A; Bollag, D; Follana, P; Hilpert, F; Kristensen, G; Mirza, MR; Oaknin, A; Pereira, D; Poveda, A; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Sorio, R; Vergote, I; Weber, B; Wimberger, P; Witteveen, P, 2014) |
| "Asymptomatic patients with relapsed ovarian cancer who had responded to chemotherapy were enrolled and had CA125 measurements taken every 4 weeks, then more frequently when rising." | ( Crawford, SM; Gourley, C; Hall, MR; Kornbrot, DE; Morgan, JS; Pascoe, J; Persic, M; Petruckevitch, A; Qian, W; Rustin, GJ; Stuart, N; Tahir, S, 2014) |
| "Chk2-depleted ovarian cancer cell lines have diminished platinum sensitivity, suggesting that Chk2 should not be considered a therapeutic target along with platinum-based treatment in HGSOC patients." | ( Alkema, NG; de Jong, S; Everts, M; Hollema, H; Meersma, GJ; Tomar, T; van der Zee, AG; van Vugt, MA; Wisman, GB, 2014) |
| "Obesity is common in ovarian cancer patients, and commonly results in lower chemotherapy dosing than recommended." | ( Au-Yeung, G; Bressel, M; DeFazio, A; Fereday, S; Mileshkin, L; Webb, PM, 2014) |
| "Patients with platinum-resistant ovarian cancer were randomly assigned to chemotherapy alone (CT) or with bevacizumab (BEV-CT)." | ( Arranz, JA; de Gregorio, N; Freudensprung, U; Friedlander, M; Hales, G; Hilpert, F; Joly, F; King, MT; Lee, CK; Mirza, MR; Pujade-Lauraine, E; Sneller, V; Sorio, R; Stockler, MR; Wenzel, L, 2014) |
| "We also suggest that NIS is a new ovarian cancer marker, opening a door for the use of radioiodide in the diagnosis and treatment of ovarian cancer patients." | ( De la Vieja, A; Estevez-Cebrero, MA; Gallego, MI; Hardisson, D; Leoni, SG; Mendiola, M; Redondo, A; Riesco-Eizaguirre, G; Santisteban, P, 2014) |
| "Medical records of patients with ovarian cancer were retrospectively reviewed to select those with a history of platinum and taxane administration, clinical progression within six months of the last platinum administration, continuation of chemotherapy after the first progression during chemotherapy." | ( Inoue, K; Sonoda, T; Tsubamoto, H; Yamasaki, M, 2014) |
| "Conventional chemotherapy of ovarian cancer often fails because of initiation of drug resistance and/or side effects and trace of untouched remaining cancerous cells." | ( Barar, J; Coukos, G; Li, C; Matthaiou, EI; Omidi, Y; Sandaltzopoulos, R, 2014) |
| "Cisplatin is commonly used in ovarian cancer chemotherapy, however, chemoresistance to cisplatin remains a great clinical challenge." | ( Chen, L; Di, W; He, Y; Liu, T; Wang, W; Wang, Y; Yin, X; Zhou, J, 2014) |
| "Human ovarian cancer OVCAR3 and SKOV3 cells were treated with arctigenin, and cell proliferation and apoptosis were assessed." | ( Fu, XY; Huang, K; Li, LA; Meng, YG; Song, L; You, YQ, 2014) |
| "Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy, many patients will develop cisplatin-resistance disease, which is extremely rapid and fatal." | ( Echevarría-Vargas, IM; Valiyeva, F; Vivas-Mejía, PE, 2014) |
| "SKOV3 ovarian cancer cells were treated with curcumin (10-60 μM) and miR-9 expression, cell proliferation, and apoptosis were assessed." | ( Kan, QC; Shi, XQ; Yu, ZJ; Zhang, X; Zhang, XJ; Zhao, SF, 2014) |
| "Current treatment of ovarian cancer patients with chemotherapy leaves behind a residual tumor which results in recurrent ovarian cancer within a short time frame." | ( Abubaker, K; Ahmed, N; Burns, CJ; Findlay, JK; Luwor, RB; McNally, O; Quinn, MA; Thompson, EW; Zhu, H, 2014) |
| "Approximately 60% of ovarian cancers are positive for the estrogen receptor (ER); however, ER-targeted treatment is disappointing due to drug resistance as compared with breast cancer." | ( Fu, J; Gou, W; Han, X; Li, L; Li, X; Yang, T; Zhang, Y, 2014) |
| "High-grade serous ovarian cancer (HGSOC) that is resistant to platinum-based chemotherapy has a particularly poor prognosis." | ( Billaud, JN; Cohen, S; Dottino, P; Halpert, R; Martignetti, JA; Moshier, E; Mosig, R; Pereira, E; Prasad-Hayes, M; Rahaman, J, 2014) |
| "The role of Quercetin in ovarian cancer treatment remains controversial, and the mechanism is unknown." | ( Chen, G; Li, N; Ma, D; Sun, C; Weng, D; Xing, H; Zhou, B, 2014) |
| "Quercetin supplementation during ovarian cancer treatment may detrimentally affect therapeutic response." | ( Chen, G; Li, N; Ma, D; Sun, C; Weng, D; Xing, H; Zhou, B, 2014) |
| "Chemotherapy response in ovarian cancer patients is frequently compromised by drug resistance, possibly due to altered drug metabolism." | ( Chakravarty, P; Ferguson, MJ; Ihrig, BR; Sawers, L; Smith, G; Wolf, CR; Young, HC, 2014) |
| "We demonstrated that ALDH(+) ovarian cancer cells possess multiple stem cell characteristics, were highly chemoresistant, and were enriched in xenografts residual after platinum therapy." | ( Cardenas, H; Condello, S; Fang, F; Liu, Y; Matei, D; Nephew, KP; Segar, M; Taverna, P; Wang, Y, 2014) |
| "Using 6 ovarian cancer cell lines, we demonstrated that there is variation from cell line to cell line in the ability of IFN-α2a and IFN-γ primed monocytes to synergistically kill target tumor cells, and further, there is an additive killing effect when target cells are treated with both IFN primed monocytes and chemotherapy." | ( Green, DS; Johnson, CL; Zoon, KC, 2015) |
| "The NK-killing efficiency of ovarian cancer cells with and without pre-treatment with AEZS-126 was analysed." | ( Dietl, J; Engel, JB; Hahne, JC; Honig, A; Kurz, A; Meyer, SR, 2015) |
| "Consistently, primary cultures of ovarian cancer treated with 10058-F4 showed induction of caspase-3 activity and inhibition of cell proliferation in 15 of 18 cases." | ( Bae-Jump, VL; Chan, LL; Jones, HM; Ma, X; Song, F; Wang, J; Zhang, W; Zhou, C, 2014) |
| "Considering the high mortality of ovarian cancer, novel approaches for diagnostics and therapy are urgently needed." | ( Massuger, LF; Vallen, MJ; van der Steen, SC; van Kuppevelt, TH; van Tilborg, AA, 2014) |
| "Survival rate in ovarian cancer has not improved since chemotherapy was introduced a few decades ago." | ( Alvero, AB; Graham, E; Joo, WD; Montagna, MK; Mor, G; Sumi, NJ, 2014) |
| "Advanced ovarian cancer patients harboring BRCA1/2 mutation treated with debulking surgery and platinum-based adjuvant chemotherapy have a longer PFS." | ( Griskevicius, L; Janavicius, R; Janulynaite, D; Kanopiene, D; Rudaitis, V; Zvirblis, T, 2014) |
| "This is paramount for improving ovarian cancer patients' responses to chemotherapy, and thus increasing their survival rate." | ( Alvero, A; Bingham, J; Craveiro, V; Garofalo, F; Holmberg, J; Liang, M; Lin, ZP; Mor, G; Romanoff, E; Soteras, MG; Sumi, N; Yang-Hartwich, Y, 2015) |
| "Currently, the treatment for ovarian cancer entails cytoreductive surgery followed by chemotherapy, mainly, carboplatin combined with paclitaxel." | ( Batra, SK; Kakar, SS; Miller, DM; Moghadamfalahi, M; Powell, KS; Ratajczak, MZ; Singh, SK, 2014) |
| "Both of SKOV-3 and HO-8910 human ovarian cancer cells were divided into four groups: (1) untreated (Con); (2) treated with DEX (0." | ( Dong, Q; Guan, J; Han, Y; Hou, W; Lu, H; Zhang, R, 2014) |
| "Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy." | ( Audeh, MW; Balmaña, J; Bowen, K; Domchek, SM; Fielding, A; Fried, G; Friedlander, M; Hubert, A; Kaufman, B; Loman, N; Mitchell, G; Rosengarten, O; Schmutzler, RK; Shapira-Frommer, R; Steiner, M; Stemmer, SM, 2015) |
| "Treatment of advanced ovarian cancer involves platinum-based chemotherapy." | ( Kato, T; Maida, Y; Masutomi, K; Yamaguchi, S; Yasukawa, M; Yoshida, M, 2014) |
| "Primary systemic treatment for ovarian cancer is surgery, followed by platinum based chemotherapy." | ( Denkert, C; Győrffy, B; Krenács, T; Lánczky, A; Lénárt, J; Meggyesházi, N; Pénzváltó, Z; Pete, I; Szoboszlai, N, 2014) |
| "A database of ovarian cancer transcriptomic datasets including treatment and response information was set up by mining the GEO and TCGA repositories." | ( Denkert, C; Győrffy, B; Krenács, T; Lánczky, A; Lénárt, J; Meggyesházi, N; Pénzváltó, Z; Pete, I; Szoboszlai, N, 2014) |
| "We tested the induction of LIV1 in ovarian cancer cells and clinical samples after TSA treatment by real-time PCR and western blot analysis." | ( Duan, H; Liu, J; Ma, D; Ma, X; Mo, Q; Sun, C; Wang, J, 2015) |
| "In patients with ovarian cancer relapsing at least 6 months after end of primary treatment, the addition of paclitaxel to platinum treatment has been shown to improve survival but at the cost of significant neuropathy." | ( DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y, 2014) |
| "Since mice transplanted with human ovarian cancer cells (SKOV3) demonstrated elevated tumor size and decreased survival rate when treated with thrombin or thrombopoietin (TPO), the platelets appeared to promote primary tumor growth." | ( Liu, X; Yuan, L, 2015) |
| "46 patients diagnosed with the ovarian cancer were enrolled in the study and divided into groups according to the stage of the disease, outcome of the surgery and treatment received." | ( Brtnický, T; Fialová, A; Laštovička, J; Rob, L; Špíšek, R, 2015) |
| "The two ovarian cancer cell lines, UACC‑1598 and SKOV3, were treated with PTX and HCPT for 24 and 48 h, and the transcriptional levels of the candidate reference genes were subsequently evaluated by RT‑qPCR analysis." | ( Bai, J; Bian, Z; Chen, F; Fu, S; Guan, R; Jin, Y; Quan, C; Sun, W; Wu, J; Xu, L; Yu, Y, 2015) |
| "Partly due to delays in its diagnosis, ovarian cancer's prognosis remains dire after primary therapy." | ( Azaïs, H; Bassil, A; Betrouni, N; Collinet, P; Frochot, C; Khodja Bach, S; Mordon, S; Moussaron, A, 2014) |
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "High-grade serous ovarian cancers (HGSOC) are genomically complex, heterogeneous cancers with a high mortality rate, due to acquired chemoresistance and lack of targeted therapy options." | ( Agadjanian, H; Allen, JR; Aspuria, PJ; Cheon, DJ; Funari, V; Greenberg, D; Karlan, BY; Mizuno, T; Orsulic, S; Spiteri, E; Spurka, L; Taylor-Harding, B; Walsh, C; Wang, Q; Wiedemeyer, WR, 2015) |
| "We retrospectively evaluated ovarian cancer patients who underwent laparoscopic debulking surgery, attained a complete response to their primary chemotherapy and subsequently received consolidation HIPEC with carboplatin area under the curve of 10 (AUC of 10) and a planned 12 cycles of paclitaxel (135 mg/m(2)) maintenance chemotherapy." | ( Abaid, LN; Brown Iii, JV; Goldstein, BH; Mendivil, AA; Rettenmaier, MA; Wilcox, AM, 2015) |
| "The results from this ovarian cancer treatment evaluation suggest that the combination of consolidation HIPEC and maintenance chemotherapy is feasible and reasonably well tolerated." | ( Abaid, LN; Brown Iii, JV; Goldstein, BH; Mendivil, AA; Rettenmaier, MA; Wilcox, AM, 2015) |
| "There was significant inhibition of ovarian cancer (HeyA8-MDR and OVCAR-5) cell invasion as well as reduced production of proangiogenic cytokines in response to zoledronic acid treatment." | ( Aslan, B; Calin, G; Dalton, HJ; Del C Monroig, P; Fernandez-de Thomas, RJ; Fuentes-Mattei, E; Gonzalez-Villasana, V; Ivan, C; Kahraman, N; Kanlikilicer, P; Lopez-Berestein, G; Ozpolat, B; Pradeep, S; Previs, RA; Rodriguez-Aguayo, C; Sood, AK; Velazquez-Torres, G; Wang, H, 2015) |
| "Patients with high-grade serous ovarian cancer and high HER2 levels had poor overall survival; however, better survival in the low HER2 patient subgroup treated with platinum/taxane-based therapy correlated positively with PRP4K expression (HR = 0." | ( Corkery, DP; Dellaire, G; Le Page, C; Mes-Masson, AM; Meunier, L; Provencher, D, 2015) |
| "The application of EGFR Inhibition in ovarian cancer was hampered for its limited benefit as a solitary therapy." | ( Gao, Q; Gong, C; Jin, P; Liu, Y; Ma, D; Wei, X; Xu, S; Yang, Z; Zhang, T; Zhou, X, 2015) |
| "Effective treatment of ovarian cancer depends upon the early detection of the malignancy." | ( Aghaie, M; Barar, J; Coukos, G; Johari-Ahar, M; Karami, P; Mohammadnejad, D; Omidi, Y; Ramazani, A; Rashidi, MR, 2015) |
| "Participants were 113 women with ovarian cancer who provided salivary cortisol for three days prior to treatment for calculation of cortisol slope, variability, and night cortisol." | ( Bender, D; Cole, SW; Dahmoush, L; DeGeest, K; Goodheart, MJ; Lubaroff, DM; Lutgendorf, SK; Mendez, L; Penedo, F; Schrepf, A; Slavich, GM; Sood, AK; Thaker, PH, 2015) |
| "Cisplatin is commonly used in ovarian cancer treatment by inducing apoptosis in cancer cells as a result of lethal DNA damage." | ( He, J; Jiang, BH; Liu, LZ; Wang, L; Xu, Q; Yu, JJ; Zheng, JZ, 2015) |
| "However, treatment of advanced ovarian cancer patients with a neutralizing IL6 antibody yielded little efficacy in a previous phase II clinical trial." | ( Balkwill, FR; Bowtell, DD; Everitt, G; Gopinathan, G; Grose, R; Hochhauser, D; Hollingsworth, RE; Kulbe, H; Milagre, CS; Thompson, RG; Zhong, H, 2015) |
| "Human ovarian cancer cells were treated with paclitaxel alone or in combination with NSC23925 in vitro and in vivo." | ( Choy, E; Cote, G; Duan, Z; Feng, Y; Gao, Y; Harmon, D; Hornicek, FJ; Mankin, H; Shen, J; Yang, X; Zhang, Z, 2015) |
| "Awareness of risk factors of ovarian cancer was assessed using a self-administered questionnaire." | ( Abdul Wahab, SB; Chiu, LB; Keng, SL; Yusuf, A, 2015) |
| "Sexuality was not impaired in ovarian cancer survivors who were without evidence of disease after primary treatment and having sexual activities, compared with healthy women, whereas social functioning and financial status did deteriorate." | ( Joo, J; Kim, SI; Lee, DO; Lee, Y; Lim, MC; Park, K; Park, SY, 2015) |
| "The majority of ovarian cancer patients acquire resistance to standard platinum chemotherapy and novel therapies to reduce tumor burden and ascites accumulation are needed." | ( Bale, LK; Becker, MA; Conover, CA; Haluska, P; Oxvig, C, 2015) |
| "A majority of high-grade (HG) serous ovarian cancer (SOC) patients develop resistant disease despite high initial response rates to platinum/paclitaxel-based chemotherapy." | ( Ao, W; Bateman, NW; Conrads, KA; Conrads, TP; Darcy, KM; Dubil, E; Hamilton, CA; Hood, BL; Jaworski, E; Litzi, T; Marcus, C; Maxwell, GL; McGuire, WP; Paz, K; Phippen, NT; Sidransky, D; Teng, PN; Vasicek, LA; Wang, G, 2015) |
| "Totally, 37 ovarian cancer patients with complete data who treated with bevacizumab combined with chemotherapy were reviewed from the databases of Beijing Cancer hospital and included in this retrospective study." | ( Li, Y; Shang, YM; Yang, Y; Zheng, H, 2014) |
| "Whether metformin therapy affects ovarian cancer risk in Asian patients with type 2 diabetes mellitus has not been investigated." | ( Tseng, CH, 2015) |
| "Up to one third of ovarian cancer patients are intrinsically resistant to platinum-based treatment." | ( Amler, LC; Bais, C; Choi, Y; Firestein, R; Fu, L; Fuentes, E; Guan, Y; Huw, LY; Lackner, MR; Lu, S; Rabe, C; Ryner, L; Wang, Y; Xiao, Y, 2015) |
| "Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy." | ( Buerkle, B; Giger-Pabst, U; Reymond, MA; Solass, W; Tempfer, CB, 2015) |
| "Non-HGS ovarian cancer cells were generally more sensitive to TPT treatment compared to HGS ovarian cancer cells." | ( Annunziata, CM; James, J; Kim, MK, 2015) |
| "In this study, two human ovarian cancer cell lines, OVCAR-3 and CAOV-3, were treated by 120 μM resveratrol and their responses to the treatment and the statuses of Wnt, Notch and STAT3 signaling in them were analyzed by multiple experimental approaches." | ( Chen, XY; Li, H; Liu, J; Liu, XY; Wu, ML; Zhang, Y; Zhong, LX; Zhong, MJ, 2015) |
| "The paclitaxel-resistant ovarian cancer cells were then established in a mouse model by continuous paclitaxel treatment in combination with or without NSC23925 administration in the mice." | ( Duan, Z; Feng, Y; Gao, Y; Guan, Y; Hornicek, FJ; Mankin, H; Shen, J; Yang, X; Zhang, Z, 2015) |
| "The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy efficacy." | ( Abdul-Hai, A; Barshack, I; Carvalho, S; Cohen, Y; Korach, J; Lauriola, M; Levanon, K; Lindzen, M; Mills, G; Onn, A; Shirazi, N; Sinha, S; Yarden, Y, 2016) |
| "We found that treatment of human ovarian cancer cells with an EGFR inhibitor, gefitinib, resulted in increased STAT3 phosphorylation in a dose- and time-dependent manner." | ( Buettner, R; Dellinger, TH; Han, ES; Horne, D; Hsieh, MY; Jove, R; Liu, L; Tian, Y; Wen, W; Wu, J; Yim, JH, 2015) |
| "About 40-60% of ovarian cancer (OVCA) cases express ERα, but only a small proportion of patients respond clinically to anti-estrogen treatment with estrogen receptor (ER) antagonist tamoxifen (TAM)." | ( Guo, XQ; Li, L; Mao, LQ; Niu, XL; Qu, Y; Wang, D; Wang, Y; Xiu Hu, C; Yang, J, 2015) |
| "In a xenograft model of KRAS-mutant ovarian cancer, combining decitabine and navitoclax heightened antitumor activity beyond administration of either compound alone." | ( Chang, YM; Khabele, D; Kim, JW; Schreiber, SL; Shamji, AF; Stewart, ML; Tamayo, P; Wang, S; Wilson, AJ, 2015) |
| "p‑Src expression increased in ovarian cancer cells following paclitaxel treatment." | ( Hou, T; Huang, Y; Li, J; Xiao, J; Xu, M; Yang, C, 2015) |
| "Metformin treatment of ovarian cancer cells decreased both mRNA and protein levels of Axl and Tyro3 in a dose‑dependent manner." | ( Kim, NY; Lee, C; Lee, HY, 2015) |
| "We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not." | ( Li, Y; Ma, C; Wang, J; Wuerkenbieke, D, 2015) |
| "In women with stage III or IV ovarian cancer, survival with primary chemotherapy is non-inferior to primary surgery." | ( Bannoo, S; Dobbs, S; Essapen, S; Herod, J; Hook, J; Jayson, GC; Kehoe, S; Kitchener, H; Lopes, T; Luesley, D; Mascarenhas, M; McCluggage, G; Nankivell, M; Parmar, M; Perren, T; Swart, AM; Twigg, J, 2015) |
| "CAP chemotherapy in patients with ovarian cancer with FIGO stage III-IV induces radical formation and changes the homeostasis of the patient." | ( Abakumova, TV; Antoneeva, II; Dolgova, DR; Fomina, AV; Gening, SO; Gening, TP; Mikheenko, AA; Pirmamedova, SS, 2015) |
| "Mammary and ovarian cancer progression were induced using local ovarian DMBA treatment and subcutaneous sustained release 17β-estradiol administered starting at 7 weeks of age." | ( Delman, DM; Fabian, CJ; Kimler, BF; Petroff, BK; Yeh, H, 2015) |
| "The resistance of ovarian cancer towards front-line chemotherapy, usually cisplatin or carboplatin in combination with paclitaxel or docetaxel, remains a major clinical challenge." | ( Farrell, NP; Gottesman, MM; Hall, MD; Madigan, JP; Stukova, M; Tsotsoros, SD, 2015) |
| "Treatment of early stage ovarian cancer remains controversial despite advances in chemotherapeutic options." | ( Ozbasar, D; Sakarya, DK; Yetimalar, MH, 2015) |
| "Secondary eligibility was met when ovarian cancer was confirmed and optimally debulked, an intraperitoneal port was placed, and there were no contraindications for ketorolac administration." | ( Adams, SF; Bedrick, E; Cook, L; Guo, Y; Hudson, LG; Kang, H; Kenney, SR; Lomo, L; Muller, CY; Oprea, TI; Romero, E; Rutledge, T; Sklar, LA; Wandinger-Ness, A; Wiggins, CL, 2015) |
| "The effect of aPC on an ovarian cancer cell line (OVCAR-3) was tested in regards to i) cell migration and adhesion with the use of adhesion and wound healing assays as well as a droplet test; ii) protein phosphorylation, evaluated by cyto-ELISA; iii) cell cycle modification assessed by flow cytometric DNA quantification; and iv) anticoagulant activity evaluated by the prolongation of partial thromboplastin time (aPTT) of normal plasma in the presence or absence of aPC-treated ovarian cancer cells." | ( Alfarsi, H; Althawadi, H; Besbes, S; Ducros, E; Mirshahi, M; Mirshahi, S; Pocard, M; Rafii, A; Soria, J; Therwath, A, 2015) |
| "From 176 ovarian cancers treated in three institutions, we selected 38 patients treated with PLD monotherapy as second/third line of treatment." | ( Aglietta, M; Becco, P; Bruna, P; Canuto, EM; Di Renzo, MF; Erriquez, J; Ferrero, A; Maggiorotto, F; Olivero, M; Ponzone, R; Sapino, A; Scalzo, MS; Valabrega, G; Verdun di Cantogno, L, 2015) |
| "To review ovarian cancer cases in children and adolescents in Siriraj Hospital and assess the prognosis, recurrence of disease, and reproductive outcomes after treatment." | ( Chaopotong, P; Jaishuen, A; Kuljarusnont, S; Leelapatanadit, C; Therasakvichya, S, 2015) |
| "Disseminated high-grade serous ovarian cancer (HGS-OvCa) is an aggressive disease treated with platinum and taxane combination therapy." | ( Aittomäki, V; Auranen, A; Carpén, O; Chen, P; Grénman, S; Hautaniemi, S; Huhtinen, K; Hynninen, J; Kaipio, K; Lehtonen, R; Lindell, R; Mikkonen, P, 2015) |
| "The poor outcome of advanced ovarian cancer treated with conventional therapy stimulated the search for new strategies to improve therapeutic efficacy." | ( Li, H; Shi, C; Sui, H; Yan, Z, 2015) |
| "Multiple ovarian cancer cell lines and xenografts were treated with CDK5 small interfering RNA (siRNA) with or without paclitaxel to examine the effect on cancer cell viability, cell cycle arrest and tumor growth." | ( Ahmed, AA; Baladandayuthapani, V; Bast, RC; Jennings, N; Le, XF; Li, Z; Liu, J; Lopez-Berestein, G; Lu, Z; Mao, W; Miranda, R; Qiao, W; Rodriguez-Aguayo, C; Sood, AK; Yang, H; Zhang, S; Zhou, J, 2015) |
| "In vivo, treatment of an ovarian cancer mouse model with metformin resulted in greater tumor weight reduction in normoglycemic vs." | ( Eckert, MA; Johnson, A; Lengyel, E; Litchfield, LM; Mills, KA; Mukherjee, A; Pan, S; Romero, IL; Shridhar, V, 2015) |
| "Lipodox® for treatment of recurrent ovarian cancer did not appear to have equivalent efficacy compared to Doxil®." | ( Coleman, RL; Costales, AB; Frumovitz, M; Jaffari, M; Kutac, CK; Smith, JA; Tran, H; Urbauer, DL, 2016) |
| "Using a panel of eleven patient-derived ovarian cancer xenografts (EOC-PDX) growing orthotopically in the peritoneal cavity of nude mice we investigated the effect of cediranib as monotherapy or in combination with chemotherapy on overall survival (primary endpoint, at euthanasia), and tumor dissemination and metastasis in the peritoneal cavity (secondary endpoint, interim analysis)." | ( Belotti, D; Bettolini, R; Bizzaro, F; Cesca, M; Decio, A; Giavazzi, R; Porcu, L; Taraboletti, G; Ubezio, P, 2015) |
| "The efficacy of these compounds on ovarian cancer cell lines was evaluated in relation to their particular chemical structure and compared with cisplatin as the most common treatment modality for this type of cancer." | ( Hrstka, R; Karban, J; Koubkova, L; Ondrouskova, E; Pinkas, J; Vojtesek, B; Vyzula, R, 2015) |
| "eIF3a improves ovarian cancer patients' response to DDP-based chemotherapy via down regulating XPC and p27(Kip1)." | ( Cao, LQ; Li, ZZ; Liu, ZQ; Qian, CY; Tian, Y; Yin, JY; Yu, JJ; Zhang, CY; Zhang, SF; Zhang, W; Zhang, Y; Zhou, HH, 2015) |
| "High-grade serous ovarian cancers (HGSCs) are deadly malignancies that relapse despite carboplatin chemotherapy." | ( Janzen, DM; Lu, J; Memarzadeh, S; Paik, DY; Pellegrini, M; Salehi, JA; Tiourin, E, 2015) |
| "Moreover, the ovarian cancer tumors exposed to a single dose of combinatorial therapy were completely eradicated from the mice and the treated animals showed no evidence of cancer recurrence." | ( Cronk, LM; Escalante, CA; Jones, CV; Khalimonchuk, O; Palmer, AL; Schumann, C; Taratula, O, 2015) |
| "Primary cultures of epithelial ovarian cancer cells established from ascitic fluids of untreated ovarian cancer patients and the SKOV-3 ovarian cancer-derived cell line were used." | ( Kumar, L; Patel, S; Singh, N, 2015) |
| "The majority of women with ovarian cancer present with advanced disease, and ultimately relapse following primary surgery and platinum-taxane chemotherapy." | ( Banerjee, S; McLachlan, J, 2015) |
| "We used an orthotopic mouse model of ovarian cancer treated with trebananib (n = 9) or vehicle (n = 9)." | ( Bohndiek, SE; Gambhir, SS; Hori, S; Jokerst, JV; Machtaler, S; Sasportas, LS, 2015) |
| "Twenty patients with platinum-resistant ovarian cancer were treated with an intravenous infusion of nivolumab every 2 weeks at a dose of 1 or 3 mg/kg (constituting two 10-patient cohorts) from October 21, 2011." | ( Abiko, K; Baba, T; Chikuma, S; Hamanishi, J; Honjo, T; Hosoe, Y; Ikeda, T; Kanai, M; Kawaguchi, A; Konishi, I; Mandai, M; Matsumoto, S; Matsumura, N; Minami, M; Mori, Y; Morita, S; Murayama, T; Shimizu, A; Ueda, A; Yamaguchi, K; Yokode, M, 2015) |
| "A case of an advanced stage epithelial ovarian cancer (EOC) receiving a combination of bevacizumab, carboplatin andpaclitaxel chemotherapy was reported." | ( Bhamarapravatana, K; Mairaing, K; Piyawang, W; Poomtavorn, Y; Suwannarurk, K; Tangtiang, K; Thaweekul, Y, 2015) |
| "Cytoreductive surgery for ovarian cancer has higher rates of postoperative complication than neoadjuvant chemotherapy followed by surgery." | ( Barber, EL; Gehrig, PA; Miller, WC; Rutstein, S, 2015) |
| "Epithelial ovarian cancer (EOC) commonly acquires resistance to chemotherapy, and this is the major obstacle to the better prognosis." | ( Bae, T; Choi, JW; Eum, KH; Kim, S; Lee, JW; Weon, KY, 2015) |
| "Human ovarian cancer OVCAR3 cells were treated with various concentration of 5-aza-2-deoxycytidine (0, 1, 5, 10, 20 µmol/L, respectively) for 6 days." | ( Li, J; Sheng, X; Tan, L; Wang, Z; Zhou, D; Zhou, Y, 2015) |
| "Although 67% of high-grade serous ovarian cancers (HGSOC) express the estrogen receptor (ER), most fail antiestrogen therapy." | ( Besser, AH; Brafford, P; El-Ashry, D; Gao, W; Gu, M; Hew, KE; Ince, TA; Lu, Y; Miller, PC; Mills, GB; Simpkins, F; Slingerland, JM; Sun, J; Wei, Z; Zhang, G, 2016) |
| "Survival for women with advanced ovarian cancer may be adversely affected when initiation of chemotherapy occurs >25 days following surgery." | ( Burger, RA; Eskander, RN; Java, JJ; Monk, BJ; Tewari, KS, 2016) |
| "Primary cultures of epithelial ovarian cancer cells established from ascitic fluid of untreated ovarian cancer patients were used." | ( Kumar, L; Patel, S; Singh, N, 2015) |
| "Intraperitoneal (IP) chemotherapy for ovarian cancer treatment prolongs overall survival by 16 months compared to intravenous chemotherapy but is not widely practiced due to catheter-related complications and complexity of administration." | ( Birrer, MJ; Cima, MJ; Del Carmen, MG; Fulci, G; Mantzavinou, A; Na, YJ; Tanenbaum, LM; Ye, H, 2015) |
| "ID8-NGL mouse ovarian cancer cells stably expressing an NF-κB reporter transgene were injected intra-peritoneally into C57BL/6 mice, and mice were treated with TQ or vehicle for 10 or 30 days." | ( Barham, W; Khabele, D; Saskowski, J; Wilson, AJ; Yull, F, 2015) |
| "In 48 hours after ovarian cancer inoculation the drugs were administered i." | ( Alexeev, VV; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Gafton, GI; Guseinov, KD; Kireeva, GS; Senchik, KY; Soloviev, LA; Stukov, AN; Vasilchenko, MV, 2015) |
| "Treatment of ovarian cancer cell lines with various chemotherapeutic agents resulted in upregulated expression of MHC class I and programmed cell death 1 ligand 1 (PD-L1) in a NF-κB-dependent manner and suppression of antigen-specific T-cell function in vitro." | ( Abiko, K; Baba, T; Hamanishi, J; Horikawa, N; Hosoe, Y; Konishi, I; Mandai, M; Matsumura, N; Murat, K; Murphy, SK; Peng, J; Yamaguchi, K, 2015) |
| "Among 762 epithelial ovarian cancer patients treated with surgery and platinum chemotherapy, 53 (7%) used digoxin ever and 38 (5%) used digoxin specifically during platinum administration." | ( Jeon, C; Karlan, B; Vogel, TJ; Walsh, C, 2016) |
| "Human ovarian cancer cells were treated with estrogen, progesterone or in combination with paclitaxel in vitro." | ( Han, K; Xie, Y; Yang, Y, 2015) |
| "In patients with gBRCA1/2m ovarian cancer, 154/193 (80%) had received ≥3 prior lines of chemotherapy, of whom 137/154 (89%) had measurable disease at baseline." | ( Aghajanian, C; Audeh, MW; Balmaña, J; Domchek, SM; Fried, G; Friedlander, M; Hubert, A; Kaufman, B; Loman, N; Mann, H; Mitchell, G; Robertson, JD; Rosengarten, O; Schmutzler, RK; Shapira-Frommer, R; Stemmer, SM, 2016) |
| "Although high-grade serous ovarian cancer (HGSOC) is frequently chemoresponsive, a proportion of patients do not respond to platinum-based chemotherapy at presentation or have progression-free survival (PFS) of less than 6 months." | ( Bonito, NA; Borley, J; Brown, R; Ghaem-Maghami, S; Wilhelm-Benartzi, CS, 2016) |
| "Human ovarian cancer stem cells (OCSCs) are one of the main factors affecting ovarian cancer cell metastasis, recurrence, prognosis and tolerance to chemotherapy drugs." | ( Chen, Q; Huang, Y; Li, Q; Liu, T; Liu, X; Wang, S; Wang, Y; Xu, L, 2016) |
| "Low-grade serous ovarian cancer (LGSOC) is one of the candidates in whom efficacy of standard chemotherapy should be revised." | ( du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A, 2016) |
| "A conjugate designed for treating ovarian cancer showed that the model drug (Cy3) and polymer bound to Cy5 were colocalized at an early time point before the model drug was enzymatically cleaved from the polymer." | ( Gudheti, M; Hartley, JM; Kopeček, J; Yang, J; Zhang, R, 2016) |
| "The morbidity and mortality of ovarian cancer underscore the need for novel treatment options." | ( Greenshields, AL; Hoskin, DW; Shepherd, TG, 2017) |
| "The human ovarian cancer cell line SKOV3 were treated by the GRP78 regulator BAPTA-AM and A23187, which were used to decrease or increase the expression levels of GRP78, respectively." | ( Li, M; Qu, Q; Tian, J, 2015) |
| "Notably, ovarian cancer cells responsive to the PI3K/PARP combination displayed decreased BRCA1/2 expression upon drug treatment." | ( Bian, X; Cheng, H; Jiang, N; Liu, P; Roberts, TM; Wang, D; Wang, M; Wang, X; Zhang, Y; Zhao, JJ, 2016) |
| "Even if ovarian cancer patients are very responsive to a cisplatinum-based therapy, most will relapse with a resistant disease." | ( Damia, G; Dell'Anna, T; Fratelli, M; Fruscio, R; Guffanti, F; Porcu, L; Ricci, F; Spriano, F, 2017) |
| "The journey patients with ovarian cancer travel from non-specific symptoms causing delayed diagnosis through surgery and chemotherapy, culminating in a 5-year survival rate of 43%, must have a profound and detrimental psychological impact on patients." | ( Dave, F; Gidron, Y; Hall, M; Karteris, E; Mankarious, A; Pados, G; Pang, Y; Thomas, P; Tsolakidis, D, 2016) |
| "Treatment of ovarian cancer cells with carboplatin results in increased HuR cytoplasmic expression and elevated WEE1 expression, arresting cell cycle G2/M transition." | ( Brody, JR; Daum, GS; DuHadaway, JB; Dunton, CJ; Furuuchi, N; Huang, YH; Jimbo, M; Leiby, BE; Peng, W; Pirritano, A; Sawicki, JA, 2016) |
| "Thus, specific targeting of ovarian cancer cells by NCe-FA holds great potential as an effective therapeutic alone or in combination with standard chemotherapy." | ( Al-Wahab, Z; Chhina, J; Dar, S; Das, S; Giri, S; Gupta, A; Hijaz, M; Mert, I; Munkarah, A; Rattan, R; Seal, S; Tebbe, C, 2016) |
| "Epithelial ovarian cancer is chemotherapy responsive, and multiple lines of chemotherapy are often given." | ( Hoskins, P; Kumar, A; Le, N; Santos, J, 2018) |
| "Eligible patients had first recurrent ovarian cancer 6-24 months following completion of platinum-taxane chemotherapy." | ( Armstrong, D; Bamias, A; Fujiwara, K; Gorbunova, V; Herzog, TJ; O'Shannessy, D; Ochiai, K; Poole, C; Scambia, G; Schweizer, C; Sehouli, J; Teneriello, M; Vergote, I; Wang, W; Weil, SC, 2016) |
| "Pathogenic networks of ovarian cancer before and after treatment were identified based on known pathogenic genes (seed genes) and differentially expressed genes (DEGs) detected by Significance Analysis of Microarrays (SAM) method." | ( Qiu, SC; Wang, YZ, 2016) |
| "Only 3% of patients with epithelial ovarian cancer (EOC) have a longer treatment-free interval (TFI) after second-line intravenous (IV) platinum chemotherapy than with frontline IV therapy." | ( Beriwal, S; Boisen, MM; Edwards, RP; Kelley, JL; Lesnock, JL; Richard, SD; Zorn, KK, 2016) |
| "Recent studies in patients with ovarian cancer suggest that tumor growth may be accelerated following cessation of antiangiogenesis therapy; however, the underlying mechanisms are not well understood." | ( Afshar-Kharghan, V; Armaiz-Pena, GN; Bottsford-Miller, J; Burns, AR; Cho, MS; Choi, HJ; Dalton, HJ; Gharpure, KM; Gutschner, T; Haemmerle, M; Han, HD; Hansen, JM; Lopez-Berestein, G; Mangala, LS; Nagaraja, AS; Nick, AM; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Stone, RL; Taylor, ML; Wu, SY; Zand, B, 2016) |
| "The mainstay of treatment for ovarian cancer is platinum-based cytotoxic chemotherapy." | ( DiFeo, A; Gupta, N; Hale, JS; Hitomi, M; Lathia, JD; Nagaraj, AB; Rao, VS; Reizes, O; Saygin, C; Thiagarajan, PS; Wiechert, A, 2016) |
| "Epithelial ovarian cancer is the most lethal gynecologic cancer worldwide and chemoresistance is one of the major causes of treatment failure." | ( Chang Chien, CC; Fu, HC; Huang, CC; Lin, H; Liu, JM; Liu, SC; Ma, YY; Ou, YC; Tsai, CC, 2016) |
| "Epithelial ovarian cancer continues to have the highest case-fatality ratio of all gynecologic cancers, in spite of ongoing advances in risk-assessment, genomics, tumor biology, cytoreductive surgery, chemotherapy, and molecular-targeted interventions." | ( Bookman, MA, 2016) |
| "Epithelial ovarian cancer remains the gynecologic tumor with the highest rate of recurrence after initial optimal cytoreductive surgery followed by adjuvant chemotherapy." | ( Black, J; English, DP; Menderes, G; Santin, AD; Schwab, CL, 2016) |
| "Studies have demonstrated improved ovarian cancer survival with the administration of a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy following optimal cytoreduction." | ( Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O, 2016) |
| "In platinum-sensitive ovarian cancer cell lines the metabolism of both, glucose and glutamine was initially up-regulated in response to platinum treatment." | ( Avril, N; Avril, S; DiFeo, A; Hudson, CD; Joseph, P; Nagaraj, AB; Savadelis, A, 2016) |
| "We show that platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition, demonstrating reduced survival after treatment with either mTORC1 inhibitor everolimus or mTORC1/2 inhibitor PP242." | ( Alard, A; Blank, SV; Curtin, JP; David-West, G; Musa, F; Schneider, RJ, 2016) |
| "Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact." | ( Balmaña, J; Benitez, JJ; Bernhardy, AJ; Bouwman, P; Candido Dos Reis, FJ; Chenevix-Trench, G; Connolly, DC; Cruz, C; D'Andrea, AD; Daly, MB; Gayther, SA; Gore, M; Gourley, C; Greene, MH; Harrell, MI; Johnson, N; Johnson, SF; Jonkers, J; Karlan, B; Kjaer, SK; Krais, JJ; Lambrechts, D; Nacson, J; Nicolas, E; Nussbaum, R; O'Brien, SW; Olsson, H; Peri, S; Pharoah, PD; Sadetzki, S; Serra, V; Shapiro, GI; Swisher, EM; van der Gulden, H; van der Heijden, I; Wang, Y; Wiest, DL; Zhang, Y, 2016) |
| "To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC)." | ( Elzey, BD; Ramsey, B; Sun, B; Taha, MS; Torregrosa-Allen, S; Yeo, Y, 2016) |
| "The treatment of women with ovarian cancer in advanced stages consists of extensive surgery followed by chemotherapy initiated three weeks after surgery." | ( Brøchner, AC; Hegelund, I; Hokland, M; Mikkelsen, S; Mogensen, O; Toft, P, 2016) |
| "Epithelial ovarian cancer is recognized to be heterogeneous but is currently treated with a single treatment strategy." | ( Cross, PA; Curtin, NJ; Edmondson, RJ; Kaufmann, A; McCormick, A; O'Donnell, RL; Woodhouse, L, 2016) |
| "Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer and often is not detected until late stages when cancer cells transcoelomically metastasize to the abdomen and typically become resistant to therapy resulting in very low survival rates." | ( DiMattia, G; Greenaway, JB; Hardy, D; Osz, K; Petrik, J; Revay, T; Shepherd, T; Virtanen, C, 2016) |
| "In our novel ovarian cancer model, the mice showed significantly higher rates of survival when treated with panobinostat, carboplatin or a combination of both, compared to the controls." | ( Bischof, K; Bjørge, L; Gjertsen, BT; Helland, Ø; McCormack, E; Popa, M, 2016) |
| "After 10 years, only 57% of ovarian cancer patients with elevated urinary neopterin levels survived without disease progression following primary therapy when compared with 86% of women with normal levels (P < 0." | ( Angleitner-Boubenizek, L; Bogner, G; Denison, U; Fuchs, D; Fuith, LC; Graf, AH; Marth, C; Rohde, M; Sliutz, G; Volgger, BM; Windbichler, GH; Zeimet, AG, 2016) |
| "Human ovarian cancer cells were treated with different concentration of baicalein for 48 h, and cell viability was determined by MTT assay." | ( Pan, Q; Wan, YJ; Xiao, SS; Xu, DB; Xue, M, 2016) |
| "Clinical response to chemotherapy for ovarian cancer is frequently compromised by the development of drug-resistant disease." | ( Bray, SE; Chakravarty, P; Ferguson, MJ; Gannon, AL; Sawers, L; Scott, AL; Smith, G; Vaidyanathan, A, 2016) |
| "Treatment of ovarian cancer cells with HO-4200 and H-4318 resulted in cleavage of caspase proteins 3, 7, and 9, as well as PARP and inhibition of the pro-survival protein, Bcl-xL, resulting in significantly decreased cell survival and increased apoptosis." | ( Cohn, DE; ElNaggar, AC; Fowler, J; Kuppusamy, P; Nagane, M; Naidu, S; Saini, U; Selvendiran, K; Sudhakar, M; Wanner, R, 2016) |
| "The high mortality of ovarian cancer patients results from the failure of treatment caused by the inherent or acquired chemotherapy drug resistance." | ( Andrzejewska, M; Januchowski, R; Nowicki, M; Sosiſska, P; Sterzyſska, K; Wojtowicz, K; Zabel, M; Zawierucha, P, 2016) |
| "ASCs may regulate the progression of ovarian cancer, and possibly provide a potential target for anticancer therapy." | ( Dhanasekaran, DN; Haegeman, G; Kim, B; Kim, HS; Kim, S; Song, YS; Tsang, BK, 2017) |
| "SKOV3-derived ovarian cancer stem-like cells obtained by suspension culture in stem cell-condition medium using ultra-low adhesion plate were treated with various concentrations (5." | ( Cao, JG; Chen, YH; Fang, YL; Li, HZ; Xu, XY; Yuan, QQ; Zhong, LY, 2016) |
| "HER2 targeted delivery of ovarian cancer therapy has been beneficial for some patients, although, its efficacy is yet to be confirmed in large populations." | ( Chen, F; Dong, L; Fang, J; Huang, C; Huang, M; Jiang, J; Li, S; Ma, W; Wang, C; Wang, L; Xu, Q; Zhang, J; Zhang, X, 2016) |
| "Analyses included epithelial-invasive ovarian cancer cases (n = 793) receiving adjuvant first-line therapy of carboplatin and paclitaxel with curative intent, with median follow-up of 50 months." | ( Bandera, EV; Kushi, LH; Lee, VS; Powell, CB; Rodriguez-Rodriguez, L, 2016) |
| "Disparities in ovarian cancer treatment and survival in AA persisted among women with equal access to care." | ( Bandera, EV; Kushi, LH; Lee, VS; Powell, CB; Rodriguez-Rodriguez, L, 2016) |
| "The standard of care in advanced ovarian cancer consists of platinum-based chemotherapy combined with cytoreductive surgery." | ( Carlier, C; Ceelen, WP; De Vlieghere, E; Gullbo, J; Juntti, T; Larsson, R; Lewensohn, R; Nygren, P; Spira, J; Strese, S; Uustalu, M; Velander, E; Viktorsson, K, 2016) |
| "The development of breast and ovarian cancer is strongly connected to the inactivation of the BRCA1 and BRCA2 genes by different germline and somatic alterations, and their diagnosis has great significance in targeted tumor therapy, since recently approved PARP inhibitors show high efficiency in the treatment of BRCA-deficient tumors." | ( Gyuris, Z; Hajdu, A; Haracska, L; Határvölgyi, E; Jaksa, G; Pintér, L; Priskin, K; Sükösd, F, 2016) |
| "The current preferred treatment of ovarian cancer is combination chemotherapy, usually a platinum-based drug coupled with paclitaxel (PTX)." | ( Fiedor, E; Gregoraszczuk, EL; Grzyb, E; Kwiecińska, P; Ptak, A; Taubøll, E, 2016) |
| "Three different ovarian cancer cell lines (OVCAR-3, TOV-21G, and TOV-112D) were treated with chemotherapeutic drugs, alone or in combination with VPA." | ( Fiedor, E; Gregoraszczuk, EL; Grzyb, E; Kwiecińska, P; Ptak, A; Taubøll, E, 2016) |
| "In clinical practice, human ovarian cancer shows considerable resistance to chemotherapy." | ( Cheng, JX; Wang, J, 2017) |
| "We followed 1649 invasive epithelial ovarian cancer cases who were enrolled between 1992 and 2008 for overall mortality within the New England Case-Control Study and abstracted chemotherapy data on a subset (n=449)." | ( Babic, A; Rosner, BA; Shafrir, AL; Tamimi, RM; Terry, KL; Tworoger, SS, 2016) |
| "Due to the ability of ovarian cancer (OCa) to acquire drug resistance, it has been difficult to develop efficient and safe chemotherapy for OCa." | ( Chan, C; Duan, X; Han, W; Lin, W; Poon, C, 2016) |
| "Epithelial ovarian cancer (EOC) is one of the malignant tumors that seriously affects women's health and chemotherapy resistance is an important reason for the poor prognosis." | ( Guo, P; Peng, D; Xiong, X; Zhang, S, 2016) |
| "Our 2007 study of 32 patients with ovarian cancer reported the possible involvement of tissue factor (TF) in the development of venous thromboembolism (VTE) before treatment, especially in clear cell carcinoma (CCC)." | ( Akiyama-Abe, A; Gosho, M; Hosokawa, Y; Katoh, T; Komiya, H; Matsumoto, K; Michikami, H; Minaguchi, T; Nakao, S; Ochi, H; Onuki, M; Sakata, A; Sakurai, M; Satoh, T; Shikama, A; Tasaka, N; Tenjimbayashi, Y; Yoshikawa, H, 2017) |
| "In high-grade serous ovarian cancer (HGSOC), intrinsic and/or acquired resistance against platinum-containing chemotherapy is a major obstacle for successful treatment." | ( Alkema, NG; de Jong, S; Hoekman, RL; Klip, HG; Meersma, GJ; Tomar, T; van der Zee, AG; Wisman, GB, 2016) |
| "Women with ovarian cancer often undergo chemotherapy involving multiple agents." | ( Correa, DD; Hensley, ML; Karimi, S; Kryza-Lacombe, M; Mehta, M; Relkin, N; Root, JC, 2017) |
| "Of 497 stage I-II epithelial ovarian cancer patients, the median time between surgery and initiation of adjuvant therapy was 23days (25th-75th%: 12-33days)." | ( Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R, 2016) |
| "As most patients with ovarian cancer experience multiple remissions and relapses, oncologists must prepare ahead for long-term treatment." | ( Colombo, N; Ferrandina, G; Hardy-Bessard, AC; Marth, C; Romero, I, 2016) |
| "However, the now recognised risk of ovarian cancer (OC) patients, even those with no known family history, harbouring a mutation in BRCA1/2, together with the first poly adenosine diphosphate ribose polymerase inhibitor (PARPi; olaparib [Lynparza]) being licenced for the treatment of BRCA-mutated OC, has led to reconsideration of referral criteria for OC patients." | ( Banerjee, S; Colombo, N; Gerdes, AM; Gonzalez-Martin, A; Marth, C; Ray-Coquard, I; Sehouli, J; Stoppa-Lyonnet, D; van Asperen, C; Vaz, F; Vergote, I, 2016) |
| "The current standard treatment for ovarian cancer is aggressive surgery followed by platinum-based combination chemotherapy." | ( Cao, J; Li, S; Luo, Q; Ni, G; Tao, X; Wang, M; Xia, H; Zhang, F; Zhang, W, 2016) |
| "All current regimens for treating ovarian cancer center around carboplatin as standard first line." | ( Bastians, H; Concin, N; Dobbelstein, M; Edmunds, S; Erytch, N; Kramer, D; Moll, UM; Roßmann, L; Schulz-Heddergott, R; Stark, N, 2017) |
| "Malignant epithelial ovarian cancer (EOC) spheroids high frequently are detected in the malignant ascites of the patients with the extensive peritoneal metastasis of ovarian cancer, which represent a significant obstacle to efficacious treatment." | ( Cai, J; Chester, J; He, M; Jiang, WG; Lopes-Bastos, B; Wang, C; Wang, D; Zhou, Q; Zou, D, 2016) |
| "The high mortality of ovarian cancer is partly due to the frequent resistance of ovarian cancer to current chemotherapy agents such as paclitaxel and platinum." | ( Chanda, K; Chen, X; Fan, LL; Jiang, SW; Ren, ML; Shen, Y; Wu, YP; Zhang, XY, 2017) |
| "Tumor marker studies in ovarian cancer patients showed a trend of decreasing Cancer antigen 72-4 (CA 72-4) aka tumor-associated glycoprotein 72 (TAG-72) and tumor growth with increasing administered radioactivity." | ( Alvarez, RD; Banaga, EP; Bunch, PW; Dobelbower, MC; Lowy, AM; Meredith, RF; Rozgaja, TA; Straughn, JM; Torgue, JJ, 2018) |
| "PLD is approved for the treatment of ovarian cancer, breast cancer, multiple myeloma, and Kaposi sarcoma." | ( Gabizon, AA; La-Beck, NM; Patil, Y, 2016) |
| "Recurrent ovarian cancer patients with no limit on prior treatments were eligible." | ( Blank, SV; Boyd, L; Curtin, J; Goldberg, JD; Li, X; Ling, HT; Muggia, F; Musa, F; Pothuri, B; Speyer, JL; Tiersten, A, 2017) |
| "Knockdown of HSF1 in SKOV3 and HEY ovarian cancer cell lines attenuates the epithelial-to-mesenchymal transition (EMT) in cells treated with TGFβ, as determined by western blot and quantitative RT-PCR analysis of multiple EMT markers." | ( Aoisa, C; Menzie, CJ; Paullin, TR; Powell, CD; Ubaldini, A; Westerheide, SD, 2016) |
| "In early stage, ovarian cancer surgery may be planned preferably after 16 weeks of pregnancy, and chemotherapy can be administered from the second trimester if indicated as in non-pregnant patients." | ( Amant, F; de Haan, J; Fruscio, R; Mhallem, M; Van Calsteren, K; Verheecke, M, 2017) |
| "The TOPLMBs target both ovarian cancer cells and TAMs and provide a promising drug delivery strategy for the combination treatment of ovarian cancer and tumor microenvironment." | ( Chang, S; Hao, L; He, J; Luo, T; Pan, X; Sun, J; Wang, Q; Wang, Z; Xiao, L; Zhu, S; Zhu, Y, 2017) |
| "Pyrvinium may sensitize ovarian cancer cells to chemotherapy." | ( Hu, P; Wang, W; Zhang, C; Zhang, S; Zhang, Z, 2017) |
| "Treatment of ovarian cancer cells with APTO-253, a small molecule inducer of KLF4, enhanced the efficacy of both chemotherapy drugs." | ( Dong, P; Du, Z; Huo, W; Ouyang, X; Pfeffer, LM; Shen, A; Wang, B; Wang, Y; Watari, H; Yang, C; Yue, J; Zhang, T; Zhao, G, 2017) |
| "Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS)." | ( Auranen, A; Åvall-Lundqvist, E; dePont Christensen, R; Dørum, A; Gebski, V; Gibbs, E; Grenman, S; Hjerpe, E; Hoegberg, T; Kalling, M; Kristensen, G; Lindemann, K; Rosenberg, P; Skeie-Jensen, T; Woie, K, 2017) |
| "The majority of women with epithelial ovarian cancer present with advanced stage disease and there is a critical need for novel drugs and treatment strategies to improve outcomes." | ( Herzog, TJ; Teplinsky, E, 2017) |
| "K5 can be used to predict serous ovarian cancer prognosis and identify cancer cells that are resistant to chemotherapy." | ( Hoffmann, P; Lokman, NA; Macpherson, AM; Oehler, MK; Pyragius, CE; Ricciardelli, C; Ruszkiewicz, A; Ween, MP, 2017) |
| "The observation that some ovarian cancer cells lose AKT activity during mitotic arrest and become vulnerable to metabolic targeting is a new concept in cancer therapy." | ( Ahmed, AA; Bartholomeusz, G; Bast, RC; Hellner, K; Herrero-Gonzalez, S; Karaminejadranjbar, M; Mannion, D; Miranda, F; Taylor, C; Zheng, Y, 2017) |
| "Importantly, in cisplatin-resistant ovarian cancer cells where PGRMC1 was overexpressed, hyperoside sensitized the cells to cisplatin treatment." | ( Gao, F; Guo, Y; Han, Y; Ji, M; Yang, X; Zhang, C; Zhu, W; Zhu, X, 2017) |
| "RESULTS In 37 women with ovarian cancer, three symptoms, nausea, appetite loss, and dietary intake, were significantly improved by primarily adding aprepitant to double combination therapy in the delayed phase of MEC." | ( Abiko, K; Baba, T; Hamanishi, J; Imai, S; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yamanoi, K; Yoshioka, Y, 2017) |
| "Finally, in vivo ovarian cancer treatment using Dox/Cur-NDs combined with ultrasound irradiation resulted in efficient tumor regression." | ( Baghbani, F; Moztarzadeh, F, 2017) |
| "Herbal medicine use by patients with ovarian cancer may influence anti-cancer activity of chemotherapy." | ( Ben-Arye, E; Khamaisie, H; Lavie, O; Mahajna, J; Raz, OG; Samuels, N; Schiff, E, 2017) |
| "High grade serous ovarian cancer (HGSOC) patients have a high recurrence rate after surgery and adjuvant chemotherapy due to inherent or acquired drug resistance." | ( Ao, W; Bateman, NW; Blanton, BE; Conrads, KA; Conrads, TP; Darcy, KM; Hamilton, CA; Hood, BL; Litzi, T; Maxwell, GL; McGuire, WP; Oliver, KE; Paz, K; Sidransky, D; Teng, PN; Wang, G, 2017) |
| "We treated A2780 ovarian cancer cells with NGF, thapsigargin (Tg), an ER stress inducer and mitoxantrone (Mtx), a chemotherapeutic drug; CRT subcellular localization was analyzed by immunofluorescence followed by confocal microscopy." | ( Ferreira, A; Gabler, F; Oróstica, L; Romero, CA; Selman, A; Vega, M; Vera, CA, 2017) |
| "The prognosis of ovarian cancer has improved because of platinum- and taxane-containing chemotherapy." | ( Ariyoshi, K; Matsushita, S; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Shimokawa, M; Yamaguchi, S, 2017) |
| "Human ovarian cancer A2780 cells and SKOV3 cells were treated with Mppa-PDT and siRNA transfection was performed to inhibit Nrf2." | ( Bai, DQ; Chen, Q; Jiang, Y; Kong, YH; Li, KT; Pan, L; Tian, S; Yong, M; Yu, LH; Yu, TH; Zhang, L; Zhu, J, 2017) |
| "Epithelial ovarian cancer (EOC) management remains association of debulking surgery in combination with platinum-based chemotherapy." | ( Azaïs, H; Collinet, P; Colombeau, L; Delhem, N; Frochot, C; Grabarz, A; Khodja Bach, S; Mordon, S, 2017) |
| "Low effectiveness of chemotherapy in ovarian cancer results from development of drug resistance." | ( Brązert, M; Januchowski, R; Klejewski, A; Nowicki, M; Świerczewska, M; Zabel, M; Zaorska, K, 2017) |
| "Blood samples of 91 ovarian cancer patients before surgery and 31 matched samples after adjuvant chemotherapy were evaluated for CTCs with the AdnaTest ovarian cancer and EMT-1, analyzing the epithelial-associated transcripts EpCAM, Muc-1 and CA125 and the EMT-associated transcripts PI3Kα, Akt-2 and Twist." | ( Buderath, P; Chebouti, I; Hauch, S; Kasimir-Bauer, S; Kimmig, R; Kuhlmann, JD; Wimberger, P, 2017) |
| "OVCAR-3 and OAW-42 ovarian cancer cells were treated with the ERβ agonists ERB-041, WAY200070, Liquiritigenin and 3β-Adiol and cell growth was measured by means of the Cell Titer Blue Assay (Promega)." | ( Moehle, C; Ortmann, O; Schüler-Toprak, S; Skrzypczak, M; Treeck, O, 2017) |
| "Human ovarian cancer cell lines and patients' ascites cells were treated with paclitaxel, cisplatin, and thiostrepton or a combination for 48 hours, and cytotoxicity was assessed." | ( Chen, Y; Teng, NNH; Westhoff, GL, 2017) |
| "Murine and human ovarian cancer cells were treated with epigenetic modulators - histone deacetylase inhibitors and a DNA methyltransferase inhibitor." | ( Arend, RC; Buchsbaum, DJ; Forero, A; Katre, A; Londoño, A; Meza-Perez, S; Norian, LA; Peabody, JE; Randall, TD; Smith, HJ; Straughn, JM; Turner, TB, 2017) |
| "Medical records for advanced ovarian cancer patients who were treated at National Cancer Center (NCC) between December 2000 and March 2009 were retrospectively reviewed in the comprehensive cancer center." | ( Kang, S; Kim, SH; Lim, MC; Park, SY; Seo, SS; Song, YJ; Yoo, CW; Yoo, HJ, 2017) |
| "Low-grade serous ovarian cancer (LGSOC) constitutes 5-8% of epithelial ovarian cancers and is refractory to chemotherapy." | ( Allo, G; Carey, MS; Chhina, J; Dai, J; Giri, S; Llaurado, M; Mert, I; Munkarah, AR; Rattan, R; Seward, S, 2017) |
| "Advanced ovarian cancer is very responsive to first line platinum therapy, however almost invariably it relapses with a resistant disease." | ( Broggini, M; Damia, G; Guffanti, F; Ricci, F, 2017) |
| "The treatment of C57BL/6-derived ovarian cancer ID-8 cells with a synthetic GC, dexamethasone (DEX), induced the expression of microRNA-708, leading to decreased cell migration and invasion through targeting Rap1B." | ( Lin, KT; Sun, SP; Wang, LH; Wu, JI, 2017) |
| "Most patients with recurrent ovarian cancer are treated with multiple regimens of intravenous salvage chemotherapy." | ( Liu, FS; Wong, CN, 2017) |
| "Failure in ovarian cancer therapy, following cytoreduction and chemotherapy, is related to the presence of cancer stem cells - a small subpopulation of cells resistant to chemotherapy and irradiation - in the tumour which may cause cancer relapse and manifestation of metastases." | ( Huczyński, A; Markowska, A; Markowska, J; Sajdak, S, 2017) |
| "The goal of this study is to assess ovarian cancer cells' sensitivity to PNC-27 after surviving exposure to paclitaxel and to investigate the potential for synergy between PNC-27 and paclitaxel in the treatment of ovarian cancer." | ( Abulafia, O; Alagkiozidis, I; Amarnani, A; Chen, YA; Gorelick, C; Gupta, V; Lee, YC; Michl, J; Sarafraz-Yazdi, E; Shah, T; Stefanov, D, 2017) |
| "Human ovarian cancer cell lines and patients' ascites cells were treated with paclitaxel, cisplatin, and thiostrepton or a combination for 48 hours, and cytotoxicity was assessed." | ( Chen, Y; Teng, NNH; Westhoff, GL, 2017) |
| "KDM5A suppresses ovarian cancer cell apoptosis under PTX treatment." | ( Feng, T; Lang, Y; Wang, Y; Zhang, Y, 2017) |
| "Radiotherapy in ovarian cancer frequently invokes resistance; this severely compromises its therapeutic effect and results in poor clinical prognosis." | ( Cui, D; Li, H; Wang, P; Wang, S; Xing, X; Xing, Y, 2017) |
| "The apoptosis rate of CD117+CD44+A2780 ovarian cancer stem-like cells treated by HMSN co-delivery system were almost 3 times higher than those of the free drugs group." | ( Cai, Y; Guo, N; Guo, X; Zhao, J, 2017) |
| "Early detection of ovarian cancer, the most lethal type of gynecologic cancer, can dramatically improve the efficacy of available treatment strategies." | ( Ai, K; Jia, Y; Li, Z; Liu, J; Lu, L; Lu, Z; Pei, H; Wang, Y, 2017) |
| "The standard of care for ovarian cancer includes initial treatment with chemotherapy." | ( Abbaslou, MA; Kools, FRW; Poznansky, MC; Reeves, PM, 2017) |
| "Twenty patients with optimally debulked ovarian cancer (International Federation of Gynecology and Obstetrics stage III) with complete remission after chemotherapy were treated with intensity modulated WART as a consolidation therapy." | ( Arians, N; Benner, L; Debus, J; Herfarth, K; Katayama, S; Kieser, M; Leitzen, C; Lindel, K; Rochet, N; Schneeweiss, A; Schröder, L; Schubert, K; Sohn, C; Sterzing, F, 2017) |
| "The human epithelial ovarian cancer cell line, SKOV-3, was cultured and treated with paclitaxel, silibinin and paclitaxel plus silibinin for 48 hours." | ( Akbarzadeh, A; Ebrahimie, E; Khodadadi, K; Pashaei-Asl, F; Pashaei-Asl, R; Pashaiasl, M, 2018) |
| "Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents." | ( Banerjee, S; George, A; Marquina, G; Orbegoso, C, 2017) |
| "Human ovarian cancer SKOV3 cells were treated with DHA, Cur alone, or a combination of both." | ( Hou, Y; Li, X; Pan, Y; Wang, T; Xue, Y; Zhang, X; Zhao, J; Zhao, S, 2017) |
| "Low efficiency of chemotherapy in ovarian cancer results from the development of drug resistance." | ( Brązert, M; Iżycki, D; Januchowski, R; Klejewski, A; Nowicki, M; Świerczewska, M; Wojtowicz, K; Zabel, M, 2017) |
| "We identified that ovarian cancer cell viability was significantly reduced through treatment with AHCC compared to that in the control." | ( Choi, JY; Jeong, EH; Kim, K; Kim, YB; Lee, S; No, JH; Suh, DH; Yun, SM, 2018) |
| "In epithelial ovarian cancer (EOC), intraperitoneal (IP) administration of chemotherapy is an effective first-line treatment and may improve outcomes, compared with intravenous (IV) chemotherapy." | ( Eoh, KJ; Kim, S; Kim, SW; Kim, YT; Lee, JY; Nam, EJ, 2017) |
| "The standard treatment for ovarian cancer is chemotherapy with 2 drugs (taxanes and platinum drugs)." | ( Sun, Y; Tian, Z; Zhang, M, 2017) |
| "The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed." | ( Aoyama, T; Furuya, K; Iwahashi, H; Kato, K; Kuwahara, M; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Takano, M; Takasaki, K; Tsuda, H; Yoshikawa, T, 2017) |
| "At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes." | ( Dou, M; Gao, W; Guo, Y; Hu, K; Liu, Y; Su, J; Sun, L; Xie, Q; Xu, Y; Zhang, Y, 2018) |
| "The 5-year survival of ovarian cancer has slowly increased but to date much of this has been due to the use of more lines of treatment rather than better first-line therapy." | ( Ledermann, JA, 2017) |
| "Advanced-stage epithelial ovarian cancers are amongst the most difficult to treat tumors and have proven to be refractory to most cytotoxic, molecularly targeted, or immunotherapeutic approaches." | ( Birrer, MJ; Bruno, PM; Chen, Q; Detappe, A; Ghoroghchian, PP; Hemann, MT; Huang, X; Kang, X; Lauffer, S; Li, T; Matulonis, U; Pepin, D; Qi, R; Song, H; Wang, Y; Wei, W; Xiao, H; Yang, X; Yu, Y, 2017) |
| "Treatment of BRCA-proficient ovarian cancer cells with the BET inhibitor JQ1 downregulated the G2-M cell-cycle checkpoint regulator WEE1 and the DNA-damage response factor TOPBP1." | ( Bitler, BG; Fatkhutdinov, N; Karakashev, S; Khabele, D; Kossenkov, AV; Simpkins, F; Speicher, D; Wilson, AJ; Yokoyama, Y; Zhang, R; Zhao, B; Zhu, H, 2017) |
| "Chemotherapy resistance of advanced ovarian cancers is responsible for death of most cancer patients, so it is necessary to seek safe and effective natural ingredients to lower the chemotherapy resistance of ovarian cancer." | ( Chen, T; Feng, Y; Hu, H; Huang, G; Li, X; Tan, B; Wang, H; Wang, X, 2018) |
| "Risk of ovarian cancer with hormone therapy is associated with use of both unopposed estrogen therapy and combined estrogen-progestin therapy, whereas for endometrial cancer addition of continuous progestin decreases the estrogen induced increased risk." | ( Løkkegaard, ECL; Mørch, LS, 2018) |
| "Relapsed ovarian cancers harbor more predicted neoantigens than primary tumors, but the increase is due to pre-existing mutational processes, not mutagenesis from chemotherapy." | ( Ahuja, A; Aksoy, BA; Bowtell, DDL; Buros, J; Christie, EL; Hammerbacher, J; O'Donnell, T; Snyder, A, 2018) |
| "We report a CR case of huge ovarian cancer with peritoneal and liver metastases who was operated bilateral ovaries, uterus and peritoneal metastases at first, followed by systemic chemotherapy and performed 4 times of radiofrequency ablation (RFA)and 2 times of liver resection(LR)." | ( Akiyama, Y; Hasuike, Y; Higuchi, I; Hosomi, S; Imoto, H; Ishikawa, A; Kanaoka, Y; Miyamoto, M; Tanigawa, T, 2017) |
| "In patients with recurrent ovarian cancer, the choice of second-line therapy is complex." | ( Arenare, L; Califano, D; Cecere, SC; Di Napoli, M; Losito, NS; Orditura, M; Paciolla, I; Pignata, S; Pisano, C; Setola, SV; Ventriglia, J, 2018) |
| "FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment." | ( Huang, MJ; Li, L; Liao, SB; Wang, Q; Yang, ZJ; Zhang, W, 2018) |
| "Epithelial ovarian cancer (EOC) is notoriously difficult to diagnose in its earlier and more treatable stages, making it one of the deadliest cancers in women." | ( Kellenberger, LD; Petrik, J, 2018) |
| "Advanced-stage, platinum-resistant, ovarian cancer can be treated with dose-intense chemotherapy; one such regimen includes intravenous cisplatin and oral etoposide." | ( Clamp, AR; Hasan, J; Jayson, GC; Mescallado, N; Mitchell, C; Morgan, RD; Saunders, G; Welch, R, 2018) |
| "We developed an ovarian cancer targeting nano-carrier drug delivery system successfully, which showed perfect ovarian cancer targeting and anti-tumor effect, thus have the potential to be a new therapy strategy for ovarian cancer patients." | ( Feng, JB; Kong, BH; Li, L; Lu, ZJ; Song, K; Su, XT; Wang, K; Yan, S; Yao, S; Yuan, CZ, 2018) |
| "However, current therapies for ovarian cancer treatment are ineffective." | ( Lin, J; Liu, H; Liu, Y; Sun, C; Xu, C; Zhai, S; Zhou, H, 2018) |
| "High-grade serous ovarian cancer (HGSOC), the most common ovarian cancer subtype, is conventionally treated with surgery and paclitaxel/carboplatin combination chemotherapy." | ( Bowden, NA; Tang, D; van Zyl, B, 2018) |
| "ARHI expression patterns of three ovarian cancer cell lines (human CAOV-3, OVCAR-3 and rat NUTU-19) without and with 100 μM resveratrol treatment were checked by immunocytochemical staining, Western blotting and RT-PCR." | ( Lin, LZ; Liu, J; Nie, JH; Zhong, LX, 2018) |
| "The standard chemotherapy for ovarian cancer is paclitaxel/carboplatin." | ( Björn, N; Gréen, H; Jakobsen Falk, I; Vergote, I, 2018) |
| "Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease." | ( Aglietta, M; Genta, S; Ghisoni, E; Giannone, G; Mittica, G; Sapino, A; Valabrega, G, 2018) |
| "FIGO stage III/IV ovarian cancer or fallopian tube cancer patients who underwent interval debulking surgery (IDS) followed by neoadjuvant chemotherapy (NAC) were analyzed retrospectively." | ( Mandai, M; Matsumura, N; Murakami, K; Nakai, H; Suzuki, A; Takaya, H; Tobiume, T, 2018) |
| "Most ovarian cancer patients respond well to initial platinum-based chemotherapy." | ( Au, KM; Foley, H; Hagan, CT; Medik, Y; Mi, Y; Min, Y; Roche, K; Rodgers, Z; Tian, X; Wagner, K; Wang, AZ; Yang, F; Zhang, M, 2018) |
| "In advanced ovarian cancer, traditional therapy included debulking surgery and postoperative chemotherapy." | ( Lin, CT; Peng, HH; Su, SY; Wang, YL, 2019) |
| "Multiple Drug Resistance (MDR) of ovarian cancer is a severe trouble for clinical treatment and always contributes to a bad prognosis." | ( Chang, W; Chen, H; Ding, F; Liu, Z; Luo, Q; Shu, T; Wu, X; Zhang, Y; Zhao, P; Zhu, X, 2018) |
| "The majority of epithelial ovarian cancer (EOC) patients with metastatic disease respond well to first-line chemotherapy but most relapse with disease that is both metastatic and drug resistant, leading to a five-year survival rate under 20%." | ( Contreras, A; Dellinger, T; Glackin, CA; Parra Echavarria, L; Qu, L; Shahin, SA; Simargi, SI; Tamanoi, F; Unternaehrer, J; Wang, R; Wen, W; Zink, JI, 2018) |
| "Platinum-resistant recurrent ovarian cancer has a poor prognosis, but combined therapy with bevacizumab and anticancer agents may be useful." | ( Komiyama, S; Kubushiro, K; Kugimiya, T; Takahashi, R; Takeya, C, 2018) |
| "Emerging breast and ovarian cancer research indicate that BRCA status predicts responsiveness to platinum-based chemotherapy, as well as to inhibitors of poly(ADP-ribose) polymerase (PARP), owing to the ability of these interventions to inhibit DNA repair pathways." | ( Garber, JE; Tung, NM, 2018) |
| "Patients with ovarian cancer often report elevated anxiety at diagnosis that decreases posttreatment." | ( Armer, JS; Bender, DP; Clevenger, L; Cole, SW; Cuneo, M; Dahmoush, L; Davis, LZ; Goodheart, MJ; Lutgendorf, SK; Slavich, GM; Sood, AK; Thaker, PH, 2018) |
| "BACKGROUND Ovarian cancer is the second most common malignant tumor of the female reproductive system and is the leading cause of death of gynecological malignancies, but at present there is no effective and safe therapy." | ( Liu, T; Liu, X; Xu, Y; Zhang, H; Zhang, L, 2018) |
| "The murine ID8 cell model of ovarian cancer was used to examine the efficacy of cisplatin treatment administered perioperatively or 7 days after surgical wounding." | ( Brown, TJ; Kollara, A; Lee, Y; May, T, 2018) |
| "Apatinib may be an option for advanced ovarian cancer after failure of chemotherapy or other targeted therapy." | ( Liu, S; Shi, R; Sun, H; Xiao, M, 2018) |
| "Treatment for advanced epithelial ovarian cancer (EOC) consists of debulking surgery and (neo)adjuvant platinum-based chemotherapy." | ( Kruitwagen, RF; Lalisang, RI; Sonke, GS; Timmermans, M; Van de Vijver, KK; van der Aa, MA; Witteveen, PO, 2018) |
| "Many targeted ovarian cancer patients are resistant to olaparib treatment." | ( Chen, X; Chen, Y; Hou, X; Lin, X; Su, S; Tian, Y; Zhang, Q, 2018) |
| "The migration of ovarian cancer cell line SKOV3 cells was explored with Real time label free cell analysis (RTCA) after treatment with recombinant human IL-8." | ( Fu, HH; Miao, YL; Nie, YM; Wang, SC; Wen, JR; Wu, J; Zhao, ZW, 2018) |
| "We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins." | ( Arffman, M; Arima, R; Hautakoski, A; Hinkula, M; Ilanne-Parikka, P; Kangaskokko, J; Läärä, E; Marttila, M; Puistola, U; Sund, R; Urpilainen, E, 2018) |
| "For patients with ovarian cancer who have been diagnosed with thrombosis before surgery, adjuvant chemotherapy and anticoagulant drugs can be used to control the progression of thrombosis and cancer." | ( Cheng, H; Liu, X; Yang, Z; Zhang, G; Zhang, W, 2018) |
| "The treatment of CT on ovarian cancer cells effectively inhibited glucose uptake and lactate production in ovarian cancer cells." | ( Cao, Y; Chen, L; Cheng, X; Liu, F; Qi, Z; Wang, Z; Yang, Y, 2018) |
| "Similar effect can occur in ovarian cancer patients treated with cisplatin and supplemented with DHA." | ( Chodurek, E; Kałucka, M; Wilczok, A; Zajdel, A, 2018) |
| "In patients with recurrent ovarian cancer, there are certain situations where further surgery and/or next-line platinum-based chemotherapy is not feasible or is not the best option." | ( Ray-Coquard, I, 2018) |
| "The challenges of managing relapsed ovarian cancer increase as more advanced lines of chemotherapy are achieved." | ( Marth, C, 2018) |
| "Patients with ovarian cancer frequently develop acquired drug resistance after the long-term chemotherapy, leading to disease progression." | ( Cong, Q; Lu, YY; Xu, CJ; Zhang, M; Zhang, MX; Zhang, XY, 2019) |
| "The major cause of ovarian cancer treatment failure in cancer patients is inherent or acquired during treatment drug resistance of cancer." | ( Andrzejewska, M; Brązert, J; Januchowski, R; Kędzia, W; Klejewski, A; Nowicki, M; Rusek, D; Sobkowski, M; Sterzyńska, K; Świerczewska, M; Wojtowicz, K, 2018) |
| "The mainstay of treatment of advanced ovarian cancer (AOC) involves chemotherapy, and debulking surgery." | ( Bonneau, C; Daraï, E; Hoarau-Véchot, J; Pasquier, J; Rafii, A; Touboul, C; Vidal, F, 2018) |
| "The standard treatment of ovarian cancer is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy." | ( Monga, DK; Patibandla, NS, 2019) |
| "A 47-year-old woman with ovarian cancer developed aortitis during bevacizumab combination chemotherapy." | ( Fujino, K; Hiranuma, K; Hirayama, T; Kusunoki, S; Ota, T; Terao, Y, 2018) |
| "Human ovarian cancer cells SKOV3 and multi-drug resistant SKVCR cells were treated with various concentrations of icariin." | ( Chang, H; Deng, SJ; Fan, DY; Jiang, SY, 2018) |
| "Resistance in ovarian cancer is driven by a range of mechanisms, some of which are therapy specific whereas others confer multidrug resistance." | ( Beach, JA; Bowtell, DDL; Christie, EL; Freimund, AE, 2018) |
| "Epithelial ovarian cancer (EOC) is the most fatal gynecologic malignancy due to its late diagnosis and lack of curative therapy." | ( Bu, S; Guo, Y; Lai, D; Li, B; Sun, J, 2018) |
| "In Korean ovarian cancer patients, the safety and effectiveness of chemotherapy with bevacizumab in a real-world setting was consistent with the results from a randomized controlled study." | ( Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E, 2019) |
| "BRCA1 wildtype ovarian cancer cells (A2780 and SKOV3) were treated with a combination of CCND1 siRNA and olaparib in vitro." | ( Hu, Z; Li, J; Li, Q; Yang, H; Yi, T; Zhong, Q, 2019) |
| "In the current murine ovarian cancer model, entinostat treatment enhances beneficial immune responses." | ( Arend, RC; Buchsbaum, DJ; Forero, A; Katre, AA; Londono, AI; McCaw, TR; Meza-Perez, S; Norian, LA; Randall, TD; Smith, HJ; Straughn, JM; Yang, ES, 2018) |
| "Advanced epithelial ovarian cancer is one of the hardest human malignancies to treat." | ( Binju, M; Cohen, PA; Kaur, P; Padilla, MA; Singomat, T; Suryo Rahmanto, Y; Yu, Y, 2019) |
| "In platinum-based chemotherapy for ovarian cancer, acquired drug resistance is a frequent occurrence." | ( Jia, H; Jiang, J; Jiang, Y; Qiao, Z; Zhang, J, 2018) |
| "Forty-three ovarian cancer patients were treated by systemic treatment." | ( Buczkowska, M; Głogowska-Gruszka, A; Janyga, S; Nowak, D; Nowak, P; Roczniak, W; Słomian, GJ; Słomian, SP, 2019) |
| "In high-grade serous ovarian cancer (OC), chemotherapy eliminates the majority of tumor cells, leaving behind residual tumors enriched in OC stem cells (OCSC)." | ( Matei, D; Mitra, AK; Mitra, S; Nephew, KP; Wang, Y; Zong, X, 2018) |
| "The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking." | ( Brozick, J; Bulatovic, M; Elishaev, E; Fang, Y; Gambotto, A; Grabosch, S; Kim, E; Ma, T; P Edwards, R; Ross, M; Tseng, G; Vlad, AM; Zeng, F; Zhang, L, 2019) |
| "Keywords of "ovarian cancer, targeted therapy and phase III trial" were used for publications and information from May 2012 to May 2018." | ( Guo, Q; Jia, S; Li, J; Liu, G; Nikoulin, I; Yang, Q, 2018) |
| "Survival of serous ovarian cancer cells (OVCAR-3, OV-90, & OAW28) was significantly decreased by ATRA treatment (1-5 μM)." | ( Bonner, WM; Gunasegaran, K; Ho, R; Lokman, NA; Oehler, MK; Ricciardelli, C, 2019) |
| "Prior to treatment with DDP, ovarian cancer cells were exposed to BMP9 for 3 days." | ( Li, X; Liu, X; Wang, Y; Yang, B; Yu, X; Zhai, Z; Zhang, L; Zhang, Y; Zhao, J, 2019) |
| "Medical treatment of ovarian cancer is based on chemotherapy." | ( de la Motte Rouge, T; Ray-Coquard, I; You, B, 2019) |
| "In total, 162 primary epithelial ovarian cancer patients who underwent chemotherapy response assay for carboplatin, cisplatin, and paclitaxel by adenosine triphosphate-based chemotherapy response analysis prior to chemotherapy between December 2006 and November 2016 were retrospectively reviewed." | ( Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ, 2019) |
| "Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD)." | ( Aglietta, M; Borella, F; Di Renzo, MF; Erriquez, J; Ferrero, A; Genta, S; Ghisoni, E; Giannone, G; Katsaros, D; Maggiorotto, F; Mittica, G; Sarotto, I; Sciarrillo, A; Valabrega, G, 2019) |
| "Overexpression of PBK decreased ovarian cancer responsiveness to cisplatin treatment through inducing autophagy in vivo." | ( Gao, M; Kong, B; Li, R; Li, Y; Ma, H; Qi, G; Wang, X; Wu, H; Yan, S; Yang, N; Yuan, C, 2019) |
| "High mortality rates in ovarian cancer are due to late-stage diagnosis when extensive metastases are present, coupled with the eventual development of resistance to standard chemotherapy." | ( Bhattacharya, R; Devapatla, B; Ding, K; Dogra, S; Dwivedi, SKD; Husain, S; Jaiprasart, P; Janknecht, R; Mukashyaka, MC; Neelakantan, D; Woo, S, 2019) |
| "The current clinical paradigm for ovarian cancer treatment has a poor prognosis, partially due to the efficacy and toxicity concerns associated with the available chemotherapeutic formulations." | ( Cohn, DE; Dwivedi, M; Dwivedi, P; Han, S; Khatik, R; Mangrio, FA; Si, T; Xu, RX, 2019) |
| "The vast majority of ovarian cancer relapses on front-line therapy and the optimal treatment of recurrent ovarian cancer remains controversial." | ( Bogani, G; Lepori, S; Lorusso, D; Maltese, G; Raspagliesi, F; Sabatucci, I; Tripodi, E, 2019) |
| "SK-OV-3 and OVCAR-3 ovarian cancer cells were treated with platelets." | ( Cui, W; Guo, Y; Pei, Y; Xu, D, 2019) |
| "We included patients with advanced ovarian cancer who had undergone surgery and chemotherapy between January 1, 2004, and December 31, 2014, at our institution." | ( Bruera, E; Cohen, L; Liu, W; Lopez, G; Narayanan, S; Qdaisat, A; Ramondetta, L; Soliman, PT; Yeung, SJ; Zhou, S, 2019) |
| "Four ovarian cancer patients with severe plantar palmar erythrodysesthesia or mucositis precluding further therapy from pegylated liposomal doxorubicin on the standard every 4 week schedule were able to be treated on every 2-week schedule without recurrence of plantar palmar erythrodysesthesia or stomatitis." | ( Petersen, L; Purpura, D; Rose, PG, 2019) |
| "BACKGROUND Worldwide, ovarian cancer has a high mortality rate due to the difficulty in diagnosing early-stage disease and resistance to chemotherapy agents." | ( Fang, Y; Gui, J; Li, J; Shen, Y; Wu, Y, 2019) |
| "The poor prognosis of ovarian cancer is mainly caused by chemotherapy resistance." | ( Hou, L; Li, S; Liu, L; Liu, Z; Lu, X; Wang, R; Wei, H; Yu, H, 2019) |
| "The survival rate for patients with ovarian cancer has changed little in the past three decades since the introduction of platinum-based chemotherapy and new drugs are needed." | ( Abdullah, MI; Abed, MN; Khanim, F; Richardson, A, 2019) |
| "Up to 80% of patients with ovarian cancer develop platinum resistance over time to platinum-based chemotherapy." | ( Chai, J; Chan, DW; Chen, CW; Cheung, ANY; Li, J; Li, Z; Liu, SS; Meng, Y; Ngan, HYS; Sun, J; Sun, W; Yung, MMH; Zhang, Y; Zheng, W; Zhou, W; Zhou, Y; Zhu, W, 2019) |
| "Elderly patients with ovarian cancer are an increasing population and many of them are frailty with an increased risk of postoperative complications, chemotherapy intolerance and mortality." | ( Attianese, D; Ferrero, A; Petracchini, M; Villa, M, 2019) |
| "A subset of patients with recurrent ovarian cancer (ROC) may benefit from antiestrogen therapy with higher response rates reported in tumors that are strongly estrogen receptor (ER)-positive (ER⁺)." | ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; DeFazio, A; Friedlander, M; Goh, J; Grant, P; Kok, PS; Mapagu, C; O'Connell, RL; Scurry, J; Sjoquist, K, 2019) |
| "Pre-exposure of paclitaxel-resistant ovarian cancer cells to gliotoxin inhibited the expression of multidrug resistant-associated proteins (MDR1 and MRP1-3), disrupted the mitochondrial membrane potential, and induced caspase-dependent apoptosis through autophagy induction after subsequent treatment with paclitaxel." | ( Jeong, JY; Kim, D; Park, GB, 2019) |
| "Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy." | ( Andresen, C; Bertschi, A; Cheney, EM; Goldberg, MS; Guerriero, JL; Hartl, CA; Mittendorf, EA; Puerto, RB, 2019) |
| "Because many patients with recurrent ovarian cancer receive aggressive chemotherapy for prolonged periods, sometimes continuously, therapy-related toxicities are a major factor in treatment decisions." | ( Al-Ali, H; Azzam, DJ; Brothers, SP; Ince, TA; Lohse, I; Volmar, CH; Wahlestedt, C, 2019) |
| "Our results indicate that treatment of ovarian cancer with MF and P4 may induce similar adverse agonistic effects in the absence of classical nuclear PGRs in ovarian cancer." | ( Bernaczyk, P; Bidzinski, M; Chrusciel, M; Chrusciel, P; Huhtaniemi, IT; Ponikwicka-Tyszko, D; Rahman, NA; Scheinin, M; Stelmaszewska, J; Szamatowicz, J; Sztachelska, M; Wolczynski, S, 2019) |
| "The success of an ovarian cancer treatment depends on the stage of the cancer and the diagnostic system." | ( Chang, Y; Gopinath, SCB; Liang, T; Liu, XT; Qu, Q, 2019) |
| "Treatment of ovarian cancer often requires extensive surgical resection." | ( Bisch, SP; Cameron, A; Chu, P; Fitzmaurice, GM; Ghatage, P; Glaze, S; Kooy, J; Nation, J; Nelson, G, 2019) |
| "The standard treatment for advanced ovarian cancer is cytoreductive surgery followed by cytotoxic chemotherapy." | ( Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y, 2020) |
| "More than 80 % of women with advanced ovarian cancer relapse either during or after adjuvant therapy." | ( Berg, T; Nøttrup, TJ; Roed, H, 2019) |
| "Seventeen primary serous ovarian cancers classified as responders or nonresponders to standard treatment were screened with DigiWest protein array analysis for 279 analytes." | ( Beiter, Y; Beyer, I; Braicu, EI; Brucker, S; Darb-Esfahani, S; Fehm, T; Gottstein, J; Hartkopf, AD; Honisch, E; Naskou, J; Neubauer, H; Niederacher, D; Rudelius, M; Schlensog, M; Sehouli, J; Staebler, A; Templin, MF; van Rensburg, R; Wallwiener, D; Walter, L, 2020) |
| "Epithelial ovarian cancer (EOC) is usually diagnosed at advanced stages with highly variable clinical outcomes, even among patients with similar clinical characteristics and treatments." | ( Bartoletti, M; Cecchin, E; Dal Bo, M; De Mattia, E; De Vita, S; Dreussi, E; Gagno, S; Garziera, M; Giorda, G; Poletto, E; Puglisi, F; Quartuccio, L; Romualdi, C; Roncato, R; Scalone, S; Sorio, R; Toffoli, G; Zanusso, C, 2020) |
| "The role of S100A10 in ovarian cancer has not been well studied and the effect of S100A10 on chemotherapy remains unclear." | ( Chen, T; Cui, Z; Li, X; Liu, Z; Tian, T; Wang, L; Yan, W; Zou, L, 2019) |
| "The combined treatment attenuated ovarian cancer development." | ( Kuo, CC; Lin, YW; Liu, CY; Tsao, CH; Tsao, CW; Yen, HY, 2019) |
| "Patients with ovarian cancer, fallopian tube cancer and peritoneal cancer that treated with Olaparib in The Affiliated Cancer Hospital of Nanjing Medical University between September 2018 and June 2019 were recruited." | ( Chen, X; Cheng, X; Guo, W; Ni, J; Xu, X; Zhou, R, 2019) |
| "Advanced stage ovarian cancer patients who were treated with platinum/taxane chemotherapy via a DD regimen (n = 100), IP approach (n = 81) or a DD regimen in conjunction with HIPEC (n = 64) were retrospectively evaluated." | ( Bohart, R; Goldstein, BH; Micha, JP; Rettenmaier, MA, 2020) |
| "We treated ovarian cancer cells with erastin and examined cell viability, cellular ROS and metabolites of the transsulfuration pathway." | ( Huang, C; Lin, X; Liu, N, 2020) |
| "Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication." | ( Braunstein, M; Bruce, J; Colombo, I; Danesh, A; Garg, S; Lheureux, S; Oza, AM; Pugh, T; Quevedo, R; Shaw, P; Tan, Q, 2019) |
| "BACKGROUND Ovarian cancer (OC) is the most frequent aggressive cancer among women worldwide, and chemoresistance is the major challenge in the clinical treatment of OC." | ( Guo, J; Pan, H, 2019) |
| "Most of the ovarian cancer patients are diagnosed at advanced stages and suffer from recurrence after primary cytoreductive surgery and standard first-line chemotherapy." | ( Asano, H; Baghdadi, M; Daigo, Y; Endo, D; Endo, H; Hama, N; Ishikawa, K; Kato, H; Kato, T; Konno, Y; Miyagi, Y; Otsuka, R; Seino, KI; Suzuki, N; Takano, A; Tozawa, A; Wada, H; Watari, H; Yokose, T, 2020) |
| "shRNA depletion of MYPT1 in ovarian cancer cell lines, miRNA overexpression, RT-qPCR analysis, patient tumor samples, cell line- and tumorsphere-derived xenografts, in vitro and in vivo treatments, analysis of data from ovarian tumors in public transcriptomic patient databases and in-house patient cohorts." | ( Carnero, A; Estevez-Garcia, P; Felipe-Abrio, B; Jiménez-García, MP; Muñoz-Galván, S; Perez, M; Suarez-Martinez, E; Verdugo-Sivianes, EM, 2020) |
| "Patients diagnosed with stage III ovarian cancer are at high risk of recurrence and optimal adjuvant therapy is often debated." | ( Bivona, C; Grauer, D; Henry, D; Mahmoudjafari, Z; Martin, G; Murphy, M, 2020) |
| "According to the statement from the 5th Ovarian Cancer Consensus Conference in 2015, the primary systemic chemotherapy for advanced ovarian cancer is a combination of paclitaxel plus carboplatin administered every 3 weeks (PCq3w)." | ( Fujiwara, K; Hasegawa, K; Nagao, S, 2019) |
| "Additionally, ACAT-1 inhibited ovarian cancer cell lines displayed enhanced chemosensitivity to cisplatin treatment." | ( Ayyagari, VN; Brard, L; Diaz-Sylvester, PL; Groesch, K; Wang, X, 2020) |
| "The treatment of ovarian cancer is a big challenge for the present medicine." | ( Brzózka, Z; Flont, M; Jastrzębska, E, 2020) |
| "MiR-509-3 can sensitize ovarian cancer cells to Olaparib by impeding HR, which makes it a potential target in PARPi synergistic treatment." | ( Cao, W; Dong, R; Dongol, S; Kong, B; Li, C; Qiu, C; Song, K; Sun, C; Yang, X; Zhang, Q; Zhang, Z, 2020) |
| "We utilized cells from two ovarian cancer cell lines, SKOV3 and HeyA8, and treated them with a combination of rVEGFR1 (sFlt1) and carboplatin as well as rVEGFR1 (sFlt1) alone." | ( Kimura, T; Kumasawa, K; Miyake, T; Nakamura, H; Sato, N; Yamashita, M, 2020) |
| "The poor outcomes in epithelial ovarian cancer necessitate new treatments." | ( Hong, F; Ma, A; Qin, T; Xu, X; Xu, Y; Zhang, X; Zhu, Z, 2020) |
| "Sixteen patients with recurrent ovarian cancer, including 1 platinum-resistant, 7 partially platinum-sensitive, and 8 platinum-sensitive, accepted a median of 6 cycles of chemotherapy (range 3-10)." | ( Chang, TC; Chen, WC; Chou, HH; Huang, HJ, 2020) |
| "High-grade serous ovarian cancer (HGS-EOCs) is generally sensitive to front-line platinum (Pt)-based chemotherapy although most patients at an advanced stage relapse with progressive resistant disease." | ( Adorni, M; Ballabio, S; Beltrame, L; Benvenuto, G; Bignotti, E; Calura, E; Ceppi, L; D'Incalci, M; Delle Marchette, M; Donati, F; Fruscio, R; Grassi, T; Marchini, S; Martini, P; Odicino, F; Paracchini, L; Perego, P; Ravaggi, A; Romani, C; Romualdi, C; Sales, G; Sartori, E; Todeschini, P; Tognon, G; Zanotti, L, 2020) |
| "The epithelial ovarian cancer is one of the most lethal gynecological malignancy due to its late diagnostic and many relapses observed after first line of treatment." | ( Bellard, E; Chabot, S; Coustets, M; Ecochard, V; Ferron, G; Golzio, M; Ladurantie, C; Paquereau, L; Prat, M; Rols, MP, 2020) |
| "We used an ovarian cancer database containing the diagnosis and initial therapy of all patients at the National Cancer Center Hospital in Japan from 2007 to 2014." | ( Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M, 2020) |
| "Advanced-stage ovarian cancer has a poor prognosis; surgical resection with the intent to leave no residual tumour followed by adjuvant chemotherapy is the standard treatment." | ( Block, L; Gupta, A; Hayden, JM; Nordstrom, JL; Oras, J; Palmqvist, C; Salehi, S; Thörn, SE, 2020) |
| "Drug resistance in epithelial ovarian cancer (EOC) is reportedly attributed to the existence of cancer stem cells (CSC), because in most cancers, CSCs still remain after chemotherapy." | ( Choi, DK; Kim, DK; Kim, JH; Kim, JW; Kwon, OB; Lee, DS; Lee, H; Lee, J; Lee, S; Min, SH; Yu, JH, 2020) |
| "Treatment with calcitriol inhibited ovarian cancer cell proliferation, migration, and invasion." | ( Guo, B; Wang, L; Zhou, S, 2020) |
| "Despite initial chemotherapy response, ovarian cancer is the deadliest gynecologic cancer, due to frequent relapse and onset of drug resistance." | ( Avolio, R; Bifulco, M; Calice, G; Criscuolo, D; Crispo, F; Esposito, F; Laezza, C; Landriscina, M; Maddalena, F; Matassa, DS; Navarra, G; Pagano, C; Paladino, S, 2020) |
| "Growth inhibition studies in a panel of ovarian cancer cell lines revealed potency trends of the SymProDs mirrored those of the single treatments suggesting their dissociation in cells." | ( Contreras, JI; Karpf, AR; Kizhake, S; Kour, S; Natarajan, A; Rana, S; Robb, CM; Sonawane, YA; Zahid, M, 2020) |
| "Using multiple human ovarian cancer cell lines, a transwell co-culture system of the carboplatin or VP-16-challenged feeder and receptor cells was established to demonstrate the chemotherapy-exacerbated migration." | ( Chen, L; Cui, L; Gao, M; He, K; He, M; Jia, Y; Li, J; Pan, Y; Shao, D; Shi, T; Yang, X; Yue, F; Zhang, M; Zhao, Y; Zheng, X, 2020) |
| "Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy at our hospital between 2014 and 2018 were identified." | ( Hada, T; Ishibashi, H; Iwahashi, H; Kakimoto, S; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Suminokura, J; Takano, M, 2020) |
| "Melphalan is used to treat ovarian cancer as an intraperitoneal chemotherapy agent." | ( Feng, C; Mei, X; Shen, C; Wang, B; Wen, A; Zhang, X, 2020) |
| "Chemoresistance is a main obstacle in ovarian cancer therapy and new treatment strategies and further information regarding the mechanism of the medication cisplatin are urgently needed." | ( Cai, S; Fan, D; Fan, L; Peng, F; Tao, L; Wang, Q; Zhao, Z; Zheng, N, 2020) |
| "Forty-eight ovarian cancer patients undergoing chemotherapy were enrolled in this study." | ( Itoh, H; Nakahara, R; Sato, Y; Suzuki, K; Tanaka, R; Tatsuta, R, 2020) |
| "Therefore, the treatment of ovarian cancer needs to be improved." | ( Bae, H; Lee, JY; Lim, W; Song, G, 2020) |
| "Platinum-resistant ovarian cancer is characterized by its poor prognosis and limited treatment options." | ( Cai, S; Li, H; Sun, L; Wu, L; Yang, M; Zhang, X; Zhang, Y, 2020) |
| "Poor outcomes for patients with ovarian cancer relate to dormant, drug-resistant cancer cells that survive after primary surgery and chemotherapy." | ( Bartholomeusz, G; Bast, RC; Blessing, AM; Bollu, LR; Elmir, E; Iles, L; Langley, R; Lu, Z; Mao, W; Ning, J; Pak, D; Pang, L; Rask, P; Santiago-O'Farrill, JM; Tran, S; Yang, H, 2020) |
| "This offers hope for the treatment of ovarian cancer patients with mutations of the PI3K/AKT/mTOR pathway." | ( Chai, J; Hu, X; Su, J; Sun, L; Sun, Y; Wang, J; Xia, M; Yu, H; Zhang, Z, 2020) |
| "Around 20-30% of ovarian cancer patients exhibit chemoresistance, but there are currently no methods to predict whether a patient will respond to chemotherapy." | ( Aguirre-Ghiso, JA; Aksan, A; Azarin, SM; Geller, MA; Lam, T, 2020) |
| "In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity." | ( Bissardon, C; Bohic, S; Charlet, L; Conlan, RS; Francis, LW; Gazze, SA; Gonzalez, D; Gourlan, AT; Toubhans, B, 2020) |
| "Although initial treatment of ovarian cancer is successful, tumors typically relapse and become resistant to treatment." | ( Asare-Werehene, M; Burger, D; Carmona, E; Communal, L; Han, Y; Mes-Masson, AM; Song, YS; Tsang, BK, 2020) |
| "To improve the treatment of ovarian cancer and identify ovarian cancer-specific antibodies, we immunized mice with the human ovarian carcinoma cell line, SKOV-3, and generated hybridoma clones." | ( Chen, WY; Hwang, YC; Ke, FY; Kuo, KT; Lin, MC; Wu, HC, 2020) |
| "All women managed for an epithelial ovarian cancer between 1st January 2000 and 30th June 2016 were included if they had a FDG PET CT, before initiation of any treatment (neoadjuvant chemotherapy or frontline cytoreductive surgery)." | ( Bendifallah, S; Body, G; Bricou, A; Collinet, P; Delvallée, J; Huchon, C; Lavoue, V; Ouldamer, L; Rossard, L; Touboul, C, 2020) |
| "In particular, ovarian cancer patients often acquire drug resistance after chemotherapy." | ( Li, H; Mo, X; Qin, P; Sun, J; Xu, L; Yan, M; Zhao, N, 2020) |
| "Human ovarian cancer cell lines (IGROV-1, A2780, A2780cis) were treated with increasing concentrations (0." | ( Dell'Endice, S; Göbel, A; Jaschke, N; Kuhlmann, JD; Rachner, TD; Wimberger, P; Zinna, VM, 2020) |
| "For patients with newly diagnosed ovarian cancer, maintenance therapy with niraparib was cost effective." | ( Barrington, DA; Cohn, DE; Senter, L; Smith, HJ; Straughn, JM; Tubbs, C, 2020) |
| "We found that ovarian cancer patients treated with metformin had significantly longer overall survival than patients treated without metformin." | ( Chou, PC; Huang, CF; Lee, MH; Lin, JH; Sung, PL; Wen, KC; Wu, ATH; Yeung, SJ, 2020) |
| "In Epithelial Ovarian Cancer (EOC) patients, PT-resistant recurrences are very common and improving the response to treatment still represents an unmet clinical need." | ( Baldassarre, G; Belletti, B; Coan, M; D'Andrea, S; Dall'Acqua, A; Lorenzon, I; Lovisa, S; Pellarin, I; Polesel, J; Ranzuglia, V; Sabatelli, P; Schiappacassi, M; Segatto, I; Serraino, D; Sonego, M; Spessotto, P, 2020) |
| "Traditional chemotherapy for ovarian cancer is limited due to drug resistance and systemic side effects." | ( Chen, F; Gao, D; Li, R; Xie, H; Xue, J, 2020) |
| "Three of them were recurrent ovarian cancer, and one was the initial treatment." | ( Li, X; Qu, H; Xia, Y, 2020) |
| "Treatment for platinum-resistant ovarian cancer is difficult and challenging because available chemotherapeutic agents only offer short survival improvements." | ( Endo, Y; Fujimori, K; Furukawa, S; Kamo, N; Manabu, K; Nishigori, H; Nomura, S; Okabe, C; Sato, T; Soeda, S; Takahashi, T; Ueda, M; Watanabe, T, 2020) |
| "Treatment of multi-resistant epithelial ovarian cancer represents a clinical challenge with limited choices." | ( Adimi, P; Andersen, RF; Hansen, MKG; Jakobsen, A; Smerdel, MP; Steffensen, KD; Waldstrøm, M, 2020) |
| " Ovarian cancer (OC) is the most lethal of the gynecologic cancers, and platinum-based treatment is a part of the standard first-line chemotherapy regimen." | ( Bahar, E; Kim, HS; Kim, JY; Yoon, H, 2020) |
| "Patients with advanced ovarian cancer who have failed previous lines of chemotherapy may achieve static disease with tamoxifen with minimal side effects." | ( Chan, KKL; Chu, MMY; Ngan, HYS; Ngu, SF; Tse, KY, 2021) |
| "The main challenge in ovarian cancer treatment is the management of recurrences." | ( Bartosch, C; Henriques Abreu, M; Nunes, M; Ricardo, S, 2020) |
| "Most women with advanced ovarian cancer respond to initial treatment, consisting of surgical resection and ≈6 cycles of platinum-based chemotherapy." | ( du Bois, A; Mirza, MR; Pignata, S; Ray-Coquard, I; Romero, I; Walther, A, 2020) |
| "Overall, priming with HDACi sensitizes ovarian cancer cells to treatment with HSP90i or cisplatin and has an influence on the development of cisplatin resistance, both of which may contribute to an improved ovarian cancer treatment." | ( Bandolik, JJ; Hamacher, A; Hansen, FK; Kassack, MU; Kurz, T; Rodrigues Moita, AJ, 2020) |
| "Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies." | ( Akers, S; Attwood, KM; Chilakapati, S; Frederick, PJ; Gomez, EC; Lele, S; Liu, S; Lynam, S; Odunsi, K; Wang, C; Zsiros, E, 2021) |
| "Patients with advanced-stage ovarian cancer face a poor prognosis because of recurrent peritoneal cavity metastases following surgery and chemotherapy." | ( Bruland, ØS; Bønsdorff, TB; Jorstad, IS; Juzeniene, A; Larsen, RH; Li, RG; Napoli, E; Westrøm, S, 2021) |
| "CSCs of human ovarian cancer cell lines HO8910 were treated with lumiflavin and rapamycin and then subjected to irradiation at a cumulative dose of 8 Gy." | ( Huang, Y; Song, Z; Wu, M; Yang, R, 2021) |
| "We have previously shown that the ovarian cancer cells, SKOV3, are auxotrophic to arginine, and that arginine deprivation by treatment with the genetically engineered human arginase I (HuArgI (Co)-PEG5000) triggers the death of SKOV3 cells by autophagy." | ( Abdellatef, S; Abi-Habib, R; El-Mais, N; El-Sibai, M; Fakhoury, I, 2021) |
| "Epithelial ovarian cancer remains the leading cause of mortality among all gynecologic malignancies owing to recurrence and ultimate development of chemotherapy resistance in the majority of patients." | ( An, HJ; Cho, YB; Ghosh, M; Hong, SD; Hur, J; Kang, M; Katuwal, NB; Kim, TH; Moon, YW; Pandey, K; Park, N, 2021) |
| "Time-dependent treatment of ovarian cancer cells, ES-2, and TOV-21G with progesterone enhanced caspase -8 activity after 12 h, whereas OV-90, TOV-112D, HEC-1A, and HEC-59 cells showed increased activity after 24 h." | ( Casablanca, Y; Maxwell, GL; McGlorthan, L; Paucarmayta, A; Syed, V, 2021) |
| "More patients with ovarian cancer are being treated with poly(adenosine diphosphate-ribose) polymerase inhibitors because regulatory agencies have granted these drugs new approvals for a variety of treatment indications." | ( Fu, S; Giordano, SH; Harrison, RF; Lu, KH; Meyer, LA; Sun, CC; Zhao, H, 2021) |
| "We identified 503 patients with ovarian cancer with a median age of 55 years (interquartile range, 50-62 years); 83% of those had out-of-pocket spendings during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment." | ( Fu, S; Giordano, SH; Harrison, RF; Lu, KH; Meyer, LA; Sun, CC; Zhao, H, 2021) |
| "Patients with ovarian cancer experience high out-of-pocket costs for healthcare, both before and during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment." | ( Fu, S; Giordano, SH; Harrison, RF; Lu, KH; Meyer, LA; Sun, CC; Zhao, H, 2021) |
| "Seventy PTX-administrated ovarian cancer patients were recruited in this study for gene expression and survival rate analyses." | ( Cheng, G; Diao, X; Sun, X; Yin, X; Zhu, X, 2021) |
| "To evaluate how women with epithelial ovarian cancer (EOC), dichotomized by BRCA status, tolerate intravenous (IV) or intraperitoneal (IP) chemotherapy given with veliparib and bevacizumab (bev) on a GOG phase I study (GOG 9923, NCT00989651)." | ( Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gillen, J; Gordon, SW; Gray, HJ; Guntupalli, SR; Hagemann, AR; Hays, J; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, R; Schilder, RJ; Walker, JL, 2021) |
| "Persistence of ovarian cancer stem cells (OCSCs) at the end of therapy has been shown to contribute to resistant tumors." | ( Fang, F; Nephew, KP; Ozes, A; Wang, W, 2021) |
| "In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum-based chemotherapy." | ( Andrews Wright, N; Bernard, L; Duciaume, M; Fortuna, A; Goss, GD; Hodgson, D; Howat, WJ; Jones, GN; Lazic, SE; Leon, A; Lo, B; Lukashchuk, N; Marco-Casanova, P; Marsh, K; Pugh, TJ; Rath, P; Roudier, MP; Sekhon, HS; Torchia, J; Torti, D; Weberpals, JI; Whelan, D, 2021) |
| "The human ovarian cancer cell lines were treated with green tea extract, PTX, and green tea plus PTX for 24 h, and cell viability was assessed using the MTT method." | ( Abazari, O; Abbasi, M; Bakhshi, A; Behmard, V; Khanicheragh, P; Malekpour, M; Nayerpour Dizaj, T; Nejadbiglari, H; Panji, M; Safaeian, A; Shabanzadeh, M; Yavari, S; Zare, Z, 2021) |
| "Despite many attempts to treat ovarian cancer, 13,940 individuals perish annually due to this disease worldwide." | ( Amini-Farsani, Z; Asgharzade, S; Hashemi Sheikhshabani, S; Jazaeri, A; Mohammadi-Samani, M; Rahmati, S, 2021) |
| "The standard chemotherapy regimens of ovarian cancer are platinum-based chemotherapy (carboplatin and paclitaxel) and bevacizumab (BEV)." | ( Apaijai, N; Charoenkwan, K; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Khunamornpong, S; Kingnate, C; Kumfu, S, 2021) |
| "CP therapy is related to female ovarian cancer and causes female infertility." | ( Chen, L; Li, Y; Liang, Y; Liu, J; Wang, W; Zhao, S, 2021) |
| "The patients with advanced-stage ovarian cancer have higher factors complicating surgery; thus, the best choice for them is surgery with chemotherapy with six cycles of adjuvant chemotherapy." | ( Harsono, AB; Nisa, AS; Pasaribu, M; Suardi, D; Susanto, H; Trianasari, N; Winarno, GNA; Yuseran, H, 2021) |
| "Advanced stage ovarian cancer is challenging to treat due to widespread seeding of tumor spheroids throughout the mesothelial lining of the peritoneal cavity." | ( Azarin, SM; Choi, Y; Ferry, VE; Geller, MA; Jones, VO; Kim, DW; Lee, HR, 2021) |
| "Standard chemotherapy for ovarian cancers is often abrogated by drug resistance." | ( An, HJ; Choi, SH; Jung, D; Kim, KY; Park, KS, 2021) |
| "Most patients with ovarian cancer will relapse after receiving frontline platinum-based chemotherapy and eventually develop platinum-resistant or platinum-refractory disease." | ( Anderson, CK; Banerjee, S; Dychter, SS; Fujiwara, K; Jung, KH; Kristeleit, R; Leary, A; Ledermann, JA; Madry, R; Monk, BJ; Oza, AM; Park, SY; Pujade-Lauraine, E; Ray-Coquard, IL; Richardson, GE; Sessa, C; Stewart, RA; Tinker, AV; Wei, C; Yonemori, K; Zohren, F, 2021) |
| "The primary chemotherapy of ovarian cancer (OC) often acquires chemoresistance." | ( Guan, W; Li, X; Wang, F; Xu, G; Xu, X; Zhang, J, 2021) |
| "The poor outcomes in ovarian cancer necessitate new treatments." | ( Fu, B; Guo, Y; Hu, B; Zhu, H, 2021) |
| "Development of resistance to therapy in ovarian cancer is a major hinderance for therapeutic efficacy; however, new mechanisms of the resistance remain to be elucidated." | ( Huang, YX; Jiang, BH; Liu, BJ; Liu, LZ; Liu, WJ; Qiu, JG; Wang, W; Zhang, Y, 2021) |
| "We showed here that treatment of ovarian cancer cells with platinum led to increased RISC-bound miRNAs carrying toxic 6mer seeds and decreased miRNAs with nontoxic seeds." | ( Bartom, ET; Dhir, R; Lengyel, E; Matei, D; Murmann, AE; Nephew, KP; Patel, M; Peter, ME; Wang, Y, 2021) |
| "HO8910 and Caov3 ovarian cancer cells were treated with pentamidine." | ( Kou, Z; Wu, Y; Zhang, Z, 2021) |
| "After the patient's second relapse of ovarian cancer, she was administered olaparib as maintenance therapy following successful completion of docetaxel and carboplatin therapy." | ( Himeji, D; Marutsuka, K; Matsumoto, R; Moriguchi, S; Morishita, H; Shiiba, R; Takamura, K; Tanaka, GI; Taniguchi, S, 2022) |
| "2292 patients with ovarian cancer received at least two lines of therapy." | ( Havrilesky, LJ; Moss, HA; Perhanidis, JA; Secord, AA, 2021) |
| "Finally, 34 studies including 40 ovarian cancer cases receiving chemotherapy during pregnancy were included." | ( Fang, Q; Jiang, X; Jiang, Y; Ye, Z; Yu, W, 2021) |
| "Chemotherapy for end-of-life ovarian cancer patients is a complex and delicate problem." | ( Fukasawa, I; Hasegawa, K; Kiuchi, K; Kosaka, N; Motegi, E; Watanabe, M, 2022) |
| "Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum." | ( Gorski, JW; Kolesar, JM; Lin, N; Liu, J; McCorkle, JR; McDowell, AB; Riggs, MB; Ueland, FR; Wang, C, 2021) |
| "Carboplatin-resistant ovarian cancer cells were generated by continuous treatment over six months." | ( Ahn, J; Cha, H; Jeong, HS; Kang, YJ; Koo, HS; Lee, D; Yoon, MJ, 2021) |
| "We treated the human ovarian cancer cell lines SKOV3 and A2780 with low concentrations of DEHP/MEHP, and found that although no significant effect on cell proliferation was observed, ovarian cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT) were promoted by submicromolar MEHP but not DEHP." | ( Chen, C; Chen, H; Chen, K; Fu, Z; Héroux, P; Leng, J; Li, H; Lu, W; Niu, Y; Wang, F; Wu, Y; Xia, D; Yang, J; Yuan, X; Zhang, L; Zhu, X, 2021) |
| "The current treatment of ovarian cancer is chemotherapy using paclitaxel in combination with carboplatin as a frontline agent, and paclitaxel is also used in salvage treatment as a second line drug with a dose intensive regimen following recurrence." | ( Amaya, C; Baigorri, J; Baucells, R; Luo, S; Smith, ER; Xu, XX, 2021) |
| "Our data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes." | ( Bilandzic, M; Green, E; Jobling, TW; Karimnia, N; Matthews, A; Plebanski, M; Stephens, AN; Wilson, AL, 2021) |
| "This population based study of ovarian cancer patients found that a quarter of patients may be sub-optimally adherent to PARP inhibitor therapy." | ( Chen, L; Davidson, B; Hershman, DL; Moss, HA; Wright, JD, 2021) |
| "Human ovarian cancer cells and normal human ovarian epithelial cell line IOSE-80 were cultured and administrated with deferoxamine (DFO) or ferric ammonium citrate (FAC)." | ( Chao, H; Li, D; Zhang, M, 2021) |
| "No other prior treatment for ovarian cancer, other than the frontline platinum regimen, is permitted." | ( Coleman, RL; Fujiwara, K; Goble, S; Grechko, N; Herzog, TJ; Hume, S; Kristeleit, RS; Lin, KK; Lorusso, D; Maloney, L; Marmé, F; McNeish, IA; Monk, BJ; N Eskander, R; O'Malley, DM; Oaknin, A; Oza, AM; Safra, T; Shih, D; Westin, SN; Wilson, MK, 2021) |
| "For epithelial ovarian cancer, cytoreductive surgery and platinum-based chemotherapy is the mainstay management." | ( Chan, KK; Ngan, HY; Ngu, SF, 2022) |
| "Microarray analysis of both Cu-treated ovarian cancer cell lines OVCAR3 and A2780 and the mesothelial cell line Met-5A revealed the upregulation of the angiogenesis biological process." | ( Fujita, Y; Mizutani, T; Onuma, T; Yamada, S; Yoshida, Y, 2021) |
| "Platinum-resistant ovarian cancer patients have a poor prognosis and few treatment options are available." | ( Braicu, E; Carbone, V; Cibula, D; Colombo, N; Frenel, JS; Ghizzoni, V; Giolitto, S; Giudice, E; Lorusso, D; Musacchio, L; Perri, MT; Pignata, S; Ricci, C; Salutari, V; Scambia, G; Zagouri, F, 2021) |
| "Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options." | ( Armstrong, D; Burger, RA; Dean, E; Domchek, S; Drapkin, R; Gaillard, S; Giuntoli, R; Haggerty, A; Hwang, WT; Latif, N; Martin, LP; Morgan, M; Pagan, C; Rodriguez, D; Shah, PD; Shih, IM; Simpkins, F; Smith, SA; Tanyi, J; Torigian, DA; Wethington, SL; Zarrin, H, 2021) |
| "The resistance of ovarian cancer for Paclitaxel seriously limits the clinical efficacy in chemotherapy for ovarian cancer patients." | ( Ye, Y; Zhang, J; Zhang, R, 2021) |
| "The search for biomarkers to evaluate ovarian cancer (OC) homologous recombination (HR) function and predict the response to therapy is an urgent clinical need to improve the selection of patients who could benefit from platinum- and olaparib (poly-ADP ribose polymerase inhibitors, PARPi)-based therapies." | ( Alvisi, MF; Anastasia, A; Bani, MR; Chiappa, M; Damia, G; Degasperi, A; Fruscio, R; Giavazzi, R; Guffanti, F; Llop-Guevara, A; Lupia, M; Nik-Zainal, S; Ricci, F; Rulli, E; Serra, V, 2022) |
| "Results suggest a subset of ovarian cancer patients with enhanced susceptibility to Vigil immunotherapy." | ( Aaron, P; Bognar, E; Choucair, K; Morand, S; Nemunaitis, J; Robinson, M; Sliheet, E; Stanbery, L; Willoughby, D, 2022) |
| "This study aims to determine ovarian cancer (OC) patients with platinum resistance for alternative treatment protocols by using metabolomic methodologies." | ( Eroglu, EC; Geckil, OF; Gulec, UK; Paydas, S; Tunug, S; Vardar, MA, 2021) |
| "Most women with ovarian cancer are treated with chemotherapy before or after surgery." | ( Condello, M; Gallo, FR; Meschini, S; Multari, G; Pellegrini, E; Vecchiotti, D; Zazzeroni, F, 2022) |
| "Leveraging four ovarian cancer with chronic stress (OCCS) mouse models, we explore the therapeutic efficacy of platinum, Niraparib, and Docetaxel treatment in vivo, and compare the efficacy of these anti-tumor drugs in vitro using cell viability assays." | ( Liu, M; Liu, T; Sun, L; Tan, S; Tang, J; Xiao, W; Zhou, X, 2022) |
| "Luciferised syngeneic mouse ovarian cancer cells (ID8-luc) were treated with the HDACi panobinostat alone or combined with olaparib and effects on cell viability, apoptosis, DNA damage and HR efficiency determined." | ( Crispens, MA; Gupta, VG; Khabele, D; Liu, Q; Wilson, AJ; Yull, F, 2022) |
| "Platinum-resistant ovarian cancer (PROC) is usually treated with single-agent chemotherapy." | ( Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T, 2022) |
| "Treatment for ovarian cancer includes platinum-based chemotherapy, but many women become resistant to chemotherapy, becoming platinum-resistant." | ( Clarke, A; Day, E; de la Rosa, CN; Fiorentino, F; Krell, J; Reddi, M; Webber, L, 2022) |
| "Most patients with ovarian cancer (OC) get remission after undergoing cytoreductive surgery and platinum-based standard chemotherapy, but more than 50% of patients with advanced OC relapse within the first 5 years after treatment and develop resistance to standard chemotherapy." | ( Hu, Y; Kong, B; Liu, J; Qu, P; Wang, P; Zhao, J; Zhao, Y, 2022) |
| "For women with ovarian cancer, a staggering 70% will become resistant to the front-line therapy, cisplatin." | ( Carrion, KC; Miles, W; Quiñones-Díaz, BI; Rabelo-Fernández, RJ; Rajasekaran, S; Rivera, RAN; Rivera, YS; Roche-Lima, A; Santiago-Sánchez, GS; Sharma, RK; Siddiqui, J; Valiyeva, F; Vivas-Mejia, PE, 2022) |
| "Patients with epithelial ovarian cancer (EOC), treated with niraparib maintenance, present with haematological and gastrointestinal toxicities." | ( Agouridis, AP; Mamais, I; Michalinos, A; Pagkali, A, 2022) |
| "Because elderly patients with ovarian cancer are underrepresented in randomized studies, this study aimed to expand our knowledge on the safety and effectiveness of frontline treatment with bevacizumab in combination with standard carboplatin and paclitaxel chemotherapy in patients aged 70 years and older with a diagnosis of Federation of Gynecology and Obstetrics (FIGO) stage IV ovarian cancer in routine clinical practice in Belgium." | ( Claes, N; De Maeseneer, D; De Waele, S; Debrock, G; Denys, H; Dirix, L; Gennigens, C; Graas, MP; Honhon, B; Lamot, C; Martinez Mena, C; Mebis, J; Pelgrims, G; Spoormans, I; Van den Bulck, H; van Gorp, T; Van Nieuwenhuysen, E; Van Steenberghe, M; Vergote, I; Verhoeven, D; Vroman, P; Vulsteke, C; Vuylsteke, P, 2022) |
| "Thirty-seven ovarian cancer patients treated with carboplatin desensitization therapy were reviewed retrospectively." | ( Hisanori, S; Kamei, D; Kanao, H; Kawakami, K; Kobayashi, K; Murase, R; Shibata, N; Taki, I; Yamaguchi, M; Yunokawa, M, 2022) |
| "There are limited treatment options for ovarian cancer patients with early relapse after platinum chemotherapy." | ( Abadie-Lacourtoisie, S; Blanc-Fournier, C; Brachet, PE; Briand, M; Clarisse, B; Fabbro, M; Floquet, A; Follana, P; Frenel, JS; Gavoille, C; Giffard, F; Gladieff, L; Joly, F; Just, PA; Kalbacher, E; Leary, A; Leconte, A; Lequesne, J; Lesoin, A; Medioni, J; Poulain, L; Weiswald, LB; You, B, 2022) |
| "Although oral maintenance therapy for ovarian cancer is relatively new, patients appear willing to take olaparib long term; and they seem to take great lengths to remain adherent, despite having sometimes had a long cancer journey." | ( Asiedu, G; Ehret, C; Hanna, M; Jatoi, A; Martin, NA, 2022) |
| "Patient-derived ovarian cancer xenografts (OC-PDX) were transplanted subcutaneously to evaluate the effect of treatment on tumor growth, or orthotopically in the peritoneal cavity to evaluate the effect on metastatic spread." | ( Anastasia, A; Baakza, H; Bani, MR; Cadogan, EB; Chiorino, G; Dellavedova, G; Ghilardi, C; Giavazzi, R; James, N; Ramos-Montoya, A; Russo, M; Wilson, J, 2022) |
| "Recurrent ovarian cancer patients treated between 2007 and 2017 were divided into two groups according to their bevacizumab status." | ( Akilli, H; Aliyeva, K; Altundag, O; Ayhan, A; Kuscu, UE; Rahatli, S, 2022) |
| "Moreover, ZC-22 sensitized breast and ovarian cancer cells to cisplatin treatment, a widely used chemotherapeutic agent." | ( Chang, A; Chen, Y; Fan, Y; Huang, Z; Li, J; Lin, Y; Lv, X; Sun, P; Tian, C; Wang, Q; Wei, Y; Xiang, R; Yang, S, 2022) |
| "Epithelial ovarian cancer has poor outcomes with standard therapy and limited options for treatment of recurrent disease." | ( Dubashi, B; Ganesan, P; Goenka, L; Selvarajan, S, 2022) |
| "The standard initial treatment for ovarian cancer is surgery and platinum-based chemotherapy and potentially maintenance therapy with avastin or inhibitors of poly-ADP ribose polymerase (PARP)." | ( de la Rosa, CN; Fiorentino, F; Krell, J; Webber, L, 2022) |
| "CAOV3 and OVCAR3 ovarian cancer cell lines were treated with carboplatin or docetaxel to induce PGCC formation." | ( Andrade, MF; Bowers, RR; Delaney, JR; Jones, CM; Voelkel-Johnson, C; White-Gilbertson, S, 2022) |
| "Over the past decade, the treatment of ovarian cancer has been revolutionised by poly(ADP-ribose polymerase (PARP)) inhibitors." | ( Gou, R; Horikawa, N; Kosaka, K, 2022) |
| "A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy." | ( Bommer, C; du Bois, A; Dutilh, G; Heinzelmann-Schwarz, V; Klar, M; Kurzeder, C; Marth, C; McLaughlin, PMJ; Reuss, A; Schade-Brittinger, C; Vetter, M; Zwimpfer, TA, 2022) |
| "Altogether 68 patients with epithelial ovarian cancer who were treated with chemotherapy in our hospital from June 2018 to June 2019 were selected." | ( Ma, C, 2022) |
| "High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecologic cancer, in part due to resistance to platinum-based chemotherapy reported among 20% of patients." | ( Choi, J; Duan, QL; Nesdoly, S; Nicol, CJB; Tarnouskaya, A; Topouza, DG, 2022) |
| "This study elucidated that CA induces ovarian cancer cell death through classical and non-classical pyroptosis pathways, which may be beneficial as an ovarian cancer therapy." | ( Peng, C; Qian, W; Shen, S; Wang, T; Wang, X; Yin, Y; Zhao, S, 2022) |
| "Among epithelial ovarian cancers, ovarian clear cell carcinoma (OCCC) remains markedly resistant to platinum-based chemotherapy, leading to poor clinical outcomes." | ( Kim, KH; Moon, Y; Nagappan, A, 2023) |
| "Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo." | ( Anderson, C; Barlin, JN; Bessette, P; Chou, HH; Christopoulou, A; Chudecka-Glaz, A; Coleman, RL; Collins, DC; Demirkiran, F; Drochýtek, V; Fujiwara, K; Ghamande, S; Goble, S; Hume, S; Kristeleit, RS; Lim, MC; Lin, KK; Lindahl, G; Littell, RD; Lorusso, D; Marme, F; McNeish, IA; Mikheeva, O; Monk, BJ; Moore, K; Morgan, MA; O'Malley, DM; Oaknin, A; Parkinson, C; Prendergast, E; Provencher, D; Safra, T; Schenker, M; Shih, D; Ueland, F; Van Gorp, T; Westin, SN; Wilson, MK; Yeku, O, 2022) |
| "Treatment of an ovarian cancer cell line with Silybin interfered with glutamine metabolism and the tricarboxylic acid cycle." | ( Dong, X; Feng, H; Lin, X; Liu, Q; Wei, Z; Yao, J; Ye, S; Zeng, C; Zeng, L; Zeng, X, 2022) |
| "Patients with histologically confirmed ovarian cancer who had experienced disease progression during or within 6 months of discontinuing any prior line of treatment with platinum-based chemotherapy were eligible." | ( Cao, L; Guan, N; Hou, Z; Huang, Y; Jiang, K; Li, L; Li, N; Liu, Z; She, F; Tang, J; Wang, T; Wang, W; Wu, L; Yang, H; Yin, R; Zhang, J; Zhou, Q, 2022) |
| "The ES2 and NIH:OVACAR3 ovarian cancer cell lines were treated with 0, 5, 10, or 20 µM of bexarotene." | ( Hongying, P; Kobayashi, T; Kojima, K; Mitsuhashi, A; Nishikimi, K; Shioya, M; Shozu, M; Yahiro, K, 2022) |
| "Emerging studies suggest ovarian cancer stem cells (OCSCs) contribute to chemotherapy resistance and tumor relapse." | ( Alejo, S; He, Y; Johnson, JD; Kost, ER; Lai, Z; Loeffel, I; Pratap, UP; Sareddy, GR; Tekmal, RR; Venkata, PP; Zou, Y, 2022) |
| "Epithelial-like ovarian cancer cells show decreased sensitivity to cisplatin after cisplatin treatment." | ( Dehghanian, F; Ebrahimi Ghahnavieh, L; Naghsh-Nilchi, A, 2022) |
| "In this study, using MTT and SKOV3 ovarian cancer cells deficient in SND1 were observed to be more apoptotic and to express more apoptotic protein after treatment with cisplatin through the MTT, clone formation, and flow cytometry assays, while cells overexpressing SND1 exhibited a decreased number of apoptotic cells and expression of apoptotic proteins." | ( Ha, C; Hu, L; Ren, Y; Xin, L; Yang, J, 2022) |
| "Human ovarian cancer cell lines MES and its PTX-resistant counterpart MES-TP cell lines were used and were treated with Asparagus officinalis and paclitaxel alone as well as in combination." | ( Bae-Jump, VL; Buckingham, L; Fan, Y; Hao, T; Hawkins, GM; Kong, W; O'Donnell, J; Paraghamian, SE; Sun, D; Sun, W; Suo, H; Wang, J; Yin, Y; Zhang, X; Zhao, L; Zhao, Z; Zhou, C, 2023) |
| "We isolated exosomes from ovarian cancer cells treated and untreated with drugs, and then normal human fibroblasts were treated with the isolated exosomes." | ( Bednarek, I; Borzdziłowska, P, 2022) |
| "Naringenin suppresses epithelial ovarian cancer by inhibiting PI3K pathway expression and ameliorating the gut microbiota, and the oral route is more effective than parenteral administration." | ( Cao, D; Chen, H; Gao, Z; Lin, C; Lin, H; Lin, Y; Liu, H; Liu, SL; Luo, L; Luo, Y; Shi, Y; Wang, P; Wang, W; Xie, K; Yang, H; Yang, J; Zeng, Z; Zhao, Y, 2022) |
| "In newly diagnosed, advanced ovarian cancer, maintenance olaparib plus bevacizumab provided continued benefit beyond first progression, with a significant PFS2 improvement and a time to second subsequent therapy or death delay versus placebo plus bevacizumab." | ( Bazan, F; Berger, R; Canzler, U; Colombo, N; Costan, C; Cropet, C; de Gregorio, N; Desauw, C; Dohollou, N; Fasching, PA; Gargiulo, P; González-Martín, A; Guerra-Alia, EM; Heitz, F; Levaché, CB; Marmé, F; Milenkova, T; Mirza, MR; Ochi, H; Pautier, P; Ray-Coquard, I; Rubio-Pérez, MJ; Scambia, G; Tazi, Y; Vergote, I; Zamagni, C, 2022) |
| "The hallmark of ovarian cancer is its high mortality rate attributed to the existence of cancer stem cells (CSCs) subpopulations which result in therapy recurrence and metastasis." | ( Fang, H; Gao, Z; Jiang, Q; Li, C; Li, G; Li, N; Li, X; Nie, S; Ren, S; Wang, Z; Zhang, J, 2022) |
| "Effective treatments for ovarian cancer remain elusive, and survival rates have long been considered grim." | ( Niu, X; Su, M; Wang, Y; Yin, X; Zhou, X; Zou, M, 2022) |
| "Salvage radiotherapy for recurrent ovarian cancer resulted in local control with improved chemotherapy-free survival in carefully selected patients." | ( Bae, BK; Cho, WK; Choi, CH; Kim, TJ; Lee, JW; Lee, YY; Park, W, 2023) |
| "High-grade serous ovarian cancer, the most frequent type of ovarian cancer, has a poor prognosis and novel treatments are needed for patients with platinum resistant/refractory disease." | ( Colombo, N; Credille, KM; Gao, B; Konstantinopoulos, PA; Lee, JM; Lee, JY; Lin, AB; McNeely, S; Miller, R; Shapira-Frommer, R; Vergote, I; Wang, XA; Young, SR, 2022) |
| "Patients with ovarian cancer (N = 169) were assigned to 4 cohorts as part of the Phase 2 multicenter trial (NCT03414047): Cohort 1: platinum resistant, BRCA-wildtype with ≥3 lines prior therapy; Cohort 2: platinum resistant BRCA-wildtype with <3 lines prior therapy; Cohort 3: platinum resistant, BRCA-mutated with prior PARP inhibitor therapy; Cohort 4: platinum refractory, BRCA-mutated, or BRCA-wildtype with any number of prior therapy lines." | ( Colombo, N; Credille, KM; Gao, B; Konstantinopoulos, PA; Lee, JM; Lee, JY; Lin, AB; McNeely, S; Miller, R; Shapira-Frommer, R; Vergote, I; Wang, XA; Young, SR, 2022) |
| "Besides, ROS generation in ovarian cancer cells after treatment with SP induced, while blocking of NK1R with Aprepitant reduced the level of ROS generation." | ( AlAlikhan, A; Ebrahimi, S; Ghahremanloo, A; Hashemy, SI; Javid, H, 2022) |
| "Disease recurrence in high-grade serous ovarian cancer may be due to cancer stem-like cells (CSC) that are resistant to chemotherapy and capable of reestablishing heterogeneous tumors." | ( Alexander, LJ; Bitler, BG; Camillo, JR; Cruz, LS; Gilbert, SF; Holmberg, R; House, CD; Huxford, T; Kogan, E; Lara, J; Lujano-Olazaba, O; Mu, EM; Robinson, M; Stevenson, D; Velasquez, CLR; Waters, JA, 2023) |
| "Resistance to chemotherapy drugs makes ovarian cancer (OC) difficult to treat and ultimately kills patients." | ( Li, Y; Li, Z; Xia, X; Ye, F; Zhou, X, 2022) |
| "Hospitals associated with the Spanish Ovarian Cancer Research Group (GEICO) recruited patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated with rucaparib 600 mg twice daily as maintenance or treatment (Pt-S/Pt-R) in the RAP." | ( Alarcón, J; Barquín, A; Calzas, J; Casado, V; Constenla, M; Dosil, A; Estévez, P; Fuentes, J; Gaba, L; González-Martín, A; Gutiérrez, M; Herrero, A; Madani, J; Manso, L; Márquez, R; Marquina, G; Merino, M; Pajares, B; Reche, P; Salvador, C; Sánchez, L; Santaballa, A; Taus, Á; Yubero, A, 2022) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| "Treatment of epithelial ovarian cancer (EOC) is a challenge because it still leads to unsatisfactory clinical prognosis." | ( An, Q; Geng, HX; Li, XT; Liu, JT; Lu, XH; Tang, L; Wang, YJ; Wang, YY, 2023) |
| "Treatment of epithelial ovarian cancer (EOC) is a challenge because it still leads to unsatisfactory clinical prognosis." | ( An, Q; Geng, HX; Li, XT; Liu, JT; Lu, XH; Tang, L; Wang, YJ; Wang, YY, 2023) |
| "The tumour burden of ovarian cancer should be assessed before deciding on IP/IV versus IV treatment." | ( Chen, Y; Guo, Y; Jia, H; Jiang, R; Shen, L; Wu, Z; Xiang, L; Zang, R; Zhang, W, 2022) |
| "The tumour burden of ovarian cancer should be assessed before deciding on IP/IV versus IV treatment." | ( Chen, Y; Guo, Y; Jia, H; Jiang, R; Shen, L; Wu, Z; Xiang, L; Zang, R; Zhang, W, 2022) |
| "Treatment of ovarian cancer models with a broad-spectrum antibiotic cocktail (ABX, vancomycin, neomycin sulfate, metronidazole, ampicillin) changed the gut microbiome and increased tumor growth and development of cisplatin resistance." | ( Hawkins, SM; Nephew, KP, 2022) |
| "Treatment of ovarian cancer models with a broad-spectrum antibiotic cocktail (ABX, vancomycin, neomycin sulfate, metronidazole, ampicillin) changed the gut microbiome and increased tumor growth and development of cisplatin resistance." | ( Hawkins, SM; Nephew, KP, 2022) |
| "Chemoresistance in ovarian cancer results in treatment failure, yet underlying mechanisms that regulate chemoresistance remain largely unclear." | ( Jian, L; Zou, J, 2023) |
| "Post the co-culture, we treated ovarian cancer cells with carboplatin and elucidated the function of programmed death-ligand 1 (PD-L1) in carboplatin chemoresistance." | ( Jang, SH; Jang, YS; Jeon, S; Kim, JH; Kim, TW; Kong, HJ; Nam, GH; Ryu, JS, 2023) |
| "In addition to inducing ovarian cancer cell cycle arrest and promoting cell apoptosis, CBD treatment significantly affected the expression of LAIR-1 and inhibited the PI3K/AKT/mTOR signaling axis and mitochondrial respiration in ovarian cancer cells." | ( An, J; Cao, Q; Li, H; Liu, C; Liu, M; Liu, Y; Ma, L; Qu, G; Shangguan, F; Song, S; Yang, S; Zhang, H, 2023) |
| "Epithelial ovarian cancer is the most lethal gynecological malignancy, owing notably to its high rate of therapy-resistant recurrence in spite of good initial response to chemotherapy." | ( Carmona, E; Leclerc-Desaulniers, K; Lheureux, S; Mes-Masson, AM; Oza, AM; Provencher, DM; Radulovich, N; Rottapel, R; Sauriol, A; Udaskin, ML, 2023) |
| "Patients with recurrent or persistent ovarian cancer often have poor prognoses, and their optimal treatment regimen remains unclear." | ( Chen, J; Fang, H; Pan, G; Wang, H; Wang, X; Zhang, Y, 2023) |
| "Thirty-two patients with advanced ovarian cancer were treated with a combination of vinorelbine and cisplatin." | ( Jo, DY; Ko, YB; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yeon, SH; Yun, HJ, 2023) |
| "Human ovarian cancer OVCAR-3 cells were cultured in vitro and divided into 5-ALA/PDT group, CDDP group and combined treatment group (5-ALA/PDT combined with different concentrations of CDDP)." | ( Fan, J; Lv, H; Sun, Q; Suo, Y; Wang, Q, 2023) |
| "Platinum-resistant recurrent ovarian cancer has a poor prognosis and few treatment options with limited efficacy." | ( Cainap, C; Cainap, SS; Havasi, A; Havasi, AT, 2023) |
| "To identify genetic associations in ovarian cancer chemotherapy-induced toxicities and therapy outcomes, we examined a cohort of 101 patients receiving carboplatin-paclitaxel treatment with advanced high-grade serous ovarian cancers." | ( Deng, F; Hautaniemi, S; Huhtinen, K; Hynninen, J; Laasik, M; Lapatto, L; Lehtonen, R; Li, Y; Niemi, M; Salminen, L, 2023) |
| "We treated human ovarian cancer cells with 0-1000 nM BPA/BPS and found that 100 nM BPA/BPS treatment significantly increased Cancer Stem Cell (CSC) markers expression including OCT4, NANOG and SOX2." | ( Chen, K; Cui, Z; Li, Y; Ni, H; Qin, Y; Wang, F; Wang, Y; Wu, Y; Xia, D; Xu, S; Yuan, X; Zheng, F, 2023) |
| "The standard therapy for ovarian cancer still poses numerous pitfalls due to the irrational use of drugs affecting healthy cells." | ( Gajbhiye, KR; Gajbhiye, V; Jagdale, S; Kesharwani, P; Md, S; Narwade, M; Salve, R; Sheikh, A, 2023) |
| "Standard platinum-based therapy for ovarian cancer is inefficient against ovarian clear cell carcinoma (OCCC)." | ( Bhowmick, NA; Chien, W; Gery, S; Gopinatha Pillai, MS; Koeffler, HP; Li, LY; Lin, DC; Nam, C; Tyner, JW; Zheng, Y, 2023) |
| "It is mainly used in the treatment of ovarian cancer, but also used in testicular, bladder and lung cancers." | ( Bednarek, I; Zoń, A, 2023) |
| "In this study, human ovarian cancer cell lines A2780 and OVCAR3 were used as experimental objects, and the expression of ferroptosis-related protein GPX4 after treatment with apatinib and olaparib was detected by Western blot." | ( Jun, C; Kui, J; Yue, W; Yupeng, G, 2023) |
| "To verify whether PDLIM2 regulates ovarian cancer progression via regulating the transforming growth factor-β (TGF-β)/Smad pathway, exogenous TGF-β (10 ng/mL) treatment was performed on the PDLIM2-overexpressed ovarian cancer cells." | ( Guo, H; Lv, W; Ma, R; Niu, L; Shang, Y; Wang, J, 2023) |
| "ME can enhance the sensitivity of ovarian cancer cells to cisplatin toxicity by inhibiting HSP90AB1/IGF1R interactions, and this might represent a novel target for overcoming cisplatin resistance in ovarian cancer chemotherapy." | ( Huang, Y; Ruan, J; Su, Z; Tang, X; Tao, G; Wang, D; Wang, H; Wang, R; Wang, T; Wang, Y; Weng, Y; Wu, X; Zhang, Y; Zhu, Z, 2023) |
| "High grade serous ovarian cancer (HGSOC) is highly lethal, partly due to chemotherapy resistance and limited availability of targeted approaches." | ( Bonvissuto, D; Buttarelli, M; Caggiano, C; Camarda, F; Cesari, E; Ciucci, A; De Bonis, M; Gallo, D; Greco, V; Loverro, M; Minucci, A; Nero, C; Pieraccioli, M; Piermattei, A; Scambia, G; Sette, C; Sillano, F; Urbani, A; Vizzielli, G, 2023) |
| "Patients with newly diagnosed advanced ovarian cancer with complete or partial response (CR or PR) to first-line platinum-based chemotherapy received niraparib or placebo once daily (2:1 ratio)." | ( Backes, F; Compton, N; Freyer, G; González-Martín, A; Graybill, W; Heitz, F; Lorusso, D; Malinowska, IA; McCormick, CC; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Shtessel, L; Vergote, I; Vulsteke, C, 2023) |
| "The resistance to chemotherapy in ovarian cancer treatment has been a thorny issue." | ( Li, W; Xie, J; Zhang, G; Zhang, R; Zhao, X, 2023) |
| "The risk of ovarian cancer did not increase with the increase of duration of hormonal therapy." | ( Ali, SW; Iqbal, S; Khan, SA; Safdar, W; Sheas, MN; Tariq, MR; Yamen, R, 2023) |
| "In addition, ovarian cancer, BMI < 25 percentile, previous VT, antiplatelet treatment, non-steroidal anti-inflammatory drug use and high leucocyte count at baseline were associated with AT." | ( Brekke, J; Dahm, AEA; Enden, T; Frøen, H; Garresori, H; Ghanima, W; Jacobsen, EM; Larsen, TL; Paulsen, PQ; Porojnicu, AC; Ree, AH; Sandset, PM; Svalastoga, M; Torfoss, D; Velle, EO; Wik, HS, 2023) |
| "Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy owing to relapse caused by resistance to chemotherapy." | ( Choi, KU; Kim, D; Kim, DK; Kim, JH; Kim, JS; Lee, SY; Shin, MJ; Suh, DS, 2023) |
| "The mechanisms of ovarian cancer generate chemotherapy resistance are still unclear." | ( Jiang, X; Li, B; Lin, J; Xu, X; Zhang, G; Zheng, L, 2023) |
| "Immunotherapy for ovarian cancer has been studied for many years and programmed cell death protein 1 ligand/programmed cell death protein 1 (PD-L1/PD-1) blockade has been attempted in several clinical trials; however, the expected therapeutic effect has not been achieved." | ( Taki, M, 2023) |
| "As reported in ovarian cancer, however, sensitivity and resistance to these treatments could partially overlap." | ( Berardi, R; Boscolo Bielo, L; Cortesi, L; Curigliano, G; Del Mastro, L; Favero, D; Gandini, S; Giarratano, T; Guarneri, V; Lambertini, M; Marra, A; Moscetti, L; Pistelli, M; Sposetti, C; Trapani, D; Valenza, C; Vernieri, C; Zambelli, A, 2023) |
| "However, chemotherapy for ovarian cancer was continued while maintaining the quality of life under certain conditions, such as maintenance of platelet levels in collaboration with a hematologist." | ( Abe, R; Kawamura, N; Kawanishi, M; Murakami, M; Nagatsuji, M; Okajima, S; Suruga, M; Tokuyama, O; Yamane, T, 2023) |
| "Treatment of ovarian cancer xenografts with the anti-VEGF drug bevacizumab positively selected for GDR clones that disclosed increased tumorigenic properties in NOD/SCID mice." | ( Boso, D; Brillo, V; Brisotto, G; Brunelli, L; Caporali, L; Carlet, J; Curtarello, M; Del Ben, F; Esposito, G; Grassi, A; Indraccolo, S; Lazzarini, E; Marra, L; Masgras, I; Minuzzo, S; Navaglia, F; Pastorelli, R; Piga, I; Rasola, A; Tognon, M; Trento, C; Turetta, M, 2023) |
| "Currently, the cell viability of ovarian cancer cells under the hypoxia treatment was evaluated by CCK-8 assay, and cell migration and invasion were measured by transwell assay and western blot." | ( Lou, G; Tan, S; Xu, Y; Yu, H; Zhao, Y, 2023) |
| "Patients with metastatic ovarian cancer who develop resistance to standard therapy with or without platinum need to search for other therapeutic choices." | ( Bayram, E; Boga, I; Gulec, HR; Guney, B; Khatib, G; Kilicbagir, E; Paydas, S, 2023) |
| "Most ovarian cancer patients develop recurrent cancers which are often resistant to commonly employed chemotherapy agents, such as cisplatin." | ( Cheon, DJ; Heiserman, JP; Minhas, Z; Nikpayam, E, 2023) |
| "In many patients with ovarian cancer who are treated with platinum-based chemotherapy after surgery, the tumor comes back several months later." | ( Corbaux, P; Freyer, G; Gonzalez, A; Hasegawa, K; Lim, MC; Nieuwenhuysen, EV; Raspagliesi, F; Ray-Coquard, I; Sghaier, S, 2023) |
| "Bevacizumab, Ovarian cancer, Platinum-based chemotherapy, Tolerability, Adverse clinical events." | ( Ates, O; Buyukkor, M; Tay, F, 2023) |
| "Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer, and presents a major clinical challenge due to limited treatment options." | ( Jiang, Y; Li, J; Li, Q; Liu, X; Mai, J; Sun, T; Wu, L; Yang, L; Yin, R, 2023) |
| "For platinum-sensitive relapsed ovarian cancer, maintenance therapy with poly-ADP ribose polymerase (PARP) inhibitors after chemotherapy is considered; however, olaparib treatment does not always lead to sufficient progression-free survival (PFS)." | ( Asano, F; Haruna, Y; Kobayashi, Y; Matsumoto, H; Momomura, M; Morisada, T; Shibuya, H; Tsushima, K, 2023) |
| "More than 75% of epithelial ovarian cancer (EOC) patients experience disease recurrence after initial treatment, highlighting our incomplete understanding of how chemoresistant populations evolve over the course of EOC progression post chemotherapy treatment." | ( Dawson, MR; Ghosh, D; Hsu, J; Mejia Peña, C; Schechter, I; Skipper, TA, 2023) |
| "PINK1 promotes ovarian cancer metastasis and chemotherapy resistance through the regulation of PTEN." | ( Chen, K; Lu, W; Shen, Z; Shi, Y; Tang, S; Wang, F; Wang, S; Wu, Y; Xia, D; Yuan, X; Zheng, F; Zhong, J, 2023) |
| "Platinum is a commonly used drug for ovarian cancer (OvCa) treatment, but drug resistance limits its clinical application." | ( Chen, X; Li, J; Ma, J; Ma, Y, 2024) |